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Introduction 
Human Biomonitoring (HBM) is defined as the determination of chemical substances 
and/or their metabolites in biological matrices for exposure assessment (Angerer et al. 
2007). In contrast to ambient monitoring (the determination of chemicals in the 
environment to estimate exposures) HBM captures all routes of exposure (e.g. 
inhalative, dermal and oral; Figure 1) and all relevant – known or unknown - sources 
(e.g. air, foodstuff, product use, individual lifestyle). Thus, HBM is an important tool not 
only for exposure but also for risk assessment and risk management. HBM can identify 
chemical exposures, time trends and changes in exposure, the distribution of exposure 
among the general population or in specific subsets and collectives (Angerer et al. 2007; 
Angerer 2012). 
 
Figure 1: Ambient and biological monitoring 
Urine is the most preferred biological matrix for HBM purposes, because it is easy, non-
invasively, accessible in adequate amounts under routine conditions without emerging 
discomfort to the sample donor. Blood is also a preferred matrix in HBM studies but has 
the disadvantage of the invasive sample collection which can only be done by authorized 
health personnel. However, depending on the characteristics of the target analytes (e.g. 
persistent chemicals), blood is the sole matrix of choice, and blood or urine cannot be 
used interchangeably. Further, other biological matrices like hair, pulmonary air, nails, 
salvia, and even teeth have been used in HBM studies. Drawbacks arising from the 
application of these matrices in HBM studies, however, are inter alia more complex 
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sample preparation, sensitivity to contamination, reduced accessibility (teeth) and most 
of all the lack of established standard operating procedures (SOPs) and external quality 
assessment schemes, leading to uncertainties in the interpretation and reliability of HBM 
data obtained from these matrices (Angerer et al. 2007). 
One of the first HBM studies was conducted in the 1970´s to assess blood lead 
concentrations by atomic absorption spectroscopy in a large population. It turned out that 
the general population of industrialized countries was exposed to lead to a high degree. 
As a result the lead content in gasoline was reduced and HBM methods were used to 
control the success adopted measures. In 1977 the Commission of the European 
Communities enacted the Council directive 77/312/EEC “on biological screening of the 
general population for lead” (Council of the European Communities; Angerer et al. 2007). 
Nowadays there is a great variety in SOPs of analytical HBM methods elaborated, 
collected, and published by the working group Analysis of Hazardous Substances in 
Biological Material of the Commission for the Investigation of Health Hazards of 
Chemical compounds of the German Research Foundation. These methods have been 
tested for analytical reliability and reproducibility. The collection includes about 140 
methods for the determination of about 200 parameters (Angerer et al. 2007). These 
parameters include, amongst others, metals, polyaromatic hydrocarbons, phthalates, 
pesticides, aromatic amines, environmental tobacco smoke and perfluorinated 
substances (Weiss and Angerer 2002; Koch et al. 2003; Federal Environment Agency 
2006; Calafat et al. 2006; Center for Disease Control 2009).  
HBM continuously evolves and new methods (and new biomarkers) are developed 
continuously for substances or substance classes of concern when e.g. new substances 
are introduced into the market, awareness for emerging pollutants arises or new 
toxicological findings are occurring. Recently developed HBM methods include for 
example di(isononyl)cyclohexane-1,2-dicarboxylate (DINCH), a phthalate substitute 
(Schütze et al. 2012), N-ethyl-2-pyrrolidone (NEP) an industrial solvent used to substitute 
N-methyl-2-pyrrolidone (NMP) that came under scrutiny because of developmental toxic 
and teratogenic effects in rodents (Koch et al. 2013a), and parabens, the esters of p-
hydroxybenzoic acid which are widely used as preservatives in cosmetics and also came 
under scrutiny because of possible endocrine disrupting properties (Moos et al. 2014). 
Pharmaceuticals are another class of emerging environmental pollutants which have 
been object of ambient/environmental monitoring for a while. Residues of 
pharmaceuticals or their metabolites are constantly detectable in the aquatic 
environment (Benotti et al. 2009; López-Serna et al. 2010; Deblonde et al. 2011). 
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One of the most popular pharmaceuticals nowadays is paracetamol (PCM), an analgesic 
(pain-relieving) and antipyretic (fever reducing) drug which is commonly used and sold 
as over-the-counter (OTC, without need for prescription) medication in large amounts 
worldwide. In 2008, two of the ten most sold pharmaceuticals in Germany contained 
PCM (Landschneider 2011). 55 pharmaceutical formulations which are approved for sale 
in Germany contain PCM, according to the German pharmaceutical register (Rote Liste) 
(Glaeske et al. 2009). Over 35 million packages of PCM, each containing 20 or 40 pills, 
were sold in Spain in 2009 (Ortiz García et al. 2013). 127 million defined daily doses 
(DDD, defined by the World Health Organization) were sold in Denmark in 2010 (The 
Danish National Institute of Public Health 2012). This equals to 762 million pills (500 mg) 
and 1 pill per inhabitant every third day (Nielsen et al. 2014). PCM is also approved for 
veterinary use in the European Union with no specific maximum residue limit. Even 
though use of PCM in food production is restricted to pigs there is evidence that PCM is 
as well used in cattle and poultry (Committee for veterinary medicinical products 1999; 
European Commission 2010). In a recent pilot study PCM was found in milk samples 
from Canada albeit at very low concentrations of about 1.5-2 ng/g (Baron et al. 2014). 
PCM is described as short on adverse effects and therefore considered as safe when 
taken in therapeutic dosages, but PCM overdosing has been described as the major 
cause for acute liver failure in developed countries (Tonoli et al. 2012).  
PCM was recommended for use during pregnancy for the treatment of pain and fever by 
the United States Food and Drug Administration (US EPA) during all three trimesters 
(Black and Hill 2003; Thiele et al. 2013). In compliance, several large birth cohort studies 
indicate that PCM (and analgesics in general) are commonly taken by pregnant women 
with positive rates ranging from 30-80% (for PCM use at least once during pregnancy), 
depending on the study (for details see Chapter III). PCM can freely cross the placenta 
barrier, therefore the unborn is exposed to paracetamol by intake of the expecting 
mother (Levy et al. 1975). 
Since 2002, when a working group from the United Kingdom suggested a possible link 
between maternal use of PCM during pregnancy and an increased risk of asthma in 
infants (Shaheen et al. 2002), PCM came under scientific scrutiny concerning adverse 
pregnancy outcomes like asthma (Shaheen et al. 2002; Scialli et al. 2010b; Andersen et 
al. 2012b, 2012a; Gonzalez-Barcala et al. 2012; Persky et al. 2008), congenital 
abnormalities (Abe et al. 2003; Jensen et al. 2010; Philippat et al. 2011; Rebordosa et al. 
2009; Rebordosa et al. 2008; Snijder et al. 2012; Thiele et al. 2013; Scialli et al. 2010a) 
and adverse neurodevelopmental outcomes (Brandlistuen et al. 2014). The possibility of 
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endocrine disrupting properties of PCM was substantiated by various in vitro, ex vivo, 
and animal experiments wherein potential mechanisms of action were identified, as e.g. 
reduced testosterone production, inhibited prostaglandin synthesis, and reduced 
anogenital distance in the male offspring (Albert et al. 2013; Christiansen et al. 2012; 
Kristensen et al. 2010; Kristensen et al. 2012; Kristensen et al. 2011). 
Based on these recent toxicological findings, we decided to develop an analytical 
method for the determination of PCM in urine via high performance liquid 
chromatography coupled with tandem mass spectrometry (HPLC-MS/MS). The aim was 
to assess the exposure of the general population to PCM for a profound exposure- and 
risk assessment (Chapter I). Because PCM is mainly excreted in form of its glucuronide- 
and sulfate conjugates which in sum represent approx. 80% of the dose (Prescott 1980), 
enzymatic hydrolysis of the conjugates has to be applied to facilitate analysis with PCM 
as target analyte. Designed to be used in HBM studies, the method had to fulfill certain 
requirements like rapidness and a small amount of sample preparation, to achieve high 
sample throughput, high sensitivity, selectivity, and a wide range of linearity to detect 
recent exposure (intake of PCM) as well as past exposures and possible environmental 
exposures. The reduction of required sample preparation (except for enzymatic 
hydrolysis and crude cleanup) was realized by using a two column assembly with a time 
controlled switching valve for on-line cleanup and enrichment of the samples. In 
particular, after injection of the samples into the HPLC system, the analytes are captured 
on the first column (enrichment column) whereas matrix components are not retained 
and flushed into waste (Figure 2, valve position A). 
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Figure 2: Two column assembly; (A) cleanup and enrichment, (B) separation and detection 
 
When the valve is switched into position B the flow direction on the enrichment column 
changes (backflush) and the analytes are eluted with an eluent composition strong 
enough to elute them from the enrichment column but not strong enough to perform 
separation on the analytical column. To enable this use of columns with different 
retention mechanisms is required. This leads to a refocussing of the analytes at the 
beginning of the analytical column and reduces peak broadening. After chromatographic 
separation analytes are detected by tandem mass spectrometry with electrospray 
ionization (ESI). Analytes are quantified by isotope dilution using isotope labelled 
analogs of the analytes (in this case ring deuturated paracetamol-d4) as internal 
standards. The use of tandem mass spectrometry and isotope dilution quantification 
leads to high robustness and reduces matrix interferences. The described analysis 
procedure is well established and has been proved in several studies to deliver reliable 
results (Koch et al. 2003; Koch et al. 2007; Kasper-Sonnenberg et al. 2012; Schütze et 
al. 2012). All analysis procedures in this thesis are based on this approach and were 
furthermore developed and modified to fit the analytical requirements, scientific 
questions and designs of the concerning studies and experiments (Chapters II-V). 
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As method validation parameters intra-day precision, day-to-day precision, accuracy 
(relative recovery), limit of detection (LOD) and limit of quantification (LOQ) were 
determined. Method imprecision was proved to be less than 5% in all precision 
experiments, mean accuracies (percent recoveries from spiked urinary samples with 
varying creatinine contents) ranged from 98-102%, underlining reliability of the method 
and absence of interfering matrix effects.  
Creatinine is constantly excreted by the kidney and accumulates in the urine. Low 
hydration leads therefore to highly concentrated urines with a high creatinine level and 
vice versa. Due to this the creatinine concentration gives information about the 
concentration of the urinary matrix and, more important, can be used for normalizing 
concentration values to diminish the influence of urinary dilution on the concentration 
values when comparing spot urine samples (Boeniger et al. 1993). In the present work 
all creatinine concentrations were determined using a Beckman Coulter AU 5822 
analyzer, that determines creatinine based on its color formation reaction with picric acid 
(Jaffé-method)(Jaffe M 1886).  
After this proof of suitability the method was applied to urine samples from 21 volunteers 
in a HBM pilot study. PCM intake of the volunteers was assessed beforehand via 
questionnaire.  
Surprisingly, PCM could be detected and quantified in every urine sample, even in 
samples of volunteers who declared to never have taken PCM. The median PCM 
concentration was 85.7 µg/L, the highest concentration of about 2.2 mg/L was measured 
in the urine sample of one volunteer who quoted to have taken paracetamol during the 
last 24 h before the study. At this time, the sources for the ubiquitous background 
concentrations remained unclear. 
As a final conclusion of the work displayed in Chapter I aniline (phenylamine) was 
suspected as possible source of PCM background concentrations because PCM 
appears as the major metabolite in the metabolism of aniline. It is known from animal 
studies that aniline is mainly excreted in form of glucuronide and sulfate conjugates of 
PCM, plus an additional small amount of unconjugated PCM, in urine summarizing to a 
metabolite share of approx. 56-76% of the aniline dose (Figure 3)(Kao et al. 1978).  
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Figure 3: Mean urinary excretion rates of aniline metabolites in various animal species (pigs, sheep and 
rats) (Kao et al. 1978) 
Aniline itself is an important source material in the chemical industry and is inter alia 
used as a building block in pesticides and colorants and is also contained in cigarette 
smoke as well as indoor and outdoor air (Palmiotto et al. 2001; Human Biomonitoring 
Commission of the German Federal Environment Agency 2011). The ubiquitous 
exposure of the general population to aniline is well known from various HBM studies 
(Lewalter and Korallus 1985; Riffelmann et al. 1995; Ward et al. 1996; Sabbioni and 
Jones 2002; Weiss and Angerer 2002). Chapter I finishes with the conclusion that 
aniline (or aniline releasing substances) possibly play a major role in the ubiquitous 
background excretion of PCM, besides the intake of paracetamol itself, and that further 
investigation of sources is strongly needed. Chapter I is closed with the suggestion to 
determine aniline specific metabolites and paracetamol specific metabolites together with 
paracetamol in future studies (see Chapters II and V).  
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Chapter I was published as peer reviewed paper: Hendrik Modick, André Schütze, 
Claudia Pälmke, Tobias Weiss, Thomas Brüning, Holger M Koch. Rapid determination of 
N-acetyl-4-aminophenol (Paracetamol) in urine by tandem mass spectrometry coupled 
with on-line clean-up by two dimensional turbulent flow/reversed phase liquid 
chromatography.       Journal of Chromatography B 03/2013; 925:33-39. 
 
My contribution to the scientific work presented in Chapter I was: de novo 
development and validation of the analytical method; design, organization and 
conduction of the pilot study; sample collection, administration and analysis; data 
processing and interpretation; writing and revision of the publication. 
 
The original publication of Chapter I is shown in Appendix V.  
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In Chapter II the conclusion of Chapter I is picked up and concretized. The aim of the 
study presented in Chapter II was to further elucidate the origins of the ubiquitous PCM 
excretion and to contribute to the knowledge on human metabolism of aniline (and PCM, 
as the main metabolite of aniline). Therefore, the developed method was modified to 
include the aniline specific metabolite acetanilide, which represents approx. 3% of an 
aniline dose. In previous HBM studies aniline was determined via gas chromatography 
after acidic hydrolysis (hydrochloric acid, 80°C, 1h) of acetanilide into aniline and acetic 
acid (Weiss and Angerer 2002). Additionally the (tentative) aniline metabolite N-acetyl-2-
aminophenol was included for determination and quantification. N-acetyl-2-aminophenol 
was found as an aniline metabolite after incubation in sheep intestine (Turner et al. 
1976), but not after oral administration (Kao et al. 1978). After method validation as 
described above the method was applied to three different sets of sample groups, which 
originated from different exposure scenarios. Group 1 consisted of 31 samples from the 
general population with no known (occupational) exposure to aniline and known not to 
have used PCM containing medication one week before sampling. Group 2 included 
samples from 6 individuals with exposure to aniline (in a simulated occupational setting) 
and no PCM use in the week prior to the study. The exposure of the individuals took 
place at the IPA in a whole body exposure chamber (Monsé et al. 2012). The aniline 
exposure of these individuals determined by air measurements was within the legal limits 
of the German AGW (occupational limit value of 7.7 mg/m3) (Käfferlein et al. 2014). 
Group 3 consisted of samples from two individuals known to have been using PCM- 
containing medication within a day before the study.  
The ubiquitous PCM excretion even without intake of paracetamol or obvious 
(occupational) exposure to aniline was confirmed in this study. Paracetamol was found in 
every sample of group 1 with concentrations ranging from 8.4 to 2263 µg/L and a median 
of 80 µg/L, which is very close to the median found in the study displayed in chapter I. 
Paracetamol was also found in every sample of group 2 but in considerably higher 
concentrations compared to group 1, ranging between 4150 µg/L and 10,885 µg/L 
(median 5720 µg/L). The two samples in group 3 exhibited urinary paracetamol values 
that were in the mg/L range (159 and 275 mg/L) and approx. 15 times higher than the 
maximum concentration value of group 2 and further about 70-120 times higher than the 
maximum value of group 1.  
Unexpectedly, acetanilide was only detected in the urine samples of group 2 in 
concentrations ranging from 41.2 µg/L to 122 µg/L and a median of 78.8 µg/L. These 
levels were about one hundred times lower than the paracetamol levels in the same 
samples. However, with knowledge of previous studies which reported the ubiquitous 
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exposure of aniline in the general population, it was expected to detect acetanilide in at 
least some of the samples of group 1. Taking the paracetamol/acetanilide ratio of 100:1 
from the samples of group 2 into account, the maximum PCM value from group 1 (2263 
µg/L) should have been accompanied by an acetanilide value of about 20 µg/L.  
N-acetyl-2-aminophenol was detected in all samples of group 1 and 2. But apparently 
without any relation to aniline exposure or correlation to paracetamol levels. Individuals 
from group 1 excreted comparable or even higher levels of N-acetyl-2-aminophenol than 
individuals from group 2. The excretion of N-acetyl-2-aminophenol was therefore 
concluded not to be a significant or specific metabolite for aniline exposure.  
From the observations of these experiments four major conclusions were drawn in the 
end of Chapter II:  
(1) Other sources than exposure to aniline may be responsible for the ubiquitous 
paracetamol excretion in the general population, otherwise at least some of the samples 
from the general population would exhibit measurable acetanilide values. Other sources 
may be possible aniline or paracetamol precursors or even paracetamol itself through its 
use in production of food of animal origin. 
(2) Acetanilide is a metabolite of aniline in man. This confirms the findings of the animal 
metabolism studies (Kao et al. 1978). Acetanilide can be used as a valuable and specific 
marker of aniline exposure in occupational settings.  
(3) Urinary aniline levels from the general population, measured after acidic hydrolysis 
(Weiss and Angerer 2002; Human Biomonitoring Commission of the German Federal 
Environment Agency 2011), do not seem to originate from acetanilide and, therefore, not 
from direct exposure to aniline itself. In consequence there have to be other urinary 
precursors than acetanilide, which are hydrolyzed to aniline during the sample 
preparation of these methods. 
(4) N-acetyl-2-aminophenol is not a metabolite of aniline in humans, contradictory to the 
findings of N-acetyl-2-aminophenol being a metabolite after incubation of sheep intestine 
with aniline. 
A final conclusion drawn from the work in Chapter II was, that further investigations 
concerning the human metabolism of aniline and paracetamol and possible linkages 
between them (see Chapters III and V), of food as a possible exposure source (Chapter 
III) and the body burdens of paracetamol in the general population (Chapter III) and 
specific subsets of the population (Chapter IV) are warranted.  
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Chapter II was published as peer review paper: Georg Dierkes, Tobias Weiss, Hendrik 
Modick, Heiko Udo Käfferlein, Thomas Brüning, Holger M Koch. N-acetyl-4-aminophenol 
(paracetamol), N-acetyl-2-aminophenol and acetanilide in urine samples from the 
general population, individuals exposed to aniline and paracetamol users. International 
Journal of Hygiene and Environmental Health 04/2014; 217(4-5): 592–599. 
My contributions to the scientific work presented in Chapter II were: substantial 
support in method development and validation; assistance in study design, 
organization of the study; sample collection, administration and analysis; data 
processing and evaluation; endorsement in the writing and revision process of the 
publication. 
The original publication of Chapter II is shown in Appendix VI.  
Chapter III consists of a review article which gives an overview of the currently available 
data on possible endocrine disrupting effects of paracetamol, its role in aniline 
metabolism, recent HBM data and possible sources of exposure. Additionally this article 
consists of an experimental part. The aim of the work presented in this experimental part 
was to further elucidate the paracetamol excretion in the general population, the 
metabolism of aniline and to investigate food as a source of paracetamol excretion. For 
this reason urinary concentrations of paracetamol and acetanilide were determined 
(using the analytical method from Chapter II) in four different types of experiments: (1) in 
a huge number of urine samples from the general (German) population; (2) after 
therapeutic paracetamol use; (3) after aniline exposure and (4) during a controlled 2-day 
fasting study. The main observations and conclusions from these experiments are 
summarized in the following: 
 
(1) The analysis of 2098 urine samples from the general population confirmed the 
ubiquitous presence of paracetamol in urine which was found in the previous HBM pilot 
studies on a larger scale. Paracetamol was found in every sample analyzed, with a 
median concentration of 61.7 µg/L and a 95th percentile of approx. 4000 µg/L. Urinary 
paracetamol levels were not normally distributed before and after logarithmic 
transformation. After splitting the values into a low exposure group and a high exposure 
group, at the 95th percentile, normal distribution was found for the values in both groups. 
Additionally, because aniline is a known constituent of cigarette smoke (Human 
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Biomonitoring Commission of the German Federal Environment Agency 2011) we 
divided the population into the subgroups of smokers and non-smokers. We found a 
significant difference between the median PCM levels of non-smokers and smokers 
which indicates that smoking may be a possible source for aniline exposure and 
therefore internal body burdens of paracetamol. However, as in the pilot studies, 
acetanilide could not be detected in any of the samples. (2) For investigation of urinary 
elimination characteristics of paracetamol after therapeutic use one individual took a 
single tablet of paracetamol (500 mg). Urine samples were continuously collected over 
the following 48 h and urinary paracetamol levels were quantified. Urinary paracetamol 
levels rose rapidly after intake and maximum concentrations of about 200-400 mg/L were 
reached between 4 and 12 h after intake. Afterwards concentrations declined in a 
monotonic manner, which indicates single-phasic decline, but clearly stayed in the mg/L 
range until about 36 h after dosage. These concentrations are comparable to the findings 
of Chapters I and II from the individuals who had used paracetamol medication the day 
before sampling. Paracetamol concentrations remain above the 95th percentile of the 
general population (~ 4000 µg/L) until about 36-48 h (Figure 4). Considering the 
elimination behavior and the findings from the general population, the concentration level 
of 4000 µg/L was defined as a preliminary cutoff value to distinguish between 
paracetamol background concentrations and concentrations from actual paracetamol 
medication (which took place in the last 36-48 h).  
 
Figure 4: Urinary concentrations of paracetamol following oral intake of a single 500 mg tablet; dotted line 
indicates the preliminary cutoff value 
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(3) Four volunteers were exposed to aniline in a controlled (occupational) exposure 
setting via air for 8 h at the occupational threshold limit value of 2 ppm (7.7 mg/m³ air). 
Exposure took place in the whole body exposure chamber at the IPA (Monsé et al. 2012; 
Käfferlein et al. 2014). Complete urine voids were collected before, during, and for 16 h 
after exposure. Urinary paracetamol and acetanilide concentrations in µg/L and adjusted 
concentrations for creatinine are shown in Figure 5. Before exposure, urinary 
paracetamol levels of the volunteers were comparable to the levels in the general 
population (40-170 µg/L), acetanilide levels were below the LOQ (0.09 µg/L). Urinary 
paracetamol concentrations increased steadily during exposure and peaked at a 
maximum of 10-60 mg/L between 10 and 13 h after beginning of the study (2-5 h after 
end of exposure). Urinary acetanilide concentrations followed a similar pattern, but with 
urinary concentrations of about 100-200 times lower than the paracetamol 
concentrations. However, these findings clearly confirm aniline as a metabolic precursor 
of paracetamol and acetanilide excretion.  
Additionally the findings of this experiment confirm the findings, which were already 
suspected at the end of Chapter II, that acetanilide concentrations in urine can be used 
as a valuable indicator for aniline exposure at the workplace.  
Unfortunately, based on this metabolism data it is not possible to accurately determine 
the conversion ratios of aniline into the investigated metabolites because the dose which 
was actually taken up by the volunteers cannot be determined without uncertainties. 
Knowledge of the metabolic conversion of aniline can only be gathered in a defined 
single dose experiment with an oral dose of aniline (Chapter V). 
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Figure 5: Urinary paracetamol and acetanilide concentration curves of four volunteers during and after 
controlled aniline exposure at the occupational threshold limit value (7.7 mg/ m³ air) 
(4) To investigate the hypothesis of food being a source of paracetamol (either by 
contamination with paracetamol itself or precursors as aniline) urine samples of a 48 h 
fasting study were analyzed for paracetamol and acetanilide concentrations. These 
samples were originally collected to investigate the influence of food intake on the 
excretion of phthalate metabolites and bisphenol A. (Koch et al. 2013b). Four volunteers 
collected full volume urine samples over the course of a 48 h fasting phase as well as 
several samples before and after the time of fasting. During the phase of fasting any 
foodstuff (and food related items e.g. chewing gum) was excluded except for bottled 
water. Urinary paracetamol concentrations adjusted for creatinine are shown in Figure 6. 
At the beginning of the study, urinary paracetamol concentrations are comparable with 
the concentrations from the general population, increase considerably after the pre-fast 
meal and peak at maximum concentrations from 700 to 5000 µg/g creatinine (1100-5300 
µg/L) approx. 2-6 h after the meal. The maximum urinary concentration even exceeded 
the preliminary cutoff value of 4000 µg/L, indicating remaining uncertainties concerning 
this cutoff value. During fasting paracetamol concentrations decreased considerably 
reaching minimum values of 50-70 µg/g creatinine (5-75 µg/L). After the volunteers 
started eating again, paracetamol levels tended to increase again. Acetanilide could not 
be detected in any of the samples.   
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Figure 6: Creatinine adjusted urinary paracetamol concentrations in four volunteers during a 48h fasting 
study on semi-logarithmic scale (A) and normal scale (B) 
Taken together, these findings clearly hint to food as a possible source for internal body 
burdens of paracetamol, even though the question, if this burdens result from direct 
paracetamol intake (by contamination) or aniline intake (or substances releasing aniline 
in human metabolism) or a combination of both, still remains unclear.  
In conclusion, the experimental work in Chapter III confirmed previous suggestions e.g. 
of food being a possible source of exposure, and provides new findings e.g. on the 
ubiquitous body burden of paracetamol, the impact of smoking and acetanilide as marker 
for aniline exposure in the occupational setting.  
However, the definite sources of paracetamol excretion in the general population still 
remain obscure. According to the conducted experiments there exist several possible 
sources: 1) direct intake of paracetamol (primary source for high urinary concentrations 
up to g/L range); 2) (occupational) exposure to aniline; 3) nonpoint exposure from 
environmental sources (food, air); and 4) tobacco smoking, although the impact seems 
to be rather small compared with e.g. food intake.  
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Finally, because of the complexity of the subject, an interdisciplinary approach was 
demanded to investigate the sources, routes and amounts of exposure and to investigate 
and confirm (in mechanistic as well as epidemiological studies) if therapeutic intake or 
even background exposure is a risk factor for male developmental disorders. In this 
connection HBM can play an important role in the assessment of paracetamol exposure 
in specific sensible cohorts (Chapter IV) and in the investigation of differences and 
similarities in aniline and paracetamol metabolism in humans (Chapter V).  
Chapter III was published as peer review paper: Hendrik Modick, Tobias Weiss, Georg 
Dierkes, Thomas Brüning, Holger Koch. Ubiquitous presence of paracetamol in human 
urine: sources and implications. Reproduction 03/2014; 147(4):R105-R117. 
My contribution to the work presented in Chapter III was: literature search, 
organization and survey for the review part of the publication; sample 
administration and analysis for the experimental studies; data evaluation, 
processing and interpretation; writing and revision of the publication. 
 
The original publication of Chapter III is shown in Appendix VII.  
 
 
In Chapter IV the internal body burden of paracetamol in the Danish population was 
investigated. 288 morning urine samples from 6 to 11-year-old Danish school children 
and their mothers were analyzed for paracetamol. These samples originated from the 
European DEMOCOPHES (DEMOnstration of a study to Coordinate and Perform 
Human biomonitoring on a European Scale) project to improve and harmonize HBM in 
Europe (Becker et al. 2014; Schindler et al. 2014). The school children and their mothers 
were recruited from urban (n = 75; Genofte) and rural (n = 70; Viby Sj.) areas in 
Denmark. The children were equally distributed for age and gender. Sample collection 
was carried out in the school nurse premises by trained field workers. The mothers 
answered a basic questionnaire concerning lifestyle, dietary and exposure habits. An 
additional questionnaire regarding self-rated health, pain and the use of OTC-
medications for them and the children was conducted. Samples were collected from 
September to December in 2011. The collection was conducted parallel in the rural and 
urban areas to avoid seasonal variations between the two groups.  
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The work was a cooperation project between the Institute for Prevention and 
Occupational Medicine of the German Social Accident Insurance (IPA) and the Section 
of Occupational and Environmental Health at the Department of Public Health (University 
of Copenhagen). 
All samples were analyzed for their paracetamol concentrations with the method 
described in Chapter II.  
Paracetamol was detected in the samples of all individuals except for one urban child. 
Paracetamol concentrations varied widely between 4.9 µg/L and ~3 g/L (median 120 
µg/L) for the mothers and from not detectable to ~2 g/L (median 27 µg/L) for the children. 
Although there seemed to be a slight tendency for higher concentrations in the urban 
samples, no significant difference could be observed in the concentrations between the 
rural and urban areas neither for the mothers nor for the children (figure 7).  
 
Figure 7: Tukey boxplots of urinary paracetamol concentrations of mother-child pairs from urban and rural 
areas of Denmark; circles indicate values within 1.5-3 fold interquartile range; stars indicate values out of the 
3 fold interquartile range   
 
After applying the soft cutoff value derived from Chapter III a weak but significant 
correlation could be observed between the mother and child pairs in the group <4000 
µg/L. This correlation did not persist in the >4000 µg/L group.  
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In the questionnaires 79 of 130 participating mothers (60.8%) declared never/almost 
never (within the last year) to have taken paracetamol containing medication, whereas 
51 of the mothers (39.2%) declared to have taken paracetamol containing medication at 
least once a month. For their children the mothers declared that 89 of them (68.5%) had 
not taken paracetamol within the last three months.  
Many of the self-declared non-paracetamol users exhibited high urinary paracetamol 
levels (>4000 µg/L), whereas many mothers/children in the user group had values 
comparable to non-users. This is conclusive and caused by uncertainties occurring from 
the cutoff value and the questionnaire. Urinary measurements of paracetamol are, taking 
the excretion kinetics into account, only able to detect recent (within the last 24-48 h) 
paracetamol use, while the questionnaire asked for use during the last three months. On 
the other hand, previous urinary measurements had shown paracetamol levels >4000 
µg/L without use of paracetamol.  
Summarized, the work presented in Chapter IV confirms the findings from previous 
studies of the ubiquitous excretion of paracetamol, this time in a sensible subset from the 
general population (mothers and their children). The work revealed uncertainties in the 
soft cutoff for distinguishing between paracetamol users-and non-users due to 
background concentrations which can exceed the cutoff value even without intake of 
paracetamol and due to the restriction that only exposure which occurred in the last two 
days before sampling is captured. Additionally false positive indications are reported in 
presence of other (not yet known) sources of exposure. For the first time a correlation of 
urinary paracetamol concentrations in mother-child pairs was observed as was already 
reported for phthalate metabolites (Kasper-Sonnenberg et al. 2012). Although this 
correlation was rather weak, it was still statistically significant and therefore indicates that 
exposure might be related to common environment and lifestyle because mothers and 
children usually share same meals and living environments. These findings support 
previous assumptions of e.g. food being a possible source of exposure. Besides other 
sources of exposure, there are many factors contributing to weakening the correlations, 
like inter individual differences and, more likely, general differences in the elimination 
kinetics between adults and children. It is known that children exhibit different metabolite 
shares and slightly prolonged elimination half-lives for paracetamol compared to adults 
(Peterson and Rumack 1978). Thus, since in this study morning urine samples, collected 
several hours after the last exposure, different elimination half-lives might lead to 
distortions when comparing the concentration values between mothers and children. 
These effects could be moderated by analyzing pooled urines (over 24 h) from mother-
child pairs, which could be conducted in a prospective study. This could be supported by 
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parallel ambient monitoring of the living environments (air sampling, house dust) to see if 
correlations can be observed between environmental aniline concentrations and urinary 
paracetamol concentrations. This approach, of course, could be also used to assess 
work place exposure as well.  
Chapter IV was published as peer review paper: Jeanette K.S. Nielsen, Hendrik Modick, 
Thit A. Mørck, Janne F. Jensen, Flemming Nielsen, Holger M. Koch, Lisbeth E. 
Knudsen:           N-acetyl-4-aminophenol (paracetamol) in urine samples of 6-11-year-old 
Danish school children and their mothers, International Journal of Hygiene and 
Environmental Health, 218 (2015) 28-33, DOI: 
http://dx.doi.org/10.1016/j.ijheh.2014.07.001 
My contribution to the work presented in Chapter IV was: sample preparation, 
analysis and evaluation; correspondence with cooperation partners; writing 
(analytical) method section of the publication and parts of discussion and 
conclusion section; general support in writing and revision of the publication.  
The original publication of Chapter IV is shown in Appendix VIII.  
To assess exposure and to calculate from a urinary concentration to an actual absorbed 
dose, it is essential to know the urinary conversion factors of the concerning substance 
and its corresponding metabolites. For aniline, urinary conversion factors, until now, 
were only available from animal studies conducted over 30 years ago (Kao et al. 1978). 
On account of this, the aim of the work presented in Chapter V was to investigate the 
urinary conversion and metabolism kinetics of aniline in humans based on a single oral 
dose with modern analysis techniques (HPLC-MS/MS and GC-MS methods with isotope 
dilution quantification). Additionally, for the first time, parallels in aniline and paracetamol 
metabolism were investigated by determination of a metabolite which has by now only 
been reported in connection with paracetamol metabolism (paracetamol-3-
mercapturate). Additionally the influence of the N-acetyltransferase 2 (NAT2) enzyme, 
which catalyzes the acetylation of the amino group, on the metabolism was investigated. 
Due to polymorphisms in the NAT2 enzymes in humans two classes (phenotypes) exist, 
distinguishing between fast and slow acetylators (Wolf et al. 1980; Lewalter and Korallus 
1985), which was reported to have an influence in individual susceptibility to aromatic 
amine induced cancers (Hein et al. 1992).  
Because of the ubiquitous background concentrations of paracetamol and aniline 
exposure, aniline was administered in isotope labelled (ring deuturated) form, and is 
hence metabolized to isotope labelled metabolites, which facilitates highly specific 
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determination. An overview of the target analytes and internal standards used for 
quantification is shown in Figure 8.  
Target analytes were free aniline (as aniline-d5), acetanilide (as acetanilide-d5), 
paracetamol (as paracetamol-d4) and paracetamol mercapturic acid (paracetamol 
mercapturic acid-d3). Aniline and acetanilide are both specific markers for aniline 
exposure. Paracetamol, after enzymatic hydrolysis of conjugates, is a known metabolite 
of aniline as well as paracetamol. Paracetamol mercapturic acid was chosen as target 
metabolite because it has, until now, only been investigated in connection with 
paracetamol metabolism and has not been subject to investigation in the context of 
aniline metabolism. After therapeutic use approx. 3% of the paracetamol dose has been 
described to be excreted as the mercapturic acid conjugate (Ladds et al. 1987). Since 
paracetamol was reported to be the major metabolite of aniline in animal studies with 
approx. 56-76% (Kao et al. 1978) the formation of the mercapturic acid of paracetamol 
during the metabolism of aniline is highly likely and was therefore subject to 
investigation. Formation of the mercapturic acid would be of important toxicological 
relevance because this would hint to reactive intermediates (Prescott 1980).  
For the investigation of aniline metabolism four healthy male volunteers (30-32 years old, 
71 – 95 kg, non-smokers), with various acetylation phenotypes (2 fast, 2 slow) were 
dosed orally with each 5 mg of isotope labelled aniline-d5. An application for ethics 
approval was written and submitted to the ethics commission of the Ruhr-University 
Bochum. The study was approved by the ethics commission in August 2013 (Reg.No. 
4333-12). After dosage, complete urine voids were collected over the following 48 h and 
time and volume of each void was documented by the volunteers. Additionally, from 
each volunteer one urine sample was collected before dosing. 
 
Introduction 
21 
 
Figure 8: Metabolism of aniline (as aniline-d5) showing the target analytes and their corresponding internal 
standards; * indicate spots in the molecule where the isotope labelling is located 
 
Aniline was determined by a well-established GC-MS method (Weiss and Angerer 2002) 
with o-toluidine-d7 used as internal standard for quantification.  
Acetanilide, paracetamol and paracetamol mercapturic acid were determined via HPLC-
MS/MS. Isotope labelled analogs of the target analytes, with labelling spots and 
molecular masses different from the target analytes, were used as internal standards for 
quantification. HPLC-MS/MS analysis was based on the methods described in Chapters 
I and II, but was modified to fit the requirements of the present study.  
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Figure 9: Urinary concentrations of aniline and aniline metabolites adjusted for creatinine on semi-
logarithmic scale; black graphs represent fast acetylators, grey graphs slow acetylators 
 
The urinary excretion kinetics of the metabolites are shown in Figure 9. After dosage 
paracetamol and its mercapturic acid conjugate were detectable in all urine samples 
throughout the whole duration of the study. Aniline and acetanilide were rapidly excreted 
and were only detectable during the first 12 h of the study. This is reflected in the 
elimination half-lives of the metabolites which showed a rather small variation between 
the volunteers but differed considerably between the metabolites. Aniline and acetanilide 
were rapidly excreted with elimination half-lives of 0.6-1.2 h (based on creatinine 
adjusted values). Elimination half-lives of paracetamol were considerably longer with 3.4-
4.3 h, whereas the mercapturic acid of paracetamol showed the slowest elimination, 
exhibiting half-lives of 4.1-5.5 h.  
It can be observed that elimination half-lives are prolonged with increasing complexity of 
the metabolites and more transformation steps needed to build the metabolites. 
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Figure 10: Urinary conversion factors of aniline and aniline metabolites calculated as molar equivalents of 
the aniline dose in % 
 
The dose shares of the metabolites on the aniline dose are given in Figure 10. 
Paracetamol was by far the major metabolite representing 55.7-69.8% of the dose. The 
mercapturic acid conjugate of paracetamol accounted for 2.5-6.1% of the dose, whereas 
acetanilide and aniline constituted minor metabolites, both with dose shares between 
0.14 and 0.36%. These findings are in good accordance with the data known from 
animal studies (Kao et al. 1978). In sum 62.4-72.7% of the aniline dose was recovered in 
form of the investigated metabolites. 
It can only be speculated about the remaining dose share. Since paracetamol-3-
mercapturate has until now only been subject to investigation in context of paracetamol 
and not aniline metabolism, formation of other known paracetamol metabolites can be 
expected e.g. paracetamol-3-cysteine and 3-hydroxyparacetamol-4-sulfate which 
represent a share of 0.6-13.7% and 0.4-4.8 of a given paracetamol dose (Ladds et al. 
1987). Furthermore, excretion of reported aniline metabolites is expected e.g. conjugates 
of ortho- and para-aminophenol, which represent ~ 20% of an oral aniline dose (Kao et 
al. 1978).  
Acetylation phenotype of the volunteers showed no influence regarding elimination 
kinetics and urinary conversion factors of paracetamol and paracetamol-3-mercapturate, 
whereas the urinary conversion from aniline to acetanilide was about 1.5 to 2 times 
higher in the two fast acetylators (0.31% and 0.36%) than in the two slow acetylators 
(0.16% and 0.19%). The same pattern was observed for the urinary maximum 
concentrations of acetanilide. The acetylation status has to be taken into account in 
exposure assessment of aniline by urinary acetanilide measurements. Because, 
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according to these findings, in slow acetylators the aniline dose has to be 1.5-2 times 
higher to reach the same urinary acetanilide concentrations as a fast acetylator. 
Taken together, the study presented in Chapter V is the first to investigate human 
metabolism of aniline and to make a linkage between the metabolism paths of aniline 
and paracetamol. These findings will in the future contribute to exposure- and risk-
assessment of aniline and its major metabolite paracetamol in occupational as well as in 
environmental settings.  
 
Chapter V was submitted and is currently under review for publication in Archives of 
Toxicology. 
 
My contribution to the work presented in Chapter V was: support in study design 
and planning; support in writing of the ethics approval application; support in 
development of the analytical method (HPLC); method validation (HPLC); study 
conduction, sample collection, sample preparation and analysis (HPLC method); 
data processing, evaluation and interpretation; writing and revision of the 
publication.  
 
The pdf-file for approval of the submitted manuscript of Chapter IV is shown in 
Appendix IX.  
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Einleitung 
Der Begriff Human Biomonitoring (HBM) wird definiert als die quantitative Bestimmung 
chemischer Substanzen und/ oder ihrer Metaboliten in biologischen Medien zur 
Expositionserfassung. Im Gegensatz zum Umgebungsmonitoring (der Bestimmung 
chemischer Substanzen in z.B. Raumluft, Wasser etc.) erfasst das HBM alle möglichen 
Expositionswege (inhalativ, dermal, oral) und relevanten Expositionsquellen (Luft, 
Nahrung, dermaler Kontakt, Abbildung 1), was das HBM zu einem wichtigen Instrument 
zur Risikoabschätzung und zum Risikomanagement macht. Durch das HBM lassen sich 
chemische Expositionen, deren zeitliche Schwankungen und ihre Verteilungen in 
bestimmten Gruppen oder Untergruppen der Bevölkerung erfassen (Angerer et al. 2007; 
Angerer 2012). 
 
Abbildung 1: Umgebungs- und biologisches Monitoring 
Im HBM stellt Urin das bevorzugte Analysenmaterial dar, da es non-invasiv unter 
Routinebedingungen einfach und in ausreichender Menge gesammelt werden kann ohne 
beim Spender übermäßige Unannehmlichkeiten zu verursachen. Blut ist ebenfalls eine 
gern gewählte Matrix, hat jedoch eine invasive Probenahme, welche nur von 
qualifiziertem und autorisiertem Personal durchgeführt werden kann, zum Nachteil. 
Andere biologische Medien, wie Haar, Ausatemluft, Fingernägel, Speichel und sogar 
Zähne wurden bereits in HBM-Studien verwendet. Defizite bei der Verwendung dieser 
Matrizes in HBM-Studien entstehen unter anderem durch eine komplexere 
Probenaufarbeitung, Kontaminationsanfälligkeit, reduzierte Erhältlichkeit (z.B. Zähne) 
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und vor allem aus dem Mangel an standardisierten Aufarbeitungs- und 
Analysevorschriften (standard operating procedures oder SOPs) und Möglichkeiten der 
externen Qualitätssicherungsmaßnahmen, was zu Unsicherheiten in der Interpretation 
und der Verlässlichkeit von HBM-Daten aus diesen Matrizes führt (Angerer et al. 2007). 
Die erste HBM-Studie wurde in den 70er Jahren durchgeführt. Dabei wurde die 
Konzentration an Blei in Blutproben eines größeren Bevölkerungskollektivs mittels 
Atomabsorptionsspektroskopie bestimmt, wobei sich herausstellte, dass die 
Allgemeinbevölkerung industrialisierter Länder in hohem Maße gegenüber Blei exponiert 
war. In Folge dessen wurde der Bleigehalt in Benzin beschränkt und HBM-Methoden 
verwendet, um die Wirksamkeit der Beschränkungen zu kontrollieren. 1977 erließ die 
Kommission der europäischen Gemeinschaften die Verordnung 77/312/EEC „über das 
Screening der Bleibelastung der Bevölkerung. (Rat der Europäischen Gemeinschaft 
1977; Angerer et al. 2007). 
Heutzutage existiert eine Vielzahl an standardisierten Analysevorschriften, welche von 
der Arbeitsgruppe "Analysen im biologischen Material“ (AIBM) der Kommission zur 
Prüfung gesundheitsschädlicher Arbeitsstoffe der Deutschen Forschungsgemeinschaft 
(DFG) elaboriert, gesammelt und publiziert werden. Derzeit umfasst die AIBM-
Sammlung etwa 140 Methoden, welche bezüglich ihrer analytischen Verlässlichkeit und 
Reproduzierbarkeit geprüft wurden, für die Bestimmung von mehr als 200 Parametern 
(Angerer et al. 2007), unter anderem polyzyklische aromatische Kohlenwasserstoffe, 
Phthalate, Organophosphatpestizide, aromatische Amine, Marker zur Erfassung von 
Passivrauch und perfluorierte Kohlenstoffverbindungen (Weiss and Angerer 2002; Koch 
et al. 2003; Federal Environment Agency 2006; Calafat et al. 2006; Center for Disease 
Control 2009). 
Das HBM und die zugehörigen Analysemethoden werden ständig aktualisiert und um 
spezielle Substanzen oder Substanzklassen erweitert z.B. bei der Markteinführung neuer 
chemischer Stoffe oder wenn für bestimmte Stoffe neue toxikologische Erkenntnisse 
erlangt werden. Neuere HBM-Methoden wurden z.B. entwickelt zur Erfassung der 
Belastung mit Di(isononyl)cyclohexan-1,2-dicarboxylat (DINCH), einem Phthalat-
Ersatzprodukt (Schütze et al. 2012), N-ethyl-2-pyrrolidon (NEP), ein industriell genutztes 
Lösemittel zum Ersatz von N-methyl-2-pyrrolidone (NMP), das wegen 
entwicklungstoxischer Effekte in Nagern in die Kritik geraten ist (Koch et al. 2013a), und 
Parabenen, den Estern der para-Hydroxybenzoesäure, welche ebenfalls wegen 
möglicher reproduktions- und entwicklungstoxischer Effekte im Fokus der 
Aufmerksamkeit stehen (Moos et al. 2014). 
Einleitung 
27 
Medikamente stellen eine weitere Klasse von Substanzen dar, welche bereits seit 
geraumer Zeit im Umweltmonitoring erfasst werden und deren Rückstände und 
Metaboliten zunehmend in der aquatischen und der terrestrischen Umwelt 
nachgewiesen werden können (Benotti et al. 2009; López-Serna et al. 2010; Deblonde et 
al. 2011).  
Paracetamol ist eines der meistbekannten schmerzlindernden und fiebersenkenden 
Medikamente das landläufig verwendet und, da es nicht verschreibungspflichtig ist, 
weltweit in großen Mengen verkauft und konsumiert wird. Im Jahr 2008 enthielten zwei 
der zehn in Deutschland meistverkauften Medikamente Paracetamol (Landschneider 
2011). Laut der „Roten Liste“, dem deutschen Arzneimittelverzeichnis, sind für den 
deutschen Markt 55 Medikamente zugelassen, die Paracetamol enthalten (Glaeske et al. 
2009). Allein in Spanien wurden im Jahr 2009 über 35 Millionen Packungen 
Paracetamol, jede mit 20 oder 40 Tabletten Inhalt, verkauft (Ortiz García et al. 2013). 
127 Millionen definierte Tagesdosen (defined daily doses; DDD) Paracetamol wurden im 
Jahr 2010 in Dänemark verkauft (The Danish National Institute of Public Health 2012). 
Dies entspricht umgerechnet etwa 762 Millionen Tabletten (500 mg) und bezogen auf die 
Einwohnerzahl etwa einer Tablette pro Einwohner etwa jeden dritten Tag (Nielsen et al. 
2014). Darüber hinaus ist Paracetamol in der Europäischen Union als Tierarzneimittel, 
für Tiere die der Lebensmittelgewinnung dienen, zugelassen. Eine spezifische 
Rückstandshöchstmenge, ab welcher das betreffende Lebensmittel nicht mehr 
verkehrstauglich ist, wurde von der EU nicht festgelegt (European Commission 2010}. 
Auch wenn die Verwendung von Paracetamol als Tierarzneimittel auf die Verwendung in 
Schweinen beschränkt ist, gibt es Hinweise, dass ebenfalls eine Verwendung bei der 
Behandlung von Rindern und Geflügel erfolgt (Committee for veterinary medicinical 
products 1999; European Commission 2010). In einer kürzlich veröffentlichten Pilotstudie 
wurde Paracetamol in Milchproben aus Kanada nachgewiesen, wenn auch in geringen 
Konzentrationen zwischen 1,5 und 2 ng/g (Baron et al. 2014). 
Paracetamol werden nur geringe Nebenwirkungen zugeschrieben weswegen dessen 
Einnahme in therapeutischen Dosen generell als sicher angesehen wird. Allerdings sind 
Überdosierungen von Paracetamol einer der Hauptgründe für akutes Leberversagen in 
Industrieländern (Tonoli et al. 2012). 
Für die Behandlung von Schmerzen und Fieber während der Schwangerschaft ist 
Paracetamol das von der US Lebens- und Arzneimittelbehörde (US EPA) für alle 
Trimester empfohlene Medikament (Black and Hill 2003; Thiele et al. 2013). In 
Übereinstimmung deuten die Ergebnisse verschiedener größerer 
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Geburtskohortenstudien darauf hin, dass Paracetamol (sowie milde Analgetika generell) 
von etwa 30-80% (in Abhängigkeit der Studie; siehe Kapitel III) der schwangeren 
Frauen, mindestens einmal während der Schwangerschaft eingenommen wird. Da 
Paracetamol die Plazentaschranke überwinden kann, wird, durch die Einnahme der 
Mutter, auch das Ungeborene gegenüber Paracetamol exponiert (Levy et al. 1975). 
Seit dem Jahr 2002, als eine britische Forschergruppe über einen möglichen 
Zusammenhang zwischen der Einnahme von Paracetamol während der 
Schwangerschaft und einem erhöhten Asthmarisiko bei Kleinkindern berichtete 
(Shaheen et al. 2002), steht Paracetamol zunehmend im wissenschaftlichen Fokus 
hinsichtlich möglicher unerwünschter Nebenwirkungen während der Schwangerschaft, 
wie ein erhöhtes Asthmarisiko (Shaheen et al. 2002; Scialli et al. 2010b; Andersen et al. 
2012b, 2012a; Gonzalez-Barcala et al. 2012; Persky et al. 2008), genitale Fehlbildungen 
(Abe et al. 2003; Jensen et al. 2010; Philippat et al. 2011; Rebordosa et al. 2009; 
Rebordosa et al. 2008; Snijder et al. 2012; Thiele et al. 2013; Scialli et al. 2010a) und 
Beeinträchtigungen der neuronalen Entwicklung (Brandlistuen et al. 2014). Der Verdacht 
der endokrinen Wirksamkeit von Paracetamol wurde durch die Ergebnisse einiger in 
vitro, ex vivo und tierexperimenteller Studien erhärtet, die potentielle endokrine 
Wirkmechanismen von Paracetamol wie z.B. eine Hemmung der Testosteronproduktion 
und Inhibierung der Prostaglandinsynthese nachweisen konnten (Albert et al. 2013; 
Christiansen et al. 2012; Kristensen et al. 2010; Kristensen et al. 2012; Kristensen et al. 
2011).  
Aufgrund dieser neuen toxikologischen Erkenntnisse sollte eine analytische Methode für 
die Bestimmung von Paracetamol in Urin mittels 
Hochleistungsflüssigkeitschromatographie gekoppelt mit Tandem-Massenspektrometrie 
(HPLC-MS/MS) für HBM-Zwecke entwickelt werden, mit dem Ziel, die Belastung der 
Allgemeinbevölkerung für eine fundierte Expositions- und Risikoabschätzung zu 
erfassen (Kapitel I).  
Da Paracetamol hauptsächlich in Form von Glucuronid- und Sulfatkonjugaten 
ausgeschieden wird, welche insgesamt einem Dosisanteil von etwa 80% entsprechen 
(Prescott 1980), wurde Paracetamol als Zielanalyt nach enzymatischer Hydrolyse der 
Konjugate ausgewählt. Für den Einsatz in HBM-Studien standen hinsichtlich des 
Methodendesigns verschiedene Anforderungen im Fokus: Schnelligkeit und ein geringer 
Aufwand bei der Probenvorbereitung, um einen hohen Probendurchsatz zu 
gewährleisten; ein großer linearer Arbeitsbereich um kürzlich aufgetretene Expositionen 
(z.B. direkte Einnahme von Paracetamol) und länger zurück liegende Expositionen, 
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sowie mögliche Hintergrundbelastungen erfassen zu können; hohe Empfindlichkeit und 
Selektivität. 
Die Reduzierung der erforderlichen Probenaufarbeitung (mit Ausnahme der 
enzymatischen Hydrolyse und grober Aufreinigung) wurde durch die Verwendung eines 
Aufbaus mit zwei chromatographischen Säulen und einem Schaltventil erreicht, womit 
die Anreicherung und Aufreinigung der Proben online erfolgt.  
Hierbei werden die Analyten, nach Injektion in das HPLC-System, auf der ersten Säule 
(Anreicherungssäule) retardiert, während Matrixkomponenten von der Säule nicht 
zurückgehalten und somit in den Abfall gespült werden (Abbildung 2; Ventil Position A). 
 
 
Abbildung 2: Zwei-Säulen-HPLC Aufbau mit Schaltventil (A) Aufreinigung und Anreicherung, (B) 
chromatographische Trennung und Detektion 
 
Nach dem Umschalten des Ventils in Position B werden die Analyten in 
entgegengesetzter Flussrichtung (Backflush) von der Anreicherungssäule eluiert. Hierfür 
muss die Fließmittellzusammensetzung so gewählt werden, dass einerseits die Analyten 
von der Anreicherungssäule eluiert werden aber noch keine Elution oder Trennung auf 
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der analytischen Säule stattfindet. Dies führt zu einer Refokussierung der Analyten am 
Anfang der analytischen Säule und zu einer Verringerung der Peakverbreiterung, und 
somit zu schärferen Peaks und, infolgedessen zu einer besseren Trennung. Um dies zu 
gewährleisten, werden Säulen mit unterschiedlichem Retentionsverhalten oder 
unterschiedlicher Selektivität benötigt.   
 
Nach der chromatographischen Trennung werden die Analyten mittels Tandem-
Massenspektrometrie und Elektrospray Ionisation (ESI) detektiert. Die Quantifizierung 
erfolgt mittels Isotopenverdünnungsanalyse unter der Verwendung von 
isotopenmarkierten Strukturanaloga (in diesem Fall ringdeuteriertes Paracetamol-d4) der 
Analyten. Die Verwendung von Tandem-Massenspektrometrie und 
Isotopenverdünnungsquantifizierung führt zu einer hohen Robustheit der 
Analysemethode und einer Verringerung störender Matrixeffekte.  
Der beschriebene Analysenaufbau ist gut etabliert und hat sich in einer Vielzahl von 
Studien bewährt, um sichere und verlässliche Analysenergebnisse zu liefern (Koch et al. 
2003; Koch et al. 2007; Kasper-Sonnenberg et al. 2012; Schütze et al. 2012). Alle 
Analyseprozeduren in der vorliegenden Arbeit basieren auf diesem Aufbau und wurden, 
je nach analytischen Anforderungen, wissenschaftlichen Fragestellungen und Designs 
der jeweiligen Studien und Experimente, weiterentwickelt und angepasst (Kapitel II-V). 
Zur Methodenvalidierung wurden die Präzision in Serie, die Präzision von Tag zu Tag, 
die Wiederfindungsrate (relative Wiederfindung) sowie Nachweis- und 
Bestimmungsgrenzen ermittelt. Die relativen Standardabweichungen der Methode für die 
Bestimmung von Paracetamol in Urin lagen bei allen durchgeführten 
Validierungsexperimenten unter 5%, die durchschnittliche relative Wiederfindung 
(ermittelt durch Analyse dotierter Urinproben mit verschiedenen 
Kreatininkonzentrationen) lag zwischen 98-102%, was die Verlässlichkeit der Methode 
und die Abwesenheit störender Matrixeffekte unterstreicht. 
Kreatinin (2-Imino-1-methylimidazolidin-4-on) wird mit konstanter Rate von den Nieren 
gebildet, ausgeschieden und im Urin akkumuliert. Geringe Flüssigkeitszufuhr führt daher 
zu höher konzentrierten Urinen mit hohen Kreatiningehalten und umgekehrt. Der 
Kreatiningehalt gibt daher Aufschluss über die Konzentration der Urinmatrix und, noch 
wichtiger, kann über den Kreatiningehalt die Konzentration an Substanzen im Urin 
normiert werden, was den Einfluss der Wasserzufuhr und Verdünnungsgrad des Urins 
verringert und die Vergleichbarkeit zwischen Einzelurinproben gewährleistet (Boeniger et 
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al. 1993). In der vorliegenden Arbeit wurden alle Kreatininkonzentrationen unter 
Verwendung eines Beckman Coulter AU 5822 Analysators ermittelt. Dieser bestimmt 
Kreatinin im Urin über seine Farbreaktion mit Pikrinsäure (auch Jaffé-Reaktion) (Jaffé 
1886). 
Nachdem die Tauglichkeit der Methode nachgewiesen wurde, wurden in einer HBM-
Pilotstudie Urinproben von 21 Freiwilligen auf deren Gehalte an Paracetamol untersucht. 
Vor der Untersuchung wurde die Einnahme von Paracetamol seitens der Probanden per 
Fragebogen ermittelt. Entgegen der Erwartungen konnte Paracetamol in jeder der 21 
Proben nachgewiesen und quantifiziert werden, sogar in Proben bei denen die 
Probanden angegeben hatten, noch nie Paracetamol eingenommen zu haben. Die 
Paracetamolkonzentrationen lagen im Median bei 85,7 µg/L, die höchste Konzentration 
wies eine Probe auf, bei welcher der Proband angegeben hatte, Paracetamol innerhalb 
der letzten 24 h vor Probennahme zu sich genommen zu haben, diese lag bei 22,1 mg/L. 
Die Quellen für die Belastungen der übrigen Probanden mit Paracetamol blieben unklar. 
Die Arbeit, die in Kapitel I wiedergegeben wird, schließt mit der Annahme, dass Anilin 
(Phenylamin) eine mögliche Quelle für die Hintergrundbelastungen mit Paracetamol 
darstellt. Aus Metabolismusstudien an Versuchstieren ist bekannt, dass Anilin 
hauptsächlich in Form von Glucuronid- und Sulfatkonjugaten, sowie einem kleinen Anteil 
an nicht-konjugiertem Paracetamol, mit einem Dosisanteil von insgesamt 56-76% über 
den Urin ausgeschieden wird (Abbildung 3)(Kao et al. 1978). 
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Abbildung 3: Durchschnittliche Eliminationsraten von Anilinmetaboliten in verschiedenen Tierarten 
(Schweine, Schafe und Ratten) nach Kao et al. 1978 
 
 
Anilin ist ein wichtiges Ausgangsmaterial und Intermediat in der chemischen Industrie. 
Es findet unter anderem Anwendung als Baustein von Pestiziden und Farbstoffen und ist 
enthalten in Zigarettenrauch und nachweisbar in Innenraum- und Außenluft (Palmiotto et 
al. 2001; Human Biomonitoring Kommission des Umweltbundesamtes 2011). Die 
ubiquitäre Belastung der Allgemeinbevölkerung mit Anilin ist durch diverse HBM-Studien 
hinlänglich bekannt und erwiesen (Lewalter und Korallus 1985; Riffelmann et al. 1995; 
Ward et al. 1996; Sabbioni und Jones 2002; Weiss und Angerer 2002). Kapitel I wird 
daher mit der Vermutung abgeschlossen, dass Anilin (oder Substanzen, die Anilin 
freisetzen können) bei der Entstehung der Hintergrundbelastung mit Paracetamol, neben 
der direkten Einnahme von Paracetamol als Medikament, eine wichtige Rolle spielen 
und weitere Untersuchungen dringend notwendig sind. Das Kapitel wird beendet mit 
dem Ausblick, in zukünftigen Studien Anilin-spezifische Metaboliten und Paracetamol-
spezifische Metaboliten zusammen mit Paracetamol selbst zu erfassen und zu 
quantifizieren (siehe Kapitel II und V). 
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Kapitel I wurde veröffentlicht als Peer-Review-Publikation: 
Hendrik Modick, André Schütze, Claudia Pälmke, Tobias Weiss, Thomas Brüning, 
Holger M Koch. Rapid determination of N-acetyl-4-aminophenol (Paracetamol) in urine 
by tandem mass spectrometry coupled with on-line clean-up by two dimensional 
turbulent flow/reversed phase liquid chromatography. Journal of Chromatography B 
03/2013; 925:33-39.  
Meine Beiträge zu der in Kapitel I dargestellten wissenschaftlichen Arbeit 
beinhalteten: Entwicklung und Validierung der Analysenmethode; Design, 
Organisation und Durchführung der Pilotstudie, Probensammlung, Organisation 
und Analyse; Datenauswertung und Interpretation; Schreiben, Überarbeiten und 
Durchführung des Veröffentlichungsprozesses der Publikation. 
Die Originalpublikation zu Kapitel I ist in Anhang V dargestellt.  
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In Kapitel II werden die Schlussfolgerungen aus Kapitel I aufgegriffen und konkretisiert. 
Ziel der Studie in Kapitel II war es, die Ursachen der in Kapitel I nachgewiesenen 
ubiquitären Hintergrundbelastungen von Paracetamol weiter zu untersuchen, sowie im 
Allgemeinen neue Erkenntnisse bezüglich des Humanmetabolismus von Anilin zu 
sammeln. Aus diesem Grund wurde die bestehende analytische Methode zur Erfassung 
von Paracetamol im Urin modifiziert und um den Anilin-spezifischen Metaboliten 
Acetanilid erweitert, welcher etwa 3% der aufgenommenen Anilindosis entspricht. In 
früheren HBM-Studien wurde Anilin mittels Gaschromatographie nach der sauren 
Hydrolyse von Acetanilid (HCl, 80°C für 1 h) in Anilin und Essigsäure bestimmt (Weiss 
und Angerer 2002). Darüber hinaus wurde vermutet, dass im Metabolismus von Anilin 
auch N-Acetyl-2-aminophenol (nach N-Acetylierung von 2-Aminophenol) entstehen 
kann. Dieser Parameter wurde ebenfalls in die Analysemethode übernommen. N-Acetyl-
2-aminophenol wurde als Metabolit nach der Inkubation von Schafsinnereien mit Anilin 
nachgewiesen (Turner et al. 1976), nicht jedoch nach oraler Verabreichung von Anilin 
(Kao et al. 1978). Nach Durchführung der  Methodenvalidierung (analog wie in Kapitel I 
beschrieben) wurde die entwickelte Methode auf drei verschiedene Gruppen von Proben 
angewendet. Gruppe 1 bestand aus insgesamt 31 Urinproben aus der 
Allgemeinbevölkerung. Die Personen in dieser Gruppe hatten keine bekannte 
(arbeitsplatzbezogene) Exposition gegenüber Anilin, darüber hinaus fand mindestens 
seit einer Woche vor Probenahme keine Einnahme von Paracetamol statt. Gruppe 2 
beinhaltete Urinproben von sechs Personen unmittelbar nach (simulierter) 
arbeitsplatzbezogener Exposition gegenüber Anilin, jedoch ohne Einnahme von 
Paracetamol mindestens eine Woche vor Probennahme. Die Exposition der Individuen in 
Gruppe 2 wurde in einer Expositionskammer am IPA durchgeführt (Monsé et al. 2012). 
Die Exposition der Individuen, bestimmt durch Luftmessungen, lag hierbei innerhalb der 
erlaubten Grenzen des deutschen Arbeitsplatzgrenzwertes von 2 ppm (7,7 mg Anilin/ m³ 
Luft) (Käfferlein et al. 2014). Gruppe 3 beinhaltete Proben von zwei Individuen, welche 
innerhalb der letzten 24 h vor Probenahme Paracetamol eingenommen hatten. 
Die ubiquitäre Belastung der Allgemeinbevölkerung mit Paracetamol konnte durch die 
Untersuchungen dargestellt in Kapitel II bestätigt werden. Paracetamol konnte in jeder 
Probe aus Gruppe 1 im Konzentrationsbereich von 8,4-2263 µg/L und einem Median von 
80 µg/L gefunden werden, wobei sowohl Konzentrationsbereich als auch Median sehr 
gut mit den Werten der Arbeit in Kapitel I übereinstimmen. Paracetamol konnte auch in 
jeder Probe aus Gruppe 2 bestimmt werden. Mit Konzentrationen zwischen 4150 µg/L 
und 10.885 µg/L (Median 5720 µg/L) lagen diese Werte jedoch erheblich höher als in 
Gruppe 1. Die zwei Proben in Gruppe 3 wiesen Paracetamol-Konzentrationen im 
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höheren mg/L-Bereich (159 und 275 mg/L) auf und lagen damit etwa um das 15-fache 
höher als die Werte in Gruppe 2 und um etwa das 70 bis 120-fache höher als in Gruppe 
1.  
Acetanilid konnte, unerwarteter Weise, lediglich in den Urinproben aus Gruppe 2 in 
einem Konzentrationsbereich von 41,2 µg/L bis 122 µg/L und einem Median von 78,8 
µg/L nachgewiesen werden. Die Konzentrationen betrugen damit etwa ein Hundertstel 
der Paracetamolkonzentrationen. Mit dem Wissen aus vorherigen Studien über die 
ubiquitäre Hintergrundbelastung der Allgemeinbevölkerung mit Anilin wurde erwartet, 
Acetanilid in zumindest einigen Proben aus Gruppe 1 nachzuweisen. Unter 
Berücksichtigung der Verhältnisse von Paracetamol zu Acetanilid in den Proben aus 
Gruppe 2 von ca. 100:1, wäre zu erwarten, dass der Paracetamol-Maximalwert aus 
Gruppe 1 (2263 µg/L) mit einem Acetanilidgehalt um die 20 µg/L einhergeht.   
N-Acetyl-2-aminophenol wurde in allen Proben der Gruppen 1 und 2 nachgewiesen, 
jedoch ohne erkennbaren Zusammenhang mit der Exposition gegenüber Anilin oder den 
Konzentrationen an Paracetamol. Die Proben der Gruppe 1 wiesen ähnliche und sogar 
höhere Konzentrationen an N-Acetyl-2-aminophenol auf als die der Gruppe 2. Bei N-
Acetyl-2-aminophenol scheint es sich aufgrund dieser Ergebnisse daher nicht um einen 
bedeutenden oder spezifischen Metaboliten von Anilin zu handeln. 
Aus den Beobachtungen dieser Experimente werden am Ende von Kapitel II vier 
Schlussfolgerungen gezogen: 
(1) Neben der Exposition gegenüber Anilin gibt es noch andere Quellen für die 
Belastung mit Paracetamol in der Allgemeinbevölkerung, andernfalls würden zumindest 
einige der Proben aus der Allgemeinbevölkerung messbare Konzentrationen an 
Acetanilid aufweisen. Bei diesen anderen Quellen könnte es sich um Anilin- oder 
Paracetamol- freisetzende Substanzen handeln oder sogar Paracetamol selbst durch die 
Anwendung in der Erzeugung tierischer Lebensmittel.  
(2) Acetanilid ist ein Produkt des Humanmetabolismus von Anilin, was die Ergebnisse 
der tierexperimentellen Metabolismusstudien bestätigt (Kao et al. 1978). Acetanilid kann 
daher als verlässlicher und spezifischer Indikator für eine Exposition gegenüber Anilin 
(am Arbeitsplatz) verwendet werden.  
(3) Die Anilinkonzentrationen in Urinproben der Allgemeinbevölkerung, bestimmt nach 
saurer Hydrolyse, (Weiss und Angerer 2002; Human Biomonitoring Kommission des 
Umweltbundesamtes 2011) stammen nicht zwangsläufig aus hydrolysiertem Acetanilid 
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und daher nicht aus direkter Exposition gegenüber Anilin. In Konsequenz hieraus muss 
es andere Anilin-Vorläufer im Urin geben, die während der Probenaufarbeitung dieser 
Methoden zu Anilin hydrolysiert werden.  
(4) N-acetyl-2-aminophenol ist kein Produkt im Humanmetabolismus von Anilin.  
Schlussfolgerungen aus der Arbeit dargestellt in Kapitel II waren, dass weitere 
Untersuchungen zwingend notwendig sind zur Aufklärung des Humanmetabolismus von 
Anilin und Paracetamol, sowie möglicher Verknüpfungen dieser (siehe Kapitel III und V), 
zur Untersuchung ob Lebensmittel eine mögliche Expositionsquelle darstellen (Kapitel 
III) und der weiteren Bestimmung der Paracetamolbelastung in der 
Allgemeinbevölkerung (Kapitel III) und in speziellen Untergruppen der 
Allgemeinbevölkerung (Kapitel IV). 
Kapitel II wurde veröffentlicht als Peer-Review-Publikation: 
Georg Dierkes, Tobias Weiss, Hendrik Modick, Heiko Udo Käfferlein, Thomas Brüning, 
Holger M Koch. N-acetyl-4-aminophenol (paracetamol), N-acetyl-2-aminophenol and 
acetanilide in urine samples from the general population, individuals exposed to aniline 
and paracetamol users. International Journal of Hygiene and Environmental Health 
04/2014; 217(4-5): 592–599. 
Meine Beiträge zu der wissenschaftlichen Arbeit dargestellt in Kapitel II 
beinhalteten: Unterstützung bei Methodenentwicklung und Methodenvalidierung; 
Assistenz in Studiendesign und Organisation der Studie; Probensammlung und 
Analyse; Datenauswertung; Beteiligung bei Schreiben und Revision der 
Veröffentlichung. 
Die Originalpublikation zu Kapitel II ist in Anhang VI dargestellt.  
Kapitel III enthält einen Übersichtsartikel (Review) welcher Einsicht gibt in die derzeitig 
verfügbaren wissenschaftlichen Daten über die möglichen endokrinen Wirkungen von 
Paracetamol, seine Rolle im Metabolismus von Anilin, aktuelle HBM-Daten und mögliche 
Expositionsquellen. Zusätzlich ist ein experimenteller Teil in dem Artikel enthalten. 
Zweck dieses experimentellen Teils war eine tiefere Untersuchung der 
Paracetamolbelastung in der Allgemeinbevölkerung, des Humanmetabolismus von Anilin 
und dem Einfluss der Nahrungsaufnahme auf die Paracetamolausscheidung. Aus diesen 
Gründen wurden die Konzentrationen von Paracetamol und Acetanilid im Urin (mit der 
Methode die in Kapitel II beschrieben wurde) in vier verschiedenen Experimenten 
bestimmt: (1) in einer großen Anzahl von Urinproben aus der (deutschen) 
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Allgemeinbevölkerung; (2) nach therapeutischer Einnahme von Paracetamol; (3) nach 
Anilin-Exposition und (4) in einer kontrollierten 2-Tage-Fastenstudie. Die Beobachtungen 
aus diesen Experimenten werden im Folgenden zusammengefasst: 
(1) Die Analyse von 2098 Urinproben aus der deutschen Allgemeinbevölkerung 
bestätigte die allgemeine Gegenwart von Paracetamol, welche bereits in früheren 
Pilotstudien nachgewiesen wurde. Paracetamol wurde dabei in jeder der untersuchten 
Proben gefunden. Der Median der Konzentrationen betrug 61,7 µg/L und das 95. 
Perzentil lag bei ca. 4000 µg/L. Die Konzentrationen waren sowohl vor, als auch nach 
logarithmischer Umrechnung nicht normalverteilt. Nach Gruppierung der Werte, wofür 
das 95. Perzentil als Grenzwert zur Unterscheidung herangezogen wurde, in eine niedrig 
belastete und eine hoch belastete Gruppe konnte in beiden Gruppen eine 
Normalverteilung festgestellt werden. Zusätzlich wurde ein signifikanter Unterschied 
zwischen den Konzentrationsmedianen bei Rauchern und Nichtrauchern festgestellt 
werden, was auf Tabakrauch als mögliche Quelle der inneren Belastung mit 
Paracetamol hindeutet, da in diesem Anilin enthalten ist (Human Biomonitoring 
Kommission des Umweltbundesamtes 2011). Wie zuvor schon in den Pilotstudien 
konnte Acetanilid in keiner der untersuchten Proben nachgewiesen werden.  
(2) Für die Untersuchung der Eliminationskinetik von Paracetamol nach therapeutischer 
Anwendung wurden die Urinproben eines Individuums kontinuierlich und vollständig über 
48 h nach Einnahme einer 500 mg Tablette Paracetamol gesammelt und anschließend 
die Konzentrationen von Paracetamol in diesen Proben bestimmt. Dabei stiegen die 
Konzentrationen bereits kurz nach Einnahme stark an, wobei Maximalkonzentrationen 
von 200 bis 400 mg/L zwischen 4 und 12 h nach der Einnahme erreicht wurden. Trotz 
der folgenden kontinuierlichen Abnahme der Konzentrationen, was auf eine einphasige 
Eliminationskinetik hindeutet, lagen die Konzentrationen bis etwa 36 h nach Einnahme 
immer noch deutlich im mg/L-Bereich. Dies ist vergleichbar mit den 
Paracetamolkonzentrationen der Probanden aus den Pilotstudien der Kapitel I und II, 
welche angegeben hatten in den 24 h vor Probenahme Paracetamol zu sich genommen 
zu haben. Die Paracetamolkonzentrationen blieben für die restliche Dauer der Studie 
(36-48 Stunden) weiterhin über dem 95. Perzentil von ~4000 µg/L (siehe Abbildung 4). 
Deshalb wurde, in Anbetracht dieses Eliminationsverhaltens und den 
Untersuchungsergebnissen aus der Allgemeinbevölkerung der Wert von 4000 µg/L 
Paracetamol als (vorläufiger) Grenzwert festgelegt, um zwischen 
Hintergrundkonzentrationen und Konzentrationen resultierend aus aktiver Einnahme von 
Paracetamol (welche in einem Zeitraum von 36-48 h vor Probenahme erfolgte) zu 
unterscheiden. 
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Abbildung 4: Konzentrationen von Paracetamol im Urin nach therapeutischer (500 mg) Dosis; die 
gestrichelte Linie stellt den vorläufig festgelegten Grenzwert zur Unterscheidung zwischen 
Hintergrundkonzentrationen und Konzentrationen aus direkter Einnahme 
 
(3) Vier Probanden wurden in einer kontrollierten Expositionsstudie 8 Stunden lang über 
die Luft gegenüber Anilin exponiert. Die Anilin-Luftkonzentration betrug dabei 2 ppm (7,7 
mg/m³ Luft), was die maximal zulässige Arbeitsplatzkonzentration in Deutschland 
darstellt (Monsé et al. 2012; Käfferlein et al. 2014). Die Exposition wurde in einer 
Expositionskammer am IPA durchgeführt. Von den Probanden wurden kontinuierlich und 
vollständig Urinproben vor, während und bis zu 16 h nach Exposition gesammelt. Der 
Zeitverlauf der Konzentrationen von Paracetamol und Acetanilid, ausgedrückt in µg/L 
und adjustiert über Kreatinin, in allen vier Probanden ist in Abbildung 5 dargestellt.  
Vor Exposition waren die Paracetamolkonzentrationen in den Urinen der Probanden 
vergleichbar mit den Konzentrationen aus der (nicht exponierten) Allgemeinbevölkerung 
(40-170 µg/L), die Konzentrationen von Acetanilid lagen unterhalb der 
Bestimmungsgrenze der Methode (0,09 µg/L). Während der Anilinexposition nahmen die 
Paracetamolkonzentrationen stetig zu und erreichten Maximalwerte von 10-60 mg/L 
zwischen 10 und 13 h nach Beginn der Studie (etwa 2-5 h nach Ende der Exposition). 
Der Verlauf der Konzentrationen von Acetanilid folgt dem gleichen Muster, jedoch liegen 
die Konzentrationen etwa um einen Faktor 100-200 niedriger als die Konzentrationen 
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von Paracetamol. Die Untersuchungen belegen jedoch eindeutig, dass Anilin ein 
metabolischer Vorgänger von Paracetamol im Menschen ist. 
 
Abbildung 5: Konzentrationen von Paracetamol und Acetanilid in Urinproben von vier Probanden nach 
kontrollierter Anilin-Exposition an der maximalen Arbeitsplatzkonzentration (7,7 mg/m³ Luft) 
 
Weiterhin bestätigen sich die Vermutungen aus Kapitel II, dass die Erfassung der 
Acetanilidkonzentration als zuverlässiger Indikator für eine Exposition gegenüber Anilin 
am Arbeitsplatz herangezogen werden kann. 
Aus den gewonnenen Metabolismusdaten, ist es jedoch nicht möglich eine zuverlässige 
Aussage über die Konversionsraten von Anilin zu den untersuchten Metaboliten zu 
treffen, da die tatsächlich von den Probanden aufgenommene Dosis nicht mit Sicherheit 
bestimmt werden kann. Aussagen über die metabolische Konversion lassen sich nur 
über Experimente treffen, in welchen eine definierte Einzeldosis aufgenommen wird 
(siehe Kapitel V). 
(4) Um zu untersuchen, ob Lebensmittel eine potentielle Quelle für die innere Belastung 
mit Paracetamol darstellen (entweder durch Kontamination mit Paracetamol selbst oder 
durch Vorstufen wie Anilin),wurden die Urinproben einer 2-Tage-Fastenstudie auf ihre 
Gehalte an Paracetamol und Acetanilid hin untersucht. Diese Studie wurde ursprünglich 
durchgeführt, um den Einfluss der Nahrungsaufnahme auf die Konzentrationen von 
Phtalat-Metaboliten und Bisphenol A im Urin zu untersuchen. Hierfür wurden die Urine 
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von vier Probanden über einen Fastenzeitraum von zwei Tagen (48 h), sowie einige 
Proben vor und nach diesem Zeitraum, komplett und vollständig gesammelt. Das Fasten 
bezog sich auf sämtliche Lebensmittel (und lebensmittelähnliche Produkte z.B. 
Kaugummi) mit Ausnahme von Mineralwasser. Die mittels Kreatinin normalisierten 
Paracetamolkonzentrationen von allen vier Probanden über den gesamten Zeitraum der 
Studie sind in Abbildung 6 dargestellt.  
 
Abbildung 6: Kreatinin-korrigierte Paracetamolkonzentrationen in Urinen von vier Probanden während einer 
2-Tage Fastenstudie semi-logarithmisch aufgetragen (A) und normal aufgetragen (B) 
 
Am Anfang der Studie waren die Paracetamolkonzentrationen in den Urinen der 
Probanden vergleichbar mit den Konzentrationen aus der Allgemeinbevölkerung. Nach 
der letzten Mahlzeit, die die Probanden zusammen vor Beginn des Fastens 
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eingenommen hatten stiegen die Konzentrationen deutlich an und erreichten ca. 2-6 h 
nach der Mahlzeit Maximalwerte von 700-5000 µg/g Kreatinin (1100-5300 µg/L). Die 
höchste gemessene Konzentration lag sogar über dem vorher festgelegten Grenzwert 
von 4000 µg/L zur Unterscheidung zwischen Hintergrundbelastung und aktiver 
Einnahme, was die noch bleibenden Unsicherheiten diesen Wert betreffend aufzeigt. 
Während der Fastenzeit sanken die Paracetamolkonzentrationen deutlich bis 
Minimumwerte von 50-70 µg/g Kreatinin (5-75 µg/L) erreicht wurden. Nachdem das 
Fasten beendet war und die Probanden wieder Nahrungsmittel zu sich nahmen, war ein 
Wiederanstieg der Paracetamolkonzentrationen in den Urinproben zu verzeichnen. 
Acetanilid konnte in keiner der untersuchten Proben nachgewiesen werden.  
Zusammengenommen weisen die Ergebnisse dieser Untersuchungen deutlich darauf 
hin, dass die Aufnahme von Lebensmitteln eine Quelle für die innere Belastung mit 
Paracetamol darstellt, auch wenn weiterhin Unklarheit besteht ob diese durch 
Paracetamol selbst (als eventuelle Kontamination) oder durch Anilin (oder Anilin-
freisetzende Substanzen) oder eine Kombination aus beidem herbeigeführt werden.  
Die Ergebnisse der Experimente in Kapitel III bestätigen die vorher getroffenen 
Vermutungen, dass z.B. Nahrungsmittel eine mögliche Expositionsquelle für die innere 
Belastung mit Paracetamol darstellen. Weiterhin wurden neue Erkenntnisse 
hinzugewonnen was die ubiquitären Belastungen mit Paracetamol betrifft. Der Einfluss 
des Rauchens auf die Paracetamolkonzentrationen im Urin wurde aufgezeigt, und mit 
Acetanilid wurde ein verlässlicher Indikator zur Expositionsbestimmung für Anilin 
gefunden.  
Die definitiven Quellen für die Hintergrundbelastung mit Paracetamol in der 
Allgemeinbevölkerung bleiben jedoch noch unklar. Den durchgeführten Experimenten 
zufolge existieren verschiedene mögliche Expositionsquellen: 1) direkte Einnahme von 
Paracetamol als Medikament (verantwortlich für hohe Konzentrationen im Urin bis in den 
g/L-Bereich); 2) Exposition gegenüber Anilin (am Arbeitsplatz); 3) diffuse Exposition aus 
umfeld- und umweltrelevanten Quellen (Nahrungsmittel; Luft); 4) Tabakrauch, auch 
wenn der Einfluss dieser Quelle verglichen mit z.B. Nahrungsmitteln eher gering scheint. 
Letztendlich wird am Ende von Kapitel III ein interdisziplinärer Ansatz gefordert, um 
Quellen, Expositionswege und Ausmaß der Exposition zu ermitteln. Des Weiteren soll 
sowohl durch mechanistische als auch durch epidemiologische Studien untersucht 
werden, ob therapeutische Einnahme oder sogar Hintergrundbelastungen mit 
Paracetamol einen Risikofaktor für reproduktionstoxische Effekte darstellen. Das HBM 
kann hierbei wichtige Beiträge zur Expositionserfassung in speziellen und potentiell 
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sensiblen Kohorten (Kapitel IV) sowie Beiträge zur Untersuchung von Verknüpfungen im 
Humanmetabolismus von Anilin und Paracetamol (Kapitel V) liefern.  
Kapitel III wurde veröffentlicht als Peer-Review-Publikation: 
Hendrik Modick, Tobias Weiss, Georg Dierkes, Thomas Brüning, Holger Koch. 
Ubiquitous presence of paracetamol in human urine: sources and implications. 
Reproduction 03/2014; 147(4):R105-R117. 
 
Meine Beiträge zu den in Kapitel III dargestellten wissenschaftlichen Arbeiten 
waren: Literaturrecherche, Organisation und Sichtung für den Übersichtsteil 
(Review) der Publikation; Probenorganisation, Überwachung und Analyse; 
Datensammlung, Auswertung und Interpretation; Schreiben, Überarbeiten und 
Durchführung des Veröffentlichungsprozesses der Publikation.  
Die Originalpublikation zu Kapitel III befindet sich in Anhang VII.  
In der Arbeit, die in Kapitel IV dargestellt wird, wurde die innere Belastung an 
Paracetamol in einem Subkollektiv der dänischen Allgemeinbevölkerung erfasst. Hierfür 
wurden die Paracetamolkonzentrationen in 288 Proben Morgenurin von 6 bis 11-jährigen 
Schulkindern und deren Müttern bestimmt. Die untersuchten Proben stammten aus dem 
europäischen DEMOCOPHES-Projekt (DEMOnstration of a study to Coordinate and 
Perform Human biomonitoring on a European Scale), welches dazu diente- die 
Methoden des HBM in Europa weiterzuentwickeln und zu harmonisieren (Becker et al. 
2014; Schindler et al. 2014). Die Kinder und ihre Mütter wurden aus städtischen (n = 75, 
Genofte) und ländlichen (n = 70, Viby Sj.) Gebieten Dänemarks rekrutiert. In beiden 
Gruppen waren Alter und Geschlecht der Kinder gleich verteilt. Die Probensammlung 
erfolgte durch geschultes Personal in den Räumen der Schulschwestern. 
Lebensumstände und Ernährungsgewohnheiten wurden mittels eines Basisfragebogens 
erfasst der von den Müttern im Rahmen der Probenahme ausgefüllt wurde. In einem 
zusätzlichen Fragebogen wurden die Mütter zur Selbsteinschätzung ihres 
Gesundheitszustandes, zu Schmerzen und der Verwendung von rezeptfreien 
Medikamenten für sich selbst und ihre Kinder befragt. Die Probenahme fand zwischen 
September und Dezember 2011 statt und erfolgte parallel in den städtischen und 
ländlichen Gebieten um saisonale Variationen zwischen beiden Gruppen zu vermeiden.  
Bei der präsentierten Arbeit handelte es sich um ein Kooperationsprojekt zwischen dem 
Institut für Prävention und Arbeitsmedizin der Deutschen Gesetzlichen 
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Unfallversicherung (IPA) und der Abteilung Occupational and Environmental Health der 
Fakultät Public Health an der Universität Kopenhagen. 
Alle Proben wurden mittels der in Kapitel II dargestellten Methode auf ihren Gehalt an 
Paracetamol hin analysiert.  
Mit Ausnahme eines Kindes aus dem ländlichen Gebiet konnte Paracetamol in den 
Proben aller untersuchten Individuen nachgewiesen werden. Die 
Paracetamolkonzentrationen variierten stark zwischen 4,9 µg/L und ~3 g/L (Median 120 
µg/L) bei den Müttern und zwischen < Nachweisgrenze und ~2 g/L (Median 27 µg/L) bei 
den Kindern. Weder bei den Müttern noch bei den Kindern konnten signifikante 
Unterschiede in den Konzentrationen zwischen den städtischen und ländlichen Proben 
nachgewiesen werden, auch wenn sich eine leichte Tendenz zu höheren 
Konzentrationen in den Proben der Mütter und Kinder aus dem städtischen Umfeld 
abzuzeichnen scheint (Abbildung 7). 
 
Abbildung 7: Tukey-Boxplots der Paracetamolkonzentrationen von Mutter-Kind-Paaren aus städtischen und 
ländlichen Gebieten Dänemarks; Kreise repräsentieren Werte innerhalb des 1,5-3-fachen 
Interquartilsabstands; Sterne repräsentieren Werte oberhalb des 3-fachen Interquartilsabstands 
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Nachdem die Werte mit dem in Kapitel III abgeleiteten Grenzwert in zwei Gruppen 
unterteilt wurden, konnte in der < 4000 µg/L-Gruppe eine schwache aber signifikante 
Korrelation zwischen den Paracetamolkonzentrationen von Müttern und Kindern 
beobachtet werden. Diese Korrelation bestand nicht in der > 4000 µg/L-Gruppe. 
In den Fragebögen gaben 79 der 130 (60,8%) teilnehmenden Mütter an, nie bzw. fast 
nie (nicht innerhalb des letzten Jahres) Paracetamol oder Paracetamol-haltige 
Medikamente zu sich genommen zu haben. 51 (39,2%) der befragten Mütter berichteten, 
mindestens einmal pro Monat Paracetamol zu sich zu nehmen. Für ihre Kinder gaben 89 
(68,5%) der Mütter an, dass diese mindestens während der letzten drei Monate keine 
Medikation mit Paracetamol erhalten hätten.  
Einige der Mütter die keine Einnahme von Paracetamol angaben, zeigten hohe 
Paracetamolkonzentrationen im Urin (> 4000 µg/L), während einige Mütter/Kinder in der 
Anwendergruppe Konzentrationswerte aufwiesen, die vergleichbar mit denen von Nicht-
Anwendern sind. Dies lässt sich durch die bestehenden Unsicherheiten des abgeleiteten 
Grenzwertes und der Erfassung der Einnahme durch den Fragebogen erklären. Unter 
Berücksichtigung der Eliminationskinetik kann die Einnahme von Paracetamol durch 
Messungen im Urin nur bestimmt werden, wenn diese innerhalb der letzten 24-48 h vor 
Probenahme erfolgte. In dem Fragebogen wurde allerdings nach der Einnahme während 
der letzten drei Monate gefragt. Auf der anderen Seite wurden hohe 
Paracetamolkonzentrationen (> 4000 µg/L) ohne direkten Konsum von Paracetamol 
bereits in früheren Studien nachgewiesen.  
Zusammengenommen bestätigen die Ergebnisse, der in Kapitel IV dargestellten Arbeit, 
die Befunde der früheren Studien der ubiquitären Belastung mit Paracetamol. Diese 
Belastung wird somit ebenfalls in einer, gegenüber Exposition empfindlicher, 
Untergruppe der Allgemeinbevölkerung (Mütter und Kinder) nachgewiesen. In der Arbeit 
offenbarten sich Unsicherheiten in dem abgeleiteten Grenzwert um zwischen 
Hintergrundkonzentrationen und Konzentrationen aus kürzlich zurückliegender 
Einnahme zu unterscheiden, wenn es darum geht, länger zurückliegende Expositionen 
zu erfassen. Ebenso liefert der Grenzwert falsch positive Ergebnisse im Falle anderer 
(noch unbekannter) Expositionsquellen.   
Zum ersten Mal konnte eine Korrelation in den Urinkonzentrationen an Paracetamol 
zwischen Müttern und Kindern beobachtet werden. Über eine solche Korrelation wurde 
bereits in dem Zusammenhang mit Phthalat-Metaboliten berichtet (Kasper-Sonnenberg 
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et al. 2012). Auch wenn es sich nur um eine schwache Korrelation handelte, war diese 
dennoch signifikant, was auf gemeinsame Quellen von Müttern und Kindern hindeutet, 
welche in der Regel gemeinsame Räume bewohnen und sich Mahlzeiten und 
Lebensumfeld teilen. Dies stützt die vorher geäußerten Vermutungen, dass Nahrung 
eine Expositionsquelle darstellt. Neben anderen Expositionsquellen können einige 
Faktoren dazu beitragen, die Korrelationen abzuschwächen, wie z.B. interindividuelles 
Stoffwechselverhalten und, was noch wahrscheinlicher ist, generelle Unterschiede in der 
Verstoffwechselung und Eliminationskinetik von Paracetamol zwischen Kindern und 
Erwachsenen. Im Vergleich zu Erwachsenen weisen Kinder andere 
Metabolitenverhältnisse und verlängerte Eliminationshalbwertszeiten von Paracetamol 
auf (Peterson und Rumack 1978). Da in der dargestellten Arbeit Morgenurine als Proben 
verwendet wurden, also die letzte Exposition bereits einige Stunden zurücklag, könnten 
verschiedene Eliminationshalbwertszeiten zu einer Verzerrung der Korrelation der 
Konzentrationswerte führen, insbesondere wenn zwischen letzter Exposition und 
Probennahme einer oder mehrere Toilettengänge erfolgten. 
Diese Effekte könnten durch Verwenden von gepoolten 24-Stunden-Urinen von Mutter-
Kind-Paaren in einer zukünftigen Studie abgeschwächt werden. Unterstützt werden 
könnte dies durch ein parallel durchgeführtes Umgebungsmonitoring (z.B. Luft- und 
Staubproben), um zu untersuchen, ob ein Zusammenhang besteht zwischen den 
Umgebungskonzentrationen von Anilin und den Urinkonzentrationen von Paracetamol. 
Dieser Ansatz könnte auch zur Erfassung und Abschätzung der Exposition am 
Arbeitsplatz herangezogen werden.  
Kapitel IV wurde veröffentlicht als Peer-Review Publikation: 
Jeanette K.S. Nielsen, Hendrik Modick, Thit A. Mørck, Janne F. Jensen, Flemming 
Nielsen, Holger M. Koch, Lisbeth E. Knudsen: N-acetyl-4-aminophenol (paracetamol) in 
urine samples of 6-11-year-old Danish school children and their mothers, International 
Journal of Hygiene and Environmental Health, 218 (2015) 28-33                                                               
DOI: , http://dx.doi.org/10.1016/j.ijheh.2014.07.001 
Meine Beiträge zu den in Kapitel IV dargestellten wissenschaftlichen Arbeiten 
waren: Probenvorbereitung, Analyse und Auswertung; Korrespondenz mit 
Kooperationspartnern; Verfassen des Methodenteils der Publikation sowie Teile 
der Diskussion und Schlussfolgerung; Allgemeine Unterstützung bei Verfassen 
der Publikation und Durchführung des Veröffentlichungsprozesses.  
Die Originalpublikation zu Kapitel IV befindet sich in Anhang VIII.  
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Zur Expositionserfassung und um von einer gemessenen Urinkonzentration auf die 
tatsächlich aufgenommene Dosis zurück rechnen zu können, werden die spezifischen 
Konversionsfaktoren der betreffenden Substanz und ihrer entsprechenden Metaboliten 
benötigt. Für Anilin sind nach aktuellem Kenntnisstand lediglich Konversionsfaktoren aus 
tierexperimentellen Studien bekannt, welche über 30 Jahre zurückliegen (Kao et al. 
1978). In Anbetracht dessen war es das Ziel der Arbeit, welche in Kapitel V dargestellt 
wird, die Konversionsfaktoren und die Eliminationskinetik von Anilin und seinen 
Metaboliten im menschlichen Urin, auf Basis einer oralen Einzeldosis und unter der 
Verwendung moderner Analysetechniken (HPLC-MS/MS und GC-MS), zu untersuchen. 
Zusätzlich sollten, in einem ersten Ansatz, Verknüpfungen zwischen den 
Stoffwechselwegen von Anilin und Paracetamol untersucht werden. Aus diesem Grund 
wurde das Mercaptursäure-Addukt von Paracetamol (Paracetamol-3-mercapturat) in die 
Analysemethode integriert, welches zum bisherigen Zeitpunkt nur in Zusammenhang der 
Metabolisierung von Paracetamol untersucht wurde. Weiterhin wurde der Einfluss des 
Enzyms N-Acetyltransferase 2 (NAT2) auf die Verstoffwechselung von Anilin untersucht. 
Das NAT2-Enzym katalysiert den Schritt der Acetylierung an der Aminogruppe des 
Anilins. Durch Polymorphismen in diesem Enzym existieren beim Menschen zwei 
Klassen (Phänotypen), wodurch zwischen „schnellen“ und „langsamen“ Acetylierern 
(Wolf et al. 1980; Lewalter und Korallus 1985) unterschieden wird (auch bezeichnet als 
Acetyliererstatus). Über den Einfluss des Acetyliererstatus auf die Entstehung und die 
Empfindlichkeit gegenüber Krebsarten die durch aromatische Amine induziert werden 
wurde in der Vergangenheit berichtet (Hein et al. 1992).  
Um Störungen durch die allgemeine Verbreitung von Anilin und die daraus 
resultierenden Hintergrundkonzentrationen von Anilin und seinen Metaboliten im Urin zu 
vermeiden, wurde Anilin in stabilisotopenmarkierter Form (Deuterium-Markierung am 
aromatischen Ring) verabreicht. Dementsprechend liegen auch die 
Stoffwechselprodukte in isotopenmarkierter Form vor, was eine hohe Selektivität 
gewährleistet. Abbildung 8 gibt einen Überblick über die in der Studie untersuchten 
Zielanalyten und die internen Standards welche zur Quantifizierung verwendet wurden.  
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Abbildung 8: Erwarteter Metabolismus von Anilin (als Anilin-d5), inklusive der Zielanalyten und den 
entsprechenden internen Standards, Sterne zeigen die Lokalisierung der Deuterium-Markierungen den 
Molekülen  
 
Als Zielanalyten dienten freies Anilin (als Anilin-d5), Acetanilid (als Acetanilid-d5), 
Paracetamol (als Paracetamol-d4) und Paracetamol-Mercaptursäure (als Paracetamol-
Mercaptursäure-d3). Freies Anilin und Acetanilid sind beide spezifische Marker für eine 
Exposition mit Anilin. Paracetamol, nach enzymatischer Hydrolyse der Konjugate, kann 
sowohl als Marker für eine Anilinexposition als auch für eine Exposition gegenüber 
Paracetamol selbst dienen. Paracetamol-Mercaptursäure wurde als Zielanalyt 
ausgewählt, da dieses bis jetzt lediglich als Stoffwechselprodukt in Zusammenhang mit 
Paracetamol, nicht jedoch mit Anilin untersucht wurde. Nach therapeutischer 
Paracetamol-Verabreichung werden ungefähr 3% der aufgenommenen Dosis als 
Paracetamol-Mercaptursäure ausgeschieden (Ladds et al. 1987). Da Paracetamol mit 
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einem Dosisanteil von 56-76% (Kao et al. 1978) den Hauptmetaboliten von Anilin 
darstellt, ist es sehr wahrscheinlich, dass die Bildung von Paracetamol-Mercaptursäure 
aus Paracetamol ebenfalls im Metabolismus von Anilin erfolgt. Der Nachweis der 
Paracetamol-Mercaptursäure wäre von besonderer toxikologischer Bedeutung, da deren 
Bildung auf stark reaktive Stoffwechselzwischenprodukte hindeuten würde (Prescott 
1980). 
Zur Untersuchung des Metabolismus erhielten vier gesunde, männliche Probanden (30-
32 Jahre alt, 71-95 kg Körpergewicht, alle Nichtraucher) mit unterschiedliche NAT2-
Phänotypen (2 „schnelle“ und 2 „langsame“ Acetylierer) je eine Dosis von 5 mg Anilin-d5. 
Im Vorfeld der Studie wurde ein Ethikantrag verfasst und bei der Ethikkommission der 
medizinischen Fakultät der Ruhr-Universität Bochum eingereicht. Die 
Studiendurchführung wurde von der Kommission im August 2013 genehmigt (Reg.Nr.: 
4730-13). Nach der Dosierung wurden von allen Probanden über die folgenden 48 h 
kontinuierlich und vollständig Urinproben gesammelt. Zusätzlich gab jeder Proband eine 
Probe ab bevor die Dosierung erfolgte.  
In den Urinproben wurde freies Anilin publizierte und validierte GC-MS-
Analysenmethode (Weiss und Angerer 2002), über o-Toluidin als internen Standard, 
bestimmt. Acetanilid, Paracetamol und Paracetamol-Mercaptursäure wurden mittels 
HPLC-MS/MS quantifiziert. Dabei wurden isotopenmarkierte Analoga der Zielanalyten 
als interne Standards verwendet. Die verwendete Analysemethode basierte auf den 
bereits in den Kapiteln I und II beschriebenen Methoden, wurde jedoch hinsichtlich der 
Anforderungen der durchzuführenden Studie modifiziert und angepasst.  
Die Eliminationskinetiken von Anilin und den untersuchten Metaboliten sind in Abbildung 
9 dargestellt. Nach Dosierung waren sowohl Paracetamol als auch Paracetamol-
Mercaptursäure in allen Urinproben während der gesamten Untersuchungsdauer 
nachweisbar. Im Gegensatz dazu erfolgten die Ausscheidungen von freiem Anilin und 
Acetanilid sehr schnell, sodass die Konzentrationen dieser bereits in den ersten zwölf 
Stunden der Untersuchung unter die Nachweisgrenzen der Analysemethode sanken. 
Dies spiegelt sich auch in den Eliminationshalbwertszeiten der Metaboliten wider.  
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Abbildung 9: Urinkonzentrationen von Anilin und den untersuchten Metaboliten, halblogarithmisch 
aufgetragen; schwarze Graphen repräsentieren „schnelle“ Acetylierer, graue Graphen repräsentieren 
„langsame“ Acetylierer 
Diese zeigten eine eher geringe Variabilität zwischen den einzelnen Probanden, 
unterschieden sich jedoch stark zwischen den einzelnen Metaboliten. Die Ausscheidung 
von freiem Anilin und Acetanilid erfolgte sehr schnell mit dementsprechend kurzen 
Halbwertszeiten von 0,6 h bis 1,2 h (basierend auf Kreatinin-normierten Werten). Die 
Eliminationshalbwertszeiten von Paracetamol waren erheblich größer und lagen 
zwischen 3,4 h und 4,3 h. Paracetamol-Mercaptursäure wurde am langsamsten 
ausgeschieden, mit Halbwertszeiten die zwischen 4,1 h und 5,5 h betrugen. Es zeigt sich 
ein Anstieg der Halbwertszeiten mit zunehmender Komplexität der Metaboliten und mit 
der Anzahl der zur Bildung dieser Metaboliten notwendigen Transformationsschritte.  
Die Dosisanteile der Metaboliten an der aufgenommenen Anilindosis sind in Abbildung 
10 dargestellt. Paracetamol war mit einem Dosisanteil von 55,7-69,8% der quantitativ 
bedeutendste Metabolit. Paracetamol-Mercaptursäure repräsentierte einen Dosisanteil 
von 2,5-6,1%. Freies Anilin und Acetanilid wiesen mit 0,14-0,31 % den geringsten Anteil 
an der Anilindosis auf. Insgesamt konnten 62,4-72,7 % der Anilindosis in Form der 
untersuchten Metaboliten wiedergefunden werden. Diese Ergebnisse stimmen gut mit 
den Ergebnissen aus den tierexperimentellen Studien überein (Kao et al. 1978).  
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Abbildung 10: Konversionsfaktoren von freiem Anilin und Anilinmetaboliten (molare Dosisäquivalente in %)  
 
Über die Beschaffenheit der noch verbleibenden Dosisanteile kann lediglich spekuliert 
werden. Da es möglich war, die Bildung von Paracetamol-Mercaptursäure, welche bisher 
nur als Metabolit von Paracetamol bekannt war, im Metabolismus von Anilin 
nachzuweisen, ist die Bildung weiterer Metaboliten von Paracetamol wie z.B. 
Paracetamol-Cystein und 3-Hydroxyparacetamol-4-sulfat denkbar, welche einen Anteil 
von 0,6-13,7% bzw. 0,4-4,8 % der Paracetamoldosis ausmachen (Ladds et al. 1987). 
Weiterhin wird die Ausscheidung anderer Metaboliten von Anilin erwartet wie z.B. 
Konjugate von ortho- und para-Aminophenol (~ 20% Dosisanteil) welche das 
Metabolitenspektrum vervollständigen könnten (Kao et al. 1978).  
Der Acetylierungs-Phänotyp der Probanden hatte keinen Einfluss auf die 
Eliminationskinetiken und Konversionsfaktoren (bzw. Dosisanteile) von Paracetamol und 
Paracetamol-Mercaptursäure. Die Konversion von Anilin zu Acetanilid war bei den 
„schnellen“ Acetylierern jedoch um das etwa 1,5- bis 2-fache höher (0,33 und 0,36 %) 
als bei den beiden „langsamen“ Acetylierern (0,16 und 0,19%). Die gleiche Beobachtung 
konnte bezüglich der Maximalkonzentrationen von Acetanilid gemacht werden. In der 
Expositionsabschätzung von Anilin über Acetanilidkonzentrationen im Urin ist die 
Berücksichtigung des Acetylierer-Phänotyps also von großer Wichtigkeit, da bei 
„schnellen“ und „langsamen“ Acetylierern gleiche Urinkonzentrationen von Acetanilid aus 
einer 2-fach höheren Anilindosis der „langsamen“ Acetylierer resultieren.  
In der Arbeit, die in Kapitel V präsentiert wird, wurde zum ersten Mal der 
Humanmetabolismus von Anilin untersucht sowie Verlinkungen in den 
Stoffwechselwegen von Anilin und Paracetamol aufgezeigt. Die Ergebnisse dieser 
Studie werden in Zukunft zur Expositionserfassung und Risikoabschätzung von Anilin 
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und seinem Hauptmetaboliten Paracetamol im arbeitsmedizinischen und 
umweltmedizinischen Bereich beitragen.  
Kapitel V wurde zur Veröffentlichung in Archives of Toxicology eingereicht und befindet 
sich derzeit im Peer-Review-Prozess.. 
Meine Beiträge zu der wissenschaftlichen Arbeit dargestellt in Kapitel V waren: 
Unterstützung bei Studiendesign und Durchführung; Unterstützung beim 
Schreiben des Ethikantrages zur Durchführung der Studie; Methodenentwicklung 
(HPLC-MS/MS) und Methodenvalidierung; Durchführung der Studie, 
Probensammlung, Probenvorbereitung und Analyse (HPLC-MS/MS); 
Datenauswertung, Evaluation und Interpretation; Schreiben der Publikation.  
 
Die zur Einreichungsbestätigung des Manuscripts generierte PDF-Datei von Kapitel V 
ist in Anhang IX dargestellt.  
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Abstract 
N-acetyl-4-aminophenol (NAAP) is the major urinary metabolite of aniline. The general 
population is known to be ubiquitously exposed to aniline through various sources. 
Furthermore, NAAP, known under the trade name paracetamol (resp. Acetaminophen), 
is one of the most commonly used over-the-counter analgesics. Recent studies suggest 
anti-androgenic properties of NAAP. Although NAAP has been used as a pain reliever 
over decades and its role in aniline metabolism is well known there is a lack of internal 
exposure data both in environmental and occupational settings. 
To determine the internal NAAP exposure of the general population, workers exposed to 
aniline and users of paracetamol we developed a fast, on-line HPLC-MS/MS- method 
with isotope dilution quantification of NAAP, after enzymatic hydrolysis of its glucuronide- 
and sulphate- conjugates, in urine. We achieved minimal sample pretreatment through 
on-line extraction and enrichment of the analyte by turbulent flow chromatography on a 
Waters Oasis HLB phase followed by back-flush transfer onto the analytical column. The 
limit of quantification (LOQ) was 0.75 µg/L.  
In a pilot study, urine samples of 21 volunteers, not occupationally exposed to aniline, 
were analyzed for NAAP. NAAP was detected in all samples in a wide concentration 
range between 8.7 µg/L and 22100 µg/L (median 85.7 µg/L). The highest concentration 
was measured in a volunteer who took paracetamol one day ago. Half of the volunteers 
quoted to either never have taken paracetamol or at least not during the last weeks. 
Therefore, other routes of exposure than direct use of paracetamol, like aniline or 
paracetamol contaminated foodstuff, leading to the NAAP excretions have to be taken 
into account. 
 
Keywords: paracetamol, acetaminophen, aniline, human biomonitoring, urine, turbulent 
flow chromatography 
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Introduction 
N-acetyl-4-aminophenol (NAAP; CAS No. 103-90-2) and its conjugates occur in the 
metabolism of aniline. Kao et al. [1] found NAAP conjugated to glucuronic acid or 
sulphate to be the major urinary metabolite of aniline in the sheep (60%), pig (66%) and 
rat (56%). An additional ~10% were excreted as free NAAP in all three species 
cumulating to a total of 66% - 76% of an oral aniline dose excreted as free or conjugated 
NAAP in urine. Further urinary metabolites of aniline in these species were O-conjugates 
of 2- and 4-aminophenol (~20%), and acetanilide (~ 3%). Free aniline has not been 
detected in urine after aniline exposure [1]. A similar metabolic pattern of aniline is 
expected in humans [2]. Figure 1 shows the simplified metabolism of aniline focusing on 
the metabolites mentioned above (for detailed aniline metabolism see Human 
Biomonitoring Commission of the German Federal Ministry for Environment (2011) [3]). 
 
Figure 1: Simplified metabolism of Aniline. 
Amongst others, main routes of exposure of the general population to aniline can be 
pesticide residues and colorants in food and cosmetics, and cigarette smoke [3]. The 
ubiquitous body burden of the general German population with aniline has been 
described previously. Urinary aniline (determined routinely as hydrolyzed acetanilide) is 
found in above 90% of the samples with median levels around 3 µg/L, the 95th percentile 
around 14 µg/L and with maximum values up to 384 µg/L [4,5]. Extrapolating these 
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aniline levels to NAAP levels, taking into account that NAAP is the by far major urinary 
metabolite of aniline, would make urinary NAAP levels in the mg/L range highly likely. 
However, up to now, NAAP has not been determined in urine samples from the general 
population. 
N-acetyl-4-aminophenol is also commonly known as paracetamol or acetaminophen. 
Since its market placement in the 1950´s, paracetamol is one of the most commonly 
used over-the-counter analgesic (pain reliever) and antipyretic (fever reducer) drugs [6]. 
Structurally it belongs to the non-opioid analgesics. According to the German 
pharmaceutical register, 55 formulations containing paracetamol are approved for sale in 
Germany [7]. In 2008, two of the 10 most-sold medications in Germany contained 
paracetamol [8]. The use of paracetamol is generally considered to be safe up to a 
therapeutic dosage of 4 g per day [9]. Doses above 10 g per day lead to acute toxic 
symptoms [10]. Although paracetamol has been commonly used for almost 70 years its 
mechanism of action is not yet fully understood. Recent studies assume a selective 
inhibition of cyclooxygenase-2 (COX-2) in the spinal cord [6,11]. Metabolism and 
pharmacokinetics of paracetamol are well studied. In several animal studies maximum 
plasma concentrations of paracetamol are attained 30 to 60 minutes after oral dosage 
with plasma half- lives ranging from 1.5 to 2.5 hours. About 85% of the therapeutic dose 
of paracetamol are excreted in urine as glucuronide and sulphate conjugates, 2-5% of 
the dose are excreted unchanged in urine [12,13]. 
paracetamol is also approved for veterinary use in the European Union. In porcine 
species paracetamol is approved for oral use with no specific maximum residue limit in 
foodstuffs of animal origin (COMMISSION REGULATION (EU) No 37/2010) [14]. 
According to a report of the EU Committee for Veterinary Medicinal Products 
paracetamol is also used in cattle and poultry in some member states of the European 
Union [15]. paracetamol might also be reentering the food chain by contaminated feather 
meal which can be used as an additive in animal feed [16]. 
For a long time the use of paracetamol during pregnancy was considered as safe. 
Recent studies, however, describe anti-androgenic effects of paracetamol. Kristensen et 
al. (2012) showed that paracetamol inhibited the testosterone production in a fetal rat 
organotypic culture system [17]. Epidemiological studies suggest that intrauterine 
exposure to paracetamol is a risk factor for development of male reproductive disorders 
[17,18]. Other epidemiological studies suggest a possible association between the use of 
paracetamol during pregnancy and an increasing appearance of asthma in children [19]. 
Despite the long time paracetamol/acetaminophen has been used as a pain reliever, and 
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despite the known fact that NAAP is the major metabolite of aniline, there is a lack of 
profound human biomonitoring or exposure data on this substance. To our knowledge, 
NAAP has by now not been included in any larger population based study like the 
German GerES, the U.S. NHANES or the Canadian CHMS. In 2012, Camann et al. 
reported the presence of NAAP/paracetamol in the deciduous teeth of 9 of 21 subjects 
[20]. 
Available analytical methods to determine NAAP/paracetamol have been designed 
mainly for forensic purposes and to detect high concentrations of NAAP/paracetamol in 
human blood as occurring after over-dosing [21]. Other analytical methods are designed 
to quantify NAAP/paracetamol or its metabolites in rat plasma or rat urine for metabolism 
studies [22], for special in vitro or in vivo assays [23,24] or for pharmaceutical quality 
controls [25]. The aim of the present work was to develop a fast, robust and reliable 
method for the determination of NAAP/paracetamol in human urine covering a wide 
concentration range including trace levels in the low µg/L range. Applying this method in 
environmental, occupational and clinical studies we can describe the body burden of 
individuals or larger study populations to NAAP/paracetamol from both the generation of 
NAAP/paracetamol in human aniline metabolism and the direct exposure to or use of 
paracetamol. 
 
Experimental  
Chemicals 
N-acetyl-4-aminophenol (Paracetamol/Acetaminophen, CAS No. 103-90-2, purity 99.0 
%) was purchased from Sigma- Aldrich (Steinheim, Germany). The ring-labeled 
analogue (d4-NAAP) was purchased from LGC Standards (Wesel, Germany). Deionized 
water was obtained using a Millipore Advantage A10 with a Quantum®-cartridge. 
Methanol (LC- MS grade) was purchased from Merck (Darmstadt, Germany). 
Ammonium acetate p.a., HP2 β- glucuronidase and TRIS-Buffer (Trizma® base) were 
purchased from Sigma-Aldrich (Steinheim, Germany). 
Standard preparation and stock solutions 
The NAAP stock solution was prepared by dissolving approximately 10 mg NAAP, 
weighted exactly, in acetonitrile using a 10 mL volumetric flask. For analysis, eight 
calibration standards were prepared by gradual dilution with water to final concentrations 
in a range from 0.5 µg/L to 10,000 µg/L. Stock solutions were stored at -20°C in Teflon 
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capped glass vials until further use. The internal standard solution was prepared by 
diluting the purchased d4-NAAP solution (1.0 mg/mL in methanol) with water in a 
volumetric flask to a final concentration of 2 mg/L. 
Sample collection and preparation 
Urine samples were collected in 250 mL polyethylene containers and immediately stored 
at   -20°C. All samples were equilibrated to room temperature prior to analysis. Samples 
were vortex mixed before transferring 300 µL aliquots into a silanized 1.8 mL Teflon 
screw cap vial. 180 µL ammonium acetate buffer (0.5 M, pH 5.5-6.0), 30 µL internal 
standard solution and 6 µL of β-glucuronidase/ arylsulfatase (≥ 100,000 units/mL) were 
added to each sample. After incubation at 37°C in a water bath for 3.5 h 60 µL of TRIS- 
buffer (1M, pH 10) were added to each sample to adjust the pH value. All samples were 
frozen at -18°C over night to freeze out proteins. After thawing, all samples were 
centrifuged at 1900 g for 10 min. The supernatant was transferred into a second 
silanized 1.8 mL Teflon screw cap vial. Urinary creatinine concentrations were 
determined according to Jaffe [26]. 
Calibration procedure and quantification 
Calibration was performed with standard solutions in water. All calibration samples were 
treated equally to the urine samples. Linear calibration curves were obtained with a 1/x 
weighting by plotting the quotients of peak areas of NAAP and the peak areas of d4-
NAAP as a function of the NAAP-concentration. 
Testing the reliability of the method  
Quality control material was prepared within our laboratory using urine samples from 
different volunteers. These urine samples were pooled to obtain control material with 
low, medium and high concentrations of NAAP (Qlow, Qmed and Qhigh). The control urines 
were frozen, thawed and filtered three times before use. Reliability and precision of the 
method were determined by measuring the quality control standards eight times in a row 
for intra-day precision and at eight different days for day-to-day precision. Additionally, 
accuracy and precision were determined by analyzing eight different urine samples with 
varying creatinine concentrations ranging from 0.3 g/L to 3.0 g /L. These samples were 
analyzed non-spiked and spiked at two concentration levels (109.7 µg/L and 548.5 µg/L). 
The NAAP concentrations of the native samples were subtracted from the spiked 
concentrations before further calculation. 
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High performance liquid chromatography 
High performance liquid chromatography was carried out using a 1525 binary pump 
(loading pump) and a 1525µ binary pump (analytical pump) (Waters, Milford, USA), a 
Waters In-Line AF degasser and a Waters 2777 Sample Manager autosampler. In a two 
column assembly, previously described by [27–29] a Waters Oasis® HLB cartridge 
column (2.1 x 20 mm; 25 µm) was used as first column for cleanup and enrichment by 
turbulent flow technique. Chromatographic separation was performed using an Atlantis 
T3 (3.0 x 150 mm; 3 µm) reversed phase C18 column. Three different solvents were 
used: solvent A water, solvent B methanol and solvent C 1 mM ammonium acetate in 
water (pH 6.5- 6.8). An in-line filter (Phenomenex 0.5 µm x 3.0 mm; AF0-0378) was 
placed in front of the HLB-phase and a guard column (Fusion- RP 2.0 x 4 mm) was 
placed in front of the analytical column. 200 µL of the processed sample were injected 
with a constant flow of solvent A of 3.75 mL/min by the loading pump onto the HLB-
phase (valve position A). After 1 min the valve position was switched into position B. In 
this position the analytes retained by the HLB-phase were transferred in backflush mode 
onto the reversed phase C18 column through a time controlled switching valve (Waters 
Selector Valve). The analytes were chromatographically separated by the gradient flow 
from the analytical pump of solvents B and C. After 8 min the switching valve was set 
back into position A and the HLB- phase was flushed with high organic solvent (98% 
solvent B; 2% solvent A) and then re-equilibrated with 100% of solvent A. The gradient of 
the analytical pump used for the chromatographic separation is described in table 1. 
Figure 2 shows the backflush arrangement of the used HPLC system. All steps were 
controlled by Waters MassLynx V4.1 software. 
Table 1: Gradient program for chromatographic separation carried out by the analytical pump, solvent B: 
methanol, solvent C: 1 mM ammonium acetate (pH 6.5- 6.8) in water. 
Program 
step 
Time 
[min] 
Solvent B 
[%] 
Solvent C 
[%] 
Flow rate 
[ml/min] 
Valve 
position 
Analysis step 
       
       
1 initial 25 75 0.35 A Cleanup, 
enrichment (on 
the HLB-
column) 
2 1 25 75 0.35 B Analyte transfer 
3 2.00 25 75 0.35 B Separation 
4 2.25 50 50 0.35 B  
5 3.00 60 40 0.35 B  
6 4.50 80 20 0.35 B  
7 7.00 95 5 0.35 B  
8 8 95 5 0.35 A Washing 
9 9.90 95 5 0.35 A  
10 10.00 25 75 0.35 A Reconditioning 
11 14.95 25 75 0.35 A  
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Figure 2: Two-column HPLC system with backflush arrangement. Valve position A: Cleanup and enrichment 
of the analytes via turbulent flow chromatography. Valve position B: analyte transfer onto the C18-RP phase, 
chromatographic separation and mass spectrometric detection. 
Mass spectrometry 
The mass spectrometric detection and quantification was performed using a Waters 
Quattro Premier XE triple quadrupole mass spectrometer. Positive ionization mode was 
used with a capillary voltage of 2.89 kV. Nitrogen was used as desolvation gas at 400°C 
and a flow of 1000 L/h. Ion source temperature was set to 120°C. Analyte specific 
fragmentation patterns were acquired through full scan data via manual optimization. 
Standard analyte solutions were infused directly into the mass spectrometer for this 
purpose with a constant flow of 10 µL/min. 
Based on the parent ion of NAAP and d4-NAAP mass transitions to three daughter ions 
for NAAP and two daughter ions for d4-NAAP were tuned in. The fragment with the 
highest response was used to calculate the analyte concentration (quantifier). The 
second intense fragmentation was used to confirm the results of the quantifier ion 
(qualifier). MS/MS measurements were performed in multiple reaction monitoring (MRM) 
mode with nitrogen as collision gas with a collision gas flow of 0.25 mL/min. The specific 
MRM parameters are given in table 2. 
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Table 2: MRM- parameters for mass spectrometric detection, CE: collision energy, a: parent-daughter 
combination used for quantification. 
 
Study subjects 
The newly developed method was applied to analyze urine samples from 21 individuals 
from the general German population (10 female, 11 male, ages between 26 and 55 
years, median 30 years, 10 smokers, collected in 2012) in a pilot human biomonitoring 
study. Creatinine concentrations of the samples varied between 0.16 g and 2.2 g 
creatinine per liter. Prior to the study all volunteers completed a short questionnaire 
about their use of paracetamol and Paracetamol containing products. The sampling of 
the biological specimens (urine samples) for method development and for performing the 
small pilot human biomonitoring study has been approved by the ethical review board of 
the medical faculty of the Ruhr-University Bochum (Reg. No.: 3867-10). The study 
design was presented to the volunteers in written form and all participants provided 
written informed consent. 
Results and discussion 
General considerations 
The present method was designed for the purpose of human biomonitoring studies on 
NAAP. Therefore we focused mainly on the following requirements: speed in order to 
achieve high sample throughput, reliability and linearity over a large concentration range 
to cover exposure levels from both environmental background exposures and the 
therapeutic Paracetamol use. For this purpose we combined HPLC on-line enrichment 
by turbulent flow chromatography with MS/MS-detection. The turbulent flow approach 
enabled us to extract and enrich the analytes online from the sample matrix in a very 
short time (less than 1 minute). Transfer of the analytes onto the analytical column was 
realized by a time controlled switching valve. Because of the on-line extraction procedure 
no sample pretreatment was necessary (except enzymatic hydrolysis and precipitation of 
cryophobic proteins) reducing manual handling to a minimum and thus saving both 
Analyte Parent ion 
(Q1) 
Daughter ion 
(Q3) 
Retention 
time [min] 
CE (eV) Dwell time 
[s] 
      
NAAP 152 110a 6.01 17 0.25 
  93  22 0.05 
  65  28 0.25 
d4- NAAP 156 114a 6.01 17 0.25 
  97  22 0.1 
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manpower and chemicals (solvents). The use of ESI-MS/MS with isotope dilution 
quantification ensured both highly sensitive and selective results. 
Enzymatic hydrolysis 
Deconjugation of the metabolites, to measure the sum of conjugated and free NAAP, 
was achieved by using HP-2 β- glucuronidase (≥ 100,000 units/mL) which also contains 
sulfatase activity (≤ 7,500 units/mL). For optimization of the enzymatic hydrolysis several 
incubation times and pH-values were tested (data not shown). Enzymatic deconjugation 
of NAAP in native urine samples was found to be completed after 3.5 h of incubation at a 
pH between 5.5-6.0. 
High performance liquid chromatography  
In preparation for chromatographic analysis samples (after enzymatic deconjugation) 
were frozen overnight, thawed and centrifuged to separate any precipitate (probably 
proteins), which was found to extend the lifetime of chromatographic columns and in-line 
filters considerably. We applied a column switching method in which we combined 
turbulent flow chromatography for sample cleanup and extraction and reversed phase 
chromatography for analyte separation. In turbulent flow chromatography samples are 
injected with high flow rates (1.5-5.0 mL/min) onto a column packed with large particles 
(50-150 µm) [30,31]. The high flow rate generates a turbulent flow inside the column. 
Small analyte molecules are retained by diffusion into particle pores and adsorption to 
the stationary phase whilst macromolecules (proteins etc.) are not retained and flushed 
into waste. In our two column assembly we transferred the analytes retained on the 
turbulent flow column onto the analytical column by a change in flow direction 
(backflush), with the elution power of the gradient sufficient to desorb analytes from the 
pre-column but not too strong to perform chromatographic separation on the analytical 
column. Due to this the analytes are refocused at the beginning of the analytical column 
which leads to an increase of sensitivity. For on-line sample extraction and switching 
procedure several chromatographic considerations had to be taken into account. The 
gradient of the loading pump had to start with 100% water to ensure clean up and avoid 
analyte losses. After the switch transfer of the analytes was carried out by the analytical 
pump. The starting conditions for the gradient with 75% water and 25% methanol were 
found to be optimal for transferring the analytes from the turbulent flow column and 
refocusing them on the analytical column. Gradient parameters for the analytical column 
are shown in table 1. The gradient of the analytical column was carried out with 1mM 
aqueous solution of ammonium acetate buffer (pH 5.5-6) instead of water in order to 
enhance ionization of the analytes in the MS-source. After the second switch the 
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turbulent flow column was washed with high ratio of organic solvent (98% methanol; 2% 
water), to avoid carry-over effects of the analyte, and then re-equilibrated to starting 
conditions. Simultaneously, the analytical column was washed with 95% methanol and 
re-equilibrated to starting conditions. We also tested other eluent compositions (e.g. 
water/acetonitrile) and other pre-columns like Capcell PAK®. However, best results were 
achieved using the column assembly as described above. 
 
Figure 3: Q3 ESI positive spectrum of NAAP with tentative fragment- ion structures. 
Mass spectrometry 
As described in section 2.7. we obtained the specific fragmentation patterns of NAAP 
and its deuterated analogue through full scan data and trough MS/MS experiments via 
manual optimization. In both cases the [M + H]+molecular ion was used as the parent ion 
for specific mass transitions (m/z 152 for NAAP; m/z 156 for d4- NAAP). The specific 
parent daughter combinations for both analytes, together with the instrument 
parameters, are given in table 2. For both analytes the fragment with the highest 
response (m/z 110 for NAAP; m/z 114 for d4- NAAP) was used to calculate the analyte 
concentration (quantifier). Fragments with a less intense response were used to confirm 
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the results of the quantifier ion (qualifiers). A Q3 ESI positive spectrum of NAAP with 
tentative fragment structures is shown in figure 3. MRM-chromatograms of a calibration 
standard (40 µg NAAP/L) and two native urine samples with different NAAP 
concentrations (470 and 15 µg NAAP/L) are given in figure 4. 
 
 
Figure 4: MRM chromatograms with specific mass transitions of  NAAP (upper row) and d4-NAAP of 
calibration standard with 40 µg NAAP/L (A), a native human urine sample with 470 µg NAAP/L (B) and 
native human urine sample with 15 µg NAAP/L. 
 
Calibration graphs 
Calibration was performed with standard solutions in water. Calibration samples were 
treated equally to the urine samples. To examine a possible influence of the urinary 
matrix on the calibration we compared the calibrations in water to calibrations in urine. In 
comparison with the calibration curves obtained with the standard solutions prepared in 
water the calibration curves obtained from eight different urine samples spiked with 
NAAP (Reliability of the method) showed no influence of the urinary matrix on the slopes 
of the calibration curves. Of course, due to the presence of native NAAP in all urines 
analyzed, the y-axis intercepts of the calibrations in urine were shifted to values above 
zero depending on the content of NAAP in these samples (data not shown). Because the 
varying baseline concentration of NAAP in urine we chose to perform all further 
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calibrations in water. Calibration curves were obtained by analyzing aqueous standards 
and by plotting the quotient of peak areas of NAAP and d4-NAAP as a function of the 
NAAP concentration with a 1/x weighting. All calibration curves showed good linearity 
over the concentration range (0.5 µg/L-10000 µg/L) and produced linear correlation 
coefficients above 0.99. Samples with concentration above the highest calibration point 
were diluted with water to fit the calibration range. 
Reliability of the method 
Precision and accuracy  
We determined the intra-day precision of the method by analyzing the quality control 
standards eight times in a row. For Qlow relative standard deviation (RSD) was 1.7%. For 
Qmed and Qhigh calculated RSDs were 1.2% and 2.2% respectively. 
Table 3: Intra-day and inter-day precision of the method calculated by analysis of self-prepared quality 
control materials with three different concentration levels of NAAP. 
 
Inter-day precision was determined by analyzing Qlow, Qmed and Qhigh on eight different 
days using newly obtained calibration graphs for calculation of the NAAP- concentrations 
of the quality control samples. In inter- day- precision measurements RSDs were 4.1% 
for Qlow, 1.8% for Qmed and 2.7% for Qhigh. Results of the determination of intra-day and 
inter-day precision are listed in table 3.  
To determine the accuracy of the method we analyzed eight different urine samples with 
varying creatinine concentrations ranging from 0.3 g /L to 3.0 g /L, which were chosen to 
reflect the broad spectrum of urinary matrix. These samples were analyzed in native 
(non-spiked) condition and spiked at two concentration levels with concentrations of 
NAAP of 109.7 µg/L and 548.5 µg/L. All of these urine samples contained native NAAP 
concentrations (mean: 40.41 µg/L; range: 10.69 µg/L – 59.72 µg/L), thus the NAAP 
concentrations measured in the native samples were subtracted from the spiked 
concentrations before calculation. For the low-spiked concentration the mean calculated 
    
 Intra-day series (n = 8)  Inter-day series (n = 8) 
 Qlow Qmed Qhigh  Qlow Qmed Qhigh 
        
        
Measured conc. [µg/L] 12.6 92.9 435.8  14.5 100.6 449.9 
SD [µg/L] 0.2 1.1 9.5  0.6 1.8 12.1 
RSD [%] 1.7 1.2 2.2  4.1 1.8 2.7 
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accuracy (percent recovery) was 98.4% (90.1% - 103.4%). The mean accuracy (percent 
recovery) calculated from high concentration samples was 100.2% (96.1% - 103.1%). 
The precision data obtained from these spiking experiments with a RSD of 4.5 % for the 
low concentration and an RSD of 2.3 % for the high concentration was comparable to the 
inter- day- precision data from above, thus underlining the ruggedness of the method 
and the independence from the urinary matrix (table 4). 
 
Table 4: Precision and accuracy calculated from analysis of eight different urine samples with varying 
creatinine concentrations and two different NAAP spiking levels; native (non-spiked), spiked to 109.7 µg/L 
and spiked to 548.5 µg/L. 
 
Detection limit and quantification limit 
The limit of detection (LOD), defined as a signal-to-noise ratio of three for the registered 
fragment of NAAP was estimated to be 0.25 µg/L. The limit of quantification (LOQ) 
defined as a signal-to noise ratio of nine and was estimated to be 0.75 µg/L. Because no 
urine without native NAAP concentrations was available, all measurements to estimate 
LOD and LOQ were carried out in water. In some native urine samples the signal 
intensities of the added labeled internal standard were reduced by up to 60%, probably 
due to a quenching of the signal. However, as can be seen from the above spiking 
experiments with native urine samples this effect had no influence on accuracy or 
precision. Furthermore, as can be seen in the results of biological monitoring below, the 
lowest NAAP level determined in these samples was more than a factor of 10 above the 
LOQ. 
 
 
Spiking level 
 
low high 
   
   
Spiked conc. [µg/L] 109.7 548.5 
Native conc. measured [µg/L] 40.41 (10.7-59.7) 
Native and spiked conc. measured [µg/L] 148.4 (114.4-171.2) 589.8 (546.4-618.6) 
Spiked conc. calculated [µg/L] 
   
     Mean 107.9 549.4 
     Range 98.8-113.5 527.0-565.5 
     RSD [%] 4.5 2.3 
     Accuracy [%] 98.4 (90.1-103.4) 100.2 (96.1-103.1) 
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Results of biological monitoring 
The results of the pilot study encompassing 21 volunteers are shown in table 5; results 
for each volunteer individually are shown in supplemental table 1 (Appendix I). We 
detected NAAP in all samples analyzed with a wide range of concentrations from 8.7 
µg/L to 22120 µg/L. According to the questionnaire 4 of the 21 volunteers declared never 
to have taken paracetamol while 13 volunteers declared to have taken paracetamol at 
least once in their life, but at least a couple of weeks ago. 4 of the volunteers quoted to 
have taken paracetamol within a week prior to the study, one of them indicated that a 
single tablet of paracetamol was taken approximately 24hrs prior to the sampling. This 
volunteer also had the highest urinary paracetamol value measured in the pilot 
population (22120 µg/L). The other three (stating to have taken paracetamol recently) 
had urinary NAAP concentrations of 64.1 µg/L, 80.6 µg/L and 523.3 µg/L. In the group 
stating to have never taken paracetamol (n = 4), levels ranged from 59.1 µg/L to 424.5 
µg/L. In the group stating to use paracetamol at rare intervals but not within the last 
weeks (n = 14) the NAAP values ranged from 8.7 µg/L to 1700 µg/L (median 72.2 µg/L). 
Table 5: Results of the human biomonitoring pilot study with 21 volunteers. 
 
Urinary concentrations of  
N-acetyl-4-aminophenol 
[in µg/L] 
Paracetamol  
usage 
never / ≥ one week ago  
(n=17) 
within the last week  
(n=4) 
Mean 233.5 5697 
Median 85.7 301.9 
Range 8.7-1703 64.1-22100 
 
  
 
Obviously, there is a wide range in NAAP body burdens in all individuals of our study and 
a considerable overlap in NAAP concentrations, no matter if the individual has or has not 
taken paracetamol during the week before sample collection. As pointed out above, 
there could be several sources for the urinary NAAP/paracetamol levels observed in this 
pilot study, namely through foodstuff contaminated with paracetamol, through exposure 
to aniline (or related compounds) or through sources we are currently not aware of. As 
described in section 1, urinary aniline is determined routinely as hydrolyzed acetanilide. 
With acetanilide representing approx. 3% of the aniline dose and NAAP representing 
56% - 76% of the aniline dose [1], the ratio of these two aniline metabolites can be 
expected to be between 1:19 and 1:25.Taking into account the difference in the 
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molecular masses of acetanilide (M = 135.16 g/mol) and NAAP (151.16 g/mol) leads to a 
ratio of these two metabolites between 1:22 and 1:29 on a µg/L basis. Urinary aniline 
levels (determined as hydrolyzed acetanilide) in the general population with a 95th 
percentile around 14 µg/L [4,5] would therefore translate to NAAP concentrations of 
around 350 µg/L. A maximum aniline concentration of 384 µg/L as reported by Kütting et 
al. [4] would translate to approx. 10000 µg/L NAAP. The second highest urinary NAAP 
concentration found in our study (1700 µg/L) in an individual who reported not to have 
used Paracetamol prior to the study could thus be explained by aniline and aniline 
exposures found in the general population. 
Conclusion 
We have developed a fast, robust, sensitive and selective method to determine N-acetyl-
4-aminophenol (NAAP) in urine samples in a wide concentration range, covering the 
background body burden of the general population to this compound. We detected and 
quantified NAAP in all of the 21 volunteers of our pilot study. Our method can now be 
used to determine NAAP in larger population studies, both investigating the body burden 
to NAAP and the prevalence of paracetamol/acetaminophen usage in the general 
population or special subpopulations. 
The one individual who self-dosed paracetamol the day before the urine sample was 
collected obviously excreted NAAP at a level that was 13 times higher than the highest 
level found in the remaining 20 volunteers and approx. 250 times higher than the median 
level of all volunteers investigated. However, based upon the known aniline metabolism 
and the known exposure to aniline in the general population, NAAP levels well in the 
mg/L range can also be expected even if the individual did not use 
paracetamol/acetaminophen. Furthermore, because paracetamol/acetaminophen might 
be used in the treatment of lifestock, with apparently no specific maximum residue limit 
for this substance in foodstuffs of animal origin, contaminated foodstuff might be a direct 
route of exposure to paracetamol/acetaminophen. 
In general, the omnipresence of a pharmacologically active substance that per se is not 
naturally occurring in humans raises some concern. Recent toxicological studies (cited 
above) suggest that paracetamol might inhibit testosterone production in fetal rats, alone 
or in an additive manner together with other anti-androgens. Epidemiological studies 
suggest that paracetamol might be a risk factor for development of male reproductive 
disorders. Therefore, our findings of an omnipresent body burden to N-acetyl-4-
aminophenol (=paracetamol/acetaminophen) in samples from the general population 
strongly warrant further investigations. To investigate the possibility to distinguish 
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between the sources of the paracetamol/NAAP excretion (direct paracetamol exposure, 
aniline exposure, other sources) we plan to determine aniline, acetanilide and/or other 
aniline resp. paracetamol specific metabolites together with NAAP in a future study. 
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Abstract 
Epidemiological studies suggest associations between the use of N-acetyl-4-
aminophenol (paracetamol) during pregnancy and increased risks of reproductive 
disorders in the male offspring. Previously we have reported a ubiquitous urinary 
excretion of N-acetyl-4-aminophenol in the general population. Possible sources are (1) 
direct intake of paracetamol through medication, (2) paracetamol residues in the food 
chain and (3) environmental exposure to aniline or related substances that are 
metabolized into N-acetyl-4-aminophenol. In order to elucidate the origins of the 
excretion of N-acetyl-4-aminophenol in urine and to contribute to the understanding of 
paracetamol and aniline metabolism in humans we developed a rapid, turbulent-flow 
HPLC-MS/MS method with isotope dilution for the simultaneous quantification of N-
acetyl-4-aminophenol and two other aniline related metabolites, N-acetyl-2-aminophenol 
and acetanilide. We applied this method to three sets of urine samples: (1) individuals 
with no known exposure to aniline and also no recent paracetamol medication; (2) 
individuals after occupational exposure to aniline but no paracetamol medication and (3) 
paracetamol users. We confirmed the omnipresent excretion of N-acetyl-4-aminophenol. 
Additionally we revealed an omnipresent excretion of N-acetyl-2-aminophenol. In 
contrast, acetanilide was only found after occupational exposure to aniline, not in the 
general population or after paracetamol use. The results lead to four preliminary 
conclusions: (1) other sources than aniline seem to be responsible for the major part of 
urinary N-acetyl-4-aminophenol in the general population; (2) Acetanilide is a metabolite 
of aniline in man and a valuable biomarker for aniline in occupational settings; (3) aniline 
baseline levels in the general population measured after chemical hydrolysis do not 
seem to originate from acetanilide and hence not from a direct exposure to aniline itself; 
(4) N-acetyl-2-aminophenol does not seem to be related to aniline nor to N-acetyl-4-
aminophenol in man. 
 
Keywords: paracetamol, aniline, N-acetyl-4-aminophenol, N-acetyl-2-aminophenol, 
acetanilide, biomonitoring 
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Introduction 
N-acetyl-4-aminophenol (paracetamol/acetaminophen) is the active ingredient of several 
well-known and heavily sold over-the-counter drugs. Paracetamol has been widely used 
as first-line treatment of fever and pain during pregnancy since other over-the-counter 
pain relievers such as ibuprofen or acetylsalicylic acid are not considered to be safe for 
pregnant women. 20-75% of women have been reported to use such medications at 
least once during pregnancy (Werler et al., 2005; Thiele et al., 2013). Recently, however, 
it was suggested that the use of paracetamol during pregnancy is associated with an 
increased risk for the development of male reproductive disorders (Jensen et al. 2010; 
Kristensen et al., 2012; Snijder et al., 2012) and asthma in children (Andersen et al., 
2012). Additionally, recent mechanistic studies showed anti-androgenic effects of 
paracetamol both in the rat fetal testis (Kristensen et al. 2012) and in the human adult 
and fetal testis in vitro (Thiele et al., 2013; Mazaud-Guittot et al., 2013). Furthermore, N-
acetyl-4-aminophenol may be used in the treatment of poultry, cattle and swine with no 
holding time and no maximum residue level in the final meat products (Committee for 
Veterinary Medicinal Products (1999) Paracetamol Summary report; Regulation (EU) No. 
37/2010 of the European Commission, 2010). Because of the widespread use of 
paracetamol, even drinking water has been reported to be contaminated with 
paracetamol, albeit at rather low concentrations (Fram and Belitz, 2011). 
Recently it has been shown that the general population is ubiquitously excreting N-
acetyl-4-aminophenol in wide concentration ranges (Modick et al., 2013). Two major 
sources may be the reason for the observed ubiquitous urinary excretion: (1) direct 
exposure to N-acetyl-4-aminophenol (paracetamol/acetaminophen) via sources pointed 
out above; and/or (2) exposure to aniline or aniline precursors, which are known to 
produce N-acetyl-4-aminophenol in mammalian metabolism. In contrast to N-acetyl-4-
aminophenol, the general population has been known for some time to be ubiquitously 
exposed to aniline or aniline releasing substances (Weiss et al., 2002; Kütting et al., 
2009; el-Bayoumy et al., 1986). 
From studies in various animal species (sheep, dog and rat, Figure 1) we know that 
around 3% of an oral dose of aniline are metabolized to acetanilide and excreted via 
urine. Approx. 80 % of an aniline dose are metabolized to N-acetyl-4-aminophenol and 
excreted via urine (Kao et al., 1978; Aniline, MAK value documentation in German 
language, 1992). Thus, acetanilide is a metabolite of aniline and the metabolic precursor 
of N-acetyl-4-aminophenol. Acetanilide is not generated in the metabolism of N-acetyl-4-
aminophenol (Andrews et al., 1976; Ladds et al., 1987). By now, aniline exposure has 
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routinely been determined by measuring free aniline (el-Bayoumy et al., 1986; Aniline, 
MAK value documentation in German language, 1992) or total urinary aniline after 
hydrolyses to cleave possible aniline conjugates such as acetanilide (Weiss and 
Angerer, 2002; Kütting et al., 2009;). Aniline, determined this way, can be found in nearly 
all urine samples from the general German population with a median total aniline 
concentration of 3.5 µg/L and a maximum concentration of 384 µg/L (Kütting et al., 
2009). Based upon the data of Kütting et al. (2009) such aniline exposures could explain 
at least parts of urinary N-acetyl-4-aminophenol excretion in the general population. 
However, under strong acidic conditions aniline could also be released from other 
substances with an acid cleavable aniline moiety such as pesticides or azo dyes. Even 
partial deamination of aromatic amines was observed in urine under strong acidic 
conditions (Schettgen et al., 2011).  
Therefore, based upon the current GC-MS methods determining aniline after strong 
acidic hydrolysis it remains unclear if the aniline measured is solely derived from 
acetanilide, some residual free aniline, or other substances that can be broken down to 
aniline in the analytical process. Thus, the unequivocal and sensitive determination of 
acetanilide (next to N-acetyl-4-aminophenol) was a major aim of this study. Additionally, 
to further complement the spectrum of aniline metabolites we also included N-acetyl-2-
aminophenol in our method development. N-acetyl-2-aminophenol was found as 
metabolite of aniline after incubation of sheep intestine (Turner et al., 1976). In other 
metabolism studies after oral aniline administration urinary N-acetyl-2-aminophenol was 
not detected (Kao et al. 1978)  
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Fig. 1: Simplified aniline metabolism in animals (rats, pigs and sheep) after single oral administration of 
aniline (Kao et al., 1978). Dotted lines mark hypothetical pathway. 
 
Therefore, to further elucidate the origins of the ubiquitous excretion of N-acetyl-4-
aminophenol in urine samples from the general population (Modick et al., 2013), to 
generally contribute to the knowledge of aniline metabolism in man and to possibly 
distinguish the generation of N-acetyl-4-aminophenol via aniline metabolism from direct 
N-acetyl-4-aminophenol exposure we developed an HPLC-MS-MS method for the 
simultaneous quantification of N-acetyl-4-aminophenol and the aniline related 
metabolites, N-acetyl-2-aminophenol and acetanilide. We applied this method to three 
groups of individuals with different exposure scenarios: 1) individuals from the general 
population with no aniline exposure and known not to have used paracetamol medication 
recently; 2) individuals with occupational aniline exposure but no paracetamol medication 
prior to sampling; 3) individuals known to have used paracetamol within a day prior to 
sampling. 
 
 
 
 
Chapter II 
86 
Experimental 
Chemicals 
N-acetyl-4-aminophenol (CAS No. 103-90-2, purity 99.0 %), N-acetyl-2-aminophenol 
(CAS No. 614-80-2, purity 97 %) and acetanilide (CAS No. 103-84-4, purity 99 %) were 
purchased from Sigma-Aldrich (Steinheim, Germany). N-acetyl-4-aminophenol-d4 (0.1 
mg/mL in acetonitrile) was obtained from LGC Standards (Wesel, Germany) and 
acetanilide-d5 (CAS No. 15826-91-2, purity 99 %) was obtained from CDN Isotopes 
(Augsburg, Germany). Pyridine, dichloromethane, acetic acid-d4 and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride were purchased from Sigma-Aldrich 
(Steinheim, Gemrany). Deionized water was obtained using a Millipore Advantage A10 
with a Quantum®-cartridge. Acetonitrile (LC-MS grade) was purchased from Roth 
(Darmstadt, Germany). Ammonium acetate p.a., HP2 β-glucuronidase/arylsulfatase and 
ammonium bicarbonate were purchased from Sigma-Aldrich (Steinheim, Germany). 
Synthesis of N-acetyl-2-aminophenol-d3 
N-acetyl-2-aminophenol-d3 was synthesized by selective acetylation of 2-aminophenol at 
the amino group with activated acetic acid-d4. Activation of acetic acid was performed by 
adding acetic acid-d4 to a solution of 352 mg 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDAC) and 144 mg pyridine in 4 mL 
dichloromethane at 0°C.  
After 1 h 200 mg 2-aminophenol dissolved in 2 mL dichloromethane were added and the 
solution was stirred overnight. Afterwards the reaction mix was extracted twice with 6 mL 
1N hydrochloric acid and washed with saturated sodium chloride solution. The 
dichloromethane was evaporated and the residual N-acetyl-2-aminophenol-d3 was 
dissolved in acetonitrile. The absence of interfering non-or partially labeled N-acetyl-2-
aminophenol was verified by HPLC-MS/MS. The concentration of N-acetyl-2-
aminophenol-d3 in acetonitrile was roughly estimated by HPLC-MS/MS using unlabeled 
N-acetyl-2-aminophenol for calibration. 
Calibration standards 
Stock solutions were prepared by weighing 10 mg of each standard into a separate 10-
mL-volumetric flask, which then was filled up to the mark with acetonitrile (1 g/L). For 
analysis, eight calibration standards were prepared from these stock solutions by gradual 
dilution with water to yield final concentrations ranging from 2.2 µg/L to 2,200 µg/L for N-
acetyl-4-aminophenol, from 81 µg/L to 1,900 µg/L for N-acetyl-2-aminophenol and from 
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0.2 µg/L to 225 µg/L for acetanilide, respectively. Stock solutions and calibration 
standards were stored at -20°C in Teflon capped glass vials until further use. The 
solutions of the internal standards were prepared by mixing solutions of N-acetyl-4-
aminophenol-d4, acetanilide-d5 and N-acetyl-2-aminophenol-d3 in acetonitrile. This 
mixture was then diluted with water in a 10-mL-volumetric flask to final concentrations of 
250 µg/L, 100 µg/L and 100 µg/L, respectively. 
Specimen collection and sample preparation 
Urine samples were collected in 250-mL polyethylene containers and immediately stored 
at -20°C until further processing. All samples were equilibrated to room temperature prior 
to analysis. Samples were vortex mixed before transferring 300-µL-aliquots into a 
silanized 1.8-mL Teflon screw cap vial. Deconjugation of the metabolites, to measure the 
sum of conjugated and free analytes, was achieved by using HP-2 β-glucuronidase (≥ 
100,000 units/mL) which also contains arylsulfatase activity (≤ 7,500 units/mL) following 
the optimized protocol published for N-acetyl-4-aminophenol (Modick et al., 2013). In 
brief, 180 µL ammonium acetate buffer (0.5 M, pH 5.5 – 6.0), 30 µL internal standard 
solution and 6 µL of β-glucuronidase/arylsulfatase were added to each sample. After 
incubation at 37°C in a water bath for 3.5 h all samples were frozen at -18°C overnight to 
freeze out and precipitate proteins. After thawing, all samples were centrifuged at 4000 g 
for 10 min. The supernatant was transferred into a second silanized 1.8-mL Teflon screw 
cap vial. Urinary creatinine concentrations were determined according to Jaffe (1886). 
Calibration procedure and quantification 
Calibration was performed with aqueous standard solutions. All calibration standards 
were treated equally to the urine samples. Linear calibration curves were obtained with a 
1/x weighing by plotting the quotients of peak areas of the analytes with the respective 
deuterium labeled internal standards as a function of the analyte concentration. If the 
determined analyte concentration of a sample from a study subject was outside the 
calibration range, the sample was diluted with water and processed again. 
Quality control materials  
Quality control material was prepared within our laboratory using native urine samples 
from different volunteers. These urine samples were analyzed for their analyte 
concentration and then pooled to obtain control material with low and high 
concentrations of the three analytes (concentrations see Table 4). Due to the lack of 
acetanilide in native samples we spiked the pool urines with acetanilide standard solution 
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at two different concentration levels. The resulting materials were frozen, thawed and 
filtered three times before use. The obtained control material was divided into aliquots 
and stored at –20°C. Reliability and precision of the method were determined by 
measuring these quality control samples eight times in a row for the intra-day precision 
and on eight different days for the day to day imprecision. Additionally, accuracy and 
imprecision were determined by analyzing eight different urine samples with varying 
creatinine concentrations ranging from 0.3 g/L to 3.0 g /L. These samples were analyzed 
non-spiked and spiked at two concentration levels (ref. Table 3). The concentrations of 
the native samples were subtracted from the spiked concentrations before further 
calculation. 
 
High performance liquid chromatography 
High performance liquid chromatography was carried out using a 1525 binary pump 
(loading pump) and a 1525µ binary pump (analytical pump) (Waters, Milford, USA), a 
Waters In-Line AF degasser and a Waters 2777 Sample Manager autosampler. Detailed 
information and a schematic sketch of the two-column-assembly used have previously 
been published by Modick et al. (2013). In short, a Waters Oasis® HLB cartridge column 
(2.1 x 20 mm; 25 µm) was used as first column for cleanup and enrichment of the 
analytes by turbulent flow technique. Chromatographic separation was performed using 
a Hypercarb (Thermo Scientific) (2.1 x 100 mm; 3 µm) column. The used eluents 
consisted of a solution of 3 mM ammonium bicarbonate in water (solvent A) and 
acetonitrile (solvent B). An in-line filter (Phenomenex 0.5 µm x 3.0 mm; AF0-0378) was 
placed in front of the HLB-phase and a guard column (PFP 2.0 x 4 mm) was placed in 
front of the analytical column. 210 µL of the processed sample were injected with a 
constant flow of solvent A of 3.75 mL/min by the loading pump onto the HLB-phase. After 
1 min the valve position was switched and the analytes were transferred in backflush 
mode onto the Hypercarb column through a time controlled switching valve (Waters 
Selector Valve). The analytes were chromatographically separated by the gradient flow 
from the analytical pump of solvents A and B (Table 1). 
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Table 1: Gradient program (analytical pump) for chromatographic separation, solvent A: 3 mM ammonium 
bicarbonate; solvent B: acetonitrile 
 
 
After 6 min the switching valve was set back into position A and the HLB- phase was 
flushed with high organic solvent (98% solvent B; 2% solvent A) and then re-equilibrated 
with 100% of solvent A. All steps were controlled by Waters MassLynx V4.1 software. 
 
Mass spectrometry 
The mass spectrometric detection and quantification was performed using a Waters 
Quattro Premier XE triple quadrupole mass spectrometer as described by Modick et al. 
(2013). Positive ionization mode was used with a capillary voltage of 4.00 kV. Nitrogen 
was used as desolvation gas at 400°C and a flow of 1000 L/h. Ion source temperature 
was set to 120°C. Analyte specific fragmentation patterns were acquired through full 
scan data via manual optimization. For this purpose, standard analyte solutions (approx. 
1 mg/L) were infused directly into the mass spectrometer with a constant flow of 10 
µL/min. 
Based on the parent ion of the analytes and the internal standards mass transitions to 
two daughter ions were tuned in. The fragment with the highest response was used to 
calculate the analyte concentration (quantifier). The mass with the second intensity was 
used to confirm the results (qualifier). The measurements were performed in multiple 
Program 
step 
Time 
(min) 
Solvent 
A (%) 
Solvent 
B (%) 
Flow 
rate 
(ml/min) 
Valve 
position 
Analysis step 
       
       
1 Initial 77 23 0.2 A Cleanup, enrichment (on the 
HLB-column) 
2 1.00 77 23 0.2 B  
3 3.00 77 23 0.2 B Analyte transfer 
4 3.25 70 30 0.2 B Separation 
5 6.00 70 30 0.2 A  
6 10.00 52 48 0.2 A  
7 11.00 5 95 0.2 A  
8 13.00 5 95 0.2 A Washing 
9 13.50 77 23 0.2 A  
10 15.00 77 23 0.2 A Reconditioning 
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reaction monitoring (MRM) mode with argon as collision gas (0.25 mL/min). The specific 
MRM parameters are given in Table 2. 
 
Table 2: MRM-parameters for mass spectrometric detection, CE: collision energy, a: quantifier b: qualifier 
 
Study subjects 
The method was applied to urine samples from three different groups of volunteers. 
Group 1 consisted of 31 individuals who had no known occupational exposure to aniline 
and self-declared no use of paracetamol or paracetamol containing medications for at 
least one week before sample collection. Group 2 consisted of six volunteers with 
exposure to aniline in an occupational setting but with no recent (at least one week ago) 
use of paracetamol/acetaminophen (confirmed by questionnaire). The aniline exposure 
of these individuals determined by air measurements was rather high but still within the 
legal limits of the German AGW (occupational limit value of 7.7 mg/m3). Group 3 
consisted of two volunteers who had used paracetamol the day before sampling but who 
had no known (occupational) aniline exposure. All participants provided written informed 
consent for participation. The study was approved by the Ethics Committee of the Ruhr 
University Bochum (Reg. No.: 3867-10, Reg.-Nr.: 4730-13) and was conducted in 
accordance with the Helsinki Declaration. 
  
Analyte Rt 
[min] 
Parent 
ion (Q1) 
Daughter 
ion (Q3) 
CE 
[eV] 
Dwell time 
[s] 
      
N-acetyl-4-aminophenol 10.6 152 110a 15 0.25 
   92b 25 0.05 
N-acetyl-4-aminophenol d4 10.5 156 114a 15 0.25 
   97b 25 0.05 
N-acetyl-2-aminophenol 11.2 152 110a 15 0.25 
   92b 25 0.05 
N-acetyl-2-aminophenol d3 11.1 155 111a 15 0.25 
   93b 25 0.05 
Acetanilide 12.0 136 94a 16 0.25 
   77b 22 0.05 
Acetanilide d5 11.9 141 99a 18 0.25 
   81b 28 0.05 
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Results and discussion 
General considerations 
The present method has been designed for the simultaneous determination of N-acetyl-
4-aminophenol, N-acetyl-2-aminophenol and acetanilide in urine without the need for 
intensive sample work up or derivatisation. The method has been designed both for large 
scale human biomonitoring studies and for human metabolism studies on paracetamol, 
aniline, or substances possibly breaking down to aniline in human metabolism. Thus, we 
focused on high sample throughput, reliability and linearity over a wide concentration 
range. Due to an on-line extraction procedure by turbulent flow chromatography, thus 
efficient enrichment of the analytes, sample pretreatment was minimized. The use of 
ESI-MS-MS with isotope dilution ensured both highly sensitive and selective results. 
 
High performance liquid chromatography  
We applied a column switching method in which we combined turbulent flow 
chromatography for sample cleanup and extraction, and reversed phase 
chromatography for analyte separation. For sample enrichment we used an assembly 
consisting of a short Waters Oasis® HLB cartridge column and an automatic switching 
valve as previously described (Modick et al., 2013). Under the conditions of turbulent 
flow macromolecules (proteins etc.) show no retention on the stationary HLB phase thus 
are flushed into the waste, while small molecular weight analytes can interact with the 
stationary phase, are retained and can be transferred onto the analytical column by a 
change in flow direction (backflush) and solvent composition. To avoid peak broadening 
and misshaped peaks the elution power of the starting eluent has to be strong enough to 
desorb analytes from the HLB column but not too strong to start chromatographic 
separation on the analytical column. The choice of the analytical column was a crucial 
point during method development. Additionally, the chromatographic separation of the 
structural isomers N-acetyl-4-aminophenol and N-acetyl-2-aminophenol had to be 
realized. In the line of columns tested (Atlantis T3, Luna Phenylhexyl, Luna PFP) the 
Hypercarb column turned out to ensure baseline separation of these two analytes using 
acetonitrile and 3 mM ammonium bicarbonate in gradient elution. The overall run time of 
the method is 15 min including regeneration/equilibration of the enrichment and the 
analytical column. 
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Mass spectrometry 
We obtained the specific fragmentation patterns of the analytes and their deuterated 
analogs through full scan data and through MS-MS experiments via manual optimization. 
N-acetyl-4-aminophenol shows approximately a 12-fold intense peak response than N-
acetyl-2-aminophenol (ref. Figure 2). Due to this difference, the use of the commercially 
available deuterated N-acetyl-4-aminophenol d4 as internal standard for both isomers 
was not possible. Therefore, we synthesized deuterium labeled N-acetyl-2-aminophenol 
d3. Characterization of the product was performed by LC-MS-MS. In a purity check by 
LC-MS-MS no interfering byproducts could be detected at the mass transitions recorded 
in this method.  
For all three analytes the [M+H]+ molecular ion was used as the parent ion for specific 
mass transitions. Specific parent daughter combinations for all analytes, together with 
the instrument parameters, are given in Table 2. In all cases the fragment with the 
highest response was used to calculate the analyte concentration (quantifier). Fragments 
with a less intense response were used to confirm the results of the quantifier ion 
(qualifiers). MRM-chromatograms of a calibration standard and of two native urine 
samples with different analyte concentrations are presented in Figure 2. 
Chromatogram A1 shows the mass transitions of N-acetyl-4-aminophenol and N-acetyl-
2-aminophenol in an aqueous standard solution. The isomers are well separated; in 
urine (chromatogram B 1 and C 1) no interfering matrix compounds were detected. Peak 
widths and shapes are very good thanks to refocusing of the analytes at the beginning of 
the analytical column. Chromatogram A2 shows the mass transitions of acetanilide in an 
aqueous standard solution. In the urine sample from group 1 (B2) no acetanilide was 
detected, in the sample from group 2 (C2) a high signal for acetanilide was detected. 
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Figure 2: MRM-chromatograms with specific mass transitions for N-acetyl-4-aminophenol (NA4AP) and N-
acetyl-2-aminophenol (NA2AP) (m/z) (152 > 110) and acetanilide (AA) (m/z 136 > 94). A: aqueous standard 
solution (NA4AP: 270 µg/L; NA2AP 324 µg/L; AA 4.5 µg/L); B: urine sample from group 1 (NA4AP: 463 µg/L; 
NA2AP 2023 µg/L; AA < 0.03 µg/L); C: urine sample from group 2 (NA4AP: 4150 µg/L; NA2AP 271 µg/L; AA 
< 82 µg/L) 
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Calibration graphs 
Calibration was performed with standard solutions in water which were treated equally to 
the urine samples. We examined a possible influence of the urinary matrix on the 
calibration by comparing aqueous calibrations with calibrations in urine by using eight 
different urine samples with different creatinine content (see Reliability of the method). In 
these experiments we did not observe influences of the urinary matrix on the slopes of 
the calibration curves. However, due to the presence of all three analytes in native urines 
calibration should be carried out in water. Calibration curves of all analytes showed good 
linearity with correlation coefficients of above 0.99 (Table 3). If the determined analyte 
concentration of a sample was outside the calibration range, the urine sample was 
diluted with water and processed again. 
Table 3: Calibration ranges, correlation coefficients, LODs and LOQs 
Analyte Calibration range R² LOD LOQ 
  [µg/L]   [µg/L] [µg/L] 
N-acetyl-4-aminophenol 2.2-2,200 >0.99 0.07 0.21 
  
    N-Acetyl-2-aminophenol 81-19,400 >0.99 2.0 6.0 
  
    Acetanilide 0.2-225 >0.99 0.03 0.09 
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Reliability of the method 
The relative standard deviations (RSD) for the three analytes and the two concentrations 
are listed in Table 4. Intra-day and inter-day imprecisions of all analytes were below 15% 
in all cases. 
Table 4: Intra-day and inter-day precision of the method calculated by analysis of self-prepared quality 
control materials with two different concentration levels 
N-acetyl-4-aminophenol Acetanilide N-acetyl-2-aminophenol 
Intra-day series (n=8) 
Qlow Qhigh Qlow Qhigh Qlow Qhigh 
Measured conc. 
[µg/L] 12,8 475,6 2,0 180,7 61,2 293,0 
SD [µg/L] 1,5 15,8 0,1 4,8 6,0 8,6 
RSD [%] 11,4 3,3 2,7 2,7 9,9 2,9 
 Inter-day series (n=8) 
Measured conc. 
[µg/L] 11.9 501 1.7 190 68,0 347 
SD [µg/L] 1.7 28 0.2 13.2 10.2 33.0 
RSD [%] 14.4 5.6 10.7 6.9 15.0 9.5 
 
        
 
The mean recoveries for the three analytes were between 103 and 119 % which is highly 
acceptable taking into account that baseline concentrations in the native samples varied 
considerably. The imprecisions obtained from these spiking experiments were 
comparable to the inter-day- imprecision data, thus underlining the ruggedness of the 
method and the absence of a relevant matrix effect (Table 5). The limit of detection 
(LOD) was estimated on the basis of a signal to noise ratio of 3:1, whereas the limit of 
quantitation (LOQ) was based on a signal to noise ratio of 9:1. As no urine sample with 
sufficiently low native N-acetyl-4-aminophenol and N-acetyl-2-aminophenol 
concentrations were available we determined their LOD and LOQ in water instead of 
urine as for acetanilide. LODs and LOQs are listed in Table 3. 
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Table 5: Precision and accuracy calculated from analysis of eight different urine samples with varying 
creatinine concentrations and two different spiking levels 
 
Results of biological monitoring 
The results of the biomonitoring measurements for the three analytes encompassing 
urine samples from three different groups of volunteers are presented in Table 6 and the 
individual results for each volunteer in supplemental Table S1 (Appendix II).  
N-acetyl-4-aminophenol was detected in all urine samples of group 1 (31 volunteers 
from the general population with no aniline exposure or paracetamol medication). 
Concentrations were found in the range between 8.4 µg/L and 2,263 µg/L. The overall 
median in group 1 was 80 µg/L. These results are confirming the results of our recently 
published pilot study on N-acetyl-4-aminophenol with 21 individuals in which we reported 
a median of 85.7 µg/L and already showed the omnipresent excretion of N-acetyl-4-
aminophenol (Modick et al., 2013). In group 2 (six volunteers with exposure to aniline in 
an occupational setting) the median was 5,720 µg/L which is about 70 times higher than 
in group 1. The maximum value within this group was 10,885 µg/L. These results are 
consistent with N-acetyl-4-aminophenol being the major urinary metabolite of aniline 
(Kao et al., 1978). The highest value of group 1, however, was only lower by a factor of 5 
compared to group 2. The two individuals with paracetamol medication within 24 hours 
prior to urine sampling (group 3) exhibited urinary N-acetyl-4-aminophenol 
concentrations that were well in the mg/L range (159 and 275 mg/L) and thus 15 times 
higher than the maximum value of group 2 and 70-120 times higher than the maximum 
    
 
N-acetyl-4-aminophenol N-acetyl-2-aminophenol Acetanilide 
Spiking level low high low high low high 
 
      
Spiked conc. 
[µg/L] 
110 274 147 270 9 225 
Native conc. 
[µg/L] 
6-541 51-3493 < LOQ 
Conc. measured 
[µg/L] 
 
109-661 
 
274-832 
 
228-3644 
 
376-3785 
 
9.6-11.1 
 
237–262 
Spiked conc. 
calculated [µg/L]) 
      
     Mean 115 291 169 309 10 248 
     Range 93-134 265-319 148-191 269-369 9.6-11.1 237-262 
     RSD [%] 9.9 5.9 8.6 9.3 3.1 2.4 
     Accuracy [%] 105 (85-122) 106 (96 – 116) 103 (101-130) 119 (100-137) 114 (106-123) 110 (106-116) 
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value of group 1. Still, and this is a remarkable finding, N-acetyl-4-aminophenol values 
well in the mg/L range could be detected in all groups, including group 1.  
Table 6: Results of the human biomonitoring study; group 1: no known occupational aniline exposure and no 
known paracetamol use; group 2: known aniline exposure and no paracetamol usage; group 3: no known 
occupational aniline exposure and recent paracetamol usage; n.a. not analyzable 
 
 
 
 
 
 
 
 
 
 
 
 
Group 1 Group 2 Group 3 
  
n=31 n= 6 n=2 
N-acetyl-4-aminophenol 
Min 8.4 4150 159440 
Max 2263 10885 274862 
Median 80 5720 
  
      
N-acetyl-2-aminophenol 
Min 7.4 271 n.a. 
Max 39161 2319 n.a. 
Median 2071 918 
  
      
Acetanilid 
Min < LOQ 41.2 < LOQ 
Max < LOQ 122 < LOQ 
Median < LOQ 78.7 < LOQ 
Chapter II 
98 
N-acetyl-2-aminophenol was also detectable in all urine samples of group 1 ranging 
from 7.4 µg/L to 39,161 µg/L, with a median of 2,071 µg/L. We are not aware that N-
acetyl-2-aminophenol has previously been reported to be excreted in urine samples from 
the general population. Surprisingly, unlike for N-acetyl-4-aminophenol, we could not 
observe any relation of N-acetyl-2-aminophenol with aniline exposure (group 2). 
Individuals from group 1 excreted N-acetyl-2-aminophenol at comparable or rather 
higher levels than individuals from group 2. Therefore, N-acetyl-2-aminophenol excretion 
does not seem to be a significant metabolite in human metabolism of aniline. In the two 
urine samples from individuals having consumed paracetamol the quantitative 
determination of N-acetyl-2-aminophenol was hampered by excessively high N-acetyl-4-
aminophenol concentrations, which lead to a considerable peak broadening for N-acetyl-
4-aminophenol. Due to the peak broadening the peak of N-acetyl-4-aminophenol 
overlapped with the peak of N-acetyl-2-aminophenol, which made the unambiguous and 
sensitive quantification impossible.  
 
Surprisingly, acetanilide could neither be detected in group 1 nor in group 3, not even at 
lowest levels down to the LOD of 0.03 µg/L of our method. From previous studies 
reporting ubiquitous aniline exposure in the general population (Weiss and Angerer, 
2002; Kütting et al., 2009; el-Bayoumy et al., 1986), we would have expected acetanilide 
to show up in at least some of these individuals. However, all of the 6 individuals known 
to be exposed to aniline excreted acetanilide in levels far above the LOQ of our method 
(median of 78.7 µg/L; range 41.2–122 µg/L). In these individuals acetanilide levels were 
approximately 100 times lower than N-acetyl-4-aminophenol levels. This finding is in 
rough accordance to the known metabolism of aniline in animals, where N-acetyl-4-
aminophenol is the by far major and acetanilide is only a minor metabolite. If we used 
this acetanilide/ N-acetyl-4-aminophenol ratio of approximately 100 (from the 
occupational aniline exposure scenario), or the acetanilide/ N-acetyl-4-aminophenol ratio 
of approximately 25-50 from animal studies (Kao et al., 1978) N-acetyl-4-aminophenol 
levels of 80 µg/L (median of group 1) should be accompanied by a urinary acetanilide 
excretion of 1 to 3 µg/L, if aniline was the sole source of exposure. Seen the other way 
round, N-acetyl-4-aminophenol levels as low as 0.75 to 3 µg/L theoretically caused by 
sole exposure to aniline would lead to detectable levels of acetanilide (>0.03 µg/L). N-
acetyl-4-aminophenol levels observed in the general population are ten to a hundred 
times above these 0.75 to 3 µg/L but, still, no acetanilide can be detected in urine.  
Chapter II 
99 
Thus, our findings confirm that acetanilide is a metabolite of aniline in man and can be 
used to determine occupational exposure to aniline. Acetanilide as biomarker for aniline 
exposure is more specific than determination of aniline after acetic hydrolysis by gas 
chromatography. During acetic hydrolysis aniline may be released from other molecules 
(azo dyes, pesticides, pharmaceuticals) which are not aniline metabolites. Additionally, in 
argumentum e contrario, since N-acetyl-4-aminophenol is excreted in the individuals of 
group 1 (general population) without concurrent excretion of acetanilide, the bulk of 
excretion of N-acetyl-4-aminophenol in these individuals – especially those in the mg/L 
range - is not likely to be caused by aniline or acetanilide exposure. 
Summary and Conclusions 
Within this manuscript we present a fast, robust, sensitive and selective HPLC-MS-MS 
method for the simultaneous quantitative determination of N-acetyl-4-aminophenol 
(paracetamol, acetaminophen), N-acetyl-2-aminophenol and acetanilide in urine 
samples. The method uses turbulent flow chromatography for sample cleanup and 
analyte enrichment, reversed phase chromatography for analyte separation after column 
switching and tandem mass selective detection with deuterated internal standards for 
each analyte. The method is suitable for human biomonitoring and has proven its 
applicability in urine samples of individuals who were exposed to the analytes or their 
metabolic precursors in occupational as well environmental settings, and in persons 
using paracetamol (N-acetyl-4-aminophenol) containing medication. We detected and 
quantified N-acetyl-4-aminophenol in the entire test sample set, including samples from 
the general population (n= 31), individuals exposed to aniline in an occupational setting 
(n=6) and paracetamol users (n=2). Paracetamol users clearly exhibited the highest N-
acetyl-4-aminophenol concentrations in urine. However, aniline exposed individuals 
(known not to have taken paracetamol) as well as individuals from the general population 
without paracetamol medication also excrete N-acetyl-4-aminophenol in the mg/L range. 
We previously suggested that exposure to aniline, which is an integral part of tobacco 
smoke and a ubiquitous environmental contaminant, might be responsible for urinary N-
acetyl-4-aminophenol in the occupationally non-exposed general population (Modick et 
al., 2013). This suggestion was based on the results of Kütting et al. (2009) and Weiss 
and Angerer (2002) who both reported urinary aniline levels (after chemical hydrolysis) in 
the general population with a median at about 3 µg/L and on animal metabolism studies 
in several mammalian species (Kao et al., 1978) in which acetanilide was found as a 
minor metabolite of aniline but no unconjugated aniline itself. The aniline exposed 
individuals in this study excreted acetanilide at concentrations roughly corresponding to 
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1-2% of the N-acetyl-4-aminophenol concentrations which is in concordance with the 
animal experiments of Kao et al. (1987). However, we could not detect any urinary 
acetanilide (LOD 0.03 µg/L) in persons from the general population or in persons with 
paracetamol medication. With regard to the small sample size our findings lead to four 
basic preliminary conclusions:  
(1) Other sources than exposure to aniline seem to be responsible for the major part of 
urinary N-acetyl-4-aminophenol in the general population, e.g. various derivatives of 
aromatic amines such as 4-aminophenol or nitro-aromatic compounds or even N-acetyl-
4-aminophenol itself. As pointed out in the introduction, N-acetyl-4-aminophenol might 
enter the food-chain through its use in meat production.  
(2) Acetanilide is a metabolite of aniline in man. In the occupational setting, acetanilide 
can be used as a valuable and more specific than aniline after chemical hydrolysis 
biomarker describing exposure to aniline. 
(3) In samples from volunteers of the general population, acetanilide could not be 
detected down to levels as low as 0.03 µg/L. Therefore, urinary aniline baseline levels in 
the general population measured after chemical hydrolysis (Weiss and Angerer 2002, 
Kütting et al. 2007) do not seem to originate from acetanilide and hence not from a direct 
exposure to aniline itself. As a consequence, there have to be other (acid labile) urinary 
precursors than acetanilide, which are hydrolysable to aniline during sample processing 
in the above methods.  
(4) To our knowledge, this is the first publication that reports a (ubiquitous) excretion of 
N-acetyl-2-aminophenol in the general population. N-acetyl-2-aminophenol does not 
seem to be related to aniline nor to N-acetyl-4-aminophenol (R²= 0.02; ref. Figure S1; 
Appendix II) in man. The source and toxicological significance of this internal burden 
remains unclear so far. 
Particularly the high urinary excretion of the pharmacologically active and possibly anti-
androgenic substance N-acetyl-4-aminophenol (paracetamol, acetaminophen) in the 
mg/L range and its sources should be further investigated since they were found in 
persons of the general population who self-reported not to have taken any N-acetyl-4-
aminophenol containing medication. 
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Abstract 
 
N-acetyl-4-aminophenol (acetaminophen/paracetamol) is one of the most commonly 
used over-the-counter analgesic and antipyretic drugs. Recent studies report anti-
androgenic effects of N-acetyl-4-aminophenol in vitro and possible associations between 
intrauterine exposure to N-acetyl-4-aminophenol and the development of male 
reproductive disorders in humans.  
N-acetyl-4-aminophenol is also a major metabolite of aniline (phenylamine), representing 
75-86% of the aniline dose excreted in urine. Aniline is an important large volume 
intermediate in several industrial processes. Besides various occupational settings with 
aniline exposure, also the general population is known to be ubiquitously exposed to 
aniline. 
In this manuscript we provide an overview of the recent literature concerning the intake 
of N-acetyl-4-aminophenol during pregnancy and possibly anti-androgenic effects of N-
acetyl-4-aminophenol as well as literature concerning its known metabolic precursor 
aniline.  
We also present new research data, including first human biomonitoring data on N-
acetyl-4-aminophenol excretion in urine, showing ubiquitous N-acetyl-4-aminophenol 
body burdens in the general population in a wide range of concentrations. We found a 
small but significant impact of smoking on urinary N-acetyl-4-aminophenol 
concentrations. We further present preliminary data on N-acetyl-4-aminophenol excretion 
after therapeutic acetaminophen use, after aniline exposure in an occupational setting 
and during a controlled fasting study (excluding oral exposure to both aniline and 
acetaminophen). Our findings indicate to exposure to aniline (or aniline releasing 
substances) as well as nutrition (next to the direct use of acetaminophen as medication) 
as possible sources for internal body burdens of N-acetyl-4-aminophenol. 
Keywords: acetaminophen, paracetamol, human biomonitoring, aniline, anti-androgenic 
effects, environmental exposure 
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Introduction 
Since its market placement in 1950`s acetaminophen, in Europe generally referred to as 
paracetamol (N-acetyl-4-aminophenol, CAS No. 103-90-2, herein abbreviated with 
NA4AP), is one of the top-selling and heavily used over-the-counter analgesic (pain 
relieving) and antipyretic (fever reducing) non-steroidal anti-inflammatory drugs 
(NSAIDs). NA4AP is also approved for veterinary use in the European Union e.g. in 
poultry and swine meat production (European Commission 2010). However, it has long 
been overlooked that NA4AP is the major metabolite of aniline (phenylamine, CAS No. 
62-53-3). Aniline is an important building block in chemical industry e.g. in the production 
of rubber, pesticides and in colorants used in food, cosmetics and textiles. It is known for 
some time that the general population is ubiquitously exposed to aniline through 
environmental as well as occupational sources.  
In two recent human biomonitoring pilot studies that were carried out by our group we 
reported the ubiquitous excretion of NA4AP in urine samples from the general population 
(Modick et al. 2013, Dierkes et al. 2014). We observed maximum urinary NA4AP 
concentrations well in the mg per liter range even after the exclusion of individuals using 
NA4AP containing pharmaceuticals or individuals with possible occupational exposure to 
aniline.  
The ubiquitous presence of a pharmacologically active substance in the general 
population per se warrants further investigations. Additionally, recent in vitro studies as 
well as epidemiological studies suggest NA4AP as a possible risk factor for male 
developmental disorders in humans (Kristensen et al. 2012, Thiele et al. 2013).  
Therefore, in the present article we will give an overview of the available data on 
possible detrimental effects of NA4AP on male sexual development, its role in aniline 
metabolism, recent human biomonitoring data and possible sources of internal body 
burdens of NA4AP in the general population in environmental and occupational settings. 
We complement this article with new research data on NA4AP human biomonitoring 
from our institute. 
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Intakes and usage of NA4AP 
NA4AP in human NSAIDs 
NA4AP (acetaminophen/paracetamol) along with aspirin is one of the most commonly 
used over-the-counter (OTC) drugs for the treatment of pain and fever. The German 
pharmaceutical register lists 55 formulations containing NA4AP as a single drug or as a 
pharmaceutical ingredient in combination drugs that are approved for sale in Germany 
(Landschneider 2011). In 2008 two of the ten top-selling pharmaceuticals in Germany 
contained NA4AP (Glaeske et al. 2009). About 35.5 million packages of NA4AP each 
containing 20-40 pills were sold in Spain in 2009 (de Ortiz García et al. 2013).  
NA4AP and NA4AP containing pharmaceuticals are also commonly taken by pregnant 
women (Black & Hill 2003). Several large birth cohort studies reported general intake of 
OTC analgesics during pregnancy (see table 1). Reasons for the intake of OTC 
analgesics were mainly headache (66.5%) followed by muscle ache (8.7%) and other 
types of pain (8.7% in sum). Fever, inflammation and cold accounted for 6.9% 
(Kristensen et al. 2010).  
Table 1: Frequency of analgesic use during pregnancy in several birth cohort studies. 
Cohort  Frequency of intake  
(at least once during 
pregnancy) [%] 
Reference 
    
    
Slone Epidemiology Center 
Birth Defects Study (USA) 
n = 7,563 69.8 Werler et al. 2008 
    
National Birth Defects 
Prevention Study (USA) 
n = 2,970 65.5 Werler et al. 2008 
    
Danish National Birth Cohort  n = 
88,142 
50.3 Rebordosa et al. 
2008 
    
Danish and Finish Birth Cohort  n = 2,297 26.1–57.2b Kristensen et al. 2011 
    
Eden Mother-Child Cohort (FR) n = 903 81a Philippat et al. 2011 
    
Generation R Study (NL) n = 3,184 29.9a Snijder et al. 2012 
    
    
a
 mild analgesics in general 
b
 depending on if inquiry was done by questionnaire or by telephone interview 
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Variations between these studies may be explained by the study sizes as well as 
demographic factors like ethnicity, educational status and age. (Werler et al. 2005). 
There is also an influence whether the inquiry was realized through self-administered 
questionnaires or done by a telephone interview. Among the Danish cohort (Kristensen 
et al. 2010) 285 mothers completed both a questionnaire and a telephone interview. In 
the questionnaire 30.9% (88 out of 285) of the mothers reported use of analgesics 
opposed to 57.2% in the telephone interview (163 out of 285). The authors of this study 
came to the conclusion, that many mothers do not consider OTC analgesics as 
medication and therefore strongly underreported its use unless they were specifically 
asked.  
However, the available data clearly indicates that OTC analgesics are commonly used 
also by pregnant women. Large studies (n > 10,000) (Werler et al. 2005; Rebordosa et 
al. 2008) are indicating NA4AP and NA4AP containing pharmaceuticals as the most 
commonly taken products. 
NA4AP can freely pass the placenta (Weigand et al. 1984). NA4AP and its metabolites 
were detected in the urine of neonates after the mother had taken NA4AP a few hours 
before delivery (Levy et al. 1975a). Furthermore, since NA4AP is excreted in breast milk 
after therapeutic dosage the neonate can be exposed to NA4AP. In 1981 Bitzén et al. 
monitored levels of NA4AP in plasma and breast milk in three lactating women after a 
single 500 mg dose of NA4AP. In breast milk maximum concentrations of ~ 4 mg NA4AP 
/L were found within 2h after intake. The authors therefore estimated a dose less than 
0.1 % of the maternal dose for the infant in 100 mL breast milk (Bitzén et al. 1981). 
Comparable values were estimated by Berlin et al. with 22 lactating women who were 
given a 650 mg dose of paracetamol. The authors evaluated an ingestible amount of 
NA4AP for the neonate to be 0.04-0.23% of the maternal dose in 90 mL breast milk. 
Neither NA4AP nor its metabolites could be detected in the neonates` urines three to five 
hours after maternal dosing (two hours after nursing at peak maternal milk levels) (Berlin 
et al. 1980). In a study from 1987 NA4AP could be detected in the urines of six neonates 
whose mothers were given NA4AP although at considerably higher doses of 1-2 g. The 
authors detected free NA4AP and its glucuronide and sulphate conjugates in all urines, 
whereas cysteine and mercapturic acid conjugates could be detected in the urines of 5 
out of the 6 neonates (Notarianni et al. 1987). Thus, not only the mother but also the 
fetus and the neonates are exposed to NA4AP.  
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NA4AP in veterinary/meat production use 
According to Commission Regulation (EU) 37/2010 on pharmacologically active 
substances and their classification regarding maximum residue limits in foodstuffs of 
animal origin (European Commission 2010) NA4AP is approved for veterinary use in 
Europe. The regulation restricts the usage of NA4AP to porcine species. However, 
according to a report of the Committee for Veterinary Medicinal Products, which belongs 
to the European Agency for the Evaluation of Medicinal Products (EMEA), NA4AP is also 
used in cattle and poultry for the treatment of fermentation disorders, painful diseases 
and pyrexia (Committee for Veterinary Medicinical Products 1999). In Regulation (EU) 
37/2010 no maximum residue limit, and therefore no withdrawal period after treatment of 
animals with NA4AP was established. Suppliers of veterinary medicine formulations offer 
NA4AP as 30% solutions (30g/100mL) in package sizes up to 20L. Interestingly, one 
study conducted in the mid-1960s reported a stimulatory effect of NA4AP on chicken 
growth. NA4AP given at dietary levels between 0.1-2.0 g/kg feed increased weight gain 
in roosters and in hens by 6.5-10% compared to the controls (Dikstein et al. 1966). 
To our knowledge NA4AP has not been part of larger sized national food monitoring 
programs in the past years. In 2002 NA4AP was part of the monitoring program of the 
German national residue control plan, processed by the German Food Safety Authority. 
In sum 221 samples of animals or food products of animal origin inter alia including 
poultry, veal, cattle, swine and milk were tested for NA4AP. Residues of NA4AP could 
not be detected in any of the samples analyzed (Federal Ministry of Food, Agriculture 
and Consumer Protection 2002). However the report of the national residue control plan 
includes neither information about the analytical methods applied nor their limits of 
quantification which makes the interpretation of the results difficult. In contrast to 
antibiotics published analytical methods for the determination of NA4AP in foodstuffs of 
animal origin are rather rare. In 2010 Hu et al. (Hu et al. 2012) published a method for 
the determination of thirty NSAID residues including NA4AP in swine muscle by ultra-
high-performance liquid chromatography coupled with tandem mass spectrometry. The 
detection limit was 0.4 µg/ kg and the quantification limit was 1.0 µg/kg. The authors 
reported trace residues of NA4AP (and other NSAIDs) from 100 samples of imported 
swine muscles with a positive rate of about 7%. A similar method for the determination 
for NA4AP amongst other NSIADs in bovine milk and muscle tissue was developed by 
Gentilli et al. in 2012. The authors applied the method to 8 milk and 8 bovine muscle 
tissue samples. No residues of NA4AP could be detected in any of the samples (Gentili 
et al. 2012). In 2012 Love et al. (Love et al. 2012) detected NA4AP in feather meal (a 
byproduct made from poultry feathers) which can be used as an additive in animal feed 
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in concentrations ranging from 15.1-155 µg/kg (83% positive samples). Herein the 
authors suggested contaminated feather meal to be a possible route for reentry of 
pharmaceuticals into the food chain. 
NA4AP as the major metabolite of aniline 
NA4AP and its conjugates appear in the metabolism of aniline. Kao et al. found NA4AP 
(mainly in its glucuronic acid- or sulphate-conjugated form) to be the major urinary 
metabolite in pigs (~ 77%), sheep (~ 85%) and rats (~ 65%). Between 2-13% of NA4AP 
were excreted as free NA4AP among all three species. Other urinary metabolites were 
O-conjugates of 2- and 4-aminophenol (5.5 - 25% of the aniline dose) and acetanilide 
(0.5-3.4% of the aniline dose) (Kao et al. 1978). Fig. 1 shows the simplified metabolism 
pathway of aniline according to the findings of Kao et al. (for a more detailed aniline 
metabolism pathway scheme see German Federal Ministry of Environment 2011). A 
similar excretion pattern for aniline can be expected in humans (German Research 
Foundation 1992). 
 
Figure 1: Simplified metabolism of aniline.  
Lewalter and Korallus found NA4AP (in concentrations up to the mg/L range) and 
acetanilide (in the µg/L range) in urine samples of workers following occupational 
exposure to aniline (air concentrations below the occupational threshold limit value of 7.7 
mg/ m³ air (Lewalter & Korallus 1985, German Research Foundation 1992). NA4AP was 
also detected as a metabolite after acute aniline intoxication (Iwersen-Bergmann & 
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Schmoldt 2000). Dierkes et al. (2014) detected acetanilide and NA4AP in the urines of 
six volunteers known to be exposed to aniline. Further, in depth quantitative and kinetic 
investigations of human aniline metabolism do not exist to our knowledge. 
The ubiquitous body burden of the general German population to aniline has been well 
described previously. Total urinary aniline has routinely been determined after 
hydrolyses to cleave possible aniline conjugates such as acetanilide (el-Bayoumy et al. 
1986; Riffelmann et al. 1995; Ward et al. 1996; Weiss & Angerer 2002). Aniline, 
determined this way, has been recently found in above 90% of the urine samples 
collected from 1004 individuals from the general German population (Kütting et al. 2009) 
(table 2). Extrapolating these aniline levels, considering that NA4AP is the major 
metabolite of aniline, would result in urinary NA4AP levels up to the mg/L range. 
Variations between these studies can be explained by different study sizes, times the 
studies were conducted and mostly by differences in the analytical method especially 
concerning the hydrolysis of acetanilide. 
Table 2: Human biomonitoring data of aniline in the general population (NA, not available; ND, not 
detectable). 
  
Study  Urinary aniline concentrations [µg/L] 
  
     
 Participants Median 95th Percentile Range 
     
 
    
El Bayoumy et al. 1986 28 2.9 n.a. n.d.-8.8 
 
    
Riffelmann et al. 1995 16 0.8 n.a. n.d.-5.1 
 
    
Ward et al. 1996 26 2.9 n.a. n.a. 
 
    
Weiss et al. 2005 160 3.7 7.9 0.4-13.0 
 
    
Kütting et al. 2009 1004 3.1 14.3 0.05-384 
     
 
By now neither the specific aniline metabolite acetanilide nor NA4AP (with the exception 
of Modick et al. 2013 and Dierkes et al. 2014) have been used in human biomonitoring 
studies to determine exposure to aniline. 
Main routes of exposure of the general population to aniline have been postulated to be 
pesticide residues, pharmaceuticals, colorants used in food, cosmetics and textiles and 
cigarette smoke (Federal Ministry of Environment 2011). In 2001 Palmiotto et al. 
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detected aniline in indoor air of homes with levels ranging from 5 ng/ m³ to about 33 ng/ 
m³, with higher values in homes of smokers. Aniline was also detected in the air of 
several public buildings and in outdoor air, underlining the ubiquitous presence of aniline 
in the environment (Palmiotto et al. 2001). 
Evidences for developmental toxicity of NA4AP 
In vitro and animal studies 
Animal studies in the 1980s already suggested an association between prenatal 
exposure to analgesics and reduced masculinization. In 1989 it was found that 
administration of aspirin to mice inhibited the synthesis of prostaglandins (PGs) in male 
and female fetuses. (Gupta 1989). PGs are supposed to be involved inter alia in such 
processes as early male sexual development and masculinization and hormone 
regulation. (Gupta 1989; Amateau & McCarthy 2004). 
In 2010 Kristensen et al. showed that intrauterine exposure of Wistar rats to NA4AP led 
to a significant reduction in the anogenital distance of male offspring. In the same study 
the authors reported a reduced production of PGD2 and testosterone in ex vivo fetal rat 
testes (Kristensen et al. 2010). A study from the same group, published in 2011, showed 
that many presumed endocrine disrupting chemicals (EDCs) dose dependently inhibited 
the PGD2 synthesis in mouse Sertoli cell lines. The observed effect was comparable 
within the tested analgesics which included NA4AP, aspirin and ibuprofen and was even 
higher than the measured effect of other known EDCs like n-butylparaben and bisphenol 
A. Therefore the authors came to the conclusion that pharmaceutical PG inhibitors like 
NA4AP, aspirin and ibuprofen may act as endocrine disruptors. The authors were also 
able to pinpoint the suppression of PG synthesis to the inhibition to cyclooxygenase 
(COX) enzymes (Kristensen et al. 2011). It is thought that NA4AP acts as an inhibitor of 
COX enzymes, although the precise mechanism of action is still unclear (Hinz et al. 
2007). 
In 2012 Kristensen et al. showed that exposure to NA4AP and aspirin inhibited 
testosterone production in a rat organotypic culture system. The levels of testosterone 
produced by fetal Leydig cells were lower by about 10-50% than the controls when 
exposed to NA4AP in concentrations from 0.1-100 µM, confirming their previous in vivo 
findings. However, the anti-androgenic effects of NA4AP were not correlated with 
inhibition of PGD2 synthesis in this fetal testis culture system (Kristensen et al. 2012). 
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Human data 
Data on endocrine effects 
A recent study by Albert et al. (2013) investigated the direct effects of NA4AP (and two 
other NSAIDs) using whole human testis in organotypic culture and the NCI-H295R 
human steroidogenic cell line. The exposure levels to NA4AP were chosen in estimation 
of serum concentration in adult men after a standard dose of 1g NA4AP, 10-5 M and 10-4 
M respectively. Exposure to 10-5 M and 10-4 M NA4AP dose dependently decreased 
testosterone secretion by the human testis after 24h of exposure by 18% and 30% 
compared to the controls. Following 48 h of exposure, testosterone concentrations were 
not significantly decreased at both concentration levels any more. The testosterone 
concentration in the NCI-H295R human steroidogenic cell line was significantly lower 
after 24h treatment with 10-4 M NA4AP than in controls. The effect was not significant 
after 48h of exposure and with the 10-5 M NA4AP concentrations.  
24 h of exposure to 10-4 M NA4AP also lowered the PG concentrations significantly in 
the human testis by 28 % for PGD2 and 38% for PGE2 compared to the control 
concentrations (Albert et al. 2013). However, limitations of this study were the 
evaluations of exposure levels and durations of exposure. Although the exposure levels 
were chosen by estimated serum concentrations as occurring after therapeutic use, the 
resulting testicular concentrations in adult men are unknown and rather difficult to 
approach.  
In 2013 Mauzad-Guittot et al. used an in vitro system based on the cell culture of human 
fetal testes exposed to NA4AP and its metabolite N-(4-hydroxyphenyl)-
arachidonoylethanolamide (AM404; see Metabolism of acetaminophen and aniline) and 
other NSAIDs at concentrations from10-4 M to 10-7 M. Endocrine disrupting properties 
were investigated through measures of testosterone, Anti-Müllerian Hormone (AMH), 
insulin like factor 3 (INSL3) and prostaglandins (PGD2 and PGE2) (Mazaud-Guittot et al. 
2013).The authors found significant inhibition of INSL3 production in samples exposed to 
NA4AP and AM404 with a significant dose-response relationship indicating a decrease 
of INSL3 production with an increasing dose of NA4AP. The measured trend for AMH 
production to be increased by NA4AP was not significant. Significant inhibitory effects of 
NA4AP on PGE2 production were observed, whereas the trends for inhibition of PGD2 
were not significant. Neither NA4AP nor AM404 showed any significant effect on 
testosterone production in this study. The authors suggested the analgesic-induced 
inhibition of INSL3 to be the mechanism by which analgesics increase the risk of 
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cryptorchidism because several mutations of the INSL3 gene or its receptors were found 
to be associated with cases of cryptorchidism in humans (Foresta et al. 2008). 
Associations between acetaminophen intake during pregnancy and reproductive 
disorders 
In a study from the Danish National Birth Cohort with 88,142 pregnant women and their 
live born singletons with questionnaire information about the NA4AP use during the first 
trimester the authors found no association of NA4AP with an increased prevalence of 
congenital abnormalities (Rebordosa et al. 2008).  
Since 2011 the number of studies which found further evidence on the association 
between NA4AP use during pregnancy and reproductive disorders increased. A study 
from the Danish National Birth Cohort using the data of 47,700 mothers and their male 
offspring found that cumulative NA4AP exposure of more than 4 weeks duration may 
moderately increase the occurrence of cryptorchidism especially when exposure appears 
during the first and second trimesters (Jensen et al. 2010). These findings were 
confirmed by Kristensen et al. in a prospective birth cohort study including 2,297 Danish 
and Finish pregnant women reporting their use of mild analgesics. It was reported, that in 
the Danish birth cohort the use of mild analgesics (including NA4AP) was dose 
dependently associated with congenital cryptorchidism and, in particular, use during the 
second trimester increased the risk. The association was not found in the Finish cohort. 
Because of the birth prevalence of cryptorchidism in Finland (2.4%) is lower than in 
Denmark (9.0%) the authors noted out that the study may be statistically underpowered 
to find an association in the Finish cohort (Kristensen et al. 2010). Data from a French 
birth cohort study, published by Pilippat et al. in 2011, estimated that the association 
between maternal use of mild analgesics during pregnancy and undescended testis risk 
was similar to that in the Danish population described by Kristensen at al. before 
adjustment for maternal age, gestational duration, maternal smoking and other factors 
but weaker after adjustment. However, this study was limited by small sample size, the 
inability to distinguish between specific analgesics and lack of information on dose, 
mixture and exact timing of use (Philippat et al. 2011). The suggestion, that intrauterine 
exposure to mild analgesics, primarily NA4AP, during the second trimester of pregnancy 
is associated with increased prevalence of cryptorchidism was also made from the data 
of a large population based cohort study from the Netherlands (the Generation R study) 
(Snijder et al. 2012). The authors noted several limitations of the study mostly the limited 
number of cryptorchidism but also the definition of the different pregnancy periods. 
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However, the strength of this study was the population based approach which enabled 
the assessment and the adjustment for a large number of potential confounders. 
Metabolism of acetaminophen and aniline  
Between 75-86% of an oral aniline dose are excreted as NA4AP mostly in its conjugated 
forms in urine, as confirmed by animal experiments. Human data shows if NA4AP is 
taken directly (e.g. after therapeutic use of acetaminophen) very similar amounts of 
NA4AP are excreted renally: ~ 3% free NA4AP, ~40% NA4AP glucuronide, ~35% 
NA4AP sulphate. As additional metabolites NA4AP cysteine conjugate (~4%) and 
NA4AP mercapturate (~3%) have been reported (Ladds et al. 1987). Minor NA4AP 
metabolites include 3-hydroxy-NA4AP, 3-methoxy-NA4AP, 3-hydroxy-NA4AP-3-
sulphate, 3-methoxy-NA4AP sulphate and 3-methoxy-NA4AP glucuronide. After over 
dosage the relative amounts of cysteine and mercapturic acid conjugates in urine are 
increased (Andrews et al. 1976). N-arachinodyl-4-phenolamine (AM404) was identified 
as a possible metabolite of NA4AP in 2005. AM404 was built in brain and spinal cord 
homogenates from Wistar Hannover rats after exposure to p-aminophenol (Högestätt et 
al. 2005). By now there is no data available concerning the occurrence of AM404 in 
humans. But due to the chemical structure and the resulting highly lipophilic character of 
this metabolite its occurrence in urine is unlikely. 
Some differences in NA4AP metabolism in neonates/children and neonates and in adults 
have been reported. While in adults NA4AP glucuronide is the predominant conjugate 
(see above) in children the NA4AP sulphate conjugate (~47%) is more dominant than the 
NA4AP glucuronide conjugate (~13%) (Levy et al. 1975b; Miller et al. 1976; Peterson & 
Rumack 1978). However, the altered metabolism of NA4AP in children as compared to 
adults does not seem to affect its general rate of elimination. Plasma disappearance 
(elimination half-time) of NA4AP is comparable in adults (1.5-3.0h) and in children (1.0-
3.5h) with a slight prolongation of its half-life in neonates (2.2-5.0h) (Miller et al. 1976; 
Peterson & Rumack 1978). The similar metabolic pattern of NA4AP and aniline makes it 
difficult to decide if the NA4AP in urine is caused by exposure to aniline, to NA4AP or to 
both substances. Only specific metabolites leading from aniline (or possibly other 
precursors) to NA4AP might allow a differentiation between direct NA4AP intake and 
NA4AP generated through precursors. Such metabolites might be acetanilide, the 
amino-phenols or their conjugates (see figure 1). Acetanilide has been determined by 
Dierkes et al. and could only be found in urines from individuals after aniline exposure 
but not in any individuals from the general population (Dierkes et al. 2014). 
 
Chapter III 
117 
Human biomonitoring methods for NA4AP 
Human biomonitoring (HBM) is defined as the determination of chemical substances or 
their metabolites in human body fluids like blood or urine as an instrument of measuring 
human exposure to chemical substances for risk assessment and risk management 
(Angerer et al. 2007). Although NA4AP has been used as a pain reliever and fever 
reducer for decades, despite the veterinary use of NA4AP and the high production and 
sale volumes and despite the fact that NA4AP is the most important metabolite of aniline 
there is a lack of HBM data on this substance.  
To our knowledge NA4AP has not yet been included in larger population based HBM 
studies like the German GerES (German Environmental Survey), the U.S. NHANES 
(National Health and Nutrition Examination Survey) or the Canadian CHMS (Canadian 
Health Measures Survey). In 2012 Camann et al. detected traces of NA4AP in 9 
deciduous molars from 21 children using a HPLC-MS/MS method after a neutral, basic 
and acetic extraction procedure with acetonitrile to extract NA4AP from pulverized tooth 
crown. The measured concentrations ranged from <0.5 ng/g, which was also the limit of 
quantification of the method used, to 17.3 ng/g, with the median < LOQ and a 95th 
percentile of 10.8 ng/g. According to the authors the NA4AP concentrations were 
consistent with the NA4AP intake that was estimated from exposure questionnaires 
completed by the mothers. The authors therefore suggested that NA4AP appears to 
accumulate in deciduous molars and thus is an apparent biomarker of exposure to 
NA4AP in the first year after birth (Camann et al. 2012). We recently published an 
analytical method for determination of NA4AP in urine based on on-line extraction via 
turbulent flow chromatography coupled with LC-MS/MS (Modick et al. 2013). In an HBM 
pilot study we applied this method to analyze urine samples of 21 individuals from the 
general German population. Prior to the study all volunteers completed a questionnaire 
about the use of NA4AP or NA4AP containing products. NA4AP was detected in all 
samples analyzed with a wide concentration range from 8.7 µg/L to 22,120 µg/L and a 
median of 85.7 µg/L. We detected NA4AP even in the samples of those volunteers that 
quoted to never have taken NA4AP and reported a considerable overlap in NA4AP 
concentrations, no matter if the individual had or had not taken NA4AP during the week 
before sample collection. These findings were affirmed by our group in a second HBM 
pilot study investigating N4AP, the aniline specific metabolite acetanilide and the 
tentative aniline metabolite N-acetyl-2-aminophenol (Dierkes et al. 2014). In this study 
we confirmed the presence of NA4AP in urine samples from individuals with no 
occupational aniline exposure or paracetamol medication. Not surprisingly, though, 
NA4AP was detected in high concentrations in in the urines of two individuals using 
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paracetamol medication and six volunteers with known occupational aniline exposure. 
Contrary to NA4AP, acetanilide – the metabolic precursor of NA4AP - was only detected 
after exposure to aniline. N-acetyl-2-aminophenol was detected in most of the samples 
but without any relation to aniline exposure or correlation to the other two aniline 
metabolites. Apart from these studies we are not aware of any other HBM 
measurements of NA4AP in the general population. 
The quest for possible NA4AP sources by means of human biomonitoring 
Currently there are no indications that NA4AP is an endogenous substance naturally 
occurring in human metabolism. For the purpose of unveiling the possible sources of 
internal body burdens of NA4AP we determined urinary concentrations of NA4AP in 
different experimental settings. All urinary samples described in the following were 
analyzed via HPLC-MS/MS-Methods via isotope dilution quantification, developed and 
refined by our group (Modick et al. 2013, Dierkes et al.2014). All following values reflect 
total NA4AP in urine after enzymatic hydrolysis of the glucuronide- and sulphate-
conjugates. All urinary analyses referred to in the following have been covered by 
various ethical approvals of the Medical Faculty of the Ruhr-Universität Bochum, 
Germany (Reg. Nr.: 3867-10; Reg. Nr.: 4333-12; Reg. Nr.:4730-13).  
Analytical Method 
A detailed description of our analytical method can be found in Dierkes et al. (2014). In 
short, all urinary samples were vortex mixed before transferring aliquots into silanized 
screw cap vial. After adding incubation buffer (ammonium acetate, ph = 5.5-6.0), internal 
standard solution (deuterium labeled analouges of NA4AP and acetanilide) and 
glucuronidase/arylsulfatase solution (for enzymatic cleavage of glucuronide and sulfate 
conjugates) samples were incubated at 37°C in a water bath for 3.5 hours. Urinary 
creatinine concentrations were determined according to Jaffe 1886.  
Analysis of the samples was carried out using a Waters HPLC system coupled with a 
Waters Quattro Premier XE triple quadrupole mass spectrometer in a two column 
switching assembly, which allowed on-line cleanup and analyte enrichment followed by 
chromatographic separation and mass spectrometric detection in one step. A Waters 
Oasis ® HLB cartridge column (2.1 x 20 mm; 25 µm) was used for cleanup and 
enrichment, chromatographic separation was carried out on a Thermo Scientific 
Hypercarb TM column (2.1 x 100 mm; 3 µm) by gradient elution with 3 mM ammonium 
bicarbonate solution in water and acetonitrile as solvents. Mass spectrometric detection 
was conducted by electron spray ionization (ESI) in positive ionization mode. Argon was 
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used as collision gas for MS/MS measurements. Fragmentation patterns of the analytes 
and internal standards were obtained by full scan experiments. Based on the parent ions 
two mass transitions were confirmed and optimized manually. The mass transition with 
the highest intensity was used for quantification (quantifier) whereas the transition with 
the second highest intensity was used to confirm the results of the quantifier ion.  
Calibration was performed with standard solutions in water. Calibration standards were 
treated equally to the urine samples. Calibration curves were obtained by plotting the 
quotient of peak areas of NA4AP or acetanilide and their deuterium labeled as a function 
of their concentration with a 1/x-weighting. Intra-day precision was determined by 
analyzing quality control urines (prepared within our laboratory) eight times in a row at 
two concentration levels (Qhigh and Qlow). Inter-day precision was determined by 
analyzing the control urines on eight different days using newly prepared calibration 
samples and calibration curves. Calculated deviations of intra-day and inter-day 
precision measurements were below 15% for both analytes at both concentration levels. 
Accuracy of the method was determined by analyzing eight urine samples with varying 
creatinine contents. These samples were analyzed in native condition and spiked at two 
concentration levels. The mean recoveries were between 105 and 114 % for both 
analytes at both concentration levels. Imprecisions calculated from the spiking 
experiments were in the range of intra- and inter-day precision data underlining 
ruggedness of the method. The limit of detection (LOD) was estimated on the basis of a 
signal to noise ratio of 3:1, the limit of quantification (LOQ) was determined on a signal to 
noise ratio of 9:1. For acetanilide its LOD in urine was estimated to be 0.03 µg/L, its LOQ 
was 0.09 µg/L. The LOQ for NA4AP was set to the lowest aqueous calibration point (0.5 
µg/L). However, NA4AP concentrations in all urine samples investigated by now are 
usually more than 10 fold above this LOQ.  
 
Urinary NA4AP excretion in the general population 
In our daily laboratory routine we have analyzed n = 2,098 spot urine samples of the 
general population for concentrations of NA4AP, so far. These urine samples originated 
from various adult and control populations present in our institute. These samples, 
although taken from the general population, cannot be regarded fully representative of 
the general population. Individuals were presumably not pregnant, and occupationally 
not exposed to aniline. We had no information on the usage of acetaminophen or other 
pain relievers. The smoking status was assessed via urinary cotinine. All statistical 
analysis was performed using IBM® SPSS® Statistics version 20. NA4AP was detected in 
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all samples analyzed, in a broad range of concentrations, whereas acetanilide could not 
be detected in any of the samples. The distribution of NA4AP levels over all individuals is 
shown in figure 2A.  
 
Figure 2: Distribution of urinary NA4AP concentrations in random spot urine samples obtained from the 
general population: (A) all samples (n =2098) and (B) samples of the high-exposure group (n =106; c >4000 
mg/l). Line indicates normal distribution curve. 
Urinary NA4AP concentrations were not normally distributed before and after logarithmic 
transformation by Kolmogorov-Smirnov test. Therefore, we separated the population into 
two groups, using a cut off value of 4,000 µg/L NA4AP: a high exposed (c (NA4AP) > 
4,000 µg/L; n = 106; 56 smokers, 50 non-smokers) group and a low exposed (c (NA4AP) 
< 4,000 µg/L; n = 1,992; 996 smokers, 996 non-smokers) group. This cut-off value 
reflected the 95th percentile of the NA4AP concentration through all samples. 
Additionally, according to the elimination kinetics of NA4AP (see the following section) 
urinary levels of 4,000 µg/L NA4AP would be caused by a single tablet of 500 mg 
acetaminophen taken within 36 to 48h before sampling. Within these two groups NA4AP 
concentrations were normally distributed by Kolmogorov-Smirnov test after logarithmic 
transformation. The distribution for the high exposure group is shown in figure 2B. If we 
considered the distribution curve shown in figure 2B (with NA4AP concentrations in the 
mg/L range) indicative of therapeutic acetaminophen intake and used urinary NA4AP 
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concentrations above 4,000 µg/L as an arbitrary cut off, ~ 5 % of the >2000 individuals 
investigated would have taken NA4AP prior to sampling. 
 
Urinary NA4AP concentrations divided into the subgroups of smokers and non-smokers 
and total are shown in table 3. Levels of NA4AP differed significantly between the two 
groups according to the Mann-Whitney-U test (p = 0.01; α = 0.05) with a median NA4AP 
concentration of 68.2 µg/L in smokers compared to 54.2 µg/L in non-smokers. After 
splitting the population in the two NA4AP groups, the significant effect of smoking 
behavior on NA4AP excretion continued to hold, especially for the group with NA4AP 
levels <4,000 µg/L (p = 0.01; α = 0.05).  
Table 3: Urinary NA4AP concentrations in the general population. 
 
Smokers  
(n = 1,052) 
Non-smokers  
 (n = 1,046) 
Total 
(n = 2,098) 
 
   
Mean [µg/L] 10,834 4,116 7,484 
 
   
Median [µg/L] 68.2 54.2 61.7 
 
   
Min. [µg/L] 0.65 0.95 0.65 
 
   
Max. [µg/L] 2,274,296 580,358 2,274,296 
 
   
25 P [µg/L] 29.9 21.6 25.3 
 
   
75 P [µg/L] 164.5 150.3 155.6 
 
   
95 P [µg/L] 4,464 3,504 4,093 
 
   
 
   
 
The influence of smoking behavior on NA4AP excretion could be explained by NA4AP 
being the major metabolite of anline and aniline is being a known constituent of tobacco 
smoke. However, several previous HBM studies reported no significant impact of 
smoking behavior on urinary aniline (Riffelmann et al. 1995; Weiss & Angerer 2002; 
Kütting et al. 2009). These contradicting findings might be explained by the relatively 
small effect of smoking on NA4AP (and possibly aniline) excretion that can only be 
detected in larger population studies. Additionally, NA4AP might be more appropriate to 
detect such an effect because it is the major metabolite of aniline and excreted in 
considerably higher concentrations than aniline (or its conjugates). Comparing median 
levels of smokers vs. non-smokers, the urinary NA4AP levels of smokers were ~25% 
above those of the non-smokers. The detection of NA4AP in the urines of non-smokers 
and the higher concentrations in the urines of smokers leads to the conclusion that 
smoking indeed contributes to urinary NA4AP excretion but is not the main source of it. 
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This is supported by the lack of the aniline specific metabolite acetanilide in the samples 
that hints to other (additional) sources which might contribute to urinary NA4AP 
excretions. It is also congruent with the HBM pilot study by Dierkes et al. (2014) where 
acetanilide could not be detected in samples from the general population but only in the 
urines of individuals with high exposure to aniline. 
 
Urinary NA4AP excretion after acetaminophen use 
We investigated the urinary elimination characteristics of NA4AP in one individual (male, 
31 years, non-smoker) after oral dosage of a single tablet of acetaminophen containing 
500 mg NA4AP. One pre-dose urine sample was taken immediately before intake. We 
continuously collected and urine samples for 48hrs post dose. The urinary NA4AP 
concentrations over time are depicted in figure 3. Urinary levels of NA4AP reached 
maximum concentrations of ~ 400 mg/L between 4h-12h post dose. NA4AP levels 
decline thereafter in a rather monotonic manner (indicating to a single phasic elimination) 
but remain in the mg/L range until ~36h post dose (figure 3). The urinary NA4AP 
concentrations after dosing are comparable to the findings from Dierkes et al. (2014) 
from two individuals with NA4AP medication within approx. 24h before sampling, which 
contributed to urinary NA4AP concentrations of 160 and 275 mg/L. In none of these 
samples acetanilide could be detected. 
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Figure 3: Urinary NA4AP concentrations after oral intake of 500 mg ona semi-logarithmic scale: (A) NA4AP 
concentrations (mg/l) and (B)creatinine-adjusted NA4AP concentrations. Dotted line indicates the95th 
percentile of NA4AP concentrations over the analyzed populationsamples (4000 mg/l). 
NA4AP excretion after occupational aniline exposure 
Four individuals (2 male, 2 female; 25-45 years, non-smokers living in the greater area of 
Bochum, Germany) were exposed to aniline in an occupational setting via air for 8 hours 
at the occupational threshold limit value (7.7 mg/ m³ air), as it may e.g. occur in the 
rubber industry during the vulcanization process of rubber products (Korinth et al. 2007). 
Complete urine voids were collected before, during and for 16 h after exposure. The 
volunteers recorded the time and the void of each individual sample. All four individuals 
did not use NA4AP containing medications in the week prior to and during the study. The 
urinary NA4AP and acetanilide concentrations (in µg/L) and the creatinine adjusted 
concentrations over time for all four individuals are shown in figure 4. 
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Figure 4: Urinary NA4AP concentrations in four volunteers during and after aniline exposure in an 
occupational setting: (A) NA4AP concentrations (mg/l); (B) creatinine-adjusted NA4AP concentrations; (C) 
acetanilide concentrations (mg/l); and (D) creatinine-adjusted acetanilide concentrations. 
 
Before the (occupational) aniline exposure set in, urinary NA4AP concentrations in all 
participants were in the same range as in the general population, ranging from 40-170 
µg/g creatinine (15-80 µg/L), whereas urinary acetanilide concentrations where below 
the limit of quantification (0.09 µg/L). Urinary NA4AP concentrations increased steadily 
during exposure and reached maximum concentrations of 55,000-75,000 µg/ g creatinine 
(10,000-60,000 µg/ L) between 10-13h after beginning of the study. Excretion maxima 
occurred about 2-5h after the 8hr exposure window. 
Urinary excretion of acetanilide followed an equal pattern except that concentrations of 
acetanilide are about 100-200 times lower than NA4AP concentrations, peaking at 100-
300 µg/L. This is in good accordance with the findings of our previous HBM pilot study 
(Dierkes et al. 2014). 
In conclusion, from this small and preliminary occupational aniline exposure study we 
report urinary NA4AP levels well in the mg/L range (up to 60 mg/L or 75 mg/g creatinine) 
occurring after legally permissible occupational exposures to aniline. Maximum urinary 
NA4AP concentrations were less than 10 times below maximum levels observed after 
the therapeutic use of a single 500mg tablet of acetaminophen. 
NA4AP excretion during a controlled two day fasting study 
We above hypothesized contaminated foodstuff (either by NA4AP itself or precursors like 
aniline) to be a possible reason for the NA4AP excretion in the general population. To 
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investigate the influence of food intake on NA4AP excretion we performed a 48 hrs 
fasting study. We have previously used the urine samples of this study to investigate the 
influence of foodstuff on urinary excretion of phthalate metabolites and bisphenol A 
(Christensen et al. 2012; Koch et al. 2013). For detailed information on study design and 
execution see these publications. In short, study volunteers were five healthy employers 
from our institute all living in the area of Bochum (Germany), ages ranged from 27 to 47 
years (2 male, 3 female; body weight: 60-92kg). One volunteer was excluded from this 
study because questionnaire records indicated that this volunteer had possibly taken an 
NA4AP containing medication in the week prior to the study and during the study. The 
remaining four volunteers (2 males, 2 females) consisted of three non-smokers and one 
smoker who refrained from smoking several days before and during the study. The 
volunteers collected full volumes of urines over the course of 48h fast, as well as 
samples before and after the fasting phase. Fasting itself excluded intake of any 
foodstuff (as well as food related items e.g. chewing gum) and the intake of any liquids 
except for bottled mineral water. Timing and quantity of intake of mineral water was not 
regulated. The use of personal care products and use of any medications were not 
regulated but documented. All volunteers had no known occupational exposure to 
aniline. (Koch et al. 2013). 
Three of the volunteers (1 male, 2 females) started their fasting at approx. 1 pm after 
dining together on individual different meals. One volunteer started fasting the following 
day after a separate meal. One urine sample was taken before fasting (pre fasting 
sample) and fasting started immediately after the meal (t = 0h). 
The urinary NA4AP concentrations (in µg/L and creatinine adjusted) of the four 
volunteers over the duration of the study are shown in figure 5. One can clearly observe 
the influence of fasting (and the preceding and following food intake) on the urinary 
excretion pattern of NA4AP. At the beginning of the study urinary NA4AP concentrations 
of the volunteers ranged from 3-1700 µg NA4AP/g creatinine (10-1100 µg/L). In all 
volunteers the urinary NA4AP concentrations increased after the pre-fast meal, reaching 
maximum values ranging from 700-5000 µg NA4AP/g creatinine (1100-5300 µg/ L) 
approx. 2,5h-6h after the last meal. These values are in the same order of magnitude as 
the urinary concentrations in the general population described previously by us (Modick 
et al. 2013), although at the upper range. During the time of fasting urinary NA4AP 
concentrations in all volunteers decreased considerably by a factor of 50-100 reaching 
minimum concentrations of 5-70 µg NA4AP/ g creatinine (5-75 µg/L) at the end of the 
fast. After the volunteers resumed eating urinary NA4AP concentrations rose again 
(figure 5).  
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Figure 5: Urinary NA4AP concentrations in four volunteers during a controlled 48-h fasting study. (A) NA4AP 
concentrations (mg/l) and (B) creatinine-adjusted NA4AP concentrations. 
 
Taken together, the data obtained from this study impressively hints to food as one 
possible, major source for internal body burdens of NA4AP in the general population. 
However, by now, it cannot elucidate whether direct ingestion of NA4AP or NA4AP 
precursors like aniline lead to the changes observed in urinary NA4AP levels. In all 
samples acetanilide concentrations were below the limit of detection (0.03 µg/L).  
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Other possible NA4AP sources  
As already pointed out aniline is an important building block in several substances which 
the general population is continuously exposed to like pesticides and colorants (azo-
dyes). During metabolism of these substances free aniline might be released and further 
metabolized to NA4AP. A summary of possible aniline and therefore possible NA4AP 
precursors, according to a publication of the German Federal Environment Agency 
(2011), is shown in supplementary table 1 (Appendix III). However, this list is not 
considered being exhaustive. Environmental NA4AP might also be contributing to the 
low urinary background concentrations. For example, NA4AP and its metabolites 
respectively were detected in samples of several rivers in Spain and Portugal at levels in 
the low µg/L range (López-Serna et al. 2010; Santos et al. 2013). 
Conclusions 
We confirmed our previous results reporting the ubiquitous excretion of NA4AP 
(acetaminophen/paracetamol) in urine samples from the general population (Modick et 
al. 2013). With measurements in more than 2,000 urine samples we determined a 
median NA4AP excretion of around 60 µg/L. However, urinary NA4AP levels well in the 
mg/L range can still be observed in individuals with no obvious NA4AP exposure like 
intake of NA4AP containing medications (or occupational aniline exposure). As shown by 
the distribution of the NA4AP values in the 2,000 urine samples from the general 
population as well as the defined dosing of one tablet of acetaminophen urinary NA4AP 
concentrations above 4,000 µg/L hints to the direct intake of NA4AP through medication 
(within the last 36 to 48 hours). Recent acetaminophen users exhibit urinary NA4AP 
concentrations close to the g/L range. However, 4,000 µg NA4AP per liter urine can only 
be regarded as a soft cut-off between acetaminophen users and non-users since 
concentrations above also might be caused by food intake (as shown by our volunteer 
fasting study) or occupational aniline exposure. On the other hand, acetaminophen use 
longer than 2 days ago does not seem lead to urinary NA4AP levels above 1000 µg/L. 
The sources for the ubiquitous internal body burden of the general population to NA4AP 
remain obscure. However, our research hints to several possible sources: 
(1) Direct intake of acetaminophen or acetaminophen containing pharmaceuticals as a 
prime source for high urinary NA4AP concentrations; (2) occupational exposure to 
aniline, leading to NA4AP as the major aniline metabolite; (3) ubiquitous exposure from 
environmental sources e.g. nutrition, possibly containing NA4AP itself or aniline and 
other NA4AP precursors; (4) smoking, most probably by aniline which is contained in the 
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main and side stream smokes of cigarettes. Up to now we are not fully aware of the 
underlying mechanisms of nutrition being a source of urinary NA4AP excretion.  
The ubiquitous background excretion of NA4AP in the general population is not 
implausible. We summarized the broad use of NA4AP in human medicine above and 
also speculated about its use in veterinary medicine. The ubiquitous aniline exposure of 
the general population has previously been described, and NA4AP is known being the 
major metabolite of aniline for a long time. One major task of the future will be to 
disentangle and quantify the contribution of each possible source to the total ubiquitous 
NA4AP excretion.  
From the toxicological perspective the omnipresence of a pharmacological active 
substance, which is, to our knowledge, not naturally occurring in the human body raises 
some concern since recent animal and human studies indicate anti-androgenic effects of 
NA4AP and suggest NA4AP as a possible risk factor for male developmental disorders 
in humans. The further evaluation of our findings of an omnipresent NA4AP excretion 
depends upon at least two key questions:  
1) Can it be confirmed (by both mechanistic and epidemiological studies) that 
therapeutic doses of NA4AP cause detrimental effects in the male human 
offspring?  
2) Are urinary NA4AP concentrations in the mg/L range (as observed in non-
acetaminophen users and aniline exposed individuals) indicating to NA4AP 
doses of possible toxicological relevance? 
Therefore, to fully understand and investigate sources and routes of exposure as well as 
the resulting toxicological impacts an interdisciplinary approach in this matter is 
warranted. At this point human biomonitoring can play an important role to assess 
NA4AP exposures of specific cohorts, populations and subpopulations, to investigate 
differences and similarities in NA4AP and aniline metabolism and to uncover or refute 
linkages between NA4AP exposures and possible (adverse) effects.  
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Abstract 
Recent studies indicate an association between the use of paracetamol during 
pregnancy and reproductive disorders in male offspring. Furthermore, N-acetyl-4-
aminophenol (NAAP, paracetamol) has been shown to be ubiquitously excreted in urine 
samples of the general population. To investigate the internal body burden of the Danish 
population to NAAP for the first time, 288 morning urine samples from 6-11-year-old 
Danish school children and their mothers were analyzed for NAAP. NAAP was 
measurable in all mothers and all of the children except for one child. Results showed 
that there is a ubiquitous body burden of NAAP in Danish mothers and children even 
when paracetamol analgesics have not been used recently. Hence, several unknown 
sources of NAAP/paracetamol exposure have to exist. We found an association in NAAP 
excretion between the mothers and their children which could indicate common lifestyle 
related exposure (e.g. via food or indoor air sources). However, we did not detect any 
association between lifestyle data from questionnaires and levels of NAAP excretion in 
this study. The knowledge about possible sources of exposure leading to this 
omnipresent paracetamol excretion is limited and further investigation is wanted. 
 
Keywords: paracetamol, N-acetyl-4-aminophenol, aniline, urine, human exposure, 
biomonitoring 
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Introduction 
Paracetamol - N-acetyl-4-aminophenol (NAAP) - is the most widely used over-the-
counter analgesic in the western world, and is often used for treatment of mild pain and 
fever in both pregnant mothers and children (Werler et al. 2005). Until recently, it was 
considered safe to use paracetamol for women during pregnancy, but studies suggest 
that the use of paracetamol during early pregnancy is associated with endocrine 
disturbance in the fetal male testis (Kristensen et al. 2011; Kristensen et al. 2012; 
Mazaud-Guittot et al. 2013; Snijder et al. 2012). Paracetamol is known to freely pass the 
placental barrier and metabolites have been detected in urine of newborns after maternal 
use of paracetamol a few hours prior to delivery (Levy et al. 1975; Weigand et al. 1984). 
A recent study, indicates that paracetamol inhibits testosterone syntheses in the adult 
testis (Albert et al. 2013). What happens on the long term is still unknown. This anti-
androgenic effect is of concern, when boys in school age and young men are 
ubiquitously exposed. Apart from direct use of paracetamol as an analgesic, the general 
population is exposed indirectly by other routes for example through the chemical aniline 
that is metabolized to paracetamol in the human body. Aniline is a chemical compound 
used in industrial production of rubber, food and cosmetic colorants, and in syntheses of 
pesticides and isocyanates. The major part (56-76%) of aniline is metabolized to NAAP 
in the liver (Kao et al. 1978). Occupational exposures to aniline can result in high urinary 
concentrations of NAAP (Dierkes et al. 2013) but also environmental exposure to aniline 
has been shown to contribute to the NAAP burden in the general population (Modick et 
al. 2014). The general population can be exposed to aniline or aniline releasing 
substances in food, ground water and from tobacco smoking (Human Biomonitoring 
Commission of the German Federal Enviroment Agency, 2011). There is no data on 
aniline exposure of the general population in Denmark, but the ubiquitous body burden in 
the German population has been described previously, reporting aniline in more than 90 
% of the urine samples with median levels at 3 µg/L, the 95th percentile at 14µg/L and a 
maximum at 384µg/L (Kutting et al. 2009). Groundwater could be a possible source of 
aniline or NAAP but this is uncertain, since paracetamol and aniline are not part of the 
program for groundwater surveillance in Denmark. Although, one measurement done by 
the Geological Survey of Denmark and Greenland on drinking water from one drilling, 
showed levels below LOQ (0.025 µg/L) (personal communication). 
There is limited knowledge of NAAP levels in the general population in Denmark and of 
sources of indirect exposure in humans from aniline and paracetamol. In 2010, 127 mill 
defined daily doses (DDD, defined by WHO) of paracetamol were sold in total in 
Denmark from pharmacies and over the counter (OTC) medicine retailers. This equals to 
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762 mill tablet (500 mg) or 1 tablet per inhabitant every third day. Forty-one% of the 
medication (in OTC-dosage (500 mg/tablet)) is purchased on prescription (Danish 
Medicine and Health authority, 2012). In Denmark, a prescription is required when 
buying packages containing more than 10 tablet (dosage < or = 500 mg/tablet), dosage 
above 500 mg/tablet, depot-tablets (500 mg/tablet) and tablets containing paracetamol in 
combination with another analgesics. A survey conducted in 2010, using selfreported 
use of medicine, showed that 39.1% of the Danish population over 18 years had used 
OTC medicine within the last 14 days and 48.4% had used prescribed medicine within 
the last 14 days (The Danish National Institute of Public Health, 2012). Thus a 
considerable use of medicines including paracetamol is present.  
To improve and harmonize human biomonitoring in Europe, the European project 
DEMOCOPHES (DEMOnstration of a study to COordinate and Perform Human 
biomonitoring on a European Scale) was planned and performed in 17 European 
countries (Becker et al. 2014; Joas et al. 2012). The sampling was done simultaneously 
in all countries from September 2011 to January 2012 and involved urine and hair 
sampling of school children aged 6-11 years and their mothers along with a 
questionnaire regarding lifestyle, dietary- and exposure habits, including the use of 
medications. In all countries, mercury was measured in hair and cotinine, phthalates and 
cadmium were measured in urine. Creatinine was also measured in urine in all countries 
and used to adjust for urinary concentrations. In Denmark, a number of supplementary 
measurements were performed on the samples of the participants and in the present 
study, the urine samples from the Danish school children and their mothers participating 
in DEMOCOPHES were analyzed for concentrations of NAAP. This was done to 
investigate the levels of NAAP in the study persons and possible sources of the 
ubiquitous exposure. Although, the study subjects do not represent the general 
population, this study may give an indication of the NAAP levels in Denmark. Further, 
NAAP has not been measured in a larger group of school children in Denmark before 
and there is a limited knowledge on ubiquitous levels of NAAP in children. 
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Materials and Methods 
Study subjects 
School children and their mothers were recruited from urban (n=75) (Gentofte) and rural 
(n=70) (Viby Sj.) areas in Denmark. The Children were between 6 and 11 years old and 
equally distributed in age and gender. The participants were required to meet the 
DEMOCOPHES criteria to be included in the study: mother and child should live together 
at a minimum of 16 days a month, have been living in the area for a minimum of 5 years, 
have normal kidney function and no metabolic disturbances, as previously described 
(Frederiksen et al. 2013; Becker et al. 2014) . The current study which includes 
supplementary measurements of NAAP was approved by the local ethics committee (H-
1-2014-004) and by the Danish data protection agency (2001-41-6607). Before 
sampling, all participants gave written informed consent after receiving written 
information about the study. For the children, all holders of custody should sign the 
consent, before participating. Mother and child each received at voucher for a cinema 
ticket as appreciation for participating in the study. 
 
Collection of questionnaire data and specimen 
Sampling took place in the school nurse’s premises and was conducted by trained 
fieldworkers. A week before their appointment at the school, the participants received 
urine containers, instructions on how to collect morning urine, a questionnaire 
concerning urine sampling and a basic questionnaire regarding lifestyle. In the morning 
of the day of their appointment, mother and child collected the total volume of their first 
morning urine void and stored it cold (approximately 4°C). At the school, fieldworkers 
checked the questionnaires for missing replies and the urine containers were stored in a 
cooling box until return to the laboratory. In addition to the DEMOCOPHES sampling, a 
study about self-medication and over-the-counter analgesics for school children was 
conducted (Jensen et al. 2014). This was a supplement study and not all participants 
wished to take part. The mothers answered a supplementary questionnaire about self-
rated health, pain and the use of OTC medicine for themselves and their child. This 
questionnaire was designed to give a picture of the long-term use of OTC medicine. The 
mothers were only asked about the use of paracetamol within the last 3 months. 
Therefore we do not have specific information about paracetamol consumption within the 
last 24-48 hours. The sampling collection was done in 2011 from September to 
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December, and was conducted in parallel in urban and rural areas to avoid seasonal 
variation between the two groups. 
 
Sample preparation 
Urine was collected in 750 mL polyethylene containers. The containers were prewashed 
in 10% nitric acid (>3 hours) and rinsed twice in purified water. The filled containers were 
weighed in the laboratory and 2 mL urine were transferred to 4 mL glass tubes with crew 
caps packed with aluminum foil and stored at -20 °C until analyzed. 
Prior to analysis all samples were equilibrated to room temperature. Samples were 
vortex mixed and 300 µL were transferred into silanized 1.8 mL Teflon screw cap vials. 
180 µl ammonium acetate buffer (pH 5.5-6.0), 30 µL internal standard (ring deuterated 
NAAP-d4) solution and 6 µL of β-glucuronidase/arylsulfase solution were added to each 
sample. After incubation in a water bath at 37 °C for 3.5 hours, 60 µL Tris-buffer (1 M, pH 
10) were added to adjust pH value. To freeze out and precipitate proteins, samples were 
frozen at – 18 °C overnight. The next day samples were thawed and centrifuged for 10 
min at 1900 g. Supernatant was transferred into a new silanized 1.8 mL Teflon screw 
cap vial. Urinary concentrations of creatinine were determined according to the Jaffe 
method and used to adjust for the effect of urine dilution on NAAP concentrations. 
Chemical analysis 
NAAP levels in urine were measured at Institute for Prevention and Occupational 
Medicine of the German Social Accident Insurance (Institute of the Ruhr-Universität 
Bochum, Bochum, Germany) according to previously published methods (Modick et al., 
2013; Dierkes et al. 2014). In short, NAAP was extracted from urinary matrix and 
chromatographically separated by using a two column high performance liquid 
chromatography (HPLC) system; detection was done by tandem mass spectrometry with 
quantification via isotope-dilution (Modick et al. 2013; Dierkes et al. 2014). Cotinine in 
urine was determined after solid phase extraction by LC-MS/MS on a system consisting 
of a Themo TSQ Discovery mass spectrometer and an Agilent 1100 series HPLC system 
(unpublished method). 
Statistics 
To differentiate between general, currently undefined environmental NAAP background 
exposures and NAAP exposure occurring from recent paracetamol intake, data was split 
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into two groups, with NAAP < 4000 µg/l and NAAP > 4000 µg/L. This arbitrary cut-off is 
based on the publication of (Modick et al. 2014). The authors explained this cut-off value 
on the one hand based on the 95th percentile of the NAAP concentrations in 2098 urine 
samples from the general German population and on the other hand based on the 
excretion kinetics of a therapeutical paracetamol dose of 500 mg. The excretion kinetics 
indicate that urinary NAAP concentrations remain >4000 µg/L for 36-48h after oral intake 
of a single 500 mg paracetamol pill. Of course this cut-off has to be regarded as arbitrary 
because both (Modick et al. 2014) and (Dierkes et al. 2014) have shown that urinary 
NAAP concentrations of 4000 µg/L can also be exceeded in individuals that confirmedly 
never used NAAP containing medications (e.g. through environmental NAAP or aniline 
exposure); paracetamol use longer than 36-48h in the past will also remain undetected 
by this cut-off. For analysis of association the bivariate correlation Spearman rho was 
used. Comparing medians across groups (smokers and non-smokers, frequency of 
chicken intake) a symptomatically two tailed Mann-Whitney U-test was used. All analysis 
was done on both measured concentrations and on the creatinine adjusted 
concentrations. IBM® SPSS® Statistics 20 was used for the statistical analysis. 
Results 
The characteristics of the study population and the general intake of paracetamol are 
shown in table 1. Of the 130 mothers answering the medication questionnaire, 79 
(60.8%) declared never/almost never (within the last year) to have taken paracetamol 
containing medication, while 51 (39.2%) declared to take paracetamol at least once a 
month. As the questionnaire was not designed for this study, we do not have information 
on paracetamol consumption within the last 48 hours. The mothers also declared 
information about their child’s general use of OCT medicine, including paracetamol, and 
89 of the children had not used paracetamol within the last three months. 
Table 2 shows urinary NAAP concentrations from mothers and children, unadjusted and 
adjusted for creatinine secretion. NAAP was detectable in all samples from mothers, with 
concentrations between 4.9µg/L and 3g/L and a median of 120µg/L (table 2a). In the 
children, NAAP was detected in all samples except for one urban child. The 
concentrations ranged from not detectable to 2g/L, and the median was 27µg/L (table 
2b). Creatinine adjustment does not change the percentiles and median of the data. For 
the mothers creatinine adjusted concentration range from minimum 6.7µg/g creatinine to 
maximum 4g/g creatinine and with median at 114µg/g creatinine (table 2a). For the 
children, maximum concentrations were 1g/g creatinine and median concentration was 
at 33µg/g creatinine (table 2b). 
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Table 1: Characteristics of the study population (mean (range)) 
 
       
  
Children 
       
       
  
Urban  Rural  All 
       
       
N  75 (35 ♂, 40 ♀)  70 (35 ♂, 35 ♀)  145 
       
Age [years]  8.5 (6-11)  8.5 (6-11)  8.5 (6-11) 
       
Height [cm]  137.7 (116-165)  137.5 (118-163)  137.6 (116-165) 
       
Weight [kg]  30.2 (18-47)  31.9 (18-65)  31 (18-65) 
       
BMI [kg/m2]  15.8 ± 1.2  16.6 ± 2.3  16.2 ± 2.3 
       
Creatinine [µg/mL]  1054 ± 432 (n=74)  1055 ± 508 
(n=70) 
 1054 ± 469 
(n=144) 
       
Urinary vol [mL]  232 (20-695)  235 (15-720)  234 (15-720) 
       
Paracetamol intakea       
       
Paracetamol taken within the 
last 3 months 
     Yes: 42 
No: 89 
       
ETSb last 24h       12 
       
       
  
Mothers 
       
       
  
Urban  Rural  All 
       
       
N  75  70  145 
       
Age [years]  41.9 (31-52)  39.9 (31-50)  40.9 (31-52) 
       
Height [cm]  170.1 (154-188)  169.3 (156-190)  169.7 (154-190) 
       
Weight [kg]  63.9 (45-87)  71.2 (50-150)  67.4 (45-150) 
       
BMI [kg/m2]  22.1 ± 2.7  24.8 ± 5.7  23.4 ± 4.6 
       
Creatinine [µg/mL]  1066 ± 555 (n=74)  1131 ± 526 
(n=69) 
 1098 ± 541 
(n=143) 
       
Urinary vol [mL]  361 (60-835)  341 (29-860)  352 (29-860) 
       
Paracetamol intakea       
       
Never taken/almost never      79 
       
Once a month or more      51 
       
Smokers habits        
       
Daily      11 
       
Occasionally       5 
       
ETSb last 24h  
(non-smokers) 
     10 
       
       
BMI, body mass index 
a
 Additional questionnaire only andwered by 130 mothers 
b
 Environmental tobacco smoke  
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Table 2a: Urinary NAAP concentrations in Danish mother-child pairs 
 
There was no significant difference in measured NAAP between urban and rural areas 
neither for the mothers nor for the children (tables 2a+b). However, there seems to be a 
tendency, that the mothers in the urban area have higher levels of NAAP compared to 
mothers in the rural area. For the children, the highest concentrations of NAAP were 
seen in the urban children while none of the rural children had levels above the 4000 
µg/L (table 2b). There was no significant gender difference in NAAP excretion of the 
children. For three out of nine of the children with NAAP above 4000µg/L, the mother 
declared that the child had not been taking paracetamol within the last three months. 
Further, 13 out of 23 mothers with NAAP above 4000µg/L reported to either never take 
paracetamol or to use paracetamol less than once a month (table 3). 
       
(a) 
 
Mothers 
       
       
  
Urban (n=75)  Rural (n=70)  All 
  
     
       
  
Concentrations [µg/L] (n=145) 
       
       
Mean  52,170  77,200  64,250 
       
Minimum  4.9  8.9  4.9 
       
Maximum  3,037,000  2,546,000  3,037,000 
       
Percentiles       
       
10  18  26  22 
       
25  32  54  41 
       
50 (median)  106  143  120 
       
75  455  699  548 
       
90  26,260  124,100  86,040 
       
95  174,900  512,400  194,900 
       
       
  
Creatinine adjusted [µg/g creatinine] (n=145) 
       
       
Mean  77,320  58,350  68,170 
       
Minimum  6.7  12  6.7 
       
Maximum  4,259,000  1,723,000  4,259,000 
       
Percentiles       
       
10  19  24  22 
       
25  37  61  42 
       
50 (median)  112  121  114 
       
75  374  970  904 
       
90  21,330  149,600  105,300 
       
95  165,800  401,100  258,100 
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Table 2b: Urinary NAAP concentrations in Danish mother-child pairs 
       
(b) 
 
Children 
       
       
  
Urban (n=75)  Rural (n=68)  All 
       
       
  
Concentrations [µg/L] (n=143) 
       
       
Mean  56,800  243  29,9100 
       
Minimum  -  2.79  - 
       
Maximum  2,257,000  4222  2,257,000 
       
Percentiles       
       
10  8.3  7.4  8.0 
       
25  15  15  14.5 
       
50 (median)  25  31  27 
       
75  58  183  86 
       
90  8170  710  975 
       
95  176,400  1604  8617 
       
       
  
Creatinine adjusted [µg/g creatinine] (n=142) 
       
       
Mean  35,840  288  18,820 
       
Minimum  -  5.61  - 
       
Maximum  1,131,000  5063  1,131,000 
       
Percentiles       
       
10  8.9  7.5  7.8 
       
25  14  12  13 
       
50 (median)  32  37  33 
       
75  55  243  109 
       
90  8593  474  895 
       
95  125,700  1254  9221 
       
       
 
When comparing the mother-child pairs, a correlation between the NAAP levels of 
mother and child was found. After splitting the data into two groups, <4000µg/L and 
>4000 µg/L, correlation persisted in the <4000µg/L group, but not in the >4000 µg/L 
group.     
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Table 3: Paracetamol intake and measured NAAP concentration (<4000 µg/L and >4000 µg/L) 
 
Urinary cotinine levels were measured as part of the DEMOCOPHES basic scenario. 
Cotinine is a well-established biomarker for smoking and exposure to environmental 
tobacco smoke (ETS). There was no correlation between cotinine and NAAP excretion 
for both mothers and children and no correlation between excretion of NAAP and 
questionnaire response regarding the smoking statues or ETS within the last 24 hour 
was found. Also, there was no difference in NAAP levels of smoking and non-smoking 
mothers. Finally there was no difference in the urinary NAAP excretion in relation to 
frequency of eating chicken. 
 Discussion and conclusion 
NAAP was detected in all participants except for one child. This clearly suggests that 
there is an omnipresent body burden of NAAP in the general Danish population from 
exposure to paracetamol, aniline or both. These findings are in concordance with a 
recent pilot study that revealed omnipresent NAAP body burdens in individuals that were 
neither occupationally exposed to aniline, nor exposed to NAAP through the use of 
medications. It was thus hypothesized, that either exposure to aniline (or aniline 
releasing substances) or exposure to paracetamol itself through paracetamol 
contaminated food lead to this ubiquitous paracetamol excretion in the general 
  
 Mothers 
  
  
NAAP < 4000 µg/L  
  
Never taken/almost never taken paracetamol 66 
  
Taken paracetamol once a month or more 41 
  
  
NAAP > 4000µg/L  
 
  
Never taken/almost never taken paracetamol 13 
  
Taken paracetamol once a month or more 10 
  
  
 
Children 
  
  
NAAP < 4000 µg/L 
 
  
Paracetamol intake within the last 3 months   
  
Yes 36 
  
No 86 
  
  
NAAP > 4000µg/L 
 
  
Paracetamol intake within the last 3 months   
  
Yes 6 
  
No 3 
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population, besides direct exposure by the use of medication (Modick et al. 2014; 
Dierkes et al. 2014). 
After intake of paracetamol, human data shows that approximately 80% are excreted in 
urine as NAAP in conjugated form (Ladds et al. 1987). Animal studies showed similar 
results (75 - 86%) after oral intake of which is aniline (Kao et al. 1978). The rate of 
elimination from plasma is similar in adults (1.5 - 3.0 h) and children (1.0 – 3.5 h) (Miller 
et al. 1976;Peterson and Rumack, 1978), while a study with one adult showed urinary 
NAAP concentrations ~4000 µg/L after approximately 36 hours (Modick et al. 2014). The 
fact, that many mothers/children in the paracetamol-user group have NAAP levels 
comparable to non-users is not surprising, because urinary measurements can detect 
only recent (within 24 to 48h) paracetamol use while the questionnaire asked for 
paracetamol use in a longer period (within one to three months). Rather surprising, 
however is, that many non-paracetamol users have high urinary NAAP levels 
(>4000µg/L) which indicates paracetamol use within the last 24 to 48 hours or 
occupational aniline exposure. Other sources of paracetamol (e.g. contaminated food) 
may have caused the high paracetamol levels; or, high exposure to aniline (or aniline 
releasing substances) may have caused the high excretion of NAAP in urine. 
However, currently there is no clear explanation for the high NAAP levels in these 
individuals. One explanation could be underreporting of the mothers. In our study 9% of 
the 130 mothers that replied to the OTC questionnaire, declared that they themselves (or 
their child) had not taken paracetamol (table 3). This is a little lower than what was found 
previously in the glodbal INTERMAP study with 17 population samples from Japan, 
China, The United Kingdom and the United States (15-17%) (Loo et al. 2012). Another 
explanation might be uncertainties concerning the cut-off value of 4000 µg/L for 
separating NAAP background exposures from intentional NAAP use. As explained 
above, this arbitrary cut-off was derived from the 95th percentile of urinary NAAP levels 
in 2098 samples from the general German population in conjunction with the elimination 
kinetics after oral NAAP intake (Modick et al. 2014). There still remains the possibility of 
higher urinary NAAP concentrations without the intentional intake of paracetamol and 
therefore a slight chance of overreporting in the >4000µg/ml group. On the other hand, 
intentional paracetamol intake would remain undetected by urinary NAAP levels if the 
intake occurred 36-48h or longer ago. Furthermore, the cut-off value estimation was 
based on samples from an adult population and uncertainties might occur in 
extrapolating to children. 
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The correlation between mothers and children with NAAP excretion under 4000 µg/L, 
indicates that exposure might be related to common environmental exposure and 
lifestyle. Such common sources (of paracetamol or its precursor aniline) might be food 
consumed in common meals or indoor sources such as indoor air. Aniline was detected 
in indoor air in private homes (smokers and non-smokers) in Italy and in different public 
places (e.g. schools, hospitals, police stations and newspaper offices). Levels of aniline 
ranged from 53 ng/m3 (office of non-smokers) to 1929 ng/m3 (discotheque). But there 
was no clear association between aniline levels and cigarette smoking, in fact a hospital 
waiting ward (non-smoker) had the third highest level (351 and 483 ng/m3) of aniline 
(Palmiotto et al. 2001). This could also be the case in Denmark and therefore the living 
environment of the participants, the mothers’ workplace and the children’s school could 
be sources of aniline exposure. It has previously been shown that tobacco smoke is a 
source of aniline, but in 
this study there was no correlation between smoking or ETS exposure and NAAP 
excretion. This may be due to the low numbers of smokers in the Danish 
DEMOCOPHES participants (n=12), as it has previously been shown that smokers have 
a higher level of urinary NAAP (Modick et al. 2014). Another indirect source of 
paracetamol may be food contaminated with aniline or paracetamol. NAAP is approved 
for veterinary use in Europe (Commission Regulation (EU) 37/2010) with no maximum 
residue level in the final meat product, but with restricted usage of NAAP for porcine 
species. According to the European Agency for the Evaluation of Medical Product 
(EMA), NAAP is used in poultry and cattle hold. To our knowledge The Danish Ministry 
of Food, Agriculture and Fishing has not monitored NAAP residues in meat and on 
European level the knowledge is very limited. NAAP has been detected in feather meal, 
which is used as an additive in animal feed, and has been suggested as a source of re-
entry of pharmaceuticals into meat food products (Love et al. 2012). Recently published 
data from a 48 hour fasting study in humans showed that the excretion of NAAP 
decreased during the fasting with a factor 50-100 and increased when the study 
participants resumed eating (Modick et al. 2014). This clearly indicates that food could 
be a major source of the ubiquitous exposure of the general population to NAAP. Since 
at least some part of the daily diet of the mothers and children is similar, the correlation 
between mothers and children might indicate contaminated foodstuff as a common 
source of exposure. 
However, we did not see any association between frequency of eating chicken and 
NAAP levels in this study. Paracetamol has been speculated to be used in chicken meat 
production (Committee for Veterinary Medicinical Products, 1999). However, the use of 
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paracetamol might not be restricted to poultry farming, and could be used in other fields 
of meat production as well. As aniline is used in the syntheses of pesticides and also as 
colorant in food and cosmetics, there is a wide range of food and consumer products 
containing aniline and a specific dietary exposure may be difficult to find with the present 
limited dataset. 
NAAP data were presented in relation to volume and in relation to urinary creatinine 
concentration. Adjusting for creatinine was done to remove the influence of urinary 
dilution of measured NAAP concentrations. Thus, creatinine excretion variances in adults 
depend on different parameters such as muscle mass, gender, age and intake of meat 
(Boeniger et al. 1993). This can affect the outcome of the statistical analysis. Because 
children have a smaller muscle mass, their creatinine excretion is lower than seen in 
adults, and this can make it difficult to compare NAAP data between mothers and 
children. Based on these facts, both non-adjusted and adjusted NAAP data were 
presented in the paper. 
 
In light of the omnipresent excretion of NAAP in this study, a further investigation of the 
exposure of the general population is important, because of the suspected harmful 
effects of paracetamol. Furthermore, we have a limited knowledge on the indirect source 
of paracetamol (as aniline or paracetamol residues in consumer products). As food 
seems to be a major indirect source, it would also be of great importance to gain further 
knowledge about the possible food content of paracetamol, either as part of a national 
food monitoring program or by using a more comprehensive food questionnaire. 
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Abstract 
Aniline is an important source material in the chemical industry (e.g. rubber, pesticides, 
and pharmaceuticals). The general population is known to be ubiquitously exposed to 
aniline. Thus, assessment of aniline exposure is of both occupational and environmental 
relevance. Knowledge on human metabolism of aniline is scarce. We orally dosed four 
healthy male volunteers (2 fast, 2 slow acetylators) with 5 mg isotope labelled aniline, 
consecutively collected all urine samples over a period of two days and investigated the 
renal excretion of aniline and its metabolites by LS-MS/MS and GC-MS.  
After enzymatic hydrolysis of glucuronide and sulfate conjugates, N-acetyl-4-
aminophenol was the predominant urinary aniline metabolite representing 55.7-68.9% of 
the oral dose, followed by the mercapturic acid conjugate of N-acetyl-4-aminophenol 
accounting for 2.5-6.1%. Acetanilide and free aniline were found only in minor amounts 
accounting for 0.14-0.36% of the dose. Overall, these four biomarkers excreted in urine 
over 48h post dose represented 62.4-72.1% of the oral aniline dose. Elimination half-
lives were 3.4-4.3h for N-acetyl-4-aminophenol, 4.1-5.5h for the mercapturic acid 
conjugate and 1.3-1.6 and 0.6-1.2h for acetanilide and free aniline, respectively. Urinary 
maximum concentrations of N-acetyl-4-aminophenol were reached after about 4h hours 
and maximum concentrations of the mercapturic acid conjugate after about 6h, whereas 
concentrations of acetanilide and free aniline peaked after about one hour. 
The present study is one of the first to provide reliable urinary excretion factors for aniline 
and its metabolites in humans after oral dosage, including data on the predominant 
urinary metabolite N-acetyl-4-aminophenol, also known as an analgesic under the name 
paracetamol/acetaminophen. 
KEY WORDS: aniline, paracetamol, metabolism, excretion factors, urine, exposure 
assessment 
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Introduction 
Aniline (phenylamine, CAS 65-53-3) is an important and widely used feedstock in 
chemical industry. The vast majority of aniline (~70%) is used as a precursor in the 
production of polyurethane-based polymers. It may also be used in the manufacture of 
rubber additives (accelerators, antioxidants) and as an intermediate in the production of 
pesticides, azo dyes and pharmaceuticals (European Chemicals Bureau 2004; Human 
Biomonitoring Commission of the German Federal Environment Agency 2011; MAK 
Value Documentation in German language, 1992). Aniline has also been detected in 
indoor and outdoor air (Palmiotto et al. 2001) and in the water of drinking water treatment 
plants (Deblonde et al. 2012). Further, aniline is a known constituent of tobacco smoke 
(Grover P 1989; Human Biomonitoring Commission of the German Federal Environment 
Agency 2011).  
Depending on the occupational or environmental setting, exposure to aniline can occur 
through inhalation and/or oral uptake. In addition, aniline can be readily absorbed 
through the skin both from the liquid and gaseous phase (MAK Value Documentation in 
German language 1992; Korinth et al. 2006; American Conference of Governmental 
Industrial Hygienists 1992) thus making biological monitoring the method of choice for 
exposure assessment if appropriate biomarkers are at hand. Animal studies conducted 
in the early 1980´s identified N-acetyl-4-aminophenol (NA4AP) as the major metabolite 
of aniline in urine, representing 75-86% of the aniline dose. NA4AP is mainly excreted in 
form of its glucuronide and sulfate conjugates; whereas free NA4AP reflects about 10% 
of the dose. Other metabolites identified were O-conjugates of 2- and 4-aminophenol (5-
25% of dose). Free aniline or acetanilide (ACA) represented only 0.5-3.4% dose (Kao et 
al. 1978). Neither NA4AP (and its O-conjugates) nor 4-aminophenol have been used for 
biological monitoring of aniline exposure in humans. NA4AP (=paracetamol) is the active 
ingredient of many over-the-counter analgesics and 4-aminophenol is a moiety and 
known metabolite of chemicals such as the pesticide parathion. Therefore, NA4AP, 
NA4AP-derived metabolites or the amino phenols are not specific to aniline. 
Consequently, exposure assessments to aniline both in occupational and environmental 
practice have been carried out by either analyzing aniline in urine or aniline-derived 
hemoglobin adducts in blood (Lewalter and Gries 1985; Lewalter and Korallus 1985; 
Riffelmann et al. 1995; Weiss and Angerer 2002;). Several human biomonitoring studies 
have proven that, next to workers in occupational settings (el-Bayoumy et al. 1986; 
Riffelmann et al. 1995) the general population is ubiquitously exposed to aniline (Kütting 
et al. 2009; Weiss and Angerer 2002; Human Biomonitoring Commission of the German 
Federal Environment Agency 2011).  
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Interestingly, knowledge of the quantitative metabolism of aniline in humans is scarce 
despite the current specific use of aniline in urine or aniline-derived Hb adducts for 
exposure assessment. In example, no valid data concerning excretion kinetics and 
urinary conversion of aniline in humans is available. Furthermore, the limited data from 
animal experiments found large variations in metabolism between the surveyed animal 
species (Kao et al. 1978) thus making it difficult directly transferring results from animal 
studies to those in humans. In addition, the lack of basic toxikokinetic data of aniline in 
humans makes it difficult to re-calculate the absolute amount of aniline taken up by 
humans based on biomonitoring results. This lack of data makes it difficult to establish a 
reference dose (RfD) or a tolerable daily intake (TDI) for aniline exposure from the 
environment. A recalculation is also necessary in risk assessment and risk 
communication, i.e. to compare the absolute amount of aniline taken up in humans to 
those applied in rodent toxicity studies. 
Irrespective of the aniline specific biomarkers aniline and ACA in urine, NA4AP (either as 
the active ingredient in analgesics or the major metabolite of aniline) recently came into 
the focus of scientific interest. Epidemiological and experimental (animal, ex vivo and in 
vitro) studies suggest intrauterine exposure to NA4AP as a possible risk factor for male 
reproduction disorders and possible antiandrogenic effects (Rebordosa et al. 2008; 
Rebordosa et al. 2009; Jensen et al. 2010; Philippat et al. 2011; Christiansen et al. 2012; 
Albert et al. 2013). NA4AP is furthermore suspected to have detrimental effects on the 
neurodevelopment of the unborn, resulting in hyperkinetic disorders in early childhood 
and school-age (Liew et al. 2014; Thompson, John et al. 2014; Brandlistuen et al. 2014). 
NA4AP as the major metabolite of aniline was found in urine samples in the mg/L range 
after occupational exposure to aniline (air concentration of aniline below the German 
MAK-value of 2 ppm) (Lewalter and Korallus 1985; MAK Value Documentation in 
German language 1992). In recent studies from our group with volunteers exposed to 
(airborne) aniline we also quantified urinary NA4AP in the mg/L range ((Dierkes et al. 
2014; Modick et al. 2014). However, we detected NA4AP not only in urine samples after 
known (occupational) exposure to aniline, but also in all samples from controls and the 
general population, without exception. While for some individuals the use of analgesics 
(acetaminophen/paracetamol) could explain high urinary NA4AP levels, for many other 
individuals with high NA4AP levels we could rule out recent intake of the pharmaceutical 
by questionnaire (Modick et al. 2013; Modick et al. 2014, Nielsen et al. 2014). We 
suggested exposure to aniline to be one possible origin of the internal burden to NA4AP. 
In this context, not only the quantitative investigation of human aniline metabolism 
resulting in its “specific” biomarkers aniline and acetanilide in urine seems of utmost 
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interest, but also its metabolism resulting in its major metabolite NA4AP and NA4AP 
downstream metabolites. 
Here, we present the elimination kinetics and urinary conversion factors for aniline and 
acetanilide (ACA) but also basic toxicokinetic data for NA4AP and its mercapturic acid N-
acetyl-4-aminophenol-3-mercapturate (NA4AP-MA) (figure 1) after a single oral dose of 
isotope labelled aniline-d5 in four volunteers. 
Experimental 
Study design 
Four healthy Caucasian male volunteers (30 - 32 years old, 71 – 95 kg, non-smokers) 
were dosed orally with 4.6 mg aniline-d5 (ring deuterated) reflecting a total intake 
between 48 and 64 µg/ kg body weight. Isotope labelled aniline-d5 was dosed to avoid 
interferences occurring from the known background exposure to aniline. For this 
purpose, 1 mL of a stock solution prepared from 46 mg aniline-d5 dissolved in 10 mL 
ethanol was spiked into decaffeinated coffee or tea and ingested in a single step as part 
of a breakfast. The administered doses were approximately four hundred times lower 
than the estimated dose which leads to an increase of blood methemoglobin in rats 20 
mg/kg bw, (Jenkins et al. 1972). All volunteers had no known occupational exposure to 
aniline. Two of the volunteers were low and two were fast acetylators. The acetylator 
phenotype (NAT2) was determined according to a previously published method (Grant et 
al. 1983; Bolt et al. 2005) at the Leibniz Research Centre for Working Environment and 
Human Factors (IfADo) in Dortmund, Germany. 
Each volunteer provided one urine sample before dosage. After dosage urine samples 
were collected continuously for 48 h in 250-mL-polyethylene containers. Volunteers 
recorded the time of each urine void. Volumes of each urine void were determined as the 
mass difference between the empty and the filled sample container. When urine had to 
be collected in more than one container at a time, volumes of the containers were added 
and samples were combined and mixed before further processing. Aliquots of 15 mL of 
each sample were stored in 15-mL-polypropylene containers and frozen at -18°C within 
12 h after collection. 
The study was carried out according to the Declaration of Helsinki and was approved by 
the ethical board of the Ruhr University Bochum (Approval No. 4730-13). 
In order to investigate the human metabolism of aniline we focused on metabolites 
known from former aniline metabolism in experimental studies (Kao et al. 1978; Lewalter 
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and Korallus 1985). Given a cross-connection between the metabolism of aniline and the 
one of paracetamol, we also took into account experimental studies on paracetamol 
metabolism (Andrews et al. 1976; Ladds et al. 1987; An et al. 2012). Thus we 
determined unconjugated aniline (AN), N-acetylaniline (acetanilide, ACA), the sum of N-
acetyl-4-aminophenol (NA4AP) and its O-conjugates in terms of total NA4AP after 
enzymatic hydrolyses, and N-acetyl-4-aminophenol-3-mercapturate (NA4AP-MA), a 
mercapturic acid metabolite of NA4AP. 
Because ring-labeled aniline-d5 was administered the corresponding ring-labeled 
metabolites were formed, i.e. NA4AP-d4, NA4AP-MA-d3 and ACA-d5. Isotope-labeled 
target analytes based on the metabolism of aniline-d5 and substances used for internal 
standardization and quantitation (with isotope labels at different positions; NA4AP-d3, 
NA4AP-MA-d5, ACA-d3) are shown in figure 1. Aniline was determined applying a GC-
MS method, while NA4AP, NA4AP-MA and ACA were determined by HPLC-MS/MS. All 
analytes (except free aniline) were determined after enzymatic hydrolysis using ß-
glucuronidase/arylsufatase.  
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Figure 1: Scheme of the analytical approach of the study, including aniline suspected aniline d5 metabolites 
(target analytes, left column) and internal standards used for quantification (right column); stars indicate 
location of isotope labelled spots in the molecules 
 
Chemicals 
Aniline-d5 (CAS 4165-61-1, purity >99.0%), acetanilide (CAS 103-84-4, purity >99%), 
acetic acid-d4 (CAS 1186-52-3), ammonium acetate p.a., HP2 β-glucuronidase 
(≥100,000 U/mL), arylsulfatase activity (~7,500 U/mL), 4-aminophenol, pyridine, 
dichloromethane, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, 2-(N-
morpholino) ethanesulfonic acid (MES), and heptafluorobutyric anhydride (HFBA) were 
all purchased from Sigma- Aldrich (Steinheim, Germany). N-acetyl-4-aminophenol-d4 
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(NA4AP-d4, CAS 64315-36-2, purity 99%) was obtained from LGC Standards (Wesel, 
Germany). Acetanilide-d5 (ACA-d5, CAS 15826-91-2) was purchased from CDN Isotopes 
(Quebec, Canada). Paracetamol-3-mercapturate sodium salt (NA4AP-MA, CAS 52372-
86-8, purity 95 %) and paracetamol-3-mercapturate-d5 sodium salt (NA4AP-MA-d5, purity 
97 %) were purchased from Toronto Research Chemicals Inc. (North York, Canada). o-
Toluidine-d7 was purchased from Santa Cruz Biotechnology Inc. (Heidelberg, Germany). 
Deionized water was obtained using a Millipore Advantage A10 with a Quantum®- 
cartridge. Acetonitrile and methanol (LC-MS grade) were purchased from Roth 
(Darmstadt, Germany). Finally, N-acetyl-4-aminophenol-d3 and acetanilide-d3 were 
synthesized by selective acetylation of 4-aminophenol at the amino group and by 
acetylation of aniline, both with activated acetic acid-d4 as previously described by 
Dierkes et al.2014. 
 
Analysis of total NA4AP-d4, NA4AP-MA and ACA-d5 
Quantitation of total NA4AP-d4, NA4AP-MA and ACA-d5 was carried out by HPLC-
MS/MS. For this purpose, stock solutions of the standards and the corresponding 
internal standards were prepared (see suppl. File). Internal standards solutions of 
NA4AP-d3 and ACA-d3 were prepared as previously described by Dierkes et al. (2014). 
The internal standard solution of NA4AP-MA-d5 was prepared by dissolving 1.5 mg of 
NA4AP-MA-d5 sodium salt in 10 mL methanol. An internal standard stock solution was 
prepared by mixing the three standard solutions and further dilution in water, leading to 
final concentrations of 800 µg/L for NA4AP-d3, 500 µg/L for ACA-d3 and 500 µg/L for 
NA4AP-MA-d5 (calculated paracetamol-3-mercapturic acid-d5). 
Frozen urine samples were thawed and equilibrated to room temperature (RT) before 
analysis. All samples were vortex mixed and aliquots of 300 µL were transferred into a 
1.8-mL-screw cap vial. After adding 300 µL ammonium acetate buffer (0.5 M, pH 5.5-
6.0), 6 µL glucuronidase/arylsulfatase-solution and 30 µL of the internal standard 
solution, the samples were incubated for 3.5 h at 37°C in a water bath. After incubation 
160 µL 3M formic acid were added. All samples were frozen overnight at −18°C for 
protein precipitation. After thawing, the samples were centrifuged at 4,000 g for 10 min, 
the supernatant was transferred into a second 1.8 mL screw cap vial and 25 µL were 
analyzed by 2D-HPLC-MS/MS. The limits of quantification (LOQ, S/N 9) were 0.5 µg/L 
for total NA4AP, 1 µg/L for NA4AP-MA, and 0.02 µg/L for ACA. Relative standard 
deviations for intra-day imprecision and for inter-day imprecision were <15% for all 
analytes at two different concentrations (Qlow, Qhigh); whereas mean relative recoveries 
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were in the range between 98.8% and 109.4% depending on the analyte (see suppl. file). 
Urinary creatinine concentrations creatinine concentrations were determined using a 
Beckman Coulter AU 5822 analyzer, that determines creatinine based on its color 
formation reaction with picric acid (Jaffé-method)(Jaffe M 1886).  
Analysis of unconjugated aniline-d5 by GC-MS/MS 
Unconjugated aniline-d5 was determined using a previously described method by Weiss 
et al. (2002) with minor modifications. In short, 5 mL urine was combined with 3 mL 
MES-buffer (0,5M; pH 6) and 50 µL internal standard solution (o-toluidine-d7; 50 µg/L) 
were added. 6 mL n-hexane was added and the mixture was shaken for 20 min on a 
laboratory shaker. The n-hexane was removed and concentrated to 1 mL in a vacuum 
centrifuge (Christ RVC 2-33 IR; 1,000 g; 50°C; 5 min). 30 µL HFBA were added and 
samples were incubated for 1 h at 80°C. Afterwards, the solution was washed with 1 mL 
phosphate-buffer (0.02M, pH 8). The organic phase was then combined with 100 µL 
toluene and evaporated to 20 µL by vacuum centrifugation. From this solution 1 µL was 
injected into the GC-MS/MS for quantitative analysis (see suppl. File). The LOQ for free 
aniline estimated by a signal to noise ratio of 9 was 0.1 µg/L. Method validation was 
performed in analogy to the HPLC method validation. Intra-day and inter-day 
imprecisions of the method were below 10% for both quality control concentrations (Qlow 
and Qhigh). Mean relative recoveries ranged between 97% and 107% for both spiked 
concentration levels (see suppl. File) 
Pharmacokinetic parameters and statistical analysis  
Maximum concentrations (cmax) of all metabolites in urine and the corresponding time 
points (tmax) were determined on the basis of volume-related (mg/L) and creatinine 
adjusted (mg/g) values. The same is true for the determination of the elimination kinetics. 
The elimination half-times were calculated from the rate constant κ (t½ = ln(2)/κ) 
obtained from a first order elimination, beginning at cmax to the end of sample collection 
or to the time point where the metabolite level in question decreased below LOQ. The 
amounts of metabolites excreted (in %) were calculated based on the metabolite 
concentrations and the urinary volumes and are reflecting molecular mass corrected 
aniline dose equivalents. 
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Results and discussion 
The four volunteers provided 81 consecutive and complete urine voids within 48 h. 
Figure 2 shows HPLC-MS/MS chromatograms of the target analytes NA4AP-d4, NA4AP-
MA-d3, and ACA-d5 in a representative pre-dose urine sample (A) and a representative 
post-dose sample (B) from one volunteer. In none of the pre-dose urine samples any of 
the (labelled) target analytes was detected; whereas all analytes were found post dose in 
the first urine samples of all volunteers (taken approximately 2.3 h after oral dosage). 
Similar results were obtained for unconjugated aniline-d5 by GC-MS (fig. 3).  
 
Figure 2: HPLC-MS/MS chromatograms of urine samples from one volunteer before (column A) and 2.3h 
after dosing (column B); black lines indicate mass ion traces of the internal standards, grey lines indicate 
analyte quantifier ion traces; analyte concentrations (column B) were 1,150 µg/L for NA4AP d4, 217 µg/L for 
NA4AP-MA d3 and 12.5 µg/L for ACA d5. 
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Figure 3: GC-MS chromatograms of urine samples from one volunteer before (upper row) and after dosing 
(lower row); black lines represent mass ion traces of o-toluidine d7 (internal standard), grey lines represent 
mass ion traces of aniline d5; analyte concentration in the represented (lower row) was calculated to be 7.5 
µg/L. 
 
The elimination curves of all target analytes for all four volunteers are shown in figure 4. 
Elimination curves are plotted on semi-logarithmic scale and represent creatinine 
adjusted concentration values in µg/g creatinine. The metabolite concentrations rose 
rapidly within just a few hours after the dosage in all four volunteers, followed by a first 
order decline during the entire time of the study (48 h). NA4AP-d4 and NA4AP-MA-d3 
were detected in all post-dose urine samples of the volunteers throughout the study. In 
contrast, ACA-d5 and unconjugated aniline-d5 were excreted rather fast and at 
considerably lower concentrations. The concentrations were falling below the LOQ about 
8-12 h after dosage.  
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Figure 4: Urinary excretion of aniline and aniline metabolites after single oral dosage for all four volunteers. 
Black graphs (V1 and V2) represent the two slow and grey graphs (V3 and V4) the two fast acetylators. All 
graphs are plotted on semi-logarithmic scale and represent aniline excretion in µg/g creatinine 
 
Elimination characteristics, maximum urinary concentrations (cmax), time of maximum 
concentrations (tmax) and calculated elimination half times (t½) each based on both µg/L 
and creatinine adjusted µg/g creatinine values over all four volunteers are shown in table 
1. Maximum concentrations of NA4AP-d4 and NA4AP-MA-d3 occurred ~ 4-6 h after the 
dosage (based upon µg/L values) and ~3 h after the dosage (based upon µg/g creatinine 
values). Concentrations of ACA-d5 and unconjugated aniline-d5 peaked much faster at 
about 1 h after dosage for both the µg/L and µg/g creatinine values. The most abundant 
urinary target analyte was NA4AP-d4 with maximum urinary concentrations well in the 
mg/L range and a mean maximum concentration of 6 mg/L (range: 1,490-8,670 µg/L). 
With these numbers it has to be kept in mind that NA4AP-d4 as determined with the 
approach described above represents the total of unconjugated NA4AP-d4 and its O-
conjugates (due to an enzymatic hydrolysis step during sample preparation). The 
maximum concentration of NA4AP-MA-d3 was about 0.5 mg/L (460-586 µg/L) and 
approximately one order of magnitude below that of total NA4AP-d4. Maximum urinary 
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concentrations of ACA-d5 and unconjugated aniline-d5 were considerably lower and with 
maximum concentrations around 15-30 µg/L, each. 
Table 1: Maximum urinary concentrations (cmax), time points of maximum concentrations (tmax) and 
calculated elimination half-times (t ½) of aniline metabolites and free aniline as the mean of the four 
volunteers (ranges in brackets) 
Metabolite Maximum urinary 
concentration (c max) 
Time of maximum (t max) Estimated elimination 
half time (t ½) 
       
       
 Based on 
µg/L values 
Based on 
µg/g crea 
values 
Based on 
µg/L values 
Based on 
µg/g crea 
values 
Based on 
µg/L 
values 
Based on 
µg/g crea 
values 
       
       
NA4AP 6,108 (1,490-
8,670) 
11,084 (9,642-
12,526) 
3.8 (0.8-6.3) 2.1 (1-.5-2.4) 4.2 (3.5-5.3) 3.9 (3.4-4.3) 
 
      
 
      
NA4AP-MA 523 (460-586) 1,263 (725-
2,520) 
5.8 (3.3-9.9) 2.9 (2.3-3.8) 5.5 (4.3-6.4) 4.8 (4.1-5.5) 
 
      
 
      
ACA 20.2 (15.2-
27.8) 
113 (54.4-161) 0.9 (0.8-1.4) 1.3 (0.8-1.5) 2.2 (1.8-2.8) 1.4 (1.3-1.6) 
 
      
 
      
Free 
aniline 
18.7 (16.2-
23.3) 
60.3 (10.8-117) 1.4 (0.8-3.3) 1.5 (1.4-1.7) 1.7 (0.6-2.9) 0.9 (0.6-1.2) 
       
       
Elimination half-times were calculated based on concentration values and creatinine-adjusted concentration values over 
the time by the rate constant κ with t ½ = ln(2)/ κ 
 
 
 
Elimination half-times differed considerably between the analytes but were in good 
agreement between the four volunteers (Tab. 1). Unconjugated aniline-d5 and ACA-d5 
were rapidly excreted with mean elimination half-times of 1.7 and 2.2 h, respectively 
(based on µg/L values) and 0.9 and 1.4 h, respectively (based on µg/g creatinine 
values). Mean elimination half-times for NA4AP-d4 were 4.2 and 3.9 h. NA4AP-MA-d3 
exhibited the longest elimination half-times of around 5h.  
Urinary excretion factors (Fue) of unconjugated aniline and its metabolites (calculated as 
molar equivalents of the aniline dose in %) are shown in Tab. 2. In total, during the 48 h 
course of the study a mean of 65.2% (55.7-68.9%) of the aniline-d5 dose was excreted 
as total NA4AP-d4 in urine in terms of unconjugated NA4AP-d4 and its O-conjugates. The 
second most abundant target analyte was NA4AP-MA-d3 representing a mean of 4.0% 
(2.5-6.1%) of the dose. ACA-d5 and unconjugated aniline-d5 represented only a minor 
share of the aniline-d5 dose (0.25% each). The major fraction of all four target analytes, 
(representing 68-75% of the total dose) was excreted during the first 24 h. From 24-48 h 
only a small amount of the dose (0.5-0.9%) was excreted as total NA4AP-d4 and NA4AP-
MA-d3. Neither ACA-d5 nor unconjugated aniline-d5 was detectable any more in the 24-
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48 h post-dose samples. However, urinary concentrations of total NA4AP-d4 and 
NA4AP-MA-d3 were still measurable 48h post dose.  
 
 
Table 2: Urinary excretion factors (Fue) of aniline and aniline metabolites calculated as molar equivalents of 
the aniline dose in % 
       
Metabolite 
 
Urinary excretion factor (F ue)a as aniline dose equivalents in % 
  
     
       
  
0 - 24 h  24 - 48 h  Total (0 - 48 h) 
       
       
NA4AP 
 64.5 (54.8-
68.3) 
 0.8 (0.5-0.9)  65.2 (55.7-68.9) 
 
      
NA4AP-MA 
 3.8 (2.4-5.9)  0.15 (0.08-0.22)  4.0 (2.5-6.1) 
 
      
ACA 
 0.26 (0.18-
0.36) 
 -  0.26 (0.18-0.36) 
 
      
A 
 0.24 (0.14-
0.31) 
 -  0.24 (0.14-0.31) 
       
a 
mean values of the four volunteers, ranges in brackets 
       
       
 
As shown in our study, NA4AP and its O-conjugates are the major urinary metabolites of 
aniline and can be analyzed in terms of total NA4AP after using an enzymatic hydrolysis 
step during sample preparation. This is in accordance with Lewalter and Korallus (1985) 
who identified NA4AP (after acid hydrolysis) as the major metabolite after occupational 
exposure to aniline. However, their study design did not allow deriving urinary metabolite 
conversion factors (Lewalter and Korallus 1985). Investigating several animal species 
(pig, rat and sheep) Kao et al. (1978) recovered a total (sum of conjugated and 
unconjugated) of 75-86% of an oral aniline dose as NA4AP in urine, which is close to the 
conversion of 55.7-68.9% observed in this study in humans. About 0.5% (0.4-1.0%) of an 
oral aniline dose was excreted as ACA in the urines of rats (Kao et al. 1978), which is 
also in good accordance with the recoveries of ACA in our study. Conversion factors for 
ACA in sheep and pigs, however, were approximately 10-fold higher than those 
observed in humans and rats. Until now NA4AP-MA has not been subject of quantitative 
investigations as a metabolite of aniline in biomonitoring studies. In human metabolism 
studies after dosage of paracetamol (chemically identical to NA4AP) the NA4AP-MA 
metabolite reflected 0.5-6.1% of the paracetamol dose (Ladds et al. 1987), which is very 
similar to the conversion we found from aniline (2.4-5.9%).  
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Overall, our study shows a total recovery of 64.4-72.7% of the aniline dose in terms of 
total NA4AP, NA4AP-MA, unconjugated aniline and ACA. We can only speculate about 
the remaining 27-34%. Certainly, excretion of additional aniline related metabolites is 
highly likely e.g. ortho- and para-aminophenol and its conjugates. Aminophenols (para-
aminophenol) have been reported in animal studies to contribute to about 5.5-28.5% of 
the metabolite spectrum in urine, with large interspecies variations (sheep 10.8-18.7%; 
pigs 5.5-9%; rats 20.2-28.5% (Kao et al. 1978). Further NA4AP derived metabolites 
contributing to the aniline metabolite spectrum may be NA4AP-3-cysteine or 3-hydroxy-
NA4AP-4-sulfate which have been reported to represent 0.6-13.7% and 0.4-4.8% of an 
administered paracetamol dose, respectively (Ladds et al. 1987). 
Regarding the acetylator status of the volunteers we observed no influence on urinary 
excretion factors (Fue) and maximum urinary concentrations (cmax) for total NA4AP and 
NA4AP-MA (table 3). However, the acetylator status might have some influence on the 
formation of unconjugated aniline and ACA. ACA levels in terms of Fue of the two fast 
acetylators (0.31% and 0.36%) were about 2-fold higher than those of the two slow 
acetylators (0.16% and 0.19%). In reverse, excretion of unconjugated aniline in the slow 
acetylators (0.28 and 0.33%) was about twice as high compared to the fast acetylators 
(0.14 and 0.23%). For none of the analytes elimination half times seemed to be 
influenced by the acetylator phenotype.  
Table 3: Total urinary excretion factors (Fue), elimination half-lives and maximum urinary concentrations of 
aniline and aniline metabolites of the four volunteers arranged by acetylation status (AS) of the volunteers 
Volunteer NA4AP-d4 NA4AP-MA-d3 ACA-d5 Free aniline-d5 Total 
Recovery 
[%]b 
   
            
   
            
 AS F ue 
[%] 
t ½ 
[h]a 
cmax  
[mg/g] 
F ue 
[%] 
t ½  
[h]a 
cmax  
[µg/g] 
F ue 
[%] 
t ½  
[h]a 
cmax  
[µg/g] 
F ue 
[%] 
t ½ 
[h]a 
cmax  
[µg/g] 
 
               
               
1 slow 68.9 3.4 12.5 2.5 5.1 725 0.19 1.4 93.8 0.28 1.2 69.9 71.8 
 
             
 
2 slow 68.2 3.9 9.6 4.0 4.1 1019 0.16 1.6 54.5 0.33 0.6 10.8 72.7 
 
             
 
3 fast 68.1 4.1 10.8 3.2 5.5 971 0.31 1.4 161 0.14 1.1 44.6 71.8 
 
             
 
4 fast 55.7 4.3 11.4 6.1 4.4 2520 0.36 1.3 145 0.23 0.8 117 62.4 
               
               
a
 calculated based on µg/g creatinine values 
b
 sum of metabolites investigated calculated from molar equivalents of the aniline dose 
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Summary and Conclusion 
In summary, the present study determined the urinary excretion kinetics and metabolic 
parameters for aniline and its major metabolites in four male volunteers after oral dosage 
of deuterium labelled aniline. By dosing labelled aniline we were able to avoid 
interferences arising from omnipresent urinary background levels of aniline, paracetamol 
and their metabolites.  
NA4AP and NA4AP-MA were present in the urines of the volunteers during the whole 48 
h of sampling and exhibited elimination half-times which were long enough to capture 
aniline exposure that occurred up to 48 h in the past. However, NA4AP and NA4AP-MA 
are no specific biomarkers of aniline but are excreted to a comparable extent after 
paracetamol intake. This overlap of aniline and paracetamol metabolic pathways is of 
importance when interpreting urinary NA4AP and NA4AP-MA levels with the goal to 
specifically assess exposure either to aniline or to paracetamol. However, both ACA and 
unconjugated aniline possess short elimination half times (0.6-1.2 h) and small excretion 
factors in urine were only detectable within the first 8-12 h after a relatively high dosage 
of 5 mg. Contrary to this study and to the occupational setting with aniline exposure, 
where we were able to detect both unconjugated aniline and ACA in post exposure urine 
samples, we could not detect ACA (and unconjugated aniline) in any urine sample from 
the general population (Modick et al. 2014; Dierkes et al. 2014) or in any urine samples 
prior to dosage (this study) or prior to exposure (occupational setting). These findings are 
in contrast to previous studies, reporting omnipresent aniline in urine, but only after 
hydrolysis. Obviously, and as a logical consequence of our findings reported above, the 
urinary aniline levels reported in these studies cannot be caused by either free aniline or 
acetanilide. Future studies will have to reveal the sources leading to aniline in urine after 
hydrolysis. 
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Summary and future perspectives 
 
The commonly used over-the-counter analgesic paracetamol has been subject to 
scrutiny recently because of increasing evidence for associations between prenatal 
exposure and adverse pregnancy outcomes like male reproduction disorders and 
endocrine disrupting effects, respiratory symptoms like asthma and wheezing in the first 
years of life and effects on the neurodevelopment of the newborn, causing hyperkinetic 
disorders and poorer motoric development outcomes.  
Taken together the works and developed analytical methods presented in this thesis will 
in future research projects contribute to exposure- and risk assessment of paracetamol. 
The work displayed in the present thesis provides new findings about the ubiquitous 
body burdens of paracetamol in the general population. Possible sources for these body 
burdens were pinpointed to exposure to aniline, the metabolic precursor of paracetamol, 
and to paracetamol itself by direct usage as medication. An arbitrary cutoff value to 
distinguish between these two types of exposure was derived based on statistical and 
toxicokinetic data, although some uncertainties concerning this value remain.  
Also, the definite sources for ubiquitous aniline exposure, which results in paracetamol 
body burdens, are still obscure. To current knowledge from the experiments presented in 
this thesis, aniline from environmental or occupational sources sources (e.g. indoor air), 
aniline and paracetamol in food (either by contamination or as building block of food 
additives or pesticides), aniline from personal care products (from colorants in cosmetics 
or oxidative hair dyes) as well as direct intake of paracetamol are in all probability 
contributing to the general body burden of paracetamol in the general population.  
From the toxicological point of view the ubiquitous presence of a pharmacologically 
active substance, which is not naturally occurring in the human body, leads to some 
concerns. An interdisciplinary approach is therefore highly recommended to (I) confirm, 
(by mechanistic as well as epidemiological studies) that therapeutic doses of 
paracetamol during pregnancy cause adverse health outcomes in newborns and 
children; (II) investigate if the reported urinary paracetamol concentrations and the taken 
doses which lead to these concentrations being toxicological relevant.  
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Furthermore, this thesis includes the first study on the human metabolism of aniline 
which was ever conducted. For exposure assessment the urinary conversion factors 
established in this thesis will in the future contribute to derive mean daily intake values of 
aniline/paracetamol in the general population and specific sensitive subpopulations. 
These values can be compared with dose/response limit values from toxicological in vivo 
or in vitro experiments for further risk assessment. 
Acetanilide was found to be a valuable and specific short-time marker for occupational 
exposure to aniline. Yet, for right interpretation of measured urinary acetanilide levels the 
acetylation phenotype has to be taken into accout. These findings will contribute in future 
(occupational) exposure assessment studies of aniline.  
Also, for the fist time, in the present thesis linkages between the metabolic pathways of 
paracetamol and aniline have been shown by the determination of the mercapturic acid 
conjugate of paracetamol in the metabolism of aniline. Thus, mercapturic acid 
conjugates hint to reactive intermediates, the confirmation of the mercapturic acid 
conjugate of paracetamol as a metabolite of aniline leads to new questions concerning 
toxicological aspects of occupational aniline exposure. In metabolism of paracetamol the 
mercapturic acid is built by detoxification of N-acetyl-p-benzoquinone imine (NAPQI), 
which is a strong biochemical oxidizer and inhibits liver toxic effects, by conjugation with 
glutathione. This indicates that exposure to aniline may also be a risk factor for liver toxic 
effects. These new findings warrant further investigation in occupational- exposure and 
risk-assessment of aniline. These aspects will be addressed in future occupational 
exposure experiments at the IPA. 
Because of the shared metabolic pathways equal reproductive toxicological as for 
paracetamol effects can be expected for aniline as well. Therefore a comparative study 
on the reprotoxic effects of both substances in animal experiments was conducted at the 
University of Copenhagen with supportive measurements performed at the IPA. This 
study is currently under review for publication in Human Reproduction.  
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Zusammenfassung und Ausblick 
Das häufig verwendete rezeptfreie, schmerzstillende und fiebersenkende Medikament 
Paracetamol rückte in der letzten Zeit zunehmend in den Fokus wissenschaftlicher 
Diskussion, da sich die Hinweise auf mögliche Zusammenhänge zwischen der 
Einnahme von Paracetamol in der Schwangerschaft und unerwünschten Nebeneffekten 
bei neugeborenen und Kindern mehrten. In diesem Kontext wurde über 
reproduktionstoxische Effekte und endokrine Wirkungen, respiratorische Symptome wie 
Asthma oder erschwerte Atmung in den ersten Lebensjahren sowie über Auswirkungen 
auf die neuronale Entwicklung, einhergehend mit Aufmerksamkeitsstörungen und 
verminderter motorischer Entwicklung, berichtet.  
Die in der vorliegenden Arbeit dargestellten Befunde und entwickelten analytischen 
Methoden werden in zukünftigen Forschungsarbeiten einen wichtigen Beitrag zur 
Expositionserfassung und Risikoabschätzung von Paracetamol liefern. Darüber hinaus 
liefert die vorliegende Arbeit neue Erkenntnisse bezüglich der generellen 
Hintergrundbelastung der Allgemeinbevölkerung mit Paracetamol. Mögliche Quellen für 
diese Hintergrundbelastung wurden u.a. in der Exposition gegenüber Anilin, den 
metabolischen Vorläufer von Paracetamol und der Einnahme von Paracetamol selbst 
ausgemacht. Ein vorläufiger Grenzwert zur Unterscheidung zwischen diesen beiden 
Expositionen wurde auf Basis statistischer und toxikokinetischer Untersuchungsdaten 
abgeleitet, wobei jedoch eine Restunsicherheit verbleibt.  
Die genauen Quellen für die allgemeine Hintergrundbelastung mit Paracetamol bleiben 
jedoch unklar. Nach dem derzeitigen Wissensstand, welcher aufgrund der 
Untersuchungen in der vorliegenden Arbeit gewonnen wurde, ist es am 
wahrscheinlichsten, dass Anilin aus umwelt- oder arbeitsplatzbedingten Quellen, Anilin- 
und Paracetamolquellen in Nahrungsmitteln (entweder als Kontamination oder als 
Baustein von z.B. Pestizidrückständen), Anilin aus kosmetischen Mitteln (aus 
Farbstoffen oder oxidativen Haarfärbemitteln) sowie die direkte Einnahme von 
Paracetamol zusammen zu der gemessenen Hintergrundbelastung in der 
Allgemeinbevölkerung beitragen.  
Vom toxikologischen Standpunkt aus ist die allgemeine Präsenz einer pharmakologisch 
aktiven Substanz, welche nicht natürlicherweise im menschlichen Körper vorkommt, als 
besorgniserregend zu betrachten. Es ist deshalb ein interdisziplinärer Ansatz erforderlich 
um (I) sicherzustellen (auf Basis mechanistischer und epidemiologischer Studien), ob die 
Einnahme therapeutischer Dosen Paracetamol während der Schwangerschaft mit einem 
erhöhten Risiko unerwünschter Nebenwirkungen bei den Neugeborenen und Kindern 
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einher geht und (II) zu untersuchen ob die berichteten Urinkonzentrationen und die 
Expositionen, die diese verursachen für die genannten unerwünschten Effekte von 
toxikologischer Relevanz sind. 
Des Weiteren enthält die vorliegende Arbeit die erste überhaupt durchgeführte Studie 
zur Untersuchung des Humanmetabolismus von Anilin. Die Konversionsfaktoren, die in 
dieser Studie abgeleitet wurden, werden in zukünftigen Arbeiten eine wichtige Rolle zur 
Expositionserfassung von Paracetamol spielen. Dabei werden auf Basis der 
Konversionsfaktoren in Zusammenhang mit Konzentrationsmessungen im Urin 
durchschnittliche tägliche Aufnahmemengen berechnet, welche dann mit z.B. Dosis-
Wirkungs-Daten aus toxikologischen in vivo oder in vitro Untersuchungen zur 
Risikoabschätzung verglichen werden können. 
Mit Acetanilid wurde ein verlässlicher und spezifischer Kurzzeitindikator für eine 
Anilinexposition gefunden. Jedoch muss für eine verlässliche Interpretation von 
gemessenen Acetanilid-Konzentrationen im Urin der N-Acetyltransferase 2 Phänotyp der 
beprobten Individuen berücksichtigt werden. Diese Ergebnisse werden in zukünftigen 
Studien zur arbeitsplatzbezogenen Expositionserfassung von Anilin Anwendung finden  
Ebenfalls konnten erstmals, durch die Studien in der vorliegenden Thesis, Verlinkungen 
in den Stoffwechselwegen von Paracetamol und Anilin aufgezeigt werden, was durch 
den Nachweis des Mercaptursäure-Konjugats von Paracetamol als Metabolit von Anilin 
gezeigt werden konnte. Da Mercaptursäure-Konjugate auf reaktive Stoffwechselprodukte 
hindeuten, wirft der Nachweis der Paracetamol-Mercaptursäure als Stoffwechselprodukt 
neue Fragen bezüglich der toxikologischen Aspekte der arbeitsplatzbezogenen 
Anilinexposition auf. Im Metabolismus von Paracetamol wird die Paracetamol-
Mercaptursäure durch die Detoxifizierungsreaktion des reaktiven Intermediats N-Acetyl-
p-benzoquinonimin (NAPQI) mit Glutathion gebildet. NAPQI ist ein starkes 
biochemisches Oxidationsmittel und besitzt starke lebertoxische Eigenschaften. 
Chronische arbeitsplatzbezogene Exposition gegenüber Anilin könnte somit auch somit 
auch einen Risikofaktor für Schädigungen der Leber darstellen. Durch diese neuen 
Erkenntnisse werden weitere Untersuchungen bezüglich der Exposition gegenüber Anilin 
am Arbeitsplatz notwendig, welche in Zukunft am IPA durchgeführt werden. 
Aufgrund der gemeinsamen Stoffwechselwege können für Anilin ähnliche 
reproduktionstoxische Effekte vermutet werden, wie für Paracetamol. Aus diesem Grund 
wurde an der Universität in Kopenhagen, mit unterstützenden Messungen am IPA, eine 
Vergleichstudie der Toxizitäten der beiden Subatanzen an Versuchstieren durchgeführt. 
Zusammenfassung und Ausblick 
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Die Ergebnisse dieser Studie sollen in Human Reproduction puliziert werden. Die 
Publikation wurde beireits eingereicht und befindet sich derzeit im Reviewprozess.  
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Appendix I 
Volunteer Age  Sex Smoker Intake of Paracetamol Last Intake Creatinine [mg/L] NAAP [µg/L] NAAP [µg/g Creatinine] 
         
1 28 m yes rarely ≥ 1 month before 253 18,9 74,6 
2 50 f no rarely ≥ 1 month before 292 115,7 396,1 
3 27 f no rarely ≥ 1 month before 168 8,7 51,7 
4 55 m yes never - 2219 123,7 55,7 
5 40 m yes frequently ≤ 1 week before 1979 523,3 264,4 
6 43 m yes rarely ≥ 1 month before 826 36,1 43,7 
7 30 f yes never - 676 59,1 87,4 
8 30 f no never - 1005 211,3 210,2 
9 37 f no rarely ≥ 1 month before 568 1703,1 2998,4 
10 50 m no rarely ≥ 1 month before 1066 766,2 718,7 
11 30 m yes rarely ≥ 1 month before 1375 63,8 46,4 
12 30 f yes rarely ≥ 1 month before 346 9,2 26,6 
13 30 m no rarely ≤ 1 week before 344 64,1 186,4 
14 26 f no rarely ≥ 1 month before 920 15,0 16,3 
15 27 m yes rarely ≥ 1 week before 1277 186,3 145,8 
16 26 f no rarely ≥ 1 month before 526 85,7 163,0 
17 30 m no never - 161 424,5 2636,5 
18 29 f no rarely ≤ 1 week before 321 80,6 250,9 
19 36 m no rarely ≥ 1 month before 1039 107,2 103,1 
20 29 f yes rarely ≥ 1 month before 881 36,0 40,9 
21 30 f yes rarely ≤ 1 day before 167 22120 132455 
 
        
 
Mean 1274 6713 
 Median 85,7 145,8 
 Min 8,7 16,3 
(Individual NAAP and creatinine concentrations of the 21 volunteers in the human biominotoring pilot study) Max 22120 132455 
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Appendix II 
    
Sample No.  N-acetyl-4-aminophenol 
[µg/L] 
N-acetyl-2-aminophenol 
[µg/L] 
acetanilide 
[µg/L] 
    
    
 
Group 1 
    
    
1 139,2 4768 < LOQ 
2 80,13 885,2 < LOQ 
3 129,2 39161 < LOQ 
4 97,54 2071 < LOQ 
5 39,60 3233 < LOQ 
6 98,19 5858 < LOQ 
7 10,93 867,7 < LOQ 
8 211,1 541,3 < LOQ 
9 608,8 7,37 < LOQ 
10 95,31 8,36 < LOQ 
11 2263 206,8 < LOQ 
12 398,4 10,37 < LOQ 
13 17,11 93,56 < LOQ 
14 13,23 867,9 < LOQ 
15 8,88 3674 < LOQ 
16 463,1 2023 < LOQ 
17 14,81 984,4 < LOQ 
18 93,46 682,5 < LOQ 
19 17,61 436,3 < LOQ 
20 17,60 603,9 < LOQ 
21 57,87 3405 < LOQ 
22 52,69 517,5 < LOQ 
23 7,41 3019 < LOQ 
24 98,53 6793 < LOQ 
25 22,14 4241 < LOQ 
26 128,0 2639 < LOQ 
27 1530 3406 < LOQ 
28 29,03 2718 < LOQ 
29 51,22 5976 < LOQ 
30 187,0 4974 < LOQ 
31 18,21 6422,6 < LOQ 
 
   
 
   
Mean 225,8 3584 < LOQ 
Median 80,13 2071 < LOQ 
Min 7,41 7,37 < LOQ 
Max 2262,77 39161 < LOQ 
    
    
 
Group 2 
    
    
1 4870 2319 41,2 
2 10885 379 92,1 
3 5190 1645 75,88 
4 4150 270,9 81,58 
5 9073 1237 121,6 
6 6249 599,1 53,9 
 
   
 
   
Mean 6736 1075 77,7 
Median 5720 918,0 78,7 
Min 4150 270,9 41,2 
Max 10885 2319 121,6 
 
   
 
   
 Group 3 
 
   
 
   
1 159440 n.a. < LOQ 
2 274862 n.a. < LOQ 
    
 
Table S1: individual results for every volunteer in the human biomonitoring study 
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Figure S1: correlations between NA4AP and NA2AP in groups 1 and 2 (R²= 0.02) 
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Appendix III 
 
 
Source Example substances 
  
Pharmaceuticals metamizole, phenylbutazone 
 
 
Pesticides carboxin, chloridazon, carbetamid, 
propham, desmedipham, pencycuron  
 
 
Colorants (in personal care products)  Pigment Red 64:1; Acid Orange 10; Acid 
Red 1 and 33; Disperse Yellow 16; Acid 
Yellow 11; Solvent Red 23 and 73; Acid 
Black 1; Disperse Violet 23/27; Basic Blue 
26  
 
 
 
Oxidizing coloring agents for hair 
dyeing 
p-phenylenediamine, its N-substituted 
derivatives and its salts 
 
 
 
Rubber products, tires  1,3-diphenylguanidine  
  
  
Supplementary Table 1 Possible precursors of aniline 
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Appendix IV 
Description of the HPLC-MS/MS- method for quantification of total NA4AP-d4, 
NA4AP-MA-d3 and ACA-d5 
Stock solutions and internal standards 
Stock solutions of NA4AP-d4, ACA-d5 and NA4AP-MA (unlabeled) were prepared by 
dissolving approximately 10 mg of NA4AP-d4 and ACA-d5 and approximately 2.5 mg of 
NA4AP-MA sodium salt, each weighed exactly, in methanol using a 10 10-mL mL-
volumetric flask. All stock solutions were stored in Teflon capped glass vials at −20 °C 
until usage. For analysis, eight calibration standards were prepared by gradual dilution 
with water to final concentrations ranging from 1 to 1,000 µg/L for NA4AP-d4; 0.9 to 870 
µg/L for ACA-d5 and 2.3 to 2,250 µg/L for NA4AP-MA (calculated as paracetamol-3-
mercapturic acid). 
Internal standards solutions of NA4AP-d3 and ACA-d3 were prepared as previously 
described by Dierkes et al. (Dierkes et al. 2014). The internal standard solution of 
NA4AP-MA-d5 was prepared by dissolving 1.5 mg of purchased NA4AP-MA-d5 sodium 
salt in 10 mL methanol. An internal standard stock solution was prepared by mixing the 
three standard solutions and further dilution in water, leading to final concentrations of 
800 µg/L for NA4AP-d3, 500 µg/L for ACA-d3 and 500 µg/L for NA4AP-MA-d5 (calculated 
paracetamol-3-mercapturic acid-d5). 
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Chromatographic conditions 
Table 1: Chromatographic system 
HPLC- System 
Pumps Agilent 1260 binary pump (2x) 
Degasser Agilent 1260 HiP degasser 
Autosampler Agilent 1260 autosampler 
Column compartment Agilent 1260 thermostated column compartment 
Chromatographic setup 
Enrichment column Waters Oasis® HLB cartridge column (2.1 mm x 20 mm, 
25 µm) 
Analytical column Thermo Accucore® Phenyl-X column (3 mm x 150 mm; 
2.6 µm) 
Guard column Phenomenex PFP (4 x 2.0 mm ID) 
In-line filter Phenomenex; (3 mm; 0.5 µM porosity) 
Solvent A Water (0.05% formic acid) 
Solvent B Acetonitrile (0.05 % formic acid) 
Injection volume 25 µL 
 
HPLC was performed using an Agilent 1260 Series HPLC System consisting of two 
Agilent 1260 binary pumps, an Agilent 1260 autosampler, an Agilent 1260 thermostated 
column compartment, an Agilent 1260 HiP degasser and an Agilent 1290 thermostat. In 
a two column assembly, a Waters Oasis® HLB cartridge column (2.1 mm x 20 mm, 25 
µm) was used for sample cleanup and enrichment. Chromatographic separation was 
realized on a Thermo Scientific Accucore® Phenyl-X column (3 mm x 150 mm; 2.6 µm). 
In order to protect the columns from loss of performance by contamination an in-line filter 
(Phenomenex; 3 mm; 0.5 µM porosity) was placed in front of the HLB- column and a 
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guard column (Phenomenex PFP 4 x 2.0 mm ID) was placed in front of the Phenyl-X 
column. Chromatography was carried out using two different solvents as eluents: solvent 
A 0.05% formic acid and solvent B acetonitrile, also with 0.05 % formic acid (table 1).  
For analysis, 25 µL of the processed sample were injected with a constant flow of solvent 
A of 3.75 mL/min by pump 1 onto the HLB column (valve position 1). After two minutes 
the analytes retained on the HLB column were transferred onto the Phenyl-X column in 
backflush mode (valve position 2). This step was realized by using the six port switching 
valve, which is included in the Agilent 1260 thermostatic column compartment. The 
analytes were chromatographically separated by gradient flow. After 4.5 minutes the 
switching valve was set back into starting position and the HLB column was washed with 
solvent B at a low flow rate (100 µL/min, to spare solvent) and then re-equilibrated to 
starting conditions. A scheme of the two-column-switching assembly and the elution 
gradient used for chromatographic separation are shown in figure 1 and table 2. All steps 
were controlled by the AB Sciex Analyst® version 1.6.1. software. 
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System setup 
 
Figure 1 Scheme of the two column switching assembly 
 
Table 2: Gradient programm for chromatographic separation, solvent A: 0.05% formic 
acid; solvent B: acetonitrile 
 
       
Program 
step 
Time 
[min] 
Solvent 
A [%] 
Solvent 
B [%] 
Flow rate 
[µL/min] 
Valve 
position 
Analysis step 
       
       
1 initial 75 25 300 1 Cleanup, 
enrichment  
(on the HLB- 
column) 
2 2.00 75 25 300 2 Analyte 
transfer 
3 4.50 75 25 300 2 Separation 
4 4.60 50 50 300 2  
5 8.00 40 60 300 1  
6 9.00 3 97 300 1 Washing 
7 12.00 3 97 300 1  
8 13.00 75 25 300 1 Reconditioning 
9 15.00 75 25 300 1  
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Mass Spectrometry 
Table 3: Mass spectrometric conditions 
System  AB Sciex 4500 Triple Quad 
Ionization  ESI +/- 
Source temperature 450°C 
Curtain gas Nitrogen (25 psi) 
Heater gas (GS1; GS2) Nitrogen (25 psi) 
Ion spray voltage 4.5 kV 
Collision gas  Nitrogen 
Collision gas pressure (CAD) 5 
 
Mass spectrometric detection and quantification was carried out using an AB Sciex Triple 
Quad 4500 mass spectrometer. Ionization of the analytes was performed with an ESI 
source, which was run in positive ionization mode for NA4AP-d4 and ACA-d5 and in 
negative ionization mode for NA4AP-MA-d3. Ion spray voltage (IS) was 4.5 kV for both 
ionization modes. Source temperature was 450°C. Nitrogen was used as curtain gas at 
25 psi. Ion source gas and turbo heater gas (GS1 and GS2), also nitrogen, were both set 
to 25 psi (table 3). Analyte specific fragmentation patters were acquired by directly 
infusing standard solutions of the analytes and internal standards (concentrations 
~5mg/L) into the mass spectrometer with a constant flow of 10 µL/min. Fragmentation 
parameters were manually optimized except for NA4AP-MA-d3. Fragmentation ions and 
multiple reaction monitoring (MRM) parameters for NA4AP-MA-d3 were extrapolated 
from the MRM parameters of NA4AP-MA and NA4AP-MA-d5 and optimized manually in 
order  to achieve high sensitivity. The fragment with the highest intensity was used to 
calculate the analyte concentrations (quantifier). The second intense fragment was used 
to confirm the results of the quantifier ion (qualifier). MS/MS measurements were carried 
out in multiple reaction monitoring mode with nitrogen as 
 X 
collision gas and CAD parameter (collision gas pressure) set to 5. Optimized MRM 
parameters of target analytes and internal standards including quantifier and qualifier 
mass transitions are given in table 4. 
Linear calibration curves were obtained with standard solutions of NA4AP-d4, ACA-d5 
and NA4AP-MA in water. Calibration samples were treated equally to the urine samples 
as described above. Calibration curves were obtained with a 1/x weighting by plotting the 
quotients of peak areas of NA4AP-d4, ACA-d5 and NA4AP-MA and their corresponding 
internal standards as a function of their concentration. NA4AP-MA-d3 was determined 
using unlabeled NA4AP-MA for calibration, because no standard substance of ring 
deuterated NA4AP-MA-d3 was available. We assumed that the isotope labeling would 
have no effect on the ionization and response behavior of the substances. 
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Table 4:  MRM Parameters for mass spectrometric detection of aniline metabolites; TA = target analytes; ISTD = internal standard 
           
           
Analyte Structure Ionisation 
mode 
Precursor 
ion (Q1) 
Daughter 
ions (Q3) 
Retention time 
[min] 
MRM detection 
window [s] 
Declustering 
potential (DP) 
[V] 
Entrance 
potential (EP) 
[V] 
Collision 
Energy 
(CE)[V] 
Collision 
exit 
potential 
(CXP) [V] 
           
           
NA4AP-d4 
 
 
 
 
 
ESI + 
156 114a 5.4  
 
 
 
60 
59 12 22 7.7 
        
(TA)  97  59 12 28 6.3 
        
         
NA4AP-d3 
 
155 111a 5.4 59 12 22 7.7 
        
(ISTD)  93  59 12 28 6.3 
        
         
   
 
 
 
 
 
ESI + 
 
   
 
 
 
 
60 
    
ACA-d5 
 
 
141 99a 8.3 45 13 21 10.0 
        
(TA)  81  45 13 38 10.0 
        
         
ACA-d3 
 
139 95a 8.3 45 13 21 10.0 
        
(ISTD)  77  45 13 38 10.0 
        
         
   
 
 
 
 
 
 
 
 
 
 
ESI - 
 
 
   
 
 
 
 
 
 
 
60 
 
    
NA4AP-MA-
d3 
 
314 143a 6.5 -50 -8 -18 -6.0 
       
(TA)  185  -50 -8 -48 -7.0 
        
         
NA4AP-MA-
d5 
 
316 143a 6.5 -50 -8 -18 -4.0 
       
(ISTD)  187  -50 -8 -48 -7.0 
        
           
a
 mass transition used for quantification   
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Quality assurance 
 
Internal quality assurance was carried out by using pooled post dose urine samples from 
the four different volunteers of the dosing study. Samples were pooled in such a way that 
control material with high and low concentrations (Qlow and Qhigh) of NA4AP-d4, ACA-d5 
and NA4AP-MA-d3 was obtained. Precision and reliability of the method were determined 
by analyzing this control material eight times in a row and on eight different days (table 
5). 
Imprecisions and recoveries were additionally determined by analyzing eight different 
urine samples from laboratory routine with varying creatinine contents, ranging from 0.2 
g/L to 2.6 g/L. These samples were analyzed native (non-spiked) and spiked at a low 
and a high concentration level. As expected, no NA4AP-d4 and ACA-d5 was detected in 
any of the non-spiked samples. Native concentrations of NA4AP-MA found in all samples 
were subtracted from the spiked samples before recovery calculation (table 6), RSDs 
calculated from these measurements were comparable to the RSDs obtained from the 
intra-day and inter-day imprecision experiments. 
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Table 5: Intra-day and inter-day precision for HPLC-MS/MS analysis of aniline metabolites 
          
         
 
 
NA4AP-d4  NA4AP-MA-d3  ACA-d5  
 
         
 
         
 
Q low Q high  Q low Q high  Q low Q high  
         
 
Intra-day precision (n=8) 
        
 
 
        
 
Conc. measured [µg/L] 22.1 646  12.9 80.2  7.7 20.3  
 
        
 
SD [µg/L] 0.5 9.7  1.4 2.5  0.2 0.6  
 
        
 
RSD [%] 2.3 1.5  10.6 3.1  2.6 2.7  
 
        
 
 
        
 
Inter-day precision (n=8) 
        
 
 
        
 
Conc. measured [µg/L] 20.4 597  12.4 77.3  8.4 20.2  
 
        
 
SD [µg/L] 2.5 54.7  1.0 4.9  0.4 0.4  
 
        
 
RSD [%] 12 9.1  8.0 6.3  4.5 1.9  
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Table 6: Precision and relative recoveries from analysis of eight different urine samples with varying creatinine contents 
  
          
         
 
 
NA4AP-d4  NA4AP-MA  ACA d5  
 
         
 
         
 
low high  low high  low high  
         
 
 
        
 
 
        
 
Spiked conc. [µg/L] 20 200  45 450  1.7 17.4  
 
        
 
Native conc. measured 
[µg/L] 
< LOQ  43.4(<LOQ - 189)  < LOQ  
 
        
 
Native and spiked conc. 
measured [µg/L] 
   92.6 
(50.3 - 232) 
512 
(474 - 650) 
   
 
 
        
 
Spiked conc. calculated  
        
 
 
        
 
Mean [µg/L] 20.1 7885  49.2 469  1.7 17.9  
 
        
 
Range [µg/L] 19.0 – 21.3 7685 - 8220   38.9 – 54.5 452.9 – 485.6  1.61 – 1.85 17.3 – 
18.3 
 
 
        
 
RSD [%] 4.6 3.2  11.0 2.7  6.1 1.8  
 
        
 
Relative Recovery [%] 100.3 
(95.0 – 106.5) 
98.8 
(93.5 – 103.5) 
 109.4 
(86.4 – 121.1) 
104.3 
(100.6 – 108.7) 
 101.2 
(91.8 – 
108.8) 
103.1 
(99.4 – 
105.2) 
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Description of the GC-MS method for the determination of unconjugated aniline-d5 
Gas chromatographic analysis was carried out using an Agilent Technologies 7890A GC 
system with a CTC Analytics CombiPal autosampler and split/splitless-injector which was 
run in pulsed splitless mode. Chromatography was realized on an Agilent J&W DB-35ms 
(60 m x 250 µm, 25 µm) column. Helium was used as carrier gas.  
An Agilent Technologies 5975C MSD single quadrupole mass spectrometer was used in 
electron impact (EI) mode for mass spectrometric detection.  
Calibration standards were prepared by spiking pooled urine with aniline-d5 to final 
concentrations ranging from 0.5-50 µg/L. The calibration standards were treated equally 
to the urine samples during sample preparation. Linear calibration curves were obtained 
by plotting the quotient of the peak areas of aniline-d5 (m/z = 294) and o-toluidine-d7 (m/z 
= 310; both in form of their corresponding HFBA derivates) as a function of their 
concentrations. The LOQ for the determination of free aniline estimated by a signal to 
noise ratio of 9 was 0.1µg/L. Method validation was performed in analogy to HPLC 
method validation. Method validation data is shown in table 7. Intra-day and inter-day 
imprecisions of the method were below 10% for both quality control concentrations (Qlow 
and Qhigh).Mean relative recoveries ranged between 97% and 107% for both spiked 
concentration levels. 
Table 7 Method validation data of GC-MS analysis of unconjugated aniline 
     
      
      
 Intra-day 
precision   
(RSD [%])  
 Inter-day precision 
(RSD [%]) 
 Relative recovery 
[%] 
      
      
Q low (1 µg/L) 5.6  6.3  98 - 106 
      
      
Q high (11 µg/L) 5.2  6.0  97 - 107 
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Fig. 1. Simplified metabolism of aniline.
not been determined in urine samples from the general popula-
tion.
N-Acetyl-4-aminophenol (NAAP) is also commonly known as
paracetamol or acetaminophen. Since its market placement in the
1950’s, paracetamol is one of the most commonly used over-the-
counter analgesic (pain reliever) and antipyretic (fever reducer)
drugs [6].  Structurally it belongs to the non-opioid analgesics.
According to the German pharmaceutical register, 55  formulations
containing paracetamol are approved for sale in Germany [7].  In
2008, two of the 10 most-sold medications in Germany contained
paracetamol [8]. The use of paracetamol is  generally considered to
be safe up to a therapeutic dosage of 4 g per day [9]. Doses above
10 g per day lead to acute toxic symptoms [10]. Although paraceta-
mol  has been commonly used for  almost 70 years its mechanism of
action is not yet fully understood. Recent studies assume a selective
inhibition of cyclooxygenase-2 (COX-2) in the spinal cord [6,11].
Metabolism and pharmacokinetics of paracetamol are well stud-
ied. In several animal studies maximum plasma concentrations of
paracetamol are attained 30–60 min  after oral dosage with plasma
half-lives ranging from 1.5 to 2.5 h. About 85% of the therapeutic
dose of paracetamol are excreted in urine as  glucuronide and sul-
phate conjugates, 2–5% of the dose are excreted unchanged in urine
[12,13].
Paracetamol is also approved for veterinary use in the European
Union. In porcine species paracetamol is  approved for oral use with
no specific maximum residue limit in foodstuffs of animal origin
(COMMISSION REGULATION (EU) No. 37/2010) [14]. According to a
report of the EU Committee for Veterinary Medicinal Products para-
cetamol is also used in cattle and poultry in some member states
of the European Union [15]. Paracetamol might also be reentering
the food chain by contaminated feather meal which can be used as
an additive in animal feed [16].
For  a long time the use of paracetamol during pregnancy
was considered as safe. Recent studies, however, describe anti-
androgenic effects of paracetamol. Kristensen et al.  showed that
paracetamol inhibited the testosterone production in a fetal rat
organotypic culture system [17]. Epidemiological studies suggest
that intrauterine exposure to paracetamol is a risk factor for
development of male reproductive disorders [17,18]. Other epi-
demiological studies suggest a possible association between the
use of paracetamol during pregnancy and an increasing appearance
of asthma in children [19]. Despite the long time paraceta-
mol/acetaminophen has been used as a pain reliever, and despite
the known fact that NAAP is the major metabolite of aniline, there
is a lack of profound human biomonitoring or exposure data on this
substance. To our knowledge, NAAP has by now not  been included
in any larger population based study like the German GerES, the U.S.
NHANES or the Canadian CHMS. In  2012, Camann et al. reported
the presence of NAAP/paracetamol in the deciduous teeth of 9  of
21 subjects [20].
Available analytical methods to determine NAAP/paracetamol
have been designed mainly for forensic purposes and to detect high
concentrations of NAAP/paracetamol in human blood as occurring
after over-dosing [21]. Other analytical methods are designed to
quantify NAAP/paracetamol or its metabolites in rat plasma or rat
urine for metabolism studies [22], for special in vitro or in vivo
assays [23,24] or for pharmaceutical quality controls [25]. The
aim of the present work was  to develop a fast, robust and reli-
able method for the determination of NAAP/paracetamol in human
urine covering a wide concentration range including trace levels
in the low mg/L range. Applying this method in environmental,
occupational and clinical studies we  can describe the body bur-
den of individuals or larger study populations to NAAP/paracetamol
from both the generation of NAAP/paracetamol in human aniline
metabolism and the direct exposure to or use of paracetamol.
2. Experimental
2.1. Chemicals
N-Acetyl-4-aminophenol (paracetamol/acetaminophen, CAS
No. 103-90-2, purity 99.0%) was purchased from Sigma–Aldrich
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(Steinheim, Germany). The ring-labeled analog (d4-NAAP) was
purchased from LGC Standards (Wesel, Germany). Deionized
water was obtained using a Millipore Advantage A10 with a
Quantum®-cartridge. Methanol (LC–MS grade) was  purchased
from Merck (Darmstadt, Germany). Ammonium acetate p.a., HP2
b-glucuronidase and Tris-buffer (Trizma® base) were purchased
from Sigma–Aldrich (Steinheim, Germany).
2.2. Standard preparation and stock solutions
The NAAP stock solution was prepared by  dissolving approxi-
mately 10 mg  NAAP, weighted exactly, in acetonitrile using a 10 mL
volumetric flask. For analysis, eight calibration standards were pre-
pared by gradual dilution with water to final concentrations in a
range from 0.75 mg/L to 10,000 mg/L. Stock solutions were stored
at −20 ◦C in teflon capped glass vials until further use. The internal
standard solution was prepared by diluting the purchased d4-NAAP
solution (1.0 mg/mL  in methanol) with water in a volumetric flask
to a final concentration of 2 mg/L.
2.3. Sample collection and preparation
Urine samples were collected in 250 mL  polyethylene containers
and immediately stored at  −20 ◦C. All samples were equilibrated
to room temperature prior to analysis. Samples were vortex
mixed before transferring 300 mL aliquots into a silanized 1.8 mL
teflon screw cap vial. 180 mL ammonium acetate buffer (0.5 M,
pH 5.5–6.0), 30 mL  internal standard solution and 6 mL of b-
glucuronidase/arylsulfatase (≥ 100,000 units/mL) were added to
each sample. After incubation at 37 ◦C  in a water bath for 3.5 h 60 mL
of Tris-buffer (1 M,  pH 10) were added to each sample to adjust the
pH value. All samples were frozen at −18 ◦C over night to freeze
out and precipitate proteins. After thawing, all samples were cen-
trifuged at 1900 g  for 10 min. The supernatant was  transferred into
a second silanized 1.8 mL  teflon screw cap vial. Urinary creatinine
concentrations were determined according to Jaffe [26].
2.4. Calibration procedure and quantification
Calibration was performed with standard solutions in water. All
calibration samples were treated equally to the urine samples with
the procedure as described in Section 2.3. Linear calibration curves
were obtained with a 1/x weighting by plotting the quotients of
peak areas of NAAP and the peak areas of d4-NAAP as a function of
the NAAP-concentration.
2.5. Reliability of the method
Quality control material was prepared within our laboratory
using urine samples from different volunteers. These urine sam-
ples were pooled to obtain control material with low, medium and
high concentrations of NAAP (Qlow,  Qmed and Qhigh). The control
urines were frozen, thawed and filtered three times before use.
Reliability and precision of the method were determined by mea-
suring the quality control standards eight times in a row for intra-
day precision and at eight different days for day-to-day precision.
Additionally, accuracy and precision were determined by analyzing
eight different urine samples with varying creatinine concentra-
tions ranging from 0.3 g/L to 3.0 g/L. These samples were analyzed
non-spiked and spiked at two concentration levels (109.7 mg/L
and 548.5 mg/L). The NAAP concentrations of the native samples
were subtracted from the spiked concentrations before further
calculation.
2.6. High performance liquid chromatography
High performance liquid chromatography was  carried out using
a 1525 binary pump (loading pump) and a 1525 m binary pump
(analytical pump) (Waters, Milford, USA), a Waters In-Line AF
degasser and a Waters 2777 Sample Manager autosampler. In a two
column assembly, previously described by [27–29] a Waters Oasis®
HLB cartridge column (2.1 mm  × 20 mm;  25 mm)  was used as first
column for  cleanup and enrichment by turbulent flow technique.
Chromatographic separation was performed using an Atlantis T3
(3.0 mm × 150 mm;  3 mm) reversed phase C18 column. Three dif-
ferent solvents were used: solvent A water, solvent B  methanol
and solvent C 1 mM ammonium acetate in water (pH 6.5–6.8).
An in-line filter (Phenomenex 0.5 mm x 3.0 mm;  AF0-0378) was
placed in front of the HLB-phase and a guard column (Fusion-
RP 2.0 mm ×4 mm) was  placed in front of the analytical column.
200 mL  of the processed sample were injected with a constant
flow of solvent A of 3.75 mL/min by  the loading pump onto the
HLB-phase (valve position A). After 1 min  the valve position was
switched in to position B. In this position the analytes retained
by the HLB-phase were transferred in backflush mode onto the
reversed phase C18 column through a time controlled switching
valve (waters selector valve). The analytes were chromatograph-
ically separated by the gradient flow from the analytical pump of
solvents B  and C. After 8 min  the switching valve was  switched back
into position A and the HLB-phase was  flushed with high organic
solvent (98% solvent B; 2% solvent A) and then re-equilibrated with
100% of solvent A. The gradient of the analytical pump used for the
chromatographic separation is described in Table 1. Fig. 2  shows
the backflush arrangement of the used HPLC system. All steps were
controlled by Waters MassLynx V4.1 software.
2.7. Mass spectrometry
The  mass spectrometric detection and quantification was per-
formed using a Waters Quattro Premier XE triple quadrupole mass
spectrometer. Positive ionization mode was used with a capillary
voltage of 2.89 kV. Nitrogen was used as desolvation gas at 400 ◦C
and a  flow of 1000 L/h. Ion  source temperature was  set to 120 ◦C.
Analyte specific fragmentation patterns were acquired through full
scan data via manual optimization. Standard analyte solutions were
infused directly into the mass spectrometer for this purpose with
a constant flow of 10 mL/min.
Based on the parent ion of NAAP and  d4-NAAP mass transitions
to three daughter ions for NAAP and  two daughter ions for d4-NAAP
were tuned in. The fragment with the highest response was  used to
calculate the analyte concentration (quantifier). The second intense
fragmentation was used to confirm the results of the quantifier ion
(qualifier). MS/MS  measurements were performed in multiple reac-
tion monitoring (MRM)  mode with nitrogen as collision gas with
a collision gas flow of 0.25 mL/min. The specific MRM  parameters
are given in Table 2.
2.8. Study subjects
The newly developed method was  applied to analyze urine sam-
ples from 21 individuals from the general German population (10
female, 11  male, ages between 26  and 55 years, median 30 years, 10
smokers, collected in 2012) in a pilot human biomonitoring study.
Creatinine concentrations of the samples varied between 0.16 g  and
2.2 g creatinine per liter. Prior to the study all volunteers completed
a short questionnaire about their use of paracetamol and paraceta-
mol  containing products. The sampling of the biological specimens
(urine samples) for method development and for performing the
small pilot human biomonitoring study has been approved by  the
ethical review board of the medical faculty of the Ruhr-University
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Table  1
Gradient program for chromatographic separation carried out by the analytical pump, solvent B: methanol, solvent C: 1  mM ammonium acetate (pH 6.5–6.8) in water.
Program step Time (min) Solvent B (%) Solvent C  (%) Flow rate (ml/min) Valve position Analysis step
1 Initial 25 75 0.35 A Cleanup, enrichment (on the HLB-column)
2 1 25 75 0.35 B Analyte transfer
3 2.00  25 75 0.35 B Separation
4  2.25 50 50 0.35 B
5 3.00  60 40 0.35 B
6  4.50 80 20 0.35 B
7  7.00 95 5 0.35 B
8  8 95 5 0.35 A Washing
9 9.90 95 5 0.35 A
10  10.00 25 75 0.35 A Reconditioning
11 14.95 25 75 0.35 A
Fig. 2. Two- column HPLC system with backflush arrangement. Valve position A: cleanup and enrichment of the analytes via turbulent flow chromatography. Valve position
B:  analyte transfer onto the C18-RP phase, chromatographic separation and mass spectrometric detection.
Bochum (Reg. No.: 3867-10). The study design was presented to the
volunteers in written form and all participants provided written
informed consent.
3. Results and discussion
3.1. General considerations
The present method was designed for  the purpose of human
biomonitoring studies on NAAP. Therefore we focused mainly
on the following requirements: speed in order to achieve high
sample throughput, reliability and linearity over a large concen-
tration range to cover exposure levels from both environmental
background exposures and the therapeutic paracetamol use. For
this purpose we combined HPLC on-line enrichment by turbulent
flow chromatography with MS/MS-detection. The  turbulent flow
approach enabled us to extract and enrich the analytes online from
the sample matrix in a very short time (less than 1 min). Transfer
of the analytes onto the analytical column was  realized by a time
controlled switching valve. Because of the on-line extraction pro-
cedure no sample pretreatment was necessary (except enzymatic
hydrolysis and precipitation of proteins) reducing manual handling
to a minimum and thus saving both manpower and chemicals (sol-
vents). The use of ESI–MS/MS with isotope dilution quantification
ensured both highly sensitive and selective results.
3.2. Enzymatic hydrolysis
Deconjugation of the metabolites, to measure the sum of conju-
gated and  free NAAP, was achieved by using HP-2 b-glucuronidase
(≥100,000 units/mL) which also contains sulfatase activity (≤7500
units/mL). For optimization of the enzymatic hydrolysis several
incubation times and pH-values were tested (data not shown).
Enzymatic deconjugation of NAAP in native urine samples was
found to be completed after 3.5 h of incubation at  a pH between
5.5–6.0.
Table 2
MRM-parameters for mass spectrometric detection, CE: collision energy, a: parent–daughter combination used for  quantification.
Analyte Parent ion (Q1) Daughter ion (Q3) Retention time  (min) CE (eV) Dwell time (s)
NAAP 152 110a 6.01 17 0.25
93  22 0.05
65  28 0.25
d4-NAAP 156 114
a 6.01 17 0.25
97  22 0.1
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3.3. High performance liquid chromatography
In preparation for chromatographic analysis samples (after
enzymatic deconjugation) were frozen overnight, thawed and cen-
trifuged to separate any precipitate (probably proteins), which was
found to  extend the lifetime of the chromatographic columns and
in-line filters considerably. We  applied a column switching method
in which we combined turbulent flow chromatography for sam-
ple cleanup and extraction and reversed phase chromatography
for analyte separation. In turbulent flow chromatography samples
are injected with high flow rates (1.5–5.0 mL/min) onto a column
packed with large particles (50–150 mm) [30,31].  The high flow
rate generates a turbulent flow inside the column. Small analyte
molecules are retained by diffusion into particle pores and adsorp-
tion to the stationary phase whilst macromolecules (proteins etc)
are not retained and flushed into waste. In our two  column assem-
bly we transferred the analytes retained on the turbulent flow
column onto the analytical column by  a change in flow direction
(backflush), with the elution power of the gradient sufficient to
desorb analytes from the pre-column but not too  strong to per-
form chromatographic separation on the analytical column. Due to
this the analytes are refocused at the beginning of the analytical
column which leads to an increase of sensitivity. For on-line sam-
ple extraction and switching procedure several chromatographic
considerations had  to be taken into account. The gradient of the
loading pump had to start with 100% water to ensure clean up and
avoid analyte losses. After the switch transfer of the analytes was
carried out by the analytical pump. The starting conditions for the
gradient with 75% water and 25% methanol were found to be opti-
mal  for transferring the analytes from the turbulent flow column
and refocusing them on the analytical column. Gradient parame-
ters for the analytical column are shown in Table 1. The gradient of
the analytical column was carried out with 1 mM aqueous solution
of ammonium acetate buffer (pH 5.5–6) instead of water in order to
enhance ionization of the analytes in the MS-source. After the sec-
ond switch the turbulent flow column was washed with high ratio
of organic solvent (98% methanol; 2% water), to avoid carry-over
effects of the analyte, and then re-equilibrated to starting condi-
tions. Simultaneously, the analytical column was washed with 95%
methanol and re-equilibrated to starting conditions. We  also tested
other eluent compositions (e.g. water/acetonitrile) and other pre-
columns like Capcell PAK®. However, best results were achieved
using the column assembly as described in section 2.6.
3.4. Mass spectrometry
As described in Section 2.7. we obtained the specific fragmenta-
tion patterns of NAAP and its deuterated analog through full scan
data and trough MS/MS  experiments via manual optimization. In
both cases the [M+H]+molecular ion  was used as the parent ion
for specific mass transitions (m/z 152 for NAAP; m/z 156 for d4-
NAAP). The specific parent daughter combinations for both ana-
lytes, together with the instrument parameters, are given in Table 2.
For both analytes the fragment with the highest response (m/z 110
for NAAP; m/z  114 for d4-NAAP) was used to calculate the analyte
concentration (quantifier). Fragments with a less intense response
were used to confirm the results of the quantifier ion (qualifiers).
A Q3 ESI positive spectrum of NAAP with tentative fragment struc-
tures is shown in Fig. 3. MRM-chromatograms of a calibration
standard (40 mg NAAP/L) and two native urine samples with differ-
ent NAAP concentrations (470 and 15  mg NAAP/L) are given in Fig. 4.
3.5. Calibration graphs
Calibration was performed with standard solutions in water.
Calibration samples were treated equally to the urine samples. To
Fig. 3. Q3 ESI positive spectrum of NAAP with tentative fragment-ion structures.
examine a possible influence of the urinary matrix on  the cali-
bration we compared the calibrations in water to calibrations in
urine. In comparison with the calibration curves obtained with
the standard solutions prepared in water the calibration curves
obtained from eight different urine samples spiked with NAAP (see
Section 2.5)  showed no influence of the urinary matrix on the slopes
of the calibration curves. Of course, due to the presence of native
NAAP in all urines analyzed, the y-axis intercepts of the calibrations
in urine were shifted to values above zero depending on the content
of NAAP in these samples (data not shown). Because the  varying
baseline concentration of NAAP in urine we chose to perform all
further calibrations in water. Calibration curves were obtained by
analyzing aqueous standards and by plotting the quotient of peak
areas of NAAP and d4-NAAP as a function of the NAAP concen-
tration with a 1/x weighting. All calibration curves showed good
linearity over the concentration range (0.75 mg/L–10,000 mg/L) and
produced linear correlation coefficients above 0.99. Samples with
concentration above the highest calibration point were diluted with
water to fit the calibration range.
3.6. Reliability of the method
3.6.1. Precision and accuracy
We determined the intra-day precision of the method by ana-
lyzing the quality control standards eight times in a row. For Qlow
relative standard deviation (RSD) was 1.7%. For Qmed and Qhigh cal-
culated RSDs were 1.2% and 2.2% respectively.
Inter-day precision was determined by analyzing Qlow, Qmed
and Qhigh on eight different days using newly obtained calibration
graphs for calculation of the NAAP-concentrations of the quality
control samples. In inter- day- precision measurements RSDs were
4.1% for Qlow, 1.8% for Qmed and 2.7% for Qhigh. Results of the deter-
mination of intra-day and inter-day precision are listed in Table 4.
To determine the accuracy of the method we analyzed eight
different urine samples with varying creatinine concentrations
ranging from 0.3 g/L to 3.0 g/L, which were chosen to reflect the
broad spectrum of urinary matrix. These samples were analyzed in
native (non-spiked) condition and spiked at two concentration lev-
els with concentrations of NAAP of 109.7 mg/L and 548.5 mg/L. All of
these urine samples contained native NAAP concentrations (mean:
40.41 mg/L; range: 10.69 mg/L–59.72 mg/L), thus the NAAP concen-
trations measured in the native samples were subtracted from the
spiked concentrations before calculation. For the low-spiked con-
centration the mean calculated accuracy (percent recovery) was
98.4% (90.1%–103.4%). The mean accuracy (percent recovery) calcu-
lated from high concentration samples was 100.2% (96.1%–103.1%).
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Fig. 4. MRM  chromatograms with specific mass transitions of NAAP (upper row) and d4-NAAP of calibration standard with 500 mg NAAP/L (A) a  native human urine sample
with 470 mg NAAP/L (B) and native human urine sample with 15 mg NAAP/L (C).
The precision data obtained from these spiking experiments with
a RSD of 4.5% for the low concentration and an RSD of 2.3% for the
high concentration was comparable to the inter-day-precision data
from above, thus underlining the ruggedness of the method and the
independence from the urinary matrix (Table 3).
3.6.2. Detection limit and quantification limit
The limit of detection (LOD), defined as  a signal-to-noise ratio
of three for the registered fragment of NAAP was estimated to be
0.25 mg/L. The limit of quantification (LOQ) defined as a signal-to
noise ratio of nine and was estimated to be 0.75 mg/L. Because no
urine without native NAAP concentrations was  available, all mea-
surements to estimate LOD and LOQ were carried out in water.
In some native urine samples the signal intensities of the added
labeled internal standard were reduced by up to 60%, probably due
to a quenching of the signal. However, as can be seen from the above
spiking experiments with native urine samples this effect had  no
influence on accuracy or precision. Furthermore, as can be seen in
the results of biological monitoring below, the lowest NAAP level
determined in these samples was more than a factor of 10 above
the LOQ.
3.7. Results of biological monitoring
The results of the pilot study encompassing 21  volunteers are
shown in Table 5; results for each volunteer individually are shown
in supplemental Table 1.  We detected NAAP in all samples analyzed
with a wide range of concentrations from 8.7 mg/L to 22120 mg/L.
According to the questionnaire 4 of the 21 volunteers declared
never to have taken paracetamol while13 volunteers declared to
have taken paracetamol at least once in their life, but at least a
Table 3
Precision and accuracy calculated from analysis of  eight different urine samples with
varying creatinine concentrations and two different NAAP spiking levels; native
(non-spiked), spiked to 109.7 mg/L and spiked to 548.5 mg/L.
Spiking level
Low High
Spiked conc. (mg/L) 109.7 548.5
Native conc. measured
(mg/L)
40.41 (10.69–59.72)
Native and spiked conc.
measured (mg/L)
148.39 (114.4–171.2) 589.8 (546.4–618.6)
Spiked conc. calculated (mg/L)
Mean 108.0 549.4
Range 98.81–113.5 527.0–565.5
RSD  (%) 4.5 2.3
Accuracy (%)  98.4 (90.1–103.4) 100.2 (96.1–103.1)
couple of weeks ago.4 of the volunteers quoted to have taken para-
cetamol within a week prior to the study, one of them indicated
that a single tablet of paracetamol was taken approximately 24 h
prior to the sampling. This volunteer also had the highest urinary
paracetamol value measured in the pilot population (22120 mg/L).
The other three (stating to have taken paracetamol recently) had
urinary NAAP concentrations of 64.1 mg/L, 80.6 mg/L and523.3 mg/L.
In the group stating to have never taken paracetamol (n = 4), lev-
els ranged from 59.1 mg/L to 424.5 mg/L. In  the group stating to
use paracetamol at rare intervals but not within the last weeks
(n = 14) the NAAP values ranged from 8.7 mg/L to1700 mg/L (median
72.2 mg/L).
Supplementary material related to this article found, in the
online version, at http://dx.doi.org/10.1016/j.jchromb.2013.02.023
Table 4
Intra-day and inter-day precision of the method calculated by analysis of  self-prepared quality control materials with three different concentration levels of  NAAP.
Intra-day series (n =  8)  Inter-day series (n =  8)
Qlow Qmed Qhigh Qlow Qmed Qhigh
Measured conc. (mg/L) 12.61 92.91 435.8 14.51 100.6 449.9
SD (mg/L) 0.21 1.11 9.45 0.6 1.78 12.13
RSD  (%) 1.7 1.2 2.2 4.1 1.8 2.7
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Table  5
Results of the human biomonitoring pilot study with 21 volunteers.
Mean Median Range
Urinary concentrations
of N-acetyl-4-
aminophenol
(n = 21)
1274.2 mg/L 85.7 mg/L  8.7 mg/L–22120 mg/L
Obviously, there is a wide range in NAAP body burdens
in all individuals of our study and a considerable overlap in
NAAP concentrations, no matter if the individual has or has not
taken paracetamol during the week before sample collection. As
pointed out above, there could be several sources for the uri-
nary NAAP/paracetamol levels observed in this pilot study, namely
through foodstuff contaminated with paracetamol, through expo-
sure to aniline (or related compounds) or through sources we are
currently not aware of. As described in Section 1, urinary aniline is
determined routinely as  hydrolyzed acetanilide. With acetanilide
representing approx. 3% of the aniline dose and  NAAP represent-
ing 66%–76% of the aniline dose [1],  the ratio of these two aniline
metabolites can be expected to be between 1:19 and 1:25. Taking
into account the difference in the molecular masses of acetanilide
(M = 135.16 g/mol) and NAAP (151.16 g/mol) leads to a ratio of these
two metabolites between 1:22 and 1:29 on a mg/L basis. Urinary
aniline levels (determined as  hydrolyzed acetanilide) in the gen-
eral population with a 95th percentile around 14 mg/L [4,5] would
therefore translate to NAAP concentrations of around 350 mg/L. A
maximum aniline concentration of 384 mg/L as reported by Kütting
et al. [4] would translate to approx.10000 mg/L NAAP. The second
highest urinary NAAP concentration found in our study (1700 mg/L)
in an individual who reported not  to have used paracetamol prior to
the study could thus be explained by aniline and aniline exposures
found in the general population.
4. Conclusion
We have developed a fast, robust, sensitive and selective method
to determine N-acetyl-4-aminophenol (NAAP) in urine samples in a
wide concentration range, covering the background body burden of
the general population to this compound. We  detected and  quanti-
fied NAAP in all of the 21 volunteers of our pilot study. Our method
can now be used to determine NAAP in larger population studies,
both investigating the body burden to NAAP and the prevalence
of paracetamol/acetaminophen usage in the general population or
special subpopulations.
The one individual who self-dosed paracetamol the day before
the urine sample was collected obviously excreted NAAP at a
level that was 13 times higher than the highest level found in
the remaining 20 volunteers and  approx. 250 times higher than
the median level of all volunteers investigated. However, based
upon the known aniline metabolism and the known exposure
to aniline in the general population, NAAP levels well in the
mg/L range can also be expected even if  the individual did not
use paracetamol/acetaminophen. Furthermore, because paraceta-
mol/acetaminophen might be used in the treatment of lifestock,
with apparently no specific maximum residue limit for this sub-
stance in foodstuffs of animal origin, contaminated foodstuff might
be a direct route of exposure to paracetamol/acetaminophen.
In general, the omnipresence of a pharmacologically active sub-
stance that per se  is not naturally occurring in humans raises
some concern. Recent toxicological studies (cited above) sug-
gest that paracetamol might inhibit testosterone production in
fetal rats, alone or in an  additive manner together with other
anti-androgens. Epidemiological studies suggest that paraceta-
mol  might be a risk factor for development of male reproductive
disorders. Therefore, our  findings of an omnipresent body bur-
den to N-acetyl-4-aminophenol (=paracetamol/acetaminophen)
in samples from the general population strongly warrant fur-
ther investigations. To  investigate the possibility to distinguish
between the sources of the paracetamol/NAAP excretion (direct
paracetamol exposure, aniline exposure, other sources) we plan
to determine aniline, acetanilide and/or other aniline and para-
cetamol specific metabolites together with NAAP in a future
study.
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drinking water has been reported to be contaminated with parac-
etamol, albeit at rather low concentrations (Fram and Belitz, 2011).
Recently it has been shown that the general population is ubiq-
uitously excreting N-acetyl-4-aminophenol in wide concentration
ranges (Modick et al., 2013). Two major sources may  be the reason
for the observed ubiquitous urinary excretion: (1) direct expo-
sure to N-acetyl-4-aminophenol (paracetamol/acetaminophen) via
sources pointed out above; and/or (2) exposure to aniline or aniline
precursors, which are known to produce N-acetyl-4-aminophenol
in mammalian metabolism. In  contrast to N-acetyl-4-aminophenol,
the general population has been known for some time to be ubiq-
uitously exposed to aniline or aniline releasing substances (Weiss
and Angerer, 2002; Kütting et al., 2009; el-Bayoumy et al., 1986).
From studies in various animal species (sheep, dog and rat, Fig. 1)
we know that around 3% of an oral dose of aniline are metabolized
to acetanilide and excreted via urine. Approx. 80% of an aniline dose
are metabolized to N-acetyl-4-aminophenol and excreted via urine
(Kao et al., 1978; Aniline, MAK  value documentation in German
language, 1992). Thus, acetanilide is a metabolite of aniline and the
metabolic precursor of N-acetyl-4-aminophenol. Acetanilide is not
generated in the metabolism of N-acetyl-4-aminophenol (Andrews
et al., 1976; Ladds et al., 1987). By now, aniline exposure has rou-
tinely determined by measuring free aniline (el-Bayoumy et al.,
1986; Aniline, MAK  value documentation in German language,
1992) or total urinary aniline after hydrolyses to cleave possible
aniline conjugates such as acetanilide (Weiss and Angerer, 2002;
Kütting et al., 2009;).  Aniline, determined this way, can be found
in nearly all urine samples from the general German population
with a median total aniline concentration of 3.5 mg/L and a maxi-
mum concentration of 384 mg/L (Kütting et al., 2009). Based upon
the data of Kütting et al. (2009) such aniline exposures could
explain at least parts of urinary N-acetyl-4-aminophenol excretion
in the general population. However, under strong acidic condi-
tions aniline could also be released from other substances with an
acid cleavable aniline moiety such as pesticides or azo dyes. Even
partial desamination of aromatic amines was observed in urine
under strong acidic conditions (Schettgen et al., 2011).  Therefore,
based upon the current GC–MS methods determining aniline after
strong acidic hydrolysis it remains unclear if  the aniline measured
is solely derived from acetanilide, some residual free aniline, or
other substances that can be broken down to aniline in the ana-
lytical process. Thus, the unequivocal and sensitive determination
of acetanilide (next to N-acetyl-4-aminophenol) was a major aim
of this study. Additionally, to further complement the spectrum of
aniline metabolites we also included N-acetyl-2-aminophenol in
our method development. N-Acetyl-2-aminophenol was  found as
metabolite of aniline after incubation of sheep intestine (Turner
et al., 1976). In other metabolism studies after oral aniline admin-
istration urinary N-acetyl-2-aminophenol was not detected (Kao
et al., 1978).
Therefore, to further elucidate the origins of the ubiquitous
excretion of N-acetyl-4-aminophenol in urine samples from the
general population (Modick et al., 2013), to generally contribute
to the knowledge of aniline metabolism in man  and to pos-
sibly distinguish the generation of N-acetyl-4-aminophenol via
aniline metabolism from direct N-acetyl-4-aminophenol expo-
sure we developed an  HPLC–MS–MS method for the simultaneous
quantification of N-acetyl-4-aminophenol and the aniline related
metabolites, N-acetyl-2-aminophenol and acetanilide. We applied
this method to three groups of individuals with different expo-
sure scenarios: (1) individuals from the general population with no
aniline exposure and known not to have used paracetamol medi-
cation recently; (2) individuals with occupational aniline exposure
but no paracetamol medication prior to sampling and (3) indi-
viduals known to have used paracetamol within a day prior to
sampling.
Experimental
Chemicals
N-acetyl-4-aminophenol (CAS No. 103-90-2, purity 99.0%),
N-acetyl-2-aminophenol (CAS No. 614-80-2, purity 97%) and
acetanilide (CAS No. 103-84-4, purity 99%) were purchased from
Sigma–Aldrich (Steinheim, Germany). N-Acetyl-4-aminophenol-
d4 (0.1 mg/mL  in acetonitrile) was obtained from LGC Standards
(Wesel, Germany) and acetanilide-d5 (CAS No. 15826-91-
2, purity 99%) was obtained from CDN Isotopes (Augsburg,
Germany). Pyridine, dichloromethane, acetic acid-d4 and 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide hydrochloride were pur-
chased from Sigma–Aldrich (Steinheim, Germany). Deionized
water was  obtained using a Millipore Advantage A10 with a
Quantum®-cartridge. Acetonitrile (LC–MS grade) was  purchased
from Roth (Darmstadt, Germany). Ammonium acetate p.a., HP2
b-glucuronidase/arylsulfatase and ammonium bicarbonate were
purchased from Sigma–Aldrich (Steinheim, Germany).
Synthesis of N-acetyl-2-aminophenol-d3
N-acetyl-2-aminophenol-d3was synthesized by  selective acety-
lation of 2-aminophenol at  the amino group with activated
acetic acid-d4. Activation of acetic acid was performed by
adding acetic acid-d4 to a solution of 352 mg  1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride and 144 mg
pyridine in 4 mL  dichloromethane at 0 ◦C. After 1 h 200 mg  2-
aminophenol dissolved in 2 mL  dichloromethane were added and
the solution was  stirred overnight. Afterwards the reaction mix
was extracted twice with 6 mL  1  N hydrochloric acid and washed
with saturated sodium chloride solution. The dichloromethane was
evaporated and the residual N-acetyl-2-aminophenol-d3 was  dis-
solved in acetonitrile. The absence of interfering non- or partially
labeled N-acetyl-2-aminophenol was  verified by HPLC-MS-MS. The
concentration of N-acetyl-2-aminophenol-d3 in acetonitrile was
roughly estimated by HPLC-MS-MS using unlabeled N-acetyl-2-
aminophenol for calibration.
Calibration standards
Stock solutions were prepared by  weighing 10 mg  of each
standard into a separate 10-mL-volumetric flask, which then
was filled up to the mark with acetonitrile (1  g/L). For analysis,
eight calibration standards were prepared from these stock solu-
tions by gradual dilution with water to yield final concentrations
ranging from 2.2 mg/L to 2200 mg/L for N-acetyl-4-aminophenol,
from 81 mg/L to 1900 mg/L for N-acetyl-2-aminophenol and from
0.2 mg/L to 225 mg/L for acetanilide, respectively. Stock solutions
and calibration standards were stored at −20 ◦C  in teflon capped
glass vials until further use. The solutions of the internal standards
were prepared by mixing solutions of N-acetyl-4-aminophenol-d4,
acetanilide-d5 and N-acetyl-2-aminophenol-d3 in acetonitrile. This
mixture was  then diluted with water in a 10-mL-volumetric flask
to final concentrations of 250 mg/L, 100 mg/L and 100 mg/L, respec-
tively.
Specimen collection and sample preparation
Urine samples were collected in 250-mL polyethylene contain-
ers and immediately stored at  −20 ◦C until further processing. All
samples were equilibrated to room temperature prior to analysis.
Samples were vortex mixed before transferring 300-mL-aliquots
into a silanized 1.8-mL teflon screw cap vial. Deconjugation of the
metabolites, to measure the sum of conjugated and free analytes,
was achieved by using HP-2 b-glucuronidase (≥100,000 units/mL)
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Fig. 1. Simplified aniline metabolism in animals (rats, pigs and sheep) after single oral administration of  aniline (Kao et  al., 1978). Dotted lines  mark hypothetical pathway.
which also contains arylsulfatase activity (≤7500 units/mL) follow-
ing the optimized protocol published for N-acetyl-4-aminophenol
(Modick et al., 2013). In brief, 180 mL ammonium acetate buffer
(0.5 M,  pH 5.5–6.0), 30 mL internal standard solution and 6 mL of
b-glucuronidase/arylsulfatase were added to each sample. After
incubation at 37 ◦C in a water bath for 3.5 h all samples were frozen
at −18 ◦C overnight to freeze out and precipitate proteins. After
thawing, all samples were centrifuged at  4000 × g  for 10 min. The
supernatant was transferred into a second silanized 1.8-mL teflon
screw cap vial. Urinary creatinine concentrations were determined
according to Jaffe (1886).
Calibration procedure and quantification
Calibration was performed with aqueous standard solutions.
All calibration standards were treated equally to the urine sam-
ples. Linear calibration curves were obtained with a 1/x weighing
by plotting the quotients of peak areas of the analytes with the
respective deuterium labeled internal standards as a function of
the analyte concentration. If the determined analyte concentration
of a sample from a  study subject was outside the calibration range,
the sample was diluted with water and processed again.
Quality control materials
Quality control material was prepared within our laboratory
using native urine samples from different volunteers. These urine
samples were analyzed for their analyte concentration and then
pooled to obtain control material with low and high concentra-
tions of the three analytes (concentrations see Table 4). Due to
the lack of acetanilide in native samples we spiked the pool urines
with acetanilide standard solution at two different concentration
levels. The resulting materials were frozen, thawed and filtered
three times before use. The obtained control material was divided
into aliquots and stored at −20 ◦C. Reliability and precision of the
method were determined by  measuring these quality control sam-
ples eight times in a row for the intra-day precision and on eight
different days for the day to day imprecision. Additionally, accu-
racy and imprecision were determined by analyzing eight different
urine samples with varying creatinine concentrations ranging from
0.3 g/L to 3.0 g/L. These samples were analyzed non-spiked and
spiked at  two  concentration levels (ref. Table 3). The concentrations
of the native samples were subtracted from the spiked concentra-
tions before further calculation.
High performance liquid chromatography
High performance liquid chromatography was carried out
using a 1525 binary pump (loading pump) and a 1525 m binary
pump (analytical pump) (Waters, Milford, USA), a Waters In-Line
AF degasser and a Waters 2777 Sample Manager autosampler.
Detailed information and a schematic sketch of the two-column-
assembly used have previously been published by Modick
et al. (2013). In short, a Waters Oasis® HLB cartridge column
(2.1 mm × 20 mm;  25 mm)  was  used as  first column for  cleanup
and enrichment of the analytes by turbulent flow technique. Chro-
matographic separation was  performed using a  Hypercarb (Thermo
Scientific) (2.1 mm  × 100 mm;  3 mm)  column. The used eluents
consisted of a solution of 3 mM ammonium bicarbonate in water
(solvent A) and acetonitrile (solvent B). An in-line filter (Phen-
omenex 0.5 mm × 3.0 mm;  AF0-0378) was  placed in front of the
HLB-phase and a guard column (PFP 2.0 mm × 4 mm)  was placed
in front of the analytical column. 210 mL of the processed sample
were injected with a constant flow of solvent A of 3.75 mL/min
by the loading pump onto the HLB-phase. After 1 min  the valve
position was  switched and the analytes were transferred in back-
flush mode onto the Hypercarb column through a time controlled
switching valve (Waters Selector Valve). The analytes were chro-
matographically separated by the gradient flow from the analytical
pump of solvents A and B (Table 1).  After 6 min  the switching valve
was set back into position A and the HLB-phase was flushed with
high organic solvent (98% solvent B; 2% solvent A) and then re-
equilibrated with 100% of solvent A.  All steps were controlled by
Waters MassLynx V4.1 software.
Mass spectrometry
The mass spectrometric detection and quantification was per-
formed using a Waters Quattro Premier XE  triple quadrupole mass
spectrometer as described by Modick et al. (2013). Positive ioniza-
tion mode was used with a capillary voltage of 4.00 kV. Nitrogen
was used as desolvation gas at 400 ◦C  and  a flow of 1000 L/h. Ion
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Table  1
Gradient program (analytical pump) for chromatographic separation, solvent A:  3 mM ammonium bicarbonate; solvent B:  acetonitrile.
Program step Time (min) Solvent A (%) Solvent B (%) Flow rate (mL/min) Valve position Analysis step
1 Initial 77 23 0.2 A Cleanup, enrichment
(on the HLB-column)2  1.00 77 23 0.2 B
3  3.00 77 23 0.2 B Analyte transfer
4  3.25 70 30 0.2 B Separation
5  6.00 70 30 0.2 A
6  10.00 52 48 0.2 A
7  11.00 5 95 0.2 A
8  13.00 5 95 0.2 A Washing
9  13.50 77 23 0.2 A
10  15.00 77 23 0.2 A Reconditioning
Table 2
MRM-parameters for mass spectrometric detection.
Analyte Rt (min) Parent ion (Q1) Daughter ion (Q3) CE (eV) Dwell time (s)
N-Acetyl-4-aminophenol 10.6 152 110a 15 0.25
92b 25 0.05
N-Acetyl-4-aminophenol-d4 10.5 156 114
a 15 0.25
97b 25 0.05
N-Acetyl-2-aminophenol 11.2 152 110a 15 0.25
92b 25 0.05
N-Acetyl-2-aminophenol-d3 11.1 155 111
a 15 0.25
93b 25 0.05
Acetanilide 12.0 136 94a 16 0.25
77b 22 0.05
Acetanilide-d5 11.9 141 99
a 18 0.25
81b 28 0.05
CE: collision energy.
a Quantifier.
b Qualifier.
source temperature was set to 120 ◦C. Analyte specific fragmen-
tation patterns were acquired through full scan data via manual
optimization. For this purpose, standard analyte solutions (approx.
1 mg/L) were infused directly into the mass spectrometer with a
constant flow of 10 mL/min.
Based on the parent ion  of the analytes and the internal stan-
dards mass transitions to two daughter ions were tuned in. The
fragment with the highest response was used to calculate the ana-
lyte concentration (quantifier). The mass with the second intensity
was used to confirm the results (qualifier). The measurements
were performed in multiple reaction monitoring (MRM)  mode with
argon as collision gas (0.25 mL/min). The specific MRM  parameters
are given in Table 2.
Study subjects
The method was applied to urine samples from three different
groups of volunteers. Group 1 consisted of 31  individuals who  had
no known occupational exposure to aniline and self-declared no use
of paracetamol or paracetamol containing medications for at least
one week before sample collection. Group 2 consisted of six volun-
teers with exposure to aniline in an  occupational setting but with no
recent (at least one week ago) use of paracetamol/acetaminophen
(confirmed by questionnaire). The aniline exposure of these indi-
viduals determined by air measurements was rather high but still
within the legal limits of the German AGW (occupational limit
value of 7.7 mg/m3).  Group 3 consisted of two volunteers who had
used paracetamol the day before sampling but who had no known
(occupational) aniline exposure. All participants provided written
informed consent for participation. The study was approved by
the Ethics Committee of the Ruhr University Bochum (Reg. No.:
3867-10, Reg.-Nr.: 4333-12) and was conducted in accordance with
the Helsinki Declaration.
Results and discussion
General considerations
The present method has been designed for the  simul-
taneous determination of N-acetyl-4-aminophenol, N-acetyl-2-
aminophenol and acetanilide in urine without the need for
intensive sample work up or derivatisation. The method has been
designed both for large scale human biomonitoring studies and for
human metabolism studies on paracetamol, aniline, or substances
possibly breaking down to aniline in human metabolism. Thus, we
focused on high sample throughput, reliability and linearity over
a wide concentration range. Due to an  on-line extraction proce-
dure by turbulent flow chromatography, thus efficient enrichment
of the analytes, sample pretreatment was  minimized. The use of
ESI-MS–MS with isotope dilution ensured both highly sensitive and
selective results.
High performance liquid chromatography
We applied a column switching method in which we  combined
turbulent flow chromatography for sample cleanup and  extrac-
tion, and reversed phase chromatography for analyte separation.
For sample enrichment we used an  assembly consisting of a short
Waters Oasis® HLB cartridge column and an automatic switch-
ing valve as previously described (Modick et al., 2013).  Under
the conditions of turbulent flow macromolecules (proteins etc.)
show no retention on the stationary HLB phase thus are flushed
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Fig. 2. MRM  chromatograms with specific mass transitions for N-acetyl-4-aminophenol (NA4AP) and N-acetyl-2-aminophenol (NA2AP) (m/z 152 >  110) and acetanilide (AA)
(m/z 136 > 94). (A) Aqueous standard solution (NA4AP: 270 mg/L; NA2AP: 324 mg/L; AA: 4.5 mg/L); (B) urine sample from group 1  (NA4AP: 463 mg/L; NA2AP: 2023 mg/L; AA:
<0.03 mg/L); (C) urine sample from group 2  (NA4AP: 4150 mg/L; NA2AP: 271 mg/L; AA: 82 mg/L).
into the waste, while small molecular weight analytes can inter-
act with the stationary phase, are retained and can be transferred
onto the analytical column by a change in flow direction (back-
flush) and solvent composition. To  avoid peak broadening and
misshaped peaks the elution power of the starting eluent has to
be strong enough to desorb analytes from the HLB column but not
too strong to start chromatographic separation on the analytical
column. The choice of the analytical column was  a crucial point
during method development. Additionally, the chromatographic
separation of the structural isomers N-acetyl-4-aminophenol and
N-acetyl-2-aminophenol had  to be realized. In  the line of columns
tested (Atlantis T3, Luna Phenylhexyl, Luna PFP) the Hypercarb col-
umn  turned out to ensure baseline separation of these two analytes
using acetonitrile and 3 mM ammonium bicarbonate in gradient
elution. The overall run time of the method is 15  min  including
regeneration/equilibration of the enrichment and the analytical
column.
Mass spectrometry
We  obtained the specific fragmentation patterns of the
analytes and their deuterated analogs through full scan data
and through MS–MS  experiments via manual optimization.
N-Acetyl-4-aminophenol shows approximately a 12-fold intense
peak response than N-acetyl-2-aminophenol (ref. Fig. 2). Due to
this difference, the use of the commercially available deuterated
N-acetyl-4-aminophenol-d4 as internal standard for both isomers
was not possible. Therefore, we synthesized deuterium labeled
N-acetyl-2-aminophenol-d3.  Characterization of the product was
performed by  LC–MS–MS. In a purity check by LC–MS–MS no
interfering byproducts could be detected at the mass transitions
recorded in this method.
For all three analytes the [M+H]+ molecular ion  was  used as
the parent ion for specific mass transitions. Specific parent daugh-
ter combinations for all analytes, together with the instrument
parameters, are given in Table 2. In all cases the fragment with the
highest response was used to calculate the analyte concentration
(quantifier). Fragments with a less intense response were used
to confirm the results of the quantifier ion  (qualifiers). MRM-
chromatograms of a calibration standard and of two  native urine
samples with different analyte concentrations are presented in
Fig.  2. Chromatogram A1  shows the mass transitions of N-acetyl-4-
aminophenol and  N-acetyl-2-aminophenol in an aqueous standard
solution. The  isomers are well separated; in urine (chromatogram
B1 and C1) no interfering matrix compounds were detected. Peak
widths and shapes are very good thanks to refocusing of the
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Table  3
Precision and accuracy calculated from analysis of eight different urine samples with varying creatinine concentrations and two different spiking levels.
Spiking level N-Acetyl-4-aminophenol N-Acetyl-2-aminophenol Acetanilide
Low High Low High Low High
Spiked conc. (mg/L) 110 274 147 270 9 225
Native  conc. measured (mg/L) 6–541 51–3493 <LOQ
Native  and spiked conc. measured (mg/L) 109–661 274–832 228–3644 376–3785 9.6–11.1 237–262
Spiked  conc. calculated (mg/L)
Mean 115 291 169 309 10 248
Range 93–134 265–319 148–191 269–369 9.6–11.1 237–262
RSD (%) 9.9 5.9 8.6 9.3 3.1 2.4
Accuracy (%) 105 (85–122) 106 (96–116) 103 (101–130) 119 (100–137) 114 (106–123) 110 (106–116)
Table 4
Intra-day and inter-day precision of  the method calculated by analysis of  self-prepared quality control materials with two different concentration levels.
N-Acetyl-4-aminophenol Acetanilide N-Acetyl-2-aminophneol
Qlow Qhigh Qlow Qhigh Qlow Qhigh
Intra-day series (n =  8)
Measured conc. [mg/L] 12.8 475.6 2.0  180.7 61.2 293.0
SD [mg/L] 1.5 15.8 0.1  4.8 6.0  8.6
RSD [%] 11.4 3.3 2.7 2.7 9.9 2.9
Inter-day series (n =  8)
Measured conc. [mg/L] 11.9 501 1.7 190 68.0 347
SD [mg/L] 1.7 28 0.2  13.2 10.2 33.0
RSD [%] 14.4 5.6 10.7 6.9 15.0 9.5
analytes at the beginning of the analytical column. Chromatogram
A2 shows the mass transitions of acetanilide in an  aqueous
standard solution. In the urine sample from group 1  (B2) no
acetanilide was detected, in the sample from group 2 (C2) a high
signal for acetanilide was detected (Tables 3  and  4).
Calibration graphs
Calibration was performed with standard solutions in water
which were treated equally to the urine samples. We examined
a possible influence of the urinary matrix on the calibration by
comparing aqueous calibrations with calibrations in urine by  using
eight different urine samples with different creatinine content (see
section “Reliability of the method”). In  these experiments we did
not observe influences of the urinary matrix on the slopes of the cal-
ibration curves. However, due to the presence of all three analytes
in native urines calibration should be carried out in water. Calibra-
tion curves of all analytes showed good linearity with correlation
coefficients of above 0.99 (Table 5).  If the determined analyte con-
centration of a sample was outside the calibration range, the urine
sample was diluted with water and processed again.
Reliability of the method
The relative standard deviations (RSD) for the three analytes
and the two concentrations are listed in Table 4. Intra-day and
inter-day imprecisions of all analytes were below 15% in all cases.
The mean recoveries for the three analytes were between 103
and 119% which is highly acceptable taking into account that
Table 5
Calibration ranges, correlation coefficients, LODs and LOQs.
Analyte Calibration
range [mg/L]
R2 LOD [mg/L] LOQ [mg/L]
N-Acetyl-4-
aminophenol
2.2–2.200 >0.99 0.07 0.21
N-Acetyl-2-
aminophenol
81–19.400 >0.99 2.0 6.0
Acetanilide 0.2–225 >0.99 0.03 0.09
baseline concentrations in the native samples varied considerably.
The imprecisions obtained from these spiking experiments were
comparable to the inter-day- imprecision data, thus underlining
the ruggedness of the method and the absence of a relevant matrix
effect (Table 3). The limit of detection (LOD) was estimated on
the basis of a signal to noise ratio of 3:1, whereas the limit of
quantitation (LOQ) was  based on a signal to noise ratio of 9:1. As no
urine sample with sufficiently low native N-acetyl-4-aminophenol
and N-acetyl-2-aminophenol concentrations were available we
determined their LOD and LOQ in water instead of urine as for
acetanilide. LODs and LOQs are listed in Table 5.
Results of biological monitoring
The results of the biomonitoring measurements for the three
analytes encompassing urine samples from three different groups
of volunteers are presented in Table 6 and the individual results for
each volunteer in supplemental Table S1.
N-acetyl-4-aminophenol was  detected in all urine samples of
group 1  (31 volunteers from the general population with  no ani-
line exposure or paracetamol medication). Concentrations were
found in the range between 8.4 mg/L and 2263 mg/L. The over-
all median in group 1 was 80 mg/L. These results are confirming
the results of our recently published pilot study on N-acetyl-4-
aminophenol with 21  individuals in which we reported a median
of 85.7 mg/L and already showed the omnipresent excretion of
N-acetyl-4-aminophenol (Modick et al., 2013).  In  group 2  (six vol-
unteers with exposure to aniline in an  occupational setting) the
median was  5720 mg/L which is about 70 times higher than in
group 1.  The maximum value within this group was 10,885 mg/L.
These results are consistent with N-acetyl-4-aminophenol being
the major urinary metabolite of aniline (Kao et al., 1978).  The high-
est value of group 1, however, was only lower by a factor of 5
compared to group 2. The two  individuals with paracetamol med-
ication within 24 h  prior to urine sampling (group 3)  exhibited
urinary N-acetyl-4-aminophenol concentrations that were well in
the mg/L range (159 and 275 mg/L) and thus 15 times higher than
the maximum value of group 2 and 70–120 times higher than the
maximum value of group 1. Still, and this is  a remarkable finding,
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Table  6
Results of the human biomonitoring study; group 1:  no known occupational aniline
exposure and no known paracetamol use; group 2: known aniline exposure and no
paracetamol usage; group 3:  no known occupational aniline exposure and recent
paracetamol usage.
Group 1 Group 2 Group 3
n =  31 n =  6 n = 2
N-Acetyl-4-aminophenol
Min  8.4 4150 159,440
Max  2263 10,885 274,862
Median 80 5720
N-Acetyl-2-aminophenol
Min  7.4 271 n.a.
Max  39,161 2319 n.a.
Median 2071 918
Acetanilid
Min  <LOQ 41.2 <LOQ
Max  <LOQ 122 <LOQ
Median <LOQ 78.7 <LOQ
n.a.: not analyzable.
N-acetyl-4-aminophenol values well in the mg/L range could be
detected in all groups, including group 1 (Table 6).
N-acetyl-2-aminophenol was also detectable in all urine sam-
ples of group 1 ranging from 7.4 mg/L to 39,161 mg/L, with
a median of 2071 mg/L. We  are not aware that N-acetyl-2-
aminophenol has previously been reported to be excreted in
urine samples from the general population. Surprisingly, unlike
for N-acetyl-4-aminophenol, we could not  observe any relation of
N-acetyl-2-aminophenol with aniline exposure (group 2). Individ-
uals from group 1 excreted N-acetyl-2-aminophenol at comparable
or rather higher levels than individuals from group 2.  There-
fore, N-acetyl-2-aminophenol excretion does not seem to be a
significant metabolite in human metabolism of aniline. In  the
two urine samples from individuals having consumed paraceta-
mol  the quantitative determination of N-acetyl-2-aminophenol
was hampered by excessively high N-acetyl-4-aminophenol con-
centrations, which lead to a considerable peak broadening for
N-acetyl-4-aminophenol. Due to the peak broadening the peak of
N-acetyl-4-aminophenol overlapped with the peak of N-acetyl-
2-aminophenol, which made the unambiguous and sensitive
quantification impossible.
Surprisingly, acetanilide could neither be detected in group 1
nor in group 3, not even at  lowest levels down to the LOD of
0.03 mg/L of our method. From previous studies reporting ubiqui-
tous aniline exposure in the general population (Weiss and Angerer,
2002; Kütting et al., 2009; el-Bayoumy et al., 1986), we  would have
expected acetanilide to show up in at least some of these indi-
viduals. However, all of the 6  individuals known to be exposed
to aniline excreted acetanilide in levels far above the LOQ of our
method (median of 78.7 mg/L; range 41.2–122 mg/L). In  these indi-
viduals acetanilide levels were approximately 100 times lower than
N-acetyl-4-aminophenol levels. This finding is in rough accordance
to the known metabolism of aniline in animals, where N-acetyl-4-
aminophenol is the by far major and  acetanilide is only a minor
metabolite. If we used this acetanilide/N-acetyl-4-aminophenol
ratio of approximately 100 (from the occupational aniline expo-
sure scenario), or the acetanilide/N-acetyl-4-aminophenol ratio of
approximately 25–50 from animal studies (Kao et al., 1978) N-
acetyl-4-aminophenol levels of 80 mg/L (median of group 1) should
be accompanied by a urinary acetanilide excretion of 1–3 mg/L, if
aniline was the sole source of exposure. Seen the other way round,
N-acetyl-4-aminophenol levels as low as 0.75–3 mg/L theoretically
caused by sole exposure to aniline would lead to detectable levels of
acetanilide (>0.03 mg/L).  N-Acetyl-4-aminophenol levels observed
in  the general population are ten to a hundred times above these
0.75–3 mg/L but, still, no acetanilide can be detected in urine.
Thus, our findings confirm that acetanilide is a metabolite of ani-
line in man  and  can be used to determine occupational exposure
to aniline. Acetanilide as biomarker for aniline exposure is  more
specific than determination of aniline after acetic hydrolysis by gas
chromatography. During acetic hydrolysis aniline may be released
from other molecules (azo dyes, pesticides, pharmaceuticals) which
are not aniline metabolites. Additionally, in argumentum e con-
trario, since N-acetyl-4-aminophenol is excreted in the individuals
of group 1  (general population) without concurrent excretion of
acetanilide, the bulk of excretion of N-acetyl-4-aminophenol in
these individuals – especially those in the mg/L range – is not likely
to be caused by aniline or acetanilide exposure.
Summary and conclusions
Within this manuscript we present a fast, robust, sensi-
tive and selective HPLC–MS–MS method for the simultaneous
quantitative determination of N-acetyl-4-aminophenol (paraceta-
mol, acetaminophen), N-acetyl-2-aminophenol and acetanilide in
urine samples. The method uses turbulent flow chromatogra-
phy for sample cleanup and analyte enrichment, reversed phase
chromatography for analyte separation after column switching
and tandem mass selective detection with deuterated internal
standards for each analyte. The method is  suitable for Human
Biomonitoring and has proven its applicability in urine samples
of individuals who were exposed to the analytes or their metabolic
precursors in occupational as well environmental settings, and in
persons using paracetamol (N-acetyl-4-aminophenol) containing
medication. We  detected and quantified N-acetyl-4-aminophenol
in the entire test sample set, including samples from the general
population (n = 31), individuals exposed to aniline in an  occupa-
tional setting (n = 6) and paracetamol users (n = 2). Paracetamol
users clearly exhibited the highest N-acetyl-4-aminophenol con-
centrations in urine. However, aniline exposed individuals (known
not  to have taken paracetamol) as well as individuals from the
general population without paracetamol medication also excrete
N-acetyl-4-aminophenol in the mg/L range.
We  previously suggested that exposure to aniline, which
is an integral part of tobacco smoke and a ubiquitous envi-
ronmental contaminant, might be responsible for urinary N-
acetyl-4-aminophenol in the occupationally non-exposed general
population (Modick et al., 2013).  This suggestion was  based on the
results of Kütting et al. (2009) and Weiss and Angerer (2002) who
both reported urinary aniline levels (after chemical hydrolysis) in
the general population with a median at  about 3 mg/L and on animal
metabolism studies in several mammalian species (Kao et al., 1978)
in which acetanilide was  found as a minor metabolite of aniline
but no unconjugated aniline itself. The aniline exposed individuals
in this study excreted acetanilide at concentrations roughly corre-
sponding to 1–2% of the N-acetyl-4-aminophenol concentrations
which is in concordance with the animal experiments of Kao et al.
(1978). However, we could not  detect any urinary acetanilide (LOD
0.03 mg/L) in persons from the general population or in persons
with paracetamol medication. With regard to the small sample size
our findings lead to four basic preliminary conclusions:
(1) Other sources than exposure to aniline seem to be responsible
for the major part of urinary N-acetyl-4-aminophenol in the
general population, e.g. various derivatives of aromatic amines
such as 4-aminophenol or nitro-aromatic compounds or even
N-acetyl-4-aminophenol itself. As pointed out in the  intro-
duction, N-acetyl-4-aminophenol might enter the food-chain
through its use in meat production.
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(2) Acetanilide is a metabolite of aniline in man. In  the occupational
setting, acetanilide can be used as a valuable and more specific
than aniline after chemical hydrolysis biomarker describing
exposure to aniline.
(3) In samples from volunteers of the general population,
acetanilide could not be detected down to levels as low as
0.03 mg/L. Therefore, urinary aniline baseline levels in the gen-
eral population measured after chemical hydrolysis (Weiss and
Angerer, 2002; Kütting et al., 2009) do  not seem to originate
from acetanilide and hence not  from a direct exposure to ani-
line itself. As a consequence, there have to be other (acid labile)
urinary precursors than acetanilide, which are hydrolysable to
aniline during sample processing in the above methods.
(4) To our knowledge, this is  the first publication that reports a
(ubiquitous) excretion of N-acetyl-2-aminophenol in the gen-
eral population. N-Acetyl-2-aminophenol does not seem to be
related to  aniline nor to N-acetyl-4-aminophenol (R2 =  0.02; ref.
Fig. S1) in man. The source and toxicological significance of this
internal burden remains unclear so far.
Particularly the high urinary excretion of the pharmacologi-
cally active and possibly anti-androgenic substance N-acetyl-4-
aminophenol (paracetamol, acetaminophen) in the mg/L range and
its sources should be further investigated since they were found in
persons of the general population who self-reported not to have
taken any N-acetyl-4-aminophenol containing medication.
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Appendix VII 
 
Therefore, in this article, we give an overview of the
available data on possible detrimental effects of NA4AP
on male sexual development, its role in aniline
metabolism, recent HBM data, and possible sources of
internal body burdens of NA4AP in the general
population in environmental and occupational settings.
We complement this article with new research data on
NA4AP HBM from our institute.
Intakes and usage of NA4AP
NA4AP in human NSAIDs
NA4AP along with aspirin is one of the most commonly
used OTC drugs for the treatment of pain and fever. The
German pharmaceutical register lists 55 formulations
containing NA4AP as a single drug or as a pharma-
ceutical ingredient in combination drugs that are
approved for sale in Germany (Landschneider 2011).
In 2008, two of the ten top-selling pharmaceuticals
in Germany contained NA4AP (Glaeske et al. 2009).
About 35.5 million packages of NA4AP, each containing
20–40 pills, were sold in Spain in 2009 (Ortiz de Garcı´a
et al. 2013).
NA4AP and NA4AP-containing pharmaceuticals are
also commonly used by pregnant women (Black & Hill
2003). Several large birth cohort studies have reported
general intake of OTC analgesics during pregnancy (see
Table 1). Reasons for the intake of OTC analgesics were
mainly headache (66.5%) followed by muscle ache
(8.7%) and other types of pain (8.7% in sum). Fever,
inflammation, and cold accounted for 6.9% (Kristensen
et al. 2010).
Variations between these studies may be explained
by the study sizes as well as demographic factors such
as ethnicity, educational status, and age (Werler et al.
2005). There is also an influence based on whether the
inquiry was realized through self-administered ques-
tionnaires or by telephone interviews. In a study carried
out in a Danish cohort (Kristensen et al. 2010), 285
mothers completed both a questionnaire and a tele-
phone interview. In the questionnaire, 30.9% (88 of 285)
of the mothers reported the use of analgesics as opposed
to 57.2% in the telephone interview (163 of 285). The
authors of this study came to the conclusion that many
mothers did not consider OTC analgesics as medication
and therefore strongly underreported its use unless they
were specifically asked.
However, the available data clearly indicate that OTC
analgesics are also commonly used by pregnant women.
Large studies (Werler et al. 2005, Rebordosa et al. 2008)
have indicated NA4AP and NA4AP-containing pharma-
ceuticals as the most commonly used products.
NA4AP can freely pass the placenta (Weigand et al.
1984). NA4AP and its metabolites were detected in the
urine of neonates after their mothers had taken NA4AP
a few hours before delivery (Levy et al. 1975a).
Furthermore, as NA4AP is excreted in breast milk after
therapeutic dosing, neonates can be exposed to NA4AP.
Bitze´n et al. (1981) monitored the levels of NA4AP in
plasma and breast milk in three lactating women after the
use of a single 500 mg dose of NA4AP. In breast milk,
maximum concentrations of w4 mg NA4AP/l were
found within 2 h of intake. Therefore, the authors
estimated a dose of!0.1% of thematernal dose for infants
in 100 ml breast milk (Bitze´n et al. 1981). Comparable
values were estimated by Berlin et al. (1980) with 22
lactating women who were given a 650 mg dose of
paracetamol. The authors evaluated the ingestible amount
of NA4AP for neonates to be 0.04–0.23% of the maternal
dose in 90 ml breast milk. Neither NA4AP nor its
metabolites could be detected in the neonates’ urine
samples 3–5 h after maternal dosing (2 h after nursing at
peak maternal milk levels; Berlin et al. 1980). In a study
carried out in 1987, NA4AP could be detected in the
urine samples of six neonates whose mothers were given
NA4AP, although at considerably higher doses of 1–2 g.
The authors detected free NA4AP and its glucuronide and
sulfate conjugates in all the urine samples, whereas
cysteine and mercapturic acid conjugates could be
detected in the urine samples of five of the six neonates
(Notarianni et al. 1987). Thus, not only mothers but also
fetuses and neonates are exposed to NA4AP.
NA4AP in veterinary/meat production use
According to Commission Regulation (EU) 37/2010 on
pharmacologically active substances and their classi-
fication regarding maximum residue limits in foodstuffs
of animal origin (European Commission 2010), NA4AP is
approved for veterinary use in Europe. The regulation
restricts the usage of NA4AP for porcine species.
However, according to a report of the Committee for
Veterinary Medicinal Products, which belongs to the
Table 1 Frequency of analgesic use during pregnancy in several birth
cohort studies.
Cohort
Frequency of intake
(at least once during
pregnancy) (%) Reference
Slone Epidemiology Center
Birth Defects Study (USA),
nZ7563
69.8 Werler et al.
(2005)
National Birth Defects
Prevention Study (USA),
nZ2970
65.5 Werler et al.
(2005)
Danish National Birth
Cohort, nZ88 142
50.3 Rebordosa
et al. (2008)
Danish and Finnish Birth
Cohort, nZ2297
26.1–57.2a Kristensen
et al. (2011)
Eden Mother–Child Cohort
(FR), nZ903
81b Philippat et al.
(2011)
Generation R Study (NL),
nZ3184
29.9b Snijder et al.
(2012)
aDepending on whether inquiry was done by a questionnaire or by a
telephone interview. bMild analgesics in general.
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European Agency for the Evaluation of Medicinal
Products (EMEA), NA4AP is also used in cattle and
poultry for the treatment of fermentation disorders,
painful diseases, and pyrexia (Committee for Veterinary
Medicinal Products 1999). In Regulation (EU) 37/2010,
no maximum residue limit, and therefore no withdrawal
period after the treatment of animals with NA4AP, was
established. Suppliers of veterinary medicine formu-
lations offer NA4AP as 30% solutions (30 g/100 ml) in
package sizes of up to 20 l. Interestingly, one study
conducted in the mid-1960s reported a stimulatory effect
of NA4AP on chicken growth. NA4AP given at dietary
levels between 0.1 and 2.0 g/kg feed was found to
increase weight gain in roosters and in hens by 6.5–10%
compared with that in the controls (Dikstein et al. 1966).
To our knowledge, NA4AP has not been part of larger-
sized national food monitoring programs in the past few
years. In 2002, NA4AP was part of the monitoring
program of the German national residue control plan,
processed by the German Food Safety Authority. In sum,
221 samples of animal products or food products of
animal origin, inter alia, including poultry, veal, cattle,
swine, and milk were tested for NA4AP. Residues of
NA4AP could not be detected in any of the samples
analyzed (Federal Ministry of Food, Agriculture and
Consumer Protection 2002). However, the report of the
national residue control plan does not include any
information on either the analytical methods applied or
their limits of quantification, which makes interpretation
of the results difficult. In contrast to antibiotics, published
analytical methods for the determination of NA4AP in
foodstuffs of animal origin are rather rare. Hu et al. (2012)
published a method for the determination of 30 NSAID
residues including NA4AP in swinemuscle by ultra-HPLC
coupled with tandem mass spectrometry. The detection
limit was 0.4 mg/kg and the quantification limit was
1.0 mg/kg. The authors reported trace residues of NA4AP
(and other NSAIDs) in 100 samples of imported swine
muscle with a positive rate of about 7%. A similar method
for the determination of NA4AP among other NSAIDs in
bovine milk and muscle tissue was developed by Gentili
et al. (2012). The authors applied the method to eight milk
samples and eight bovine muscle tissue samples. No
residues of NA4AP could be detected in any of the
samples (Gentili et al. 2012). Love et al. (2012) detected
NA4AP in feather meal (a byproduct made from poultry
feathers), which can be used as an additive in animal
feed in concentrations ranging from 15.1 to 155 mg/kg
(83% positive samples). These authors suggested contami-
nated feather meal as a possible route for re-entry of
pharmaceuticals into the food chain.
NA4AP as the major metabolite of aniline
NA4AP and its conjugates appear in the metabolism of
aniline. Kao et al. (1978) found NA4AP (mainly in its
glucuronic acid- or sulfate-conjugated form) to be the
major urinary metabolite in pigs (w77%), sheep
(w85%), and rats (w65%). Between 2 and 13% of
NA4AP was excreted as free NA4AP among all three
species. Other urinary metabolites wereO-conjugates of
2- and 4-aminophenol (5.5–25% of the aniline dose) and
acetanilide (0.5–3.4% of the aniline dose) (Kao et al.
1978). Figure 1 shows the simplified metabolic pathway
of aniline according to the findings of Kao et al. (for
a more detailed aniline metabolism pathway scheme,
see German Federal Ministry of Environment (2011)).
A similar excretion pattern for aniline can be expected in
humans (German Research Foundation 1992). Lewalter &
Korallus (1985) found NA4AP (in concentrations up to
the mg/l range) and acetanilide (in the mg/l range) in the
urine samples of workers following occupational
exposure to aniline (air concentrations below the
occupational threshold limit of 7.7 mg/m3 air) (German
Research Foundation 1992). NA4AP was also detected
as a metabolite after acute aniline intoxication (Iwersen-
Bergmann & Schmoldt 2000). Dierkes et al. (2014)
detected acetanilide and NA4AP in the urine samples of
six volunteers known to be exposed to aniline. Further
in-depth quantitative and kinetic investigations of human
aniline metabolism do not exist to our knowledge.
The ubiquitous body burden of aniline in the general
German population has been well described previously.
Total urinary aniline has routinely been determined after
hydrolysis to cleave possible aniline conjugates such as
acetanilide (el-Bayoumy et al. 1986, Riffelmann et al.
1995, Ward et al. 1996, Weiss & Angerer 2002). Aniline,
determined in this way, has been recently found in over
90% of the urine samples collected from 1004 individuals
from the general German population (Ku¨tting et al. 2009;
Table 2). Extrapolation of these aniline levels, considering
that NA4AP is the major metabolite of aniline, would
result in urinary NA4AP levels up to the mg/l range.
Variations between these studies can be explained by
different study sizes, the times the studieswere conducted,
and mostly by differences in the analytical methods,
especially concerning the hydrolysis of acetanilide.
NH2
NH HO NH
HO
NH2
O
H3C
O
Acetanilide
H3C
N-acetylation
N-acety-4-aminophenol
(acetaminophen/paracetamol)
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Figure 1 Simplified metabolism of aniline.
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To date, neither the specific aniline metabolite
acetanilide nor NA4AP (with the exception of the studies
carried out by Modick et al. (2013) and Dierkes et al.
(2014)) has been used in HBM studies to determine
exposure to aniline.
The main routes of aniline exposure in the general
population have been postulated to be pesticide residues,
pharmaceuticals, colorants used in food, cosmetics, and
textiles, and cigarette smoke (German Federal Ministry of
Environment 2011). Palmiotto et al. (2001) detected
aniline in the indoor air of homes at levels ranging from
5 ng/m3 to about 33 ng/m3, with higher values being
observed in the homes of smokers. Aniline was also
detected in the air of several public buildings and in
outdoor air, highlighting the ubiquitous presence of
aniline in the environment (Palmiotto et al. 2001).
Evidence for the developmental toxicity of NA4AP
In vitro and animal studies
Animal studies carried out in the 1980s have already
suggested an association between prenatal exposure to
analgesics and reduced masculinization. In 1989, it was
found that the administration of aspirin to mice inhibited
the synthesis of prostaglandins (PGs) in male and female
fetuses (Gupta 1989). PGs are supposed to be involved,
inter alia, in processes such as early male sexual
development and masculinization and hormone
regulation (Gupta 1989, Amateau & McCarthy 2004).
Kristensen et al. (2010) showed that intrauterine
exposure of Wistar rats to NA4AP led to a significant
reduction in the anogenital distance of male offspring.
In the same study, the authors reported a reduced
production of PGD2 and testosterone in ex vivo fetal
rat testes (Kristensen et al. 2010). A study carried out
by Kristensen et al. (2011) that many presumed
endocrine-disrupting chemicals (EDCs) dose depen-
dently inhibited PGD2 synthesis in mouse Sertoli cell
lines. The observed effect was comparable within
the tested analgesics, which included NA4AP, aspirin,
and ibuprofen, and was even higher than the measured
effect of other known EDCs such as n-butylparaben and
bisphenol A. Therefore, the authors concluded that
pharmaceutical PG inhibitors such as NA4AP, aspirin,
and ibuprofen may act as endocrine disruptors. The
authors were also able to pinpoint the suppression of PG
synthesis to the inhibition of cyclooxygenase (COX)
enzymes (Kristensen et al. 2011). It is thought that
NA4AP acts as an inhibitor of COX enzymes, although
the precise mechanism of action is still unclear (Hinz
et al. 2007).
Kristensen et al. (2012) showed that exposure to
NA4AP and aspirin inhibited testosterone production in
a rat organotypic culture system. The levels of testoster-
one produced by fetal Leydig cells were lower by about
10–50% than those of the controls when exposed to
NA4AP in concentrations ranging from 0.1 to 100 mM,
confirming their previous in vivo findings. However, the
anti-androgenic effects of NA4AP were not correlated
with the inhibition of PGD2 synthesis in this fetal testis
culture system (Kristensen et al. 2012).
Human data
Data on endocrine effects
A recent study carried by Albert et al. (2013) has
investigated the direct effects of NA4AP (and two other
NSAIDs) using whole human testis in organotypic
culture and the NCI-H295R human steroidogenic cell
line. The exposure levels to NA4AP were chosen based
on the estimation of serum concentrations in adult men
after exposure to a standard dose of 1 g NA4AP, 10K5
and 10K4 M respectively. Exposure to 10K5 and 10K4 M
NA4AP dependently decreased testosterone secretion by
the human testis after 24 h of exposure by 18 and 30%
compared with that in the controls. Following 48 h
of exposure, testosterone concentrations were not
significantly decreased further at either dosages.
Testosterone concentrations in the NCI-H295R human
steroidogenic cell line were significantly lower than
those in the controls after 24 h treatment with 10K4 M
NA4AP. The effect was not significant after 48 h of
exposure and with the 10K5 M NA4AP concentration.
Furthermore, 24 h of exposure to 10K4 MNA4AP was
also found to lower PG concentrations significantly in
the human testis by 28% for PGD2 and 38% for PGE2
compared with the control concentrations (Albert et al.
2013). However, the limitations of this study were the
evaluations of exposure levels and the durations of
exposure. Although the exposure levels were chosen
based on the estimated serum concentrations as that
occurring after therapeutic use, the resulting testicular
concentrations in adult men are unknown and rather
difficult to determine.
Mazaud-Guittot et al. (2013) used an in vitro
system based on the cell culture of human fetal testes
exposed to NA4AP and its metabolite N-arachinodyl-
4-phenolamine (AM404; see ‘Metabolism of
Table 2Human biomonitoring data of aniline in the general population.
Study Participants
Urinary aniline concentrations
(mg/l)
Median
95th
percentile Range
el Bayoumy et al.
(1986)
28 2.9 NA ND–8.8
Riffelmann et al.
(1995)
16 0.8 NA ND–5.1
Ward et al. (1996) 26 2.9 NA NA
Weiss & Angerer
(2002)
160 3.7 7.9 0.4–13.0
Ku¨tting et al. (2009) 1004 3.1 14.3 0.05–384
NA, not available; ND, not detectable.
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acetaminophen and aniline’ section) and other NSAIDs
at concentrations ranging from 10K4 to 10K7 M.
Endocrine-disrupting properties were investigated
through measures of testosterone, anti-Mu¨llerian hor-
mone (AMH), insulin-like factor 3 (INSL3), and PGs
(PGD2 and PGE2) (Mazaud-Guittot et al. 2013). The
authors found significant inhibition of INSL3 production
in samples exposed to NA4AP and AM404, with a
significant dose–response relationship indicating a
decrease in INSL3 production with an increasing dose
of NA4AP. The measured trend for AMH production to
be increased by NA4AP was not significant. Significant
inhibitory effects of NA4AP on PGE2 production were
observed, whereas the trends for the inhibition of PGD2
synthesis were not significant. Neither NA4AP nor
AM404 had any significant effect on testosterone
production in this study. The authors suggested the
analgesic-induced inhibition of INSL3 production to be
the mechanism by which analgesics increase the risk of
cryptorchidism because several mutations of the INSL3
gene or its receptors were found to be associated with
cases of cryptorchidism in humans (Foresta et al. 2008).
Associations between acetaminophen intake during
pregnancy and reproductive disorders
In a study from the Danish National Birth Cohort with
88 142 pregnant women and their liveborn singletons
with questionnaire information about NA4AP use during
the first trimester, no association of NA4AP with an
increased prevalence of congenital abnormalities was
found (Rebordosa et al. 2008).
Since 2011, the number of studies that have found
further evidence of the association between NA4AP use
during pregnancy and reproductive disorders has
increased. A study from the Danish National Birth Cohort
using the data of 47 700 mothers and their male offspring
found that cumulative NA4AP exposure of more than
4 weeks’ duration may moderately increase the occur-
rence of cryptorchidism, especially when exposure
occurs during the first and second trimesters (Jensen
et al. 2010). These findings were confirmed by Kristensen
et al. (2010) in a prospective birth cohort study including
2297 Danish and Finnish pregnant women reporting their
use of mild analgesics. It was reported that in the Danish
birth cohort the use of mild analgesics (including NA4AP)
was dose dependently associated with congenital
cryptorchidism and, in particular, use during the second
trimester increased the risk. The association was not
found in the Finnish birth cohort. Because the birth
prevalence of cryptorchidism in Finland (2.4%) is lower
than that in Denmark (9.0%), the authors reported that the
study may be statistically underpowered to find an
association in the Finnish cohort (Kristensen et al.
2010). Data from a French birth cohort study, published
by Philippat et al. (2011), reported that the association
between maternal use of mild analgesics during
pregnancy and undescended testis risk was similar to
that in the Danish population described by Kristensen
et al. (2010) before adjustment for maternal age,
gestational duration, maternal smoking, and other factors,
but weaker after adjustment. However, this study was
limited by small sample size, inability to distinguish
between specific analgesics, and lack of information on
dose, mixture, and exact timing of use (Philippat et al.
2011). The suggestion that intrauterine exposure to mild
analgesics, primarily NA4AP, during the second trimester
of pregnancy is associated with an increased prevalence
of cryptorchidism was also made from the data of a large
population-based cohort study carried out in The Nether-
lands (the Generation R Study; Snijder et al. 2012). The
authors reported several limitations of the study, mostly
the limited number of cryptorchidism cases and also the
definition of the different pregnancy periods. However,
the strength of this study was its population-based
approach, which enabled the assessment and the
adjustment for a large number of potential confounders.
Metabolism of acetaminophen and aniline
Between 75 and 86% of an oral aniline dose is excreted
as NA4AP, mostly in its conjugated forms in urine, as
confirmed by animal experiments. Human data show
that if NA4AP is taken directly (for example, after
therapeutic use of acetaminophen), very similar amounts
of NA4AP are excreted renally: w3% free NA4AP,
w40% NA4AP glucuronide, andw35% NA4AP sulfate.
As additional metabolites, NA4AP cysteine conjugate
(w4%) and NA4AP mercapturate (w3%) have been
reported (Ladds et al. 1987). Minor NA4AP metabolites
include 3-hydroxy-NA4AP, 3-methoxy-NA4AP,
3-hydroxy-NA4AP-3-sulfate, 3-methoxy-NA4AP sulfate,
and 3-methoxy-NA4AP glucuronide. After overdosing,
the relative amounts of cysteine and mercapturic acid
conjugates in urine are increased (Andrews et al. 1976).
In 2005, N-arachinodyl-4-phenolamine (AM404) was
identified as a possible metabolite of NA4AP. AM404
was built in brain and spinal cord homogenates from
Wistar Hannover rats after exposure to p-aminophenol
(Ho¨gesta¨tt et al. 2008). At present, there are no data
available concerning the occurrence of AM404 in
humans. However, due to the chemical structure and
the resulting highly lipophilic character of this meta-
bolite, its occurrence in urine is unlikely.
Some differences in NA4AP metabolism in neonates,
children, and adults have been reported. While in adults
NA4AP glucuronide is the predominant conjugate (see
above), in children the NA4AP sulfate conjugate
(w47%) is more dominant than the NA4AP glucuronide
conjugate (w13%) (Levy et al. 1975b, Miller et al. 1976,
Peterson & Rumack 1978). However, the altered
metabolism of NA4AP in children when compared
with that in adults does not seem to affect its general
rate of elimination. Plasma disappearance (elimination
Human biomonitoring of acetaminophen R109
www.reproduction-online.org Reproduction (2014) 147 105–117
half-time) of NA4AP is comparable in adults (1.5–3.0 h)
and children (1.0–3.5 h), with a slight prolongation of
its half-life in neonates (2.2–5.0 h) (Miller et al. 1976,
Peterson & Rumack 1978). The similar metabolic pattern
of NA4AP and aniline makes it difficult to determine
whether the NA4AP present in urine is due to exposure
to aniline, to NA4AP, or to both substances. Only
specific metabolites leading from aniline (or possibly
other precursors) to NA4AP might allow a differentiation
between direct NA4AP intake and NA4AP generated
through precursors. Such metabolites might be acetani-
lide, the aminophenols, or their conjugates (see Fig. 1).
Acetanilide has been determined by Dierkes et al. (2014)
and could only be found in the urine samples of
individuals after aniline exposure, but not in those of
any individuals from the general population.
HBM methods for NA4AP
HBM is defined as the determination of chemical
substances or their metabolites in human body fluids
such as blood and urine for measuring exposure to
chemical substances for risk assessment and risk
management (Angerer et al. 2007). Although NA4AP
has been used as a pain reliever and fever reducer for
decades, despite the veterinary use of NA4AP and the
high production and sale volumes, and despite the fact
that NA4AP is the most important metabolite of aniline,
there is a lack of HBM data on this substance.
To our knowledge, NA4AP has not yet been included
in larger population-based HBM studies such as the
German GerES (German Environmental Survey), the US
NHANES (National Health and Nutrition Examination
Survey), and the Canadian CHMS (Canadian Health
Measures Survey). Camann et al. (2012) detected traces
of NA4AP in nine deciduous molars of 21 children using
a HPLC–MS/MS method after a neutral, basic, and acetic
extraction procedure with acetonitrile to extract NA4AP
from pulverized tooth crown. The measured concen-
trations ranged from!0.5 ng/g, which was also the limit
of quantification (LOQ) of the method used, to 17.3 ng/g,
with the median being less than LOQ and a 95th
percentile of 10.8 ng/g. According to the authors, the
NA4AP concentrations were consistent with the NA4AP
intake estimated from exposure questionnaires
completed by the mothers. Therefore, the authors
suggested that NA4AP appears to accumulate in
deciduous molars and thus is an apparent biomarker of
exposure to NA4AP in the first year after birth (Camann
et al. 2012). We have recently published an analytical
method for the determination of NA4AP in urine based
on online extraction via turbulent-flow chromatography
coupled with LC–MS/MS (Modick et al. 2013). In a HBM
pilot study, we applied this method to analyze the urine
samples of 21 individuals from the general German
population. Before the study, all the volunteers
completed a questionnaire about their in use of
NA4AP or NA4AP-containing products. NA4AP was
detected in all the samples analyzed, with a wide
concentration range from 8.7 to 22 120 mg/l and a
median of 85.7 mg/l. We detected NA4AP even in the
samples of those volunteers who indicated that they had
never taken NA4AP and reported a considerable overlap
in NA4AP concentrations, no matter whether the
individual had or had not taken NA4AP during the
week before sample collection. These findings were
confirmed by our group in a second HBM pilot study
investigating N4AP, the aniline-specific metabolite
acetanilide, and the tentative aniline metabolite N-
acetyl-2-aminophenol (Dierkes et al. 2014). In this study,
we confirmed the presence of NA4AP in urine samples
obtained from individuals with no occupational aniline
exposure or paracetamol medication. Not surprisingly,
though, NA4AP was detected in high concentrations in
the urine samples of two individuals using paracetamol
medication and six volunteers with known occupational
aniline exposure. Contrary to NA4AP, acetanilide –
the metabolic precursor of NA4AP – was only detected
after exposure to aniline. N-acetyl-2-aminophenol was
detected in most of the samples, but without any relation
to aniline exposure or correlation with the other two
aniline metabolites. Apart from these studies, we are not
aware of any other HBM measurements of NA4AP in the
general population.
The quest for possible NA4AP sources by
means of HBM
Currently, there are no indications that NA4AP is an
endogenous substance naturally occurring in the human
metabolism. For the purpose of identifying the possible
sources of internal body burdens of NA4AP, we
determined urinary concentrations of NA4AP in different
experimental settings. All urine samples described in the
following were analyzed using HPLC–MS/MS methods
via isotope dilution quantification, developed and
refined by our group (Modick et al. 2013, Dierkes et al.
2014). All the following values reflect total NA4AP in
urine after enzymatic hydrolysis of the glucuronide and
sulfate conjugates. All urinary analyses referred to in the
following have been covered by various ethical
approvals of the Medical Faculty of the Ruhr-Universita¨t
Bochum, Germany (reg. no.: 3867-10; reg. no.: 4333-
12; and reg. no.: 4730-13).
Analytical method
A detailed description of our analytical method can be
found in Dierkes et al. (2014). In short, all the urine
samples were vortex-mixed before transferring the
aliquots into silanized screw cap vials. After adding
incubation buffer (ammonium acetate, pH 5.5–6.0),
internal standard solution (deuterium-labeled analogs of
R110 H Modick and others
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NA4AP and acetanilide), and glucuronidase/arylsulfatase
solution (for enzymatic cleavage of glucuronide and
sulfate conjugates), the samples were incubated at 37 8C
in awater bath for 3.5 h.Urinary creatinine concentrations
were determined according to the method of Jaffe´ (1886).
Urine sample analysis was carried out using a Waters
HPLC system coupled with a Waters Quattro Premier XE
triple quadrupole mass spectrometer in a two-column
switching assembly, which allowed online cleanup and
analyte enrichment followed by chromatographic separ-
ation and mass spectrometric detection in one step.
A Waters Oasis HLB cartridge column (2.1!20 mm;
25 mm) was used for cleanup and enrichment; chromato-
graphic separation was carried out on a Thermo Scientific
(Franklin, MA, USA) Hypercarb column (2.1!100 mm;
3 mm) by gradient elutionwith 3 mMammoniumbicarbon-
ate solution in water and acetonitrile as solvents. Mass
spectrometric detection was conducted by electron spray
ionization in positive ionization mode. Argon was used as
the collision gas for MS/MS measurements. Fragmentation
patterns of the analytes and internal standards were
obtained by full-scan experiments. Based on the parent
ions, two mass transitions were confirmed and optimized
manually. Themass transitionwith the highest intensitywas
used for quantification (quantifier), whereas that with the
second highest intensity was used to confirm the results of
the quantifier ion.
Calibration was performed with standard solutions
in water. Calibration standards were treated similarly
to the urine samples. Calibration curves were obtained
by plotting the quotient of peak areas of NA4AP or
acetanilide and their deuterium-labeled analogs as a
function of their concentration with a 1/x-weighting.
Intraday precision was determined by analyzing quality
control urine samples (prepared in our laboratory) eight
times in a rowat two concentration levels (Qhigh andQlow).
Interday precision was determined by analyzing the
control urine samples on eight different days using newly
prepared calibration samples and calibration curves.
Calculated deviations of intraday and interday precision
measurements were below 15% for both analytes at
both concentrations. The accuracy of the method was
determined by analyzing eight urine samples with varying
creatinine concentrations. These sampleswere analyzed in
native condition and spiked at two concentration levels.
Themean recoverieswere between105 and 114% for both
analytes at both concentrations. Imprecisions calculated
from the spiking experiments were in the range of intraday
and interday precision data, underlining the ruggedness of
themethod. The limit of detection (LOD) was estimated on
the basis of a signal-to-noise ratio of 3:1, and the LOQwas
determinedon thebasis of a signal-to-noise ratio of 9:1. The
LOD for acetanilide in urine was estimated to be 0.03 mg/l
and the LOQwas 0.09 mg/l. The LOQ forNA4APwas set to
the lowest aqueous calibration point (0.5 mg/l). However,
NA4APconcentrations in all the urine samples investigated
until now are usually more than tenfold above this LOQ.
Urinary NA4AP excretion in the general population
In our daily laboratory routine, we have analyzed 2098
spot urine samples of the general population for
determining the concentrations of NA4AP so far. These
urine samples originated from various adult and control
populations present in our institute. These samples,
although collected from the general population, cannot
be considered to be fully representative of the general
population. Individuals were presumably not pregnant
and occupationally not exposed to aniline. We had no
information on the usage of acetaminophen or other pain
relievers. The smoking status was assessed via urinary
cotinine concentrations. All statistical analyses were
carried out using IBM SPSS Statistics, version 20. NA4AP
was detected in all the samples analyzed, at a broad
range of concentrations, whereas acetanilide could not
be detected in any of the samples. The distribution of
NA4AP concentrations over all the individuals is shown
in Fig. 2A. Urinary NA4AP concentrations were not
normally distributed before and after logarithmic
transformation by the Kolmogorov–Smirnov test. There-
fore, we divided the population into two groups, using a
cutoff value of 4000 mg/l NA4AP: a high-exposure group
(c (NA4AP) O4000 mg/l; nZ106: 56 smokers and
50 nonsmokers) and a low-exposure group (c (NA4AP)
!4000 mg/l; nZ1992: 996 smokers and 996 nonsmo-
kers). This cutoff value reflected the 95th percentile of
the NA4AP concentration across all the samples.
Additionally, according to the elimination kinetics of
NA4AP, urinary NA4AP concentrations of 4000 mg/l
would be caused by a single tablet of 500 mg
acetaminophen taken 36–48 h before sampling. Within
these two groups, NA4AP concentrations were normally
distributed as assessed by the Kolmogorov–Smirnov test
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Figure 2 Distribution of urinary NA4AP concentrations in random spot
urine samples obtained from the general population: (A) all samples
(nZ2098) and (B) samples of the high-exposure group (nZ106;
cO4000 mg/l). Line indicates normal distribution curve.
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after logarithmic transformation. The distribution for
the high-exposure group is shown in Fig. 2B. If we
considered the distribution curve shown in Fig. 2B (with
NA4AP concentrations in the mg/l range) indicative of
therapeutic acetaminophen intake and used urinary
NA4AP concentrations above 4000 mg/l as an arbitrary
cutoff, w5% of the O2000 individuals investigated
would have taken NA4AP before sampling.
Urinary NA4AP concentrations divided into the
subgroups of smokers and nonsmokers and total popu-
lation are given in Table 3. NA4AP concentrations differed
significantly between the two groups according to the
Mann–Whitney U test (PZ0.01; aZ0.05) with a median
NA4AP concentration of 68.2 mg/l in smokers compared
with 54.2 mg/l in the nonsmokers. After splitting the
population into the two NA4AP groups, the significant
effect of smoking behavior on NA4AP excretion con-
tinued to hold, especially for the group with NA4AP
concentrations!4000 mg/l (PZ0.01; aZ0.05).
The influence of smoking behavior onNA4APexcretion
could be explained byNA4AP being themajor metabolite
of aniline and aniline being a known constituent of
tobacco smoke. However, several previous HBM studies
have reported no significant impact of smoking behavior
on urinary aniline excretion (Riffelmann et al. 1995,Weiss
& Angerer 2002, Ku¨tting et al. 2009). These contradictory
findingsmight be explained by the relatively small effect of
smoking on NA4AP (and possibly aniline) excretion that
can only be detected in larger population studies.
Additionally, NA4AP might be more appropriate to detect
such an effect because it is the major metabolite of aniline
and excreted in considerably higher concentrations than
aniline (or its conjugates). On comparing median levels of
smokers with those of nonsmokers, the urinary NA4AP
concentrations of smokers were found to be 25% higher
than those of the nonsmokers. The detection of NA4AP in
the urine samples of nonsmokers and higher concen-
trations in the urine samples of smokers leads to the
conclusion that smoking does indeed contribute to urinary
NA4AP excretion, but that it is not its main source. This is
supported by the lack of the aniline-specific metabolite
acetanilide in the samples, which hints at other (addi-
tional) sources that might contribute to urinary NA4AP
excretion. It is also congruent with the HBM pilot study
carried out by Dierkes et al. (2014), where acetanilide
could not be detected in samples obtained from the
general population, but could be detected only in the urine
samples of individuals with high exposure to aniline.
Urinary NA4AP excretion after acetaminophen use
We investigated the urinary elimination characteristics of
NA4AP in one individual (male, 31 years, nonsmoker)
after oral intake of a single tablet of acetaminophen
containing 500 mg NA4AP. One pre-dose urine sample
was collected immediately before intake. We continu-
ously collected urine samples for 48 h after intake. The
urinary NA4AP concentrations over time are shown in
Fig. 3. Urinary NA4AP concentrations reached maximum
levels of w400 mg/l between 4 and 12 h after intake.
NA4AP concentrations declined thereafter in a rather
monotonic manner (indicative of a single phasic elimin-
ation), but remained in the mg/l range until w36 h after
intake (Fig. 3). Urinary NA4AP concentrations after intake
are comparable to the findings reported by Dierkes et al.
(2014) from two individuals who had used NA4AP
medication w24 h before sampling, which contributed
to urinary NA4AP concentrations of 160 and 275 mg/l.
Acetanilide could not be detected in any of these samples.
NA4AP excretion after occupational aniline exposure
Four individuals (two males and two females, aged 25–45
years, nonsmokers living in the greater area of Bochum,
Germany) were exposed to aniline in an occupational
Table 3 Urinary NA4AP concentrations in the general population.
Smokers
(nZ1052)
Nonsmokers
(nZ1046)
Total
(nZ2098)
Mean (mg/l) 10 834 4116 7484
Median (mg/l) 68.2 54.2 61.7
Min. (mg/l) 0.65 0.95 0.65
Max. (mg/l) 2 274 296 580 358 2 274 296
25 P (mg/l) 29.9 21.6 25.3
75 P (mg/l) 164.5 150.3 155.6
95 P (mg/l) 4464 3504 4093
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Figure 3 Urinary NA4AP concentrations after oral intake of 500 mg on
a semi-logarithmic scale: (A) NA4AP concentrations (mg/l) and (B)
creatinine-adjusted NA4AP concentrations. Dotted line indicates the
95th percentile of NA4AP concentrations over the analyzed population
samples (4000 mg/l).
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setting via air for 8 h at the occupational threshold limit
value (7.7 mg/m3 air), as that occurring, for example, in
the rubber industry during the vulcanization process of
rubber products (Korinth et al. 2006). Complete urine
voids were collected before, during, and 16 h after
exposure. The volunteers recorded the time and the
void of each individual sample. All four individuals
did not use NA4AP-containing medications in the week
before and during the study. The urinary NA4AP and
acetanilide concentrations (in mg/l) and the creatinine-
adjusted concentrations over time for all the four
individuals are shown in Fig. 4. Before (occupational)
aniline exposure, urinary NA4AP concentrations in all the
participants were in the same range as in the general
population, ranging from 40 to 170 mg/g creatinine
(15–80 mg/l), whereas urinary acetanilide concentrations
where below the LOQ (0.09 mg/l). Urinary NA4AP
concentrations increased steadily during exposure and
reached maximum levels of 55 000–75 000 mg/g creati-
nine (10 000–60 000 mg/l) between 10 and 13 h after the
start of the study. Excretion maxima occurred about 2–5 h
after the 8-h exposure window.
Urinary acetanilide excretion followed a similar
pattern, except that acetanilide concentrations were
about 100–200 times lower than NA4AP concentrations,
peaking at 100–300 mg/l. This is in good agreement with
the findings of our previous HBM pilot study (Dierkes
et al. 2014).
In conclusion, from this small and preliminary
occupational aniline exposure study, we report urinary
NA4AP concentrations well in the mg/l range (up to
60 mg/l or 75 mg/g creatinine) occurring after legally
permissible occupational exposure to aniline. Maximum
urinary NA4AP concentrations were less than ten times
below the maximum levels observed after the thera-
peutic use of a single 500 mg tablet of acetaminophen.
NA4AP excretion during a controlled 2-day
fasting study
We hypothesized above that contaminated foodstuffs
(with either NA4AP itself or precursors such as aniline)
may be a possible reason for NA4AP excretion in the
general population. To investigate the influence of food
intake on NA4AP excretion, we carried out a 48-h fasting
study. We have previously used the urine samples
collected in this study to investigate the influence of
foodstuffs on urinary excretion of phthalate metabolites
and bisphenol A (Christensen et al. 2012, Koch et al.
2013). For detailed information on study design and
execution, see these publications. In short, study
volunteers were five healthy employees of our
institute, all living in the area of Bochum (Germany),
ages ranging from 27 to 47 years (two males and three
females; body weight: 60–92 kg). One volunteer was
excluded from this study because questionnaire records
indicated that this volunteer had possibly taken an
NA4AP-containing medication during the week before
the study and during the study. The remaining four
volunteers (two males and two females) consisted of
three nonsmokers and one smoker, who refrained from
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smoking several days before and during the study. The
volunteers collected full volume urine samples over the
course of the 48-h fasting phase, as well as samples before
and after the fasting phase. Fasting itself excluded intake of
any foodstuff (as well as food-related items, for example,
chewing gum) and the intake of any liquids, except bottled
mineral water. The timing and quantity of intake of mineral
water were not regulated. The use of personal care
products and use of any medications were not regulated,
but were documented. None of the volunteers had known
occupational exposure to aniline (Koch et al. 2013).
Three of the volunteers (one male and two females)
started fasting at w1300 h after dining together on
individual different meals. One volunteer started fasting
the following day after a separate meal. One urine
sample was collected before fasting (pre-fasting sample),
and the volunteer started fasting immediately after the
meal (tZ0 h).
The urinary NA4AP concentrations (in mg/l and
creatinine adjusted) of the four volunteers over the
duration of the study are shown in Fig. 5. One can clearly
see the influence of fasting (and preceding and following
food intake) on the urinary excretion pattern of NA4AP. At
the start of the study, the urinary NA4AP concentrations
of the volunteers ranged from 3 to 1700 mg NA4AP/g
creatinine (10–1100 mg/l). In all the volunteers, urinary
NA4AP concentrations increased after the pre-fast meal,
reaching maximum values ranging from 700 to 5000 mg
NA4AP/g creatinine (1100–5300 mg/l)w2.5–6 h after the
last meal. These values are of the same order of magnitude
as the urinary concentrations in the general population
described previously by us (Modick et al. 2013), although
at the upper range. During fasting, urinary NA4AP
concentrations in all the volunteers decreased consider-
ably by a factor of 50–100, reaching minimum values of
5–70 mg NA4AP/g creatinine (5–75 mg/l) at the end of the
fast. After the volunteers resumed eating, urinary NA4AP
concentrations rose again (Fig. 5). Taken together, the
data obtained in this study impressively hint that food is
one possible, major source of internal body burdens of
NA4AP in the general population. However, whether
direct ingestion of NA4AP or NA4AP precursors such as
aniline leads to the changes observed in urinary NA4AP
concentrations has not been elucidated yet. In all the
samples, acetanilide concentrations were below the
LOD (0.03 mg/l).
Other possible NA4AP sources
As has been pointed out already, aniline is an important
building block for several substances, such as pesticides
and colorants (azo-dyes), that the general population
is continuously exposed to. During the metabolism of
these substances, free aniline might be released and
further metabolized to NA4AP. A summary of possible
aniline and therefore possible NA4AP precursors,
according to a publication of the German Federal
Ministry of Environment (2011), is given in Supple-
mentary Table 1 (see section on supplementary data
given at the end of this article). However, this list is not
considered to be exhaustive. Environmental NA4AP
might also be contributing to the low urinary background
concentrations. For example, NA4APand its metabolites
respectively were detected in water samples from several
rivers in Spain and Portugal at levels in the low mg/l range
(Lo´pez-Serna et al. 2010, Santos et al. 2013).
Conclusions
We confirmed the results of our previous studies
reporting the ubiquitous excretion of NA4AP in urine
in the general population (Modick et al. 2013). Using
measurements of more than 2000 urine samples,
we determined a median NA4AP excretion of around
60 mg/l. However, urinary NA4AP concentrations well
into the mg/l range can still be observed in individuals
with no obvious NA4AP exposure such as intake of
NA4AP-containing medications (or occupational aniline
exposure). As shown by the distribution of the NA4AP
values in the 2000 urine samples obtained from the
general population as well as the defined dosing of one
tablet of acetaminophen, urinary NA4AP concentrations
above 4000 mg/l hint at the direct intake of NA4AP
through medication (within the last 36–48 h). Recent
acetaminophen users exhibit urinary NA4AP concen-
trations close to the g/l range. However, 4000 mg NA4AP
per liter urine can only be regarded as a soft cutoff
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between acetaminophen users and nonusers, as concen-
trations above this value might also be caused by food
intake (as shown by our volunteer fasting study)
or occupational aniline exposure. On the other hand,
two days after medication related acetaminophen
uptake, urinary NA4AP concentrations can drop below
1000 mg/l.
The sources of ubiquitous internal body burden of
NA4AP in the general population remain obscure.
However, our research hints at several possible sources:
i) direct intake of acetaminophen or acetaminophen-
containing pharmaceuticals as a primary source for high
urinary NA4AP concentrations; ii) occupational
exposure to aniline, leading to NA4AP as the major
aniline metabolite; iii) ubiquitous exposure to environ-
mental sources, for example, nutrition, possibly
containing NA4AP itself or aniline and other NA4AP
precursors; and iv) smoking, most probably through
aniline, which is present in both mainstream and
sidestream cigarette smoke. Until now, we are not fully
aware of the underlying mechanisms of nutrition being a
source of urinary NA4AP excretion.
The ubiquitous background excretion of NA4AP in the
general population is not implausible. We summarized
the broad use of NA4AP in human medicine above and
also speculated about its use in veterinary medicine.
Ubiquitous aniline exposure in the general population
has been described previously, and NA4AP has been
known to be the major metabolite of aniline for a long
time. One major task for the future is to disentangle and
quantify the contribution of each possible source to the
total ubiquitous NA4AP excretion.
From the toxicological perspective, the omnipresence
of a pharmacologically active substance, which is, to our
knowledge, not naturally occurring in the human body,
raises some concern, as recent animal and human
studies indicate anti-androgenic effects of NA4AP and
suggest NA4AP to be a possible risk factor for male
developmental disorders in humans. Further evaluation
of our findings of an omnipresent NA4AP excretion
depends upon at least two key questions. i) Can it be
confirmed (by both mechanistic and epidemiological
studies) that therapeutic doses of NA4AP cause detri-
mental effects in male human offspring? ii) Are urinary
NA4AP concentrations in the mg/l range (as observed in
non-acetaminophen users and aniline-exposed individ-
uals) indicative of NA4AP doses of possible toxicological
relevance?
Therefore, to fully understand and investigate the
sources and routes of exposure as well as the resulting
toxicological impacts, an interdisciplinary approach in
this matter is warranted. At this point, HBM can play an
important role in the assessment of NA4AP exposure in
specific cohorts, populations, and subpopulations, in
the investigation of differences and similarities in NA4AP
and aniline metabolism, and in the confirmation or
refutation of links between NA4AP exposure and
possible (adverse) effects.
Discussion from meeting
Tue Søeborg (Copenhagen, Denmark): I am confused by
your term ‘body burden’ when you measure urinary
levels. If aniline is converted to paracetamol, have you
measured levels in the serum and how much of it is
bioavailable?
H M Koch (Bochum, Germany): Serum measurements
would be useful, but we have not done that. Paracetamol
was discovered following a study of aniline exposure
when the primary metabolite was found to be active and
this is a precursor of paracetamol. Therefore, if the
paracetamol in our assay was derived from aniline, then
the precursor will also be active, indicating a pharma-
cologically active body burden.
Bernard Je`gou (Rennes, France): We have just
published a paper (Albert et al. 2013) indicating
that paracetamol inhibits testosterone synthesis in the
adult testis. Some elite athletes consume large quantities
of paracetamol. Aspirin and paracetamol are not banned
substances in athletics, and high concentrations can be
used for preventative and curative muscle problems.
However, we do not know what is happening in the long
term, and its effect on performance might be counter-
productive if there is a chronic reduction in testosterone
even in the presence of muscle repair.
Andreas Kortenkamp (Uxbridge, UK): I believe that
aniline workers do not suffer pain. The endocrine
disrupter effect of paracetamol was confirmed by our
epidemiological questionnaire survey indicating that
paracetamol use was associated with cryptorchidism
but not with hypospadias, and we plan to verify the
questionnaire responses by conducting urine analyses.
Do you think that this approach is naı¨ve because your
study shows ubiquitous exposure to paracetamol?
H M Koch: We can differentiate between individuals
with low-level exposure and excessive exposure to
paracetamol. This is valuable information and we see
paracetamol users having urinary excretion in the
g/l range.
Shanna Swan (New York, USA): Waste water in Israel
is reused and is high in pharmaceuticals. Is water a
possible source of paracetamol exposure?
H M Koch: Probably not, because at the present level
in water, we would need to drink hundreds of liters to
reach the concentration found in urine in our study.
Water in Germany is tested for pharmaceuticals.
However, there might be sufficient aniline, aniline
derivatives, and/or paracetamol in the diet to explain
the urinary levels observed in our study. Regarding
paracetamol in the diet, paracetamol is approved for
veterinary use in the European Union. There is no
specific maximum residue limit for paracetamol in
foodstuffs of animal origin.
Human biomonitoring of acetaminophen R115
www.reproduction-online.org Reproduction (2014) 147 105–117
Supplementary data
This is linked to the online version of the paper at http://dx.doi.
org/10.1530/REP-13-0527.
Declaration of interest
The authors declare that there is no conflict of interest that could
be perceived as prejudicing the impartiality of the review.
Funding
This review did not receive any specific grant from any funding
agency in the public, commercial or not-for-profit sector.
This article is based on the work presented at the 7th
Copenhagen Workshop on Endocrine Disrupters, which was
supported by the Danish Ministry of the Environment –
Environmental Protection Agency. Publication of this special
issue was supported by the Society for Reproduction and
Fertility. H M Koch received funding for travel and accommo-
dation for the COW conference. All other authors declare no
relationship with the sponsors of the conference.
References
Albert O, Desdoits-Lethimonier C, Lesne L, Legrand A, Guille F, Bensalah K,
Dejucq-RainsfordN& JegouB 2013 Paracetamol, aspirin and indomethacin
display endocrine disrupting properties in the adult human testis in vitro.
Human Reproduction 28 1890–1898. (doi:10.1093/humrep/det112)
Amateau SK & McCarthy MM 2004 Induction of PGE2 by estradiol
mediates developmental masculinization of sex behavior. Nature
Neuroscience 7 643–650. (doi:10.1038/nn1254)
Andrews RS, Bond CC, Burnett J, Saunders A & Watson K 1976 Isolation
and identification of paracetamol metabolites. Journal of International
Medical Research 4 34–39.
Angerer J, Ewers U & Wilhelm M 2007 Human biomonitoring: state of
the art. International Journal of Hygiene and Environmental Health 210
201–228. (doi:10.1016/j.ijheh.2007.01.024)
el-Bayoumy K, Donahue JM, Hecht SS & Hoffmann D 1986 Identification
and quantitative determination of aniline and toluidines in human urine.
Cancer Research 46 6064–6067.
Berlin CM, Yaffe SJ & Ragni M 1980 Disposition of acetaminophen in milk,
saliva, and plasmaof lactatingwomen. Pediatric Pharmacology 1 135–141.
Bitze´n PO, Gustafsson B, Jostell KG, Melander A & Wa˚hlin-Boll E 1981
Excretion of paracetamol in human breast milk. European Journal of
Clinical Pharmacology 20 123–125. (doi:10.1007/BF00607148)
Black RA & Hill DA 2003 Over-the-counter medications in pregnancy.
American Family Physician 67 2517–2524.
Camann DE, Schultz ST, Yau AY, Heilbrun LP, Zuniga MM, Palmer RF &
Miller CS 2012 Acetaminophen, pesticide, and diethylhexyl phthalate
metabolites, anandamide, and fatty acids in deciduous molars: potential
biomarkers of perinatal exposure. Journal of Exposure Science &
Environmental Epidemiology 23 190–196. (doi:10.1038/jes.2012.71)
Christensen KLY, Lorber M, Koslitz S, Bru¨ning T & Koch HM 2012 The
contribution of diet to total bisphenol A body burden in humans: results
of a 48 hour fasting study. Environment International 50 7–14. (doi:10.
1016/j.envint.2012.09.002)
Committee for Veterinary Medicinal Products 1999 Paracetamol
Summary Report (http://www.ema.europa.eu/docs/en_GB/document_
library/Maximum_Residue_Limits_-_Report/2009/11/WC500015516.pdf).
Last accessed 8 October 2013.
Dierkes G,Weiss T, Modick H, Ka¨fferlein HU& Bru¨ning T 2014N-acetyl-4-
aminophenol (paracetamol), N-acetyl-2-aminophenol and acetanilide
in urine samples from the general population, individuals exposed to
aniline and paracetamol users. International Journal of Hygiene and
Environmental Health. (http://dx.doi.org/10.1016/j.ijheh.2013.11.005)
Dikstein S, Zor U, Ruah D & Sulman FG 1966 Stimulatory effect of
paracetamol on chicken growth. Poultry Science 45 744–746.
(doi:10.3382/ps.0450744)
European Commission 2010 Commission Regulation (EU) no. 37/2010 of
22 December 2009 on pharmacologically active substances and
their classification regarding maximum residue limits in foodstuffs of
animal origin. (http://ec.europa.eu/health/files/eudralex/vol-5/reg_2010
_37/reg_2010_37_en.pdf). Last accessed 20 February 2014.
Federal Ministry of Food, Agriculture and Consumer Protection 2002
Jahresbericht 2002 zum Nationalen Ru¨ckstandskontrollplan. (http://
www.lua.sachsen.de/download/lua/JB_2003.pdf). Last accessed 20
February 2014.
Foresta C, Zuccarello D, Garolla A & Ferlin A 2008 Role of hormones,
genes, and environment in human cryptorchidism. Endocrine Reviews
29 560–580. (doi:10.1210/er.2007-0042)
Gentili A, Caretti F, Bellante S, Mainero Rocca L, Curini R & Venditti A
2012 Development and validation of two multiresidue liquid chroma-
tography tandem mass spectrometry methods based on a versatile
extraction procedure for isolating non-steroidal anti-inflammatory drugs
from bovine milk and muscle tissue. Analytical and Bioanalytical
Chemistry 404 1375–1388. (doi:10.1007/s00216-012-6231-0)
German Federal Ministry of Environment 2011 Stoffmonographie und
Referenzwerte fu¨rmonocyklischeAminoaromaten imUrin. Stellungnahme
der Kommission Human-Biomonitoring des Umweltbundesamtes.
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 54
650–663. (doi:10.1007/s00103-011-1256-7)
German Research Foundation 1992 Anilin (MAK Value Documentation
in German language, 1992). (http://www.ecoserve.ch/uploads/media/
MAK_BAT_20141903_D_1_.pdf). Last accessed 20 February 2014.
Glaeske G, Janhsen K & Schicktanz C 2009 GEK-Arzneimittel-Report 2009:
AuswertungsergebnissederGEK-Arzneimitteldatenausden Jahren2007bis
2008, 1st edn. Sankt Augustin: Asgard. (http://www.barmer-gek.de/barmer/
web/Portale/Presseportal/Subportal/Infothek/Studien-und-Reports/GEK-
Schriftenreihe-Gesundheitsanalyse/Arzneimittel/PDF-Arzneimittel-Report-
2007,property=Data.pdf). Last accessed 20 February 2014.
Gupta C 1989 The role of prostaglandins in masculine differentiation:
modulation of prostaglandin levels in the differentiating genital tract of the
fetal mouse. Endocrinology 124 129–133. (doi:10.1210/endo-124-1-129)
Hinz B, Cheremina O & Brune K 2007 Acetaminophen (paracetamol) is a
selective cyclooxygenase-2 inhibitor in man. FASEB Journal 22 383–390.
(doi:10.1096/fj.07-8506com)
Ho¨gesta¨tt ED, Jo¨nsson BAG, Ermund A, Andersson DA, Bjo¨rk H,
Alexander JP, Cravatt BF, Basbaum AI & Zygmunt PM 2008 Conversion
of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty
acid amide hydrolase-dependent arachidonic acid conjugation in the
nervous system. Journal of Biological Chemistry 290 31405–31412.
Hu T, Peng T, Li X, Chen D, Dai H, Deng X, Yue Z, Wang G, Shen J, Xia X
et al. 2012 Simultaneous determination of thirty non-steroidal anti-
inflammatory drug residues in swine muscle by ultra-high-performance
liquid chromatography with tandem mass spectrometry. Journal of
Chromatography. A 1219 104–113. (doi:10.1016/j.chroma.2011.11.009)
Iwersen-Bergmann S & Schmoldt A 2000 Acute intoxication with aniline:
detection of acetaminophen as aniline metabolite. International
Journal of Legal Medicine 113 171–174. (doi:10.1007/s004140050292)
Jaffe´ M 1886 Ueber den Niederschlag welchen Pikrinsaure in normalen
Harn erzeugt und uber eine neue Reaction des Kreatinins. Physiological
Chemistry 10 391.
Jensen MS, Rebordosa C, Thulstrup AM, Toft G, Sørensen HT, Bonde JP,
Henriksen TB & Olsen J 2010 Maternal use of acetaminophen, ibuprofen,
and acetylsalicylic acid during pregnancy and risk of cryptorchidism.
Epidemiology 21 779–785. (doi:10.1097/EDE.0b013e3181f20bed)
Kao J, Faulkner J & Bridges JW 1978 Metabolism of aniline in rats, pigs and
sheep. Drug Metabolism and Disposition 6 549–555.
Koch HM, Lorber M, Christensen KLY, Pa¨lmke C, Koslitz S & Bru¨ning T
2013 Identifying sources of phthalate exposure with human biomonitor-
ing: results of a 48h fasting study with urine collection and personal
activity patterns. International Journal of Hygiene and Environmental
Health 216 672–681. (doi:10.1016/j.ijheh.2012.12.002)
Korinth G, Weiss T, Penkert S, Schaller KH, Angerer J & Drexler H 2006
Percutaneous absorption of aromatic amines in rubber industry workers:
impact of impaired skin and skin barrier creams. Occupational and
Environmental Medicine 64 366–372. (doi:10.1136/oem.2006.027755)
R116 H Modick and others
Reproduction (2014) 147 105–117 www.reproduction-online.org
Kristensen DM, Hass U, Lesne L, Lottrup G, Jacobsen PR, Desdoits-
Lethimonier C, Boberg J, Petersen JH, Toppari J & Jensen TK 2010
Intrauterine exposure to mild analgesics is a risk factor for development of
male reproductive disorders in human and rat. Human Reproduction 26
235–244. (doi:10.1093/humrep/deq323)
Kristensen DM, SkalkamML, Audouze K, Lesne´ L, Desdoits-Lethimonier C,
Frederiksen H, Brunak S, Skakkebæk NE, Je´gou B, Hansen JB et al. 2011
Many putative endocrine disruptors inhibit prostaglandin synthesis.
Environmental Health Perspectives 119 534–541. (doi:10.1289/ehp.
1002635)
Kristensen DM, Lesne´ L, Le Fol V, Desdoits-Lethimonier C, Dejucq-
Rainsford N, Leffers H & Je´gou B 2012 Paracetamol (acetaminophen),
aspirin (acetylsalicylic acid) and indomethacin are anti-androgenic in
the rat foetal testis. International Journal of Andrology 35 377–384.
(doi:10.1111/j.1365-2605.2012.01282.x)
Ku¨tting B, Go¨en T, Schwegler U, Fromme H, Uter W, Angerer J &
Drexler H 2009 Monoarylamines in the general population – a cross-
sectional population-based study including 1004 Bavarian subjects.
International Journal of Hygiene and Environmental Health 212
298–309. (doi:10.1016/j.ijheh.2008.07.004)
Ladds G, Wilson K & Burnett D 1987 Automated liquid chromatographic
method for the determination of paracetamol and six metabolites in
human urine. Journal of Chromatography 414 355–364. (doi:10.1016/
0378-4347(87)80060-9)
Landschneider C 2011ROTE LISTEw 2011. Pharmazie in unserer Zeit 40 286.
Levy G, Garrettson LK & Soda DM 1975a Letter: Evidence of placental
transfer of acetaminophen. Pediatrics 55 895.
Levy G, Khanna NN, Soda DM, Tsuzuki O & Stern L 1975b
Pharmacokinetics of acetaminophen in the human neonate: formation
of acetaminophen glucuronide and sulfate in relation to plasma bilirubin
concentration and D-glucaric acid excretion. Pediatrics 55 818–825.
Lewalter J & Korallus U 1985 Blood protein conjugates and acetylation of
aromatic amines. New findings on biological monitoring. International
Archives of Occupational and Environmental Health 56 179–196.
(doi:10.1007/BF00396596)
Lo´pez-Serna R, Pe´rez S, Ginebreda A, Petrovic´ M & Barcelo´ D 2010 Fully
automated determination of 74 pharmaceuticals in environmental and
waste waters by online solid phase extraction-liquid chromatography-
electrospray-tandem mass spectrometry. Talanta 83 410–424.
(doi:10.1016/j.talanta.2010.09.046)
Love DC, Halden RU, Davis MF & Nachman KE 2012 Feather meal:
a previously unrecognized route for reentry into the food supply of
multiple pharmaceuticals and personal care products (PPCPs). Environ-
mental Science & Technology 46 3795–3802. (doi:10.1021/es203970e)
Mazaud-Guittot S, Nicolaz CN, Desdoits-Lethimonier C, Coiffec I,
Maamar MB, Balaguer P, Kristensen DM, Chevrier C, Lavoue´ V,
Poulain P et al. 2013 Paracetamol, aspirin and indomethacin induce
endocrine disturbances in the human fetal testis capable of interfering
with testicular descent. Journal of Clinical Endocrinology and Metab-
olism 98 E1757–E1767. (doi:10.1210/jc.2013-2531)
Miller RP, Roberts RJ & Fischer LJ 1976 Acetaminophen elimination
kinetics in neonates, children, and adults. Clinical Pharmacology and
Therapeutics 19 284–294.
Modick H, Schu¨tze A, Pa¨lmke C, Weiss T, Bru¨ning T & Koch HM 2013
Rapid determination of N-acetyl-4-aminophenol (paracetamol) in
urine by tandem mass spectrometry coupled with on-line clean-up
by two dimensional turbulent flow/reversed phase liquid chromatography.
Journal of Chromatography. B, Analytical Technologies in the Biomedical
and Life Sciences 925 33–39. (doi:10.1016/j.jchromb.2013.02.023)
Notarianni LJ, OldhamHG& Bennett PN 1987 Passage of paracetamol into
breast milk and its subsequent metabolism by the neonate. British
Journal of Clinical Pharmacology 24 63–67. (doi:10.1111/j.1365-2125.
1987.tb03137.x)
Ortiz de Garcı´a S, Pinto Pinto G, Garcı´a Encina P & Irusta Mata R 2013
Consumption and occurrence of pharmaceutical and personal care
products in the aquatic environment in Spain. Science of the Total
Environment 444 451–465. (doi:10.1016/j.scitotenv.2012.11.057)
Palmiotto G, Pieraccini G, Moneti G & Dolara P 2001 Determination
of the levels of aromatic amines in indoor and outdoor air in Italy.
Chemosphere 43 355–361. (doi:10.1016/S0045-6535(00)00109-0)
Peterson RG & Rumack BH 1978 Pharmacokinetics of acetaminophen in
children. Pediatrics 62 877–879.
Philippat C, Giorgis-Allemand L, Chevrier C, Cordier S, Je´gou B, Charles M
& Slama R 2011 Analgesics during pregnancy and undescended testis.
Epidemiology 22 747–749. (doi:10.1097/EDE.0b013e318225bf33)
Rebordosa C, Kogevinas M, Horva´th-Puho´ E, Nørga˚rd B, Morales M,
Czeizel AE, Vilstrup H, Sørensen HT &Olsen J 2008 Acetaminophen use
during pregnancy: effects on risk for congenital abnormalities. American
Journal of Obstetrics and Gynaecology 198 e1–e7. (doi:10.1016/j.ajog.
2007.08.040)
Riffelmann M, Mu¨ller G, Schmieding W, Popp W & Norpoth K 1995
Biomonitoring of urinary aromatic amines and arylamine hemoglobin
adducts in exposed workers and nonexposed control persons.
International Archives of Occupational and Environmental Health 68
36–43. (doi:10.1007/BF01831631)
Santos LH, Paı´ga P, Arau´jo AN, Pena A, Delerue-Matos C &
Montenegro MC 2013 Development of a simple analytical method
for the simultaneous determination of paracetamol, paracetamol-
glucuronide and p-aminophenol in river water. Journal of Chromato-
graphy. B, Analytical Technologies in the Biomedical and Life Sciences
930 75–81. (doi:10.1016/j.jchromb.2013.04.032)
Snijder CA, Kortenkamp A, Steegers EA, Jaddoe VW, Hofman A, Hass U &
Burdorf A 2012 Intrauterine exposure to mild analgesics during
pregnancy and the occurrence of cryptorchidism and hypospadia in
the offspring: the Generation R Study. Human Reproduction 27
1191–1201. (doi:10.1093/humrep/der474)
Thiele K, Kessler T, Arck P, Erhardt A & Tiegs G 2013 Acetaminophen and
pregnancy: short- and long-term consequences for mother and child.
Journal of Reproductive Immunology 97 128–139. (doi:10.1016/j.jri.
2012.10.014)
Ward EM, Sabbioni G, DeBord DG, Teass AW, Brown KK, Talaska GG,
Roberts DR, Ruder AM & Streicher RP 1996 Monitoring of aromatic
amine exposures in workers at a chemical plant with a known bladder
cancer excess. Journal of the National Cancer Institute 88 1046–1052.
(doi:10.1093/jnci/88.15.1046)
Weigand UW, Chou RC, Maulik D & Levy G 1984 Assessment of
biotransformation during transfer of propoxyphene and acetaminophen
across the isolated perfused human placenta. Pediatric Pharmacology 4
145–153.
Weiss T & Angerer J 2002 Simultaneous determination of various
aromatic amines and metabolites of aromatic nitro compounds in
urine for low level exposure using gas chromatography–mass spec-
trometry. Journal of Chromatography. B, Analytical Technologies in the
Biomedical and Life Sciences 778 179–192. (doi:10.1016/S0378-
4347(01)00542-4)
Werler M, Mitchell A, Hernandezdias S & Honein M 2005 Use of over-the-
counter medications during pregnancy. American Journal of Obstetrics
and Gynecology 193 771–777. (doi:10.1016/j.ajog.2005.02.100)
Received 16 October 2013
First decision 7 November 2013
Revised manuscript received 13 December 2013
Accepted 22 January 2014
Human biomonitoring of acetaminophen R117
www.reproduction-online.org Reproduction (2014) 147 105–117
 XLIV 
Appendix VIII 
 
J.K.S. Nielsen et al. / International Journal of Hygiene and Environmental Health 218 (2015) 28–33 29
percentile at 14 mg/L and a maximum at 384 mg/L (Kutting et al.,
2009).
Groundwater could be a possible source of  aniline or NAAP but
this is uncertain, since paracetamol and aniline are  not part of
the program for groundwater surveillance in Denmark. Although,
one measurement done by the Geological Survey of Denmark and
Greenland on drinking water from one drilling, showed levels
below LOQ (0.025 mg/L) (personal communication).
There is limited knowledge of NAAP levels in the general pop-
ulation in Denmark and of  sources of indirect exposure in humans
from aniline and paracetamol. In 2010, 127 mill defined daily
doses (DDD, defined by  WHO) of paracetamol were sold in total
in Denmark from pharmacies and over the counter (OTC) medicine
retailers. This equals to 762 mill tablet (500 mg)  or 1 tablet per
inhabitant every third day. Forty-one percent of  the medication (in
OTC-dosage (500 mg/tablet)) is purchased on  prescription (Danish
Medicine and Health authority, 2012). In Denmark, a prescrip-
tion is required when buying packages containing more than
10 tablets (dosage 6 500 mg/tablet), dosage above 500 mg/tablet,
depot-tablets (500 mg/tablet) and tablets containing paracetamol
in combination with another analgesic. A survey conducted in 2010,
using self-reported use of medicine, showed that 39.1% of  the Dan-
ish population over 18 years had used OTC medicine within the last
14 days and 48.4% had used prescribed medicine within the last 14
days (The Danish National Institute of Public Health, 2012). Thus a
considerable use of medicines including paracetamol is present.
To improve and harmonize human biomonitoring in Europe,
the European project DEMOCOPHES (DEMOnstration of  a study
to COordinate and Perform Human biomonitoring on a Euro-
pean Scale) was planned and performed in 17 European countries
(Becker et al., 2014; Joas  et al., 2012). The sampling was done simul-
taneously in all countries from September 2011 to January 2012 and
involved urine and hair sampling of school children aged 6–11 years
and their mothers along with a questionnaire regarding lifestyle,
dietary- and exposure habits, including the use of medications. In
all countries, mercury was measured in hair and cotinine, phtha-
lates and cadmium were measured in urine. Creatinine was also
measured in urine in all countries and used to adjust for urinary
concentrations. In Denmark, a number of supplementary measure-
ments were performed on the samples of  the participants and in the
present study, the urine samples from the Danish school children
and their mothers participating in DEMOCOPHES were analyzed
for concentrations of NAAP. This was done to investigate the levels
of NAAP in the study persons and possible sources of the ubiqui-
tous exposure. Although, the study subjects do not represent the
general population, this study may  give an  indication of  the NAAP
levels in Denmark. Further, NAAP has not been measured in a larger
group of school children in Denmark before and there is a  limited
knowledge on ubiquitous levels of NAAP in children.
Materials and methods
Study subjects
School children and their mothers were recruited from urban
(n = 75) (Gentofte) and rural (n = 70) (Viby Sj.) areas in Denmark.
The Children were between 6 and 11 years old and equally dis-
tributed in age and gender. The participants were required to meet
the DEMOCOPHES criteria to be included in the study: mother and
child should live together at a minimum of 16 days a month, have
been living in the area for a  minimum of  5 years, have normal kidney
function and no metabolic disturbances, as previously described
(Frederiksen et al., 2013; Becker et  al., 2014).
The current study which includes supplementary measure-
ments of NAAP was approved by the local ethics committee
(H-1-2014-004) and by the Danish data protection agency (2001-
41-6607).
Before sampling, all participants gave written informed con-
sent after receiving written information about the study. For the
children, all holders of custody should sign the consent, before par-
ticipating. Mother and child each received at voucher for a cinema
ticket as appreciation for participating in the study.
Collection of questionnaire data and specimen
Sampling took place in the school nurse’s premises and was  con-
ducted by trained fieldworkers. A week before their appointment at
the school, the participants received urine containers, instructions
on how to collect morning urine, a  questionnaire concerning urine
sampling and a basic questionnaire regarding lifestyle. In the morn-
ing of the day of their appointment, mother and child collected the
total volume of  their first morning urine void and stored it  cold
(approximately 4 ◦C). At the school, fieldworkers checked the ques-
tionnaires for missing replies and the urine containers were stored
in a cooling box until return to the laboratory. In addition to the
DEMOCOPHES sampling, a study about self-medication and over-
the-counter analgesics for school children was conducted (Jensen
et al., 2014). This was a supplement study and not all participants
wished to take part. The mothers answered a supplementary ques-
tionnaire about self-rated health, pain and the use of OTC medicine
for themselves and their child. This questionnaire was designed to
give a picture of  the long-term use of  OTC medicine. The moth-
ers were only asked about the use of  paracetamol within the last
3 months. Therefore we do not have specific information about
paracetamol consumption within the last 24–48 h.
The sampling collection was done in 2011 from September to
December, and was conducted in parallel in  urban and rural areas
to avoid seasonal variation between the two  groups.
Sample preparation
Urine was collected in 750 mL polyethylene containers. The con-
tainers were prewashed in 10% nitric acid (>3 h) and rinsed twice
in purified water. The filled containers were weighed in the lab-
oratory and 2 mL  urine were transferred to 4 mL glass tubes with
crew caps packed with aluminum foil and stored at −20 ◦C until
analyzed.
Prior to analysis all samples were equilibrated to room tem-
perature. Samples were vortex mixed and 300 mL  were transferred
into silanized 1.8 mL Teflon screw cap vials. 180 mL ammonium
acetate buffer (pH 5.5–6.0), 30  mL internal standard (ring deuter-
ated NAAPd4)  solution and 6 mL of b-glucuronidase/arylsulfase
were added to each sample. After incubation in a  water bath at
37 ◦C for 3.5 h, 60 mL  Tris-buffer (1 M, pH 10) was added to adjust pH
value. To freeze out and precipitate proteins, samples were frozen
at −18 ◦C overnight. The next day samples were thawed and cen-
trifuged for 10 min  at 1900 × g. Supernatant was transferred into  a
new silanized 1.8 mL  Teflon screw cap vial.
Urinary concentrations of  creatinine were determined by enzy-
matic detection on an Abbott Architect C8000 system and used to
adjust for the effect of urine dilution on  NAAP concentrations.
Chemical analysis
NAAP levels in urine were measured at Institute for Prevention
and Occupational Medicine of the German Social Accident Insur-
ance (Institute of the Ruhr-Universität Bochum, Bochum, Germany)
according to previously published methods (Modick et al., 2013;
Dierkes et al., 2014). In short, NAAP was extracted from urinary
matrix and chromatographically separated by using a two-column
high performance liquid chromatography (HPLC) system; detection
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was done by tandem mass spectrometry with quantification via
isotope-dilution (Dierkes et al., 2014; Modick et  al.,  2013). Cotinine
in urine was determined after solid phase extraction by  LC–MS/MS
on a system consisting of a  Themo TSQ Discovery mass spectrom-
eter and a Agilent 1100 series HPLC system (unpublished method).
Statistics
To differentiate between general, currently undefined environ-
mental NAAP background exposures and NAAP exposure occurring
from recent paracetamol intake, data was split into two groups,
with NAAP < 4000 mg/L and NAAP ≥ 4000 mg/L. This arbitrary cut-
off is based on the publication of (Modick et  al.,  2014).  The authors
explained this cut-off value on the one hand based on  the 95th per-
centile of the NAAP concentrations in  2098 urine samples from the
general German population and on the other hand based on the
excretion kinetics of  a therapeutical paracetamol dose of 500 mg.
The excretion kinetics indicate that urinary NAAP concentrations
remain >4000 mg/L for 36–48 h after oral intake of a single 500 mg
paracetamol pill. Of  course this cut-off has to be regarded as arbi-
trary because both (Modick et  al., 2014)  and (Dierkes et al., 2014)
have shown that urinary NAAP concentrations of 4000 mg/L can also
be exceeded in individuals that confirmedly never used NAAP con-
taining medications (e.g. through environmental NAAP or aniline
exposure); paracetamol use longer than 36–48 h in the past will
also remain undetected by this cut-off. For analysis of association
the bivariate correlation Spearman rho was used. Comparing medi-
ans across groups (smokers and non-smokers, frequency of chicken
intake) a symptomatically two tailed Mann–Whitney U-test was
used. All analysis was done on  both measured concentrations and
on the creatinine adjusted concentrations. IBM SPSS statistics 20
was used for the statistical analysis.
Results
The characteristics of the study population and the general
intake of paracetamol are shown in Table 1.  Of the 130 moth-
ers answering the medication questionnaire, 79 (60.8%) declared
never/almost never (within the last year) to have taken parac-
etamol containing medication, while 51 (39.2%) declared to take
paracetamol at least once a month. As the questionnaire was not
designed for this study, we do not have information on  paraceta-
mol  consumption within the last 48 h.  The mothers also declared
information about their child’s general use of  OCT medicine, includ-
ing paracetamol, and 89 of the children had not used paracetamol
within the last three months.
Table 2 shows urinary NAAP concentrations from mothers and
children, unadjusted and adjusted for creatinine secretion. NAAP
was detectable in all samples from mothers, with concentrations
between 4.9 mg/L and 3 g/L and a median of 120 mg/L (Table 2a).
In the children, NAAP was detected in all samples except for one
urban child. The concentrations ranged from not detectable to 2 g/L,
and the median was 27 mg/L (Table 2b). Creatinine adjustment
does not change the percentiles and median of  the data. For the
mothers creatinine adjusted concentration range from minimum
6.7 mg/g creatinine to maximum 4 g/g creatinine and with median
at 114 mg/g creatinine (Table 2a). For the children, maximum con-
centrations were 1 g/g creatinine and median concentration was at
33 mg/g creatinine (Table 2b).
For three out of nine of  the children with NAAP above 4000 mg/L,
the mother declared that the child had not been taking paracetamol
within the last three months. Further, 13 out of  23 mothers with
NAAP above 4000 mg/L reported to either never take paracetamol
or to use paracetamol less than once a month (Table 3). Ta
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Table 2
Urinary NAAP concentration in  Danish mother–child pairs.
Mothers
Concentrations (mg/L) (n =  145) Creatinine adjusted (mg/g creatinine) (n  = 145)
Urban (n =  75) Rural (n  = 70) All Urban (n  = 75) Rural (n =  70) All
(a)
Mean 52,170 77,200 64,250 77,320 58,350 68,170
Minimum 4.9 8.9 4.9 6.7 12 6.7
Maximum 3,037,000 2,546,000 3,037,000 4,259,000 1,723,000 4,259,000
Percentiles
10  18 26 22 19 24 22
25  32 54 41 37 61 42
50  (median) 106 143 120 112 121 114
75  455 699 548 374 970 904
90  26,260 124,100 86,040 21,330 149,600 105,300
95  174,900 512,400 194,900 165,800 401,100 258,100
Children
Concentrations (mg/L) (n =  143) Creatinine adjusted (mg/g creatinine) (n  = 142)
Urban (n =  75) Rural (n = 68) All Urban (n =  74) Rural (n =  68) All
(b)
Mean 56,800 243 29,910 35,840 288 18,820
Minimum – 2.79 – – 5.61 –
Maximum 2,257,000 4222 2,257,000 1,131,000 5063 1,132,000
Percentiles
10 8.3 7.4 8.0 8.9 7.5 7.8
25  15 15 14.5 14 12 13
50  (median) 25 31 27 32 37 33
75  58 183 86 55 243 109
90  8170 710 975 8593 474 895
95  176,400 1604 8617 125,700 1254 9221
There was no significant difference in  measured NAAP between
urban and rural areas neither for the mothers nor for the children.
However, there seems to be a tendency, that the mothers in the
urban area have higher levels of NAAP compared to mothers in the
rural area. For the children, the highest concentrations of  NAAP
were seen in the urban children while none of the rural children
had levels above the 4000 mg/L (Table 2). There was no significant
gender difference in NAAP excretion of  the children.
When comparing the mother–child pairs, a correlation between
the NAAP levels of  mother and child was found. After splitting the
data into two groups, <4000 mg/L and ≥4000 mg/L, correlation per-
sisted in the <4000 mg/L group, but not in the ≥4000 mg/L group.
Urinary cotinine levels were measured as part of the DEMO-
COPHES basic scenario. Cotinine is a well-established biomarker
for smoking and exposure to environmental tobacco smoke (ETS).
Table 3
Paracetamol intake and measured NAAP concentration (<4000 mg/L and
≥4000 mg/L).
Mothers
<4000 mg/L paracetamol
Never taken/almost never taken paracetamol 66
Taken paracetamol once a  month or more 41
≥4000 mg/L paracetamol
Never taken/almost never taken paracetamol 13
Taken paracetamol once a  month or more 10
Children
<4000 mg/L paracetamol
Paracetamol intake within the last 3 months
Yes 36
No  86
≥4000 mg/L paracetamol
Paracetamol intake within the last 3 months
Yes 6
No 3
There was  no correlation between cotinine and NAAP excretion for
both mothers and children and no correlation between excretion
of NAAP and questionnaire response regarding the smoking statues
or ETS within the last 24 h was  found. Also, there was no differ-
ence in NAAP levels of smoking and non-smoking mothers. Finally,
there was  no difference in the urinary NAAP excretion in relation
to frequency of  eating chicken.
Discussion and conclusion
NAAP was detected in all participants except for one child.
This clearly suggests that there is an omnipresent body burden of
NAAP in the general Danish population from exposure to parac-
etamol, aniline or both. These findings are in  concordance with a
recent pilot study that revealed omnipresent NAAP body burdens
in individuals that were neither occupationally exposed to aniline,
nor exposed to NAAP through the use of  medications. It  was thus
hypothesized, that either exposure to aniline (or  aniline releasing
substances) or exposure to paracetamol itself through paracetamol
contaminated food lead to this ubiquitous paracetamol excretion
in the general population, besides direct exposure by the use of
medication (Modick et al., 2014; Dierkes et al., 2014).
After intake of  paracetamol, human data shows that approx-
imately 80% are  excreted in urine as NAAP in conjugated form
(Ladds et  al., 1987). Animal studies showed similar results (75–86%)
after oral intake of  which is aniline (Kao et al., 1978). The rate of
elimination from plasma is similar in  adult (1.5–3.0 h) and chil-
dren (1.0–3.5 h) (Miller et al.,  1976; Peterson and Rumack, 1978),
while a study with one adult showed urinary NAAP concentrations
∼4000 mg/L  after approximately 36 h (Modick et al., 2014). The fact,
that many mothers/children in the paracetamol-user group have
NAAP levels comparable to non-users is not surprising, because
urinary measurements can detect only recent (within 24–48 h)
paracetamol use while the questionnaire asked for paracetamol use
in a longer period (within one to three months). Rather surprising,
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however is, that many non-paracetamol users have high urinary
NAAP levels (>4000 mg/L) which indicates paracetamol use within
the last 24–48 h or occupational aniline exposure. Other sources
of paracetamol (e.g. contaminated food) may have caused the high
paracetamol levels; or, high exposure to aniline (or aniline releas-
ing substances) may  have caused the high excretion of  NAAP in
urine.
However, currently there is no clear explanation for the high
NAAP levels in these individuals. One explanation could be under-
reporting of the mothers. In our study 9% of the 130 mothers that
replied to the OTC questionnaire, declared that they themselves (or
their child) had not taken paracetamol (Table 3). This is a little lower
than what was found previously in the global INTERMAP study with
17 population samples from Japan, China, The United Kingdom and
the United States (15–17%) (Loo et al., 2012). Another explanation
might be uncertainties concerning the cut-off value of 4000 mg/L
for separating NAAP background exposures from intentional NAAP
use. As explained above, this arbitrary cut-off was  derived from
the 95th percentile of urinary NAAP levels in 2098 samples from
the general German population in conjunction with the elimina-
tion kinetics after oral NAAP intake (Modick et  al., 2014). There
still remains the possibility of  higher urinary NAAP concentrations
without the intentional intake of paracetamol and therefore a slight
chance of over-reporting in  the >4000 mg/mL group. On the other
hand, intentional paracetamol intake would remain undetected by
urinary NAAP levels if the intake occurred 36–48 h or longer ago.
Furthermore, the cut-off value estimation was based on samples
from an adult population and uncertainties might occur in  extrap-
olating to children.
The correlation between mothers and children with NAAP
excretion under 4000 mg/L, indicates that exposure might be
related to common environmental exposure and lifestyle. Such
common sources (of paracetamol or its precursor aniline) might
be food consumed in common meals or indoor sources such as
indoor air. Aniline was detected in  indoor air in private homes
(smokers and non-smokers) in  Italy and in different public places
(e.g. schools, hospitals, police stations and newspaper offices).
Levels of aniline ranged from 53 ng/m3 (office of non-smokers)
to  1929 ng/m3 (discotheque). But there was no clear association
between aniline levels and cigarette smoking, in fact a  hospital
waiting ward (non-smoker) had the third highest level (351 and
483 ng/m3) of aniline (Palmiotto et  al., 2001). This could also be the
case in Denmark and therefore the living environment of  the par-
ticipants, the mothers’ workplace and the children’s school could
be sources of aniline exposure. It  has previously been shown that
tobacco smoke is a  source of  aniline, but in this study there was
no correlation between smoking or ETS exposure and NAAP excre-
tion. This may  be due to the low numbers of  smokers in the Danish
DEMOCOPHES participants (n = 12), as it  has previously been shown
that smokers have a higher level of urinary NAAP (Modick et  al.,
2014).  Another indirect source of  paracetamol may  be food contam-
inated with aniline or paracetamol. NAAP is approved for veterinary
use in Europe (Commission Regulation (EU) 37/2010) with no max-
imum residue level in the final meat product, but with restrict usage
of NAAP for porcine species. According to the European Agency for
the Evaluation of Medical Product (EMA), NAAP is used in poultry
and cattle hold. To our knowledge The Danish Ministry of  Food,
Agriculture and Fishing has not monitored NAAP residues in meat
and on European level the knowledge is very limited. NAAP has
been detected in feather meal, which is used as an additive in
animal feed, and has been suggested as a source of re-entry of  phar-
maceuticals into meat food products (Love et al., 2012). Recently
published data from a 48 h fasting study in humans showed that
the excretion of NAAP decreased during the fasting with a factor
50–100 and increased when the study participants resumed eat-
ing (Modick et al., 2014). This clearly indicates that food could be a
major source of the ubiquitous exposure of the general population
to NAAP. Since at least some part of  the daily diet of the mothers
and children is similar, the correlation between mothers and chil-
dren might indicate contaminated foodstuff as a common source
of exposure. However, we  did not see any association between
frequency of eating chicken and NAAP levels in  this study. Parac-
etamol has been speculated to be used in chicken meat production
(Committee for Veterinary Medicinical Products, 1999). However,
the use of  paracetamol might not be restricted to poultry farming,
and could be used in other fields of  meat production as well. As
aniline is used in the syntheses of pesticides and also as  colorant
in food and cosmetics, there is a wide range of  food and consumer
products containing aniline and a specific dietary exposure may be
difficult to find with the present limited dataset.
NAAP data were presented in relation to volume and in rela-
tion to urinary creatinine concentration. Adjusting for creatinine
was done to remove the influence of urinary dilution of measured
NAAP concentrations. Thus, creatinine excretion variances in adults
depend on  different parameters such as muscle mass, gender, age
and intake of meat (Boeniger et  al., 1993). This can affect the out-
come of the statistical analysis. Because children have a  smaller
muscle mass, their creatinine excretion is lower than seen in  adults,
and this can make it  difficult to compare NAAP data between
mothers and children. Based on these facts, both non-adjusted and
adjusted NAAP data were presented in the paper.
In light of  the omnipresent excretion of NAAP in  this study, a
further investigation of the exposure of the general population is
important, because of the suspected harmful effects of paracetamol.
Furthermore, we have a limited knowledge on the indirect source
of paracetamol (as aniline or paracetamol residues in consumer
products). As food seems to be a major indirect source, it would
also be of great importance to gain further knowledge about the
possible food content of  paracetamol, either as part of a national
food monitoring program or by using a  more comprehensive food
questionnaire.
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Abstract 21 
Aniline is an important source material in the chemical industry (e.g. rubber, pesticides, and pharmaceuticals). 22 
The general population is known to be ubiquitously exposed to aniline. Thus, assessment of aniline exposure is 23 
of both occupational and environmental relevance. Knowledge on human metabolism of aniline is scarce. We 24 
orally dosed four healthy male volunteers (2 fast, 2 slow acetylators) with 5 mg isotope labelled aniline, 25 
consecutively collected all urine samples over a period of two days and investigated the renal excretion of aniline 26 
and its metabolites by LS-MS/MS and GC-MS.  27 
After enzymatic hydrolysis of glucuronide and sulfate conjugates, N-acetyl-4-aminophenol was the predominant 28 
urinary aniline metabolite representing 55.7-68.9% of the oral dose, followed by the mercapturic acid conjugate 29 
of N-acetyl-4-aminophenol accounting for 2.5-6.1%. Acetanilide and free aniline were found only in minor 30 
amounts accounting for 0.14-0.36% of the dose. Overall, these four biomarkers excreted in urine over 48h post 31 
dose represented 62.4-72.1% of the oral aniline dose. Elimination half-lives were 3.4-4.3h for N-acetyl-4-32 
aminophenol, 4.1-5.5h for the mercapturic acid conjugate and 1.3-1.6 and 0.6-1.2h for acetanilide and free 33 
aniline, respectively. Urinary maximum concentrations of N-acetyl-4-aminophenol were reached after about 4h 34 
hours and maximum concentrations of the mercapturic acid conjugate after about 6h, whereas concentrations of 35 
acetanilide and free aniline peaked after about one hour. 36 
The present study is one of the first to provide reliable urinary excretion factors for aniline and its metabolites in 37 
humans after oral dosage, including data on the predominant urinary metabolite N-acetyl-4-aminophenol, also 38 
known as an analgesic under the name paracetamol/acetaminophen. 39 
 40 
KEY WORDS: Aniline, Paracetamol, Metabolism, Excretion factors, Urine, Exposure assessment  41 
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1 Introduction 42 
Aniline (phenylamine, CAS 65-53-3) is an important and widely used feedstock in chemical industry. The vast 43 
majority of aniline (~70%) is used as a precursor in the production of polyurethane-based polymers. It may also 44 
be used in the manufacture of rubber additives (accelerators, antioxidants) and as an intermediate in the 45 
production of pesticides, azo dyes and pharmaceuticals (European Chemicals Bureau 2004; Human 46 
Biomonitoring Commission of the German Federal Environment Agency 2011; MAK Value Documentation in 47 
German language, 1992). Aniline has also been detected in indoor and outdoor air (Palmiotto et al. 2001) and in 48 
the water of drinking water treatment plants (Palmiotto et al. 2001). Further, aniline is a known constituent of 49 
tobacco smoke (Grover P 1989; Human Biomonitoring Commission of the German Federal Environment 50 
Agency 2011).  51 
Depending on the occupational or environmental setting, exposure to aniline can occur through inhalation and/or 52 
oral uptake. In addition, aniline can be readily absorbed through the skin both from the liquid and gaseous phase 53 
(MAK Value Documentation in German language, 1992); (Korinth et al. 2006; American Conference of 54 
Governmental Industrial Hygienists 1992)) thus making biological monitoring the method of choice for exposure 55 
assessment if appropriate biomarkers are at hand. Animal studies conducted in the early 1980´s identified N-56 
acetyl-4-aminophenol (NA4AP) as the major metabolite of aniline in urine, representing 75-86% of the aniline 57 
dose. NA4AP is mainly excreted in form of its glucuronide and sulfate conjugates; whereas free NA4AP reflects 58 
about 10% of the dose. Other metabolites identified were O-conjugates of 2- and 4-aminophenol (5-25% of 59 
dose). Free aniline or acetanilide (ACA) represented only 0.5-3.4% dose (Kao et al. 1978). Neither NA4AP (and 60 
its O-conjugates) nor 4-aminophenol have been used for biological monitoring of aniline exposure in humans. 61 
NA4AP (=paracetamol) is the active ingredient of many over-the-counter analgesics and 4-aminophenol is a 62 
moiety and known metabolite of chemicals such as the pesticide parathion. Therefore, NA4AP, NA4AP-derived 63 
metabolites or the amino phenols are not specific to aniline. Consequently, exposure assessments to aniline both 64 
in occupational and environmental practice have been carried out by either analyzing aniline in urine or aniline-65 
derived hemoglobin adducts in blood (Riffelmann et al. 1995; Weiss and Angerer 2002; Lewalter and Gries; 66 
Lewalter and Korallus 1985). Several human biomonitoring studies have proven that, next to workers in 67 
occupational settings (el-Bayoumy et al. 1986; Riffelmann et al. 1995) the general population is ubiquitously 68 
exposed to aniline (Human Biomonitoring Commission of the German Federal Environment Agency 2011; 69 
Kütting et al. 2009; Weiss and Angerer 2002)).  70 
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Interestingly, knowledge of the quantitative metabolism of aniline in humans is scarce despite the current 71 
specific use of aniline in urine or aniline-derived Hb adducts for exposure assessment. In example, no valid data 72 
concerning excretion kinetics and urinary conversion of aniline in humans is available. Furthermore, the limited 73 
data from animal experiments found large variations in metabolism between the surveyed animal species (Kao et 74 
al. 1978) thus making it difficult directly transferring results from animal studies to those in humans. In addition, 75 
the lack of basic toxikokinetic data of aniline in humans makes it difficult to re-calculate the absolute amount of 76 
aniline taken up by humans based on biomonitoring results. This lack of data makes it difficult to establish a 77 
reference dose (RfD) or a tolerable daily intake (TDI) for aniline exposure from the environment. A recalculation 78 
is also necessary in risk assessment and risk communication, i.e. to compare the absolute amount of aniline taken 79 
up in humans to those applied in rodent toxicity studies. 80 
Irrespective of the aniline specific biomarkers aniline and ACA in urine, NA4AP (either as the active ingredient 81 
in analgesics or the major metabolite of aniline) recently came into the focus of scientific interest. 82 
Epidemiological and experimental (animal, ex vivo and in vitro) studies suggest intrauterine exposure to NA4AP 83 
as a possible risk factor for male reproduction disorders and possible antiandrogenic effects ((Jensen et al. 2010); 84 
(Rebordosa et al. 2009; Rebordosa et al. 2008; Philippat et al. 2011; Christiansen et al. 2012; Albert et al. 2013). 85 
NA4AP is furthermore suspected to have detrimental effects on the neurodevelopment of the unborn, resulting in 86 
hyperkinetic disorders in early childhood and school-age (Liew et al. 2014; Thompson, John M D et al. 2014; 87 
Brandlistuen et al. 2014). NA4AP as the major metabolite of aniline was found in urine samples in the mg/L 88 
range after occupational exposure to aniline (air concentration of aniline below the German MAK-value of 2 89 
ppm) (Lewalter and Korallus 1985);(MAK Value Documentation in German language, 1992). In recent studies 90 
from our group with volunteers exposed to (airborne) aniline we also quantified urinary NA4AP in the mg/L 91 
range ((Dierkes et al. 2014; Modick et al. 2014). However, we detected NA4AP not only in urine samples after 92 
known (occupational) exposure to aniline, but also in all samples from controls and the general population, 93 
without exception. While for some individuals the use of analgesics (acetaminophen/paracetamol) could explain 94 
high urinary NA4AP levels, for many other individuals with high NA4AP levels we could rule out recent intake 95 
of the pharmaceutical by questionnaire (Modick et al. 2013; Modick et al. 2014, Nielsen et al. 2014). We 96 
suggested exposure to aniline to be one possible origin of the internal burden to NA4AP. In this context, not only 97 
the quantitative investigation of human aniline metabolism resulting in its “specific” biomarkers aniline and 98 
acetanilide in urine seems of utmost interest, but also its metabolism resulting in its major metabolite NA4AP 99 
and NA4AP downstream metabolites. 100 
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Here, we present the elimination kinetics and urinary conversion factors for aniline and acetanilide (ACA) but 101 
also basic toxicokinetic data for NA4AP and its mercapturic acid N-acetyl-4-aminophenol-3-mercapturate 102 
(NA4AP-MA) (figure 1) after a single oral dose of isotope labelled aniline-d5 in four volunteers. 103 
2 Experimental 104 
2.1 Study design 105 
Four healthy Caucasian male volunteers (30 - 32 years old, 71 – 95 kg, non-smokers) were dosed orally with 4.6 106 
mg aniline-d5 (ring deuterated) reflecting a total intake between 48 and 64 µg/ kg body weight. Isotope labelled 107 
aniline-d5 was dosed to avoid interferences occurring from the known background exposure to aniline. For this 108 
purpose, 1 mL of a stock solution prepared from 46 mg aniline-d5 dissolved in 10 mL ethanol was spiked into 109 
decaffeinated coffee or tea and ingested in a single step as part of a breakfast. The administered doses were 110 
approximately four hundred times lower than the estimated dose which leads to an increase of blood 111 
methemoglobin in rats 20 mg/kg bw, (Jenkins et al. 1972). All volunteers had no known occupational exposure 112 
to aniline. Two of the volunteers were low and two were fast acetylators. The acetylator phenotype (NAT2) was 113 
determined according to a previously published method (Grant et al. 1983; Bolt et al. 2005) at the Leibniz 114 
Research Centre for Working Environment and Human Factors (IfADo) in Dortmund, Germany. 115 
Each volunteer provided one urine sample before dosage. After dosage urine samples were collected 116 
continuously for 48 h in 250-mL-polyethylene containers. Volunteers recorded the time of each urine void. 117 
Volumes of each urine void were determined as the mass difference between the empty and the filled sample 118 
container. When urine had to be collected in more than one container at a time, volumes of the containers were 119 
added and samples were combined and mixed before further processing. Aliquots of 15 mL of each sample were 120 
stored in 15-mL-polypropylene containers and frozen at -18°C within 12 h after collection. 121 
The study was carried out according to the Declaration of Helsinki and was approved by the ethical board of the 122 
Ruhr University Bochum (Approval No. 4730-13). 123 
In order to investigate the human metabolism of aniline we focused on metabolites known from former aniline 124 
metabolism studies in experimental studies (Kao et al. 1978; Lewalter and Korallus 1985). Given a cross-125 
connection between the metabolism of aniline and the one of paracetamol, we also took into account 126 
experimental studies on paracetamol metabolism (An et al. 2012; Andrews et al. 1976; Ladds et al. 1987). Thus 127 
we determined unconjugated aniline (AN), N-acetylaniline (acetanilide, ACA), the sum of N-acetyl-4-128 
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aminophenol (NA4AP) and its O-conjugates in terms of total NA4AP after enzymatic hydrolyses, and N-acetyl-129 
4-aminophenol-3-mercapturate (NA4AP-MA), a mercapturic acid metabolite of NA4AP. 130 
Because ring-labeled aniline-d5 was administered the corresponding ring-labeled metabolites were formed, i.e. 131 
NA4AP-d4, NA4AP-MA-d3 and ACA-d5. Isotope-labeled target analytes based on the metabolism of aniline-d5 132 
and substances used for internal standardization and quantitation (with isotope labels at different positions; 133 
NA4AP-d3, NA4AP-MA-d5, ACA-d3) are shown in figure 1. Aniline was determined applying a GC-MS 134 
method, while NA4AP, NA4AP-MA and ACA were determined by HPLC-MS/MS. All analytes (except free 135 
aniline) were determined after enzymatic hydrolysis using ß-glucuronidas/arylsufatase.  136 
2.2 Chemicals 137 
Aniline-d5 (CAS 4165-61-1, purity >99.0%), acetanilide (CAS 103-84-4, purity >99%), acetic acid-d4 (CAS 138 
1186-52-3), ammonium acetate p.a., HP2 β-glucuronidase (≥100,000 U/mL), arylsulfatase activity (~7,500 139 
U/mL), 4-aminophenol, pyridine, dichloromethane, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 140 
hydrochloride, 2-(N-morpholino) ethanesulfonic acid (MES), and heptafluorobutyric anhydride (HFBA) were all 141 
purchased from Sigma- Aldrich (Steinheim, Germany). N-acetyl-4-aminophenol-d4 (NA4AP-d4, CAS 64315-36-142 
2, purity 99%) was obtained from LGC Standards (Wesel, Germany). Acetanilide-d5 (ACA-d5, CAS 15826-91-143 
2) was purchased from CDN Isotopes (Quebec, Canada). Paracetamol-3-mercapturate sodium salt (NA4AP-MA, 144 
CAS 52372-86-8, purity 95 %) and paracetamol-3-mercapturate-d5 sodium salt (NA4AP-MA-d5, purity 97 %) 145 
were purchased from Toronto Research Chemicals Inc. (North York, Canada). o-Toluidine-d7 was purchased 146 
from Santa Cruz Biotechnology Inc. (Heidelberg, Germany). Deionized water was obtained using a Millipore 147 
Advantage A10 with a Quantum®- cartridge. Acetonitrile and methanol (LC-MS grade) were purchased from 148 
Roth (Darmstadt, Germany). Formic acid was obtained from MERCK (Darmstadt, Germany). Finally, N-acetyl-149 
4-aminophenol-d3 and acetanilide-d3 were synthesized by selective acetylation of 4-aminophenol at the amino 150 
group and by acetylation of aniline, both with activated acetic acid-d4 as previously described by (Dierkes et al. 151 
2014).   152 
2.3 Analysis of total NA4AP-d4, NA4AP-MA and ACA-d5 153 
Quantitation of total NA4AP-d4, NA4AP-MA and ACA-d5 was carried out by HPLC-MS/MS. For this purpose, 154 
stock solutions of the standards and the corresponding internal standards were prepared (see suppl. File). Internal 155 
standards solutions of NA4AP-d3 and ACA-d3 were prepared as previously described by Dierkes et al. (2014). 156 
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The internal standard solution of NA4AP-MA-d5 was prepared by dissolving 1.5 mg of NA4AP-MA-d5 sodium 157 
salt in 10 mL methanol. An internal standard stock solution was prepared by mixing the three standard solutions 158 
and further dilution in water, leading to final concentrations of 800 µg/L for NA4AP-d3, 500 µg/L for ACA-d3 159 
and 500 µg/L for NA4AP-MA-d5 (calculated paracetamol-3-mercapturic acid-d5). 160 
Frozen urine samples were thawed and equilibrated to room temperature (RT) before analysis. All samples were 161 
vortex mixed and aliquots of 300 µL were transferred into a 1.8-mL-screw cap vial. After adding 300 µL 162 
ammonium acetate buffer (0.5 M, pH 5.5-6.0), 6 µL glucuronidase/arylsulfatase-solution and 30 µL of the 163 
internal standard solution, the samples were incubated for 3.5 h at 37°C in a water bath. After incubation 160 µL 164 
3M formic acid were added. All samples were frozen overnight at −18°C for protein precipitation. After 165 
thawing, the samples were centrifuged at 4,000 g for 10 min, the supernatant was transferred into a second 1.8 166 
mL screw cap vial and 25 µL were analyzed by 2D-HPLC-MS/MS. The limits of quantification (LOQ, S/N 9) 167 
were 0.5 µg/L for total NA4AP, 1 µg/L for NA4AP-MA, and 0.02 µg/L for ACA. Relative standard deviations 168 
for intra-day imprecision and for inter-day imprecision were <15% for all analytes at two different 169 
concentrations (Qlow, Qhigh); whereas mean relative recoveries were in the range between 98.8% and 109.4% 170 
depending on the analyte (see suppl. file). Urinary creatinine concentrations creatinine concentrations were 171 
determined using a Beckman Coulter AU 5822 analyzer, that determines creatinine based on its color formation 172 
reaction with picric acid (Jaffé-method)(Jaffe M 1886).  173 
2.4 Analyses of unconjugated aniline-d5 by GC-MS/MS 174 
Unconjugated aniline-d5 was determined using a previously described method by Weiss et al. (2002) with minor 175 
modifications. In short, 5 mL urine was combined with 3 mL MES-buffer (0,5M; pH 6) and 50 µL internal 176 
standard solution (o-toluidine-d7; 50 µg/L) were added. 6 mL n-hexane was added and the mixture was shaken 177 
for 20 min on a laboratory shaker. The n-hexanewas removed and concentrated to 1 mL in a vacuum centrifuge 178 
(Christ RVC 2-33 IR; 1,000 g; 50°C; 5 min). 30 µL HFBA were added and samples were incubated for 1 h at 179 
80°C. Afterwards, the solution was washed with 1 mL phosphate-buffer (0.02M, pH 8) The organic phase was 180 
then combined with 100 µL toluene and evaporated to 20 µL by vacuum centrifugation. From this solution 1 µL 181 
was injected into the GC-MS/MS for quantitative analysis (see suppl. File). The LOQ for free aniline estimated 182 
by a signal to noise ratio of  9 was 0.1 µg/L. Method validation was performed in analogy to the HPLC method 183 
validation. Intra-day and inter-day imprecisions of the method were below 10% for both quality control 184 
concentrations (Qlow and Qhigh).  Mean relative recoveries ranged between 97% and 107% for both spiked 185 
concentration levels (see suppl. File) 186 
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2.4. Pharmacokinetic parameters and statistical analysis  187 
Maximum concentrations (cmax) of all metabolites in urine and the corresponding time points (tmax) were 188 
determined on the basis of volume-related (mg/L) and creatinine adjusted (mg/g) values. The same is true for the 189 
determination of the elimination kinetics. The elimination half-times were calculated from the rate constant κ (t½ 190 
= ln(2)/κ) obtained from a first order elimination, beginning at cmax to the end of sample collection or to the time 191 
point where the metabolite level in question decreased below LOQ. The amounts of metabolites excreted (in %) 192 
were calculated based on the metabolite concentrations and the urinary volumes and are reflecting molecular 193 
mass corrected aniline dose equivalents. 194 
3. Results and discussion 195 
The four volunteers provided 81 consecutive and complete urine voids within 48 h. Figure 2 shows HPLC-196 
MS/MS chromatograms of the target analytes NA4AP-d4, NA4AP-MA-d3, and ACA-d5 in a representative pre-197 
dose urine sample (A) and a representative post-dose sample (B) from one volunteer. In none of the pre-dose 198 
urine samples any of the (labelled) target analytes was detected; whereas all analytes were found post dose in the 199 
first urine samples of all volunteers (taken approximately 2.3 h after oral dosage). Similar results were obtained 200 
for unconjugated aniline-d5 by GC-MS (fig. 3).  201 
The elimination curves of all target analytes for all four volunteers are shown in figure 4. Elimination curves are 202 
plotted on semi-logarithmic scale and represent creatinine adjusted concentration values in µg/g creatinine. The 203 
metabolite concentrations rose rapidly within just a few hours after the dosage in all four volunteers, followed by 204 
a first order decline during the entire time of the study (48 h). NA4AP-d4 and NA4AP-MA-d3 were detected in 205 
all post-dose urine samples of the volunteers throughout the study. In contrast, ACA-d5 and unconjugated 206 
aniline-d5 were excreted rather fast and at considerably lower concentrations. The concentrations were falling 207 
below the LOQ about 8-12 h after dosage.  208 
Elimination characteristics, maximum urinary concentrations (cmax), time of maximum concentrations (tmax) and 209 
calculated elimination half times (t½) each based on both µg/L and creatinine adjusted µg/g creatinine values 210 
over all four volunteers are shown in table 1. Maximum concentrations of NA4AP-d4 and NA4AP-MA-d3 211 
occurred ~ 4-6 h after the dosage (based upon µg/L values) and ~3 h after the dosage (based upon µg/g 212 
creatinine values). Concentrations of ACA-d5 and unconjugated aniline-d5 peaked much faster at about 1 h after 213 
dosage for both the µg/L and µg/g creatinine values. The most abundant urinary target analyte was NA4AP-d4 214 
with maximum urinary concentrations well in the mg/L range and a mean maximum concentration of 6 mg/L 215 
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(range: 1,490-8,670 µg/L). With these numbers it has to be kept in mind that NA4AP-d4 as determined with the 216 
approach described above represents the total of unconjugated NA4AP-d4 and its O-conjugates (due to an 217 
enzymatic hydrolysis step during sample preparation). The maximum concentration of NA4AP-MA-d3 was 218 
about 0.5 mg/L (460-586 µg/L) and approximately one order of magnitude below that of total NA4AP-d4. 219 
Maximum urinary concentrations of ACA-d5 and unconjugated aniline-d5 were considerably lower and with 220 
maximum concentrations around 15-30 µg/L, each. 221 
Elimination half-times differed considerably between the analytes but were in good agreement between the four 222 
volunteers (Tab. 1). Unconjugated aniline-d5 and ACA-d5 were rapidly excreted with mean elimination half-223 
times of 1.7 and 2.2 h, respectively (based on µg/L values) and 0.9 and 1.4 h, respectively (based on µg/g 224 
creatinine values). Mean elimination half-times for NA4AP-d4 were 4.2 and 3.9 h. NA4AP-MA-d3 exhibited the 225 
longest elimination half-times of around 5h.  226 
Urinary excretion factors (Fue) of unconjugated aniline and its metabolites (calculated as molar equivalents of the 227 
aniline dose in %) are shown in Tab. 2. In total, during the 48 h course of the study a mean of 65.2% (55.7-228 
68.9%) of the aniline-d5 dose was excreted as total NA4AP-d4 in urine in terms of unconjugated NA4AP-d4 and 229 
its O-conjugates. The second most abundant target analyte was NA4AP-MA-d3 representing a mean of 4.0% 230 
(2.5-6.1%) of the dose. ACA-d5 and unconjugated aniline-d5 represented only a minor share of the aniline-d5 231 
dose (0.25% each). The major fraction of all four target analytes, (representing 68-75% of the total dose) was 232 
excreted during the first 24 h. From 24-48 h only a small amount of the dose (0.5-0.9%) was excreted as total 233 
NA4AP-d4 and NA4AP-MA-d3. Neither ACA-d5 nor unconjugated aniline-d5 was detectable any more in the 24-234 
48 h post-dose samples. However, urinary concentrations of total NA4AP-d4 and NA4AP-MA-d3 were still 235 
measurable 48h post dose.  236 
As shown in our study, NA4AP and its O-conjugates are the major urinary metabolites of aniline and can be 237 
analyzed in terms of total NA4AP after using an enzymatic hydrolysis step during sample preparation. This is in 238 
accordance with Lewalter and Korallus (1985) who identified NA4AP (after acid hydrolysis) as the major 239 
metabolite after occupational exposure to aniline. However, their study design did not allow deriving urinary 240 
metabolite conversion factors (Lewalter and Korallus 1985). Investigating several animal species (pig, rat and 241 
sheep) Kao et al. (1978) recovered a total (sum of conjugated and unconjugated) of 75-86% of an oral aniline 242 
dose as NA4AP in urine, which is close to the conversion of 55.7-68.9% observed in this study in humans. 243 
About 0.5% (0.4-1.0%) of an oral aniline dose was excreted as ACA in the urines of rats (Kao et al. 1978), 244 
which is also in good accordance with the recoveries of ACA in our study. Conversion factors for ACA in sheep 245 
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and pigs, however, were approximately 10-fold higher than those observed in humans and rats. Until now 246 
NA4AP-MA has not been subject of quantitative investigations as a metabolite of aniline in biomonitoring 247 
studies. In human metabolism studies after dosage of paracetamol (chemically identical to NA4AP) the NA4AP-248 
MA metabolite reflected 0.5-6.1% of the paracetamol dose (Ladds et al. 1987), which is very similar to the 249 
conversion we found from aniline (2.4-5.9%).  250 
Overall, our study shows a total recovery of 64.4-72.7% of the aniline dose in terms of total NA4AP, NA4AP-251 
MA, unconjugated aniline and ACA. We can only speculate about the remaining 27-34%. Certainly, excretion of 252 
additional aniline related metabolites is highly likely e.g. ortho- and para-aminophenol and its conjugates. 253 
Aminophenols (para-aminophenol) have been reported in animal studies to contribute to about 5.5-28.5% of the 254 
metabolite spectrum in urine, with large interspecies variations (sheep 10.8-18.7%; pigs 5.5-9%; rats 20.2-28.5% 255 
(Kao et al. 1978). Further NA4AP derived metabolites contributing to the aniline metabolite spectrum may be 256 
NA4AP-3-cysteine or 3-hydroxy-NA4AP-4-sulfate which have been reported to represent 0.6-13.7% and 0.4-257 
4.8% of an administered paracetamol dose, respectively (Ladds et al. 1987). 258 
Regarding the acetylator status of the volunteers we observed no influence on urinary excretion factors (Fue) and 259 
maximum urinary concentrations (cmax) for total NA4AP and NA4AP-MA (table 3). However, the acetylator 260 
status might have some influence on the formation of unconjugated aniline and ACA. ACA levels in terms of Fue 261 
of the two fast acetylators (0.31% and 0.36%) were about 2-fold higher than those of the two slow acetylators 262 
(0.16% and 0.19%). In reverse, excretion of unconjugated aniline in the slow acetylators (0.28 and 0.33%) was 263 
about twice as high compared to the slow acetylators (0.14 and 0.23%). For none of the analytes elimination half 264 
times seemed to be influenced by the acetylator phenotype.  265 
4. Summary and Conclusion 266 
In summary, the present study determined the urinary excretion kinetics and metabolic parameters for aniline 267 
and its major metabolites in four male volunteers after oral dosage of deuterium labelled aniline. By dosing 268 
labelled aniline we were able to avoid interferences arising from omnipresent urinary background levels of 269 
aniline, paracetamol and their metabolites.  270 
NA4AP and NA4AP-MA were present in the urines of the volunteers during the whole 48 h of sampling and 271 
exhibited elimination half-times which were long enough to capture aniline exposure that occurred up to 48 h in 272 
the past. However, NA4AP and NA4AP-MA are no specific biomarkers of aniline but are excreted to a 273 
comparable extent after paracetamol intake. This overlap of aniline and paracetamol metabolic pathways is of 274 
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importance when interpreting urinary NA4AP and NA4AP-MA levels with the goal to specifically assess 275 
exposure either to aniline or to paracetamol. However, both ACA and unconjugated aniline possess short 276 
elimination half times (0.6-1.2 h) and small excretion factors in urine were only detectable within the first 8-12 h 277 
after a relatively high dosage of 5mg. Contrary to this study and to the occupational setting with aniline 278 
exposure, where we were able to detect both unconjugated aniline and ACA in post exposure urine samples, we 279 
could not detect ACA (and unconjugated aniline) in any urine sample from the general population (Modick et al. 280 
2014; Dierkes et al. 2014)) or in any urine samples prior to dosage (this study) or prior to exposure (occupational 281 
setting). These findings are in contrast to previous studies, reporting omnipresent aniline in urine, but only after 282 
hydrolysis. Obviously, and as a logical consequence of our findings reported above, the urinary aniline levels 283 
reported in these studies cannot be caused by either free aniline or acetanilide. Future studies will have to reveal 284 
the sources leading to aniline in urine after hydrolysis.  285 
 286 
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Table 1 Maximum urinary concentrations (c max), time points of maximum concentrations (t max) and calculated elimination half-times (t ½) of aniline metabolites and free aniline 
as the mean of the four volunteers (ranges in brackets) 
       
       
Metabolite Maximum urinary concentration (c max) Time of maximum (t max) Estimated elimination half time (t ½) 
       
       
 Based on µg/L values Based on µg/g crea 
values 
Based on µg/L values Based on µg/g crea 
values 
Based on µg/L values Based on µg/g crea 
values 
       
       
NA4AP 6,108 (1,490-8,670) 11,084 (9,642-12,526) 3.8 (0.8-6.3) 2.1 (1-.5-2.4) 4.2 (3.5-5.3) 3.9 (3.4-4.3) 
       
       
NA4AP-MA 523 (460-586) 1,263 (725-2,520) 5.8 (3.3-9.9) 2.9 (2.3-3.8) 5.5 (4.3-6.4) 4.8 (4.1-5.5) 
       
       
ACA 20.2 (15.2-27.8) 113 (54.4-161) 0.9 (0.8-1.4) 1.3 (0.8-1.5) 2.2 (1.8-2.8) 1.4 (1.3-1.6) 
       
       
AN 18.7 (16.2-23.3) 60.3 (10.8-117) 1.4 (0.8-3.3) 1.5 (1.4-1.7) 1.7 (0.6-2.9) 0.9 (0.6-1.2) 
       
       
Elimination half-times were calculated based on concentration values and creatinine-adjusted concentration values over the time by the rate constant κ with t ½ = ln(2)/ κ 
       
 
 
 
???????
Table 2 Urinary excretion factors (Fue) of aniline and aniline metabolites calculated as molar equivalents of the aniline dose in %  
 
       
Metabolite  Urinary excretion factor (F ue)
a
 as aniline dose equivalents in % 
       
       
  0 - 24 h  24 - 48 h  Total (0 - 48 h) 
       
       
NA4AP  64.5 (54.8-68.3)  0.8 (0.5-0.9)  65.2 (55.7-68.9) 
       
NA4AP-MA  3.8 (2.4-5.9)  0.15 (0.08-0.22)  4.0 (2.5-6.1) 
       
ACA  0.26 (0.18-0.36)  -  0.26 (0.18-0.36) 
       
AN  0.24 (0.14-0.31)  -  0.24 (0.14-0.31) 
       
a 
mean values of the four volunteers, ranges in brackets 
       
 
???????
Table 3 Total urinary excretion factors (Fue), elimination half times and maximum urinary concentrations of aniline and aniline metabolites of the four volunteers arranged by 
acetylation status (AS) of the volunteers 
            
   NA4AP-d4 NA4AP-MA-d3 ACA-d5 Unconjugated aniline-d5 Total Recovery 
[%]b 
                
                
Volunteer AS  F ue (48 h) 
[%] 
t ½ 
[h]a 
cmax  
[mg/g crea] 
F ue (48 h) 
[%] 
t ½  
[h]a 
cmax  
[µg/g crea] 
F ue (48 h) 
[%] 
t ½  
[h]a 
cmax  
[µg/g crea] 
F ue (48 h) 
[%] 
t ½ 
[h]a 
cmax  
[µg/g crea] 
 
                
1 slow  68.9 3.4 12.5 2.5 5.1 725 0.19 1.4 93.8 0.28 1.2 69.9 71.8 
                
2 slow  68.2 3.9 9.6 4.0 4.1 1019 0.16 1.6 54.5 0.33 0.6 10.8 72.7 
                
3 fast  68.1 4.1 10.8 3.2 5.5 971 0.31 1.4 161 0.14 1.1 44.6 71.8 
                
4 fast  55.7 4.3 11.4 6.1 4.4 2520 0.36 1.3 145 0.23 0.8 117 62.4 
                
  
 a calculated based on µg/g creatinine values 
b sum of metabolites investigated calculated from molar equivalents of the aniline dose  
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